CONTENTS

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE UPDATE 2023

Society for Endocrinology Clinical Update 2023

Workshop A: Disorders of the hypothalamus and pituitary ........................................ WA1–WA16
Workshop B: Disorders of growth and development .................................................... WB1–WB6
Workshop C: Disorders of the thyroid gland ............................................................... WC1–WC16
Workshop D: Disorders of the adrenal gland ............................................................... WD1–WD16
Workshop E: Disorders of the gonads ..................................................................... WE1–WE8
Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone .......... WF1–WF12
Workshop G: Disorders of appetite and weight ......................................................... WG1–WG6
Workshop H: Miscellaneous endocrine and metabolic disorders ............................ WH1–WH7
Additional Cases ........................................................................................................ CB1–CB69

Society for Endocrinology National Clinical Cases 2023

Oral Communications ............................................................................................. OC1–OC10
Poster Presentations ............................................................................................... P1–P48

SOCIETY FOR ENDOCRINOLOGY CLINICAL UPDATE 2023 INDEX OF AUTHORS

SOCIETY FOR ENDOCRINOLOGY NATIONAL CLINICAL CASES 2023 INDEX OF AUTHORS
Society for Endocrinology Clinical Update 2023
Hilton Birmingham Metropole Hotel, National Exhibition Centre
24–26 April 2023, Birmingham, United Kingdom

Programme Chair
Professor Maralyn Druce (London)

Strands, Convenors and Facilitators

Disorders of the hypothalamus and pituitary
Convenor: Dr Niamh Martin (London)
Facilitator: Dr Niamh Martin (London)
Facilitator: Dr Rob Murray (Leeds)

Disorders of growth and development
Convenor: Dr Talat Mushtaq (Leeds)
Facilitator: Dr Guftar Shaikh (Glasgow)
Facilitator: Dr Helena Gleeson (Birmingham)

Disorders of the thyroid gland
Convenor: Professor Simon Pearce (Newcastle)
Facilitator: Professor Simon Pearce (Newcastle)
Facilitator: Dr Catherine Napier (Newcastle)

Disorders of the adrenal gland
Convenor: Professor Michael O’Reilly (Dublin)
Facilitator: Professor Michael O’Reilly (Dublin)
Facilitator: Dr Yasir Elhassan (Birmingham)

Disorders of the gonads
Convenor: Dr Richard Quinton (Newcastle)
Facilitator: Dr Richard Quinton (Newcastle)
Facilitator: Dr Channa Jayasena (London)

Disorders of the parathyroid glands, calcium metabolism and bone
Convenor: Dr Rachel Crowley (Dublin)
Facilitator: Dr Rachel Crowley (Dublin)
Facilitator: Dr Ruth Casey (Cambridge)

Disorders of appetite and weight
Convenor: Dr Saira Hameed (London)
Facilitator: Dr Saira Hameed (London)
Facilitator: Professor Robert Semple (Edinburgh)

Miscellaneous endocrine and metabolic disorders
Convenor: Professor Maralyn Druce (London)
Facilitator: Professor Maralyn Druce (London)
Facilitator: Dr Helen Simpson (London)

CONTENTS

Workshop A: Disorders of the hypothalamus and pituitary ........................................... WA1–WA16
Workshop B: Disorders of growth and development ......................................................... WB1–WB6
Workshop C: Disorders of the thyroid gland ................................................................. WC1–WC16
Workshop D: Disorders of the adrenal gland ................................................................. WD1–WD16
Workshop E: Disorders of the gonads ............................................................................. WE1–WE8
Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone ............ WF1–WF12
Workshop G: Disorders of appetite and weight .............................................................. WG1–WG6
Workshop H: Miscellaneous endocrine and metabolic disorders ..................................... WH1–WH7
Additional Cases ............................................................................................................. CB1–CB69
Workshop A: Disorders of the hypothalamus and pituitary
WA1

Prolactinoma: a 13 year story

Natasha Galloway
NHS Lothian, Edinburgh, United Kingdom

A 73 year old male presented to his optician with reduced vision in his right eye. He was found to have a right sided visual field defect and referred to Ophthalmology. An MRI scan was arranged which showed a 29 x 22 x 17mm pituitary fossa mass, elevating and flattening the optic chiasm. He was therefore referred urgently to Endocrinology. He denied any symptoms other than some lethargy, a mild headache and erectile dysfunction. His anterior pituitary function tests were displayed below: His past medical history included hypertension, previous colorectal cancer and a microprolactinoma diagnosed 13 years prior. At that time, he had presented with erectile dysfunction and hyperprolactinaemia (664-832mU/L), with low testosterone (5.7-6.6nmol/L, FSH 5u/L, LH 1u/L). Other anterior pituitary function unremarkable at the time. An MRI pituitary at that point had shown a 5mm diameter microadenoma. He was commenced on Quinagolide with subsequent improvement in his prolactin (124 mU/L) and a rise in his testosterone to 10nmol/L, but no clear improvement in erectile dysfunction. 4 months later, he was diagnosed with colorectal cancer and was subsequently lost to endocrine clinic follow up. Following his representation recently, he was commenced on Cabergoline 500 micrograms once weekly along with Levothyroxine 75 micrograms once daily. 3 months later, he reported improvement in his vision, confirmed by repeat visual field testing. A repeat MRI pituitary showed a reduction in the size of the pituitary lesion to 25 x 17 x 15mm, with reduction in mass effect on the optic chiasm. His bloods showed a reduction in prolactin, to 305mU/L. His cabergoline was uptitrated to 750 micrograms per week. The patient’s main concern was erectile dysfunction and a trial of topical testosterone was commenced. 3 months later, there was some improvement in sexual symptoms, as well as energy levels. He continues on Cabergoline, Levothyroxine and topical testosterone, with a plan for a repeat MRI in 12 months’ time, and ongoing endocrine follow up.

Anterior pituitary function

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolactin</td>
<td>1624 mU/l</td>
<td>8-496 mU/l</td>
</tr>
<tr>
<td>Short synacthen test 0min-15min</td>
<td>241 nmol/L (494 nmol/L)</td>
<td>13-430 nmol/L</td>
</tr>
<tr>
<td>TSH</td>
<td>0.5 mU/L</td>
<td>0.2-6.6 mU/L</td>
</tr>
<tr>
<td>FSH</td>
<td>7 mU/L</td>
<td>7-17 mU/L</td>
</tr>
<tr>
<td>LH</td>
<td>0.7 u/l</td>
<td>1.5-12.4 u/L</td>
</tr>
<tr>
<td>LH</td>
<td>0.5 u/l</td>
<td>1.7-8.6 u/L</td>
</tr>
<tr>
<td>Testo</td>
<td>&lt;0.1</td>
<td>2.5-5.5 mU/L</td>
</tr>
<tr>
<td>IGF1</td>
<td>30 mg/l</td>
<td>30-186 mg/l</td>
</tr>
</tbody>
</table>

DO: 10.1530/endoabs.91.WA1

WA2

Giant prolactinoma requiring surgery

Maria Omer & Janki Panicker
Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom

35-year-old lady, has a background of Hypertension, oophorectomies for ovarian cancer and previous 2 IVF attempts, referred to endocrinology with three-week history of blurred vision, bitemporal hemianopia and large pituitary mass on MRI. Upon assessment, she reported visual disturbance and intermittent headache. She has no periods which is expected with the history of oophorectomy, but she denied galactorrhoea or any symptoms suggestive of pituitary hormone excess or deficiency. Examination was unremarkable apart from the bitemporal hemianopia.

Investigations

Prolactin 7000nmol/L (102-494nmol/L), Low FT4 was 9.9 pmol/L (12.0-22.0) with inappropriately normal TSH 2.6u/L (0.4 - 2.4). Pituitary profile otherwise normal. MRI pituitary revealed large pituitary mass measuring 45x52x23mm with invasion of the sphenoid and clivus, right cavernous sinus, and large suprasellar extension encircling the optic chiasm. A diagnosis of giant, extensive macroprolactinoma was made, and she had genetic tests done (MEN1, RET, CJD73, CDKN1B and AIP) which came back negative.

Treatment course

The case was discussed in the pituitary MDT. The patient was started on Bromocriptine initially and then switched to Cabergoline. Her prolactin dropped to 30080 in 6 weeks and continued to drop slowly with the titration of Cabergoline. Her prolactin levels ranged from 14532mU/L to 21480mU/L and her MRI scan 3 months and 6 months after treatment showed no measurable change in size of the large pituitary adenoma suggesting a weak response to treatment. Accordingly, treating team thought that with the risk of tumour progression during pregnancy, surgery would be better option compared with medical treatment alone. With patient agreement transsphenoidal surgery with debulking done, which complicated by CSF leak post-operatively allowing for infection requiring 3-week admission. She recovered well afterwards with subjective improvement in her peripheral visual field. Prolactin level drop from 21480mU/L to 4646mU/L postoperative. Further discussions about off licence use of cabergoline 5 mg per week aiming for further drop in prolactin level was agreed by the patient. Post Operative glucagon stimulation test done which showed adequate cortisol response and Growth hormone deficiency that required a regular follow-up. She was successfully weaned off steroid and currently she is awaiting IVF treatment.

Conclusion

Late diagnosis of prolactinoma in our case could be attributed to the absence of pituitary hormone excess or deficiency. Management of cabergoline-resistant prolactinomas is challenging and surgical debulking can improve the outcome. Off licence use of high dose cabergoline remain controversial.

DO: 10.1530/endoabs.91.WA2

WA3

A Challenging case of prolactinoma

Amit Verma & David Cardy
East Surrey Hospital, Redhill, United Kingdom; *Glasgow Royal Infirmary, Glasgow, United Kingdom

45/M presented to hospital with h/o assault on head (hit by meat cleaver). Background history of drug abuse and previous drug induced psychosis. Trauma CT head revealed mass in the enlarged pituitary fossa. MRI head revealed 5 x 4 cm mass in the sella turcica encasing the internal carotid vessels but sparing optic chiasma. Visual field examination was normal and no other clinical symptoms were present. Serum prolactin was 67922. Tumor was not for resection so medical treatment advised, started on cabergoline and serum prolactin levels declined. Later, on treatment, he presented with depression and compulsive shop lifting behaviour. So his medical treatment had to be stopped as per MDT and neurosurgical opinion was sought. Because of the extent of involvement of the key brain vessels, surgery was risky. Repeat MRI head was advised but patient didn’t turn up and didn’t pick up phone. Incidentally he had X-Ray skull available from 13 years ago, done to r/o skull fracture post head assault at that time, which was reported normal by radiologist at that time. But the Radiologist who reported MRI head this time was able to view the X-Ray skull 13 years ago, and reported that there was bony re-modelling present in the X-Ray in area of sella turcica, indicating the long-standing nature of this prolactinoma. This case was interesting as the patient had no clinical symptoms despite large size of the pituitary mass and he had developed the well known but rare side effect of dopamine agonist (compulsive behaviour), which improved upon stopping the therapy.

DO: 10.1530/endoabs.91.WA3

WA4

A challenging-to-manage biphasic response following pituitary surgery for acromegaly

Osada Ramlochansingh & Ben Whitelaw
Kings College Hospital, London, United Kingdom

A 51F domestic worker presented with classic clinical and biochemical features of acromegaly. This included a long history of arthralgia, increase in hand and foot size, paraesthesia requiring bilateral carpal tunnel release and coarsening of facial features. She was also newly diagnosed with hypertension and diabetes. On examination she demonstrated central adiposity, a prominent supra orbital ridge and nasal bridge, prognathism, interdental spacing, skin tags, and broad hands and feet. Pituitary MRI revealed a 16 mm X 23 mm lesion and visual fields were normal. Biochemistry showed IGF1 - 114.4 nmol/L (NR 6.5-35.5) GH 21.2 mg/L (with nadir of 18 on OGTT), decreasing to 4.2 on octreotide test dose and an otherwise normal pituitary profile. A diagnosis of acromegaly was made.

On MDT consensus, pre-treatment with the somatostatin analogue Lanreotide 120 mg, 4weekly was given for 3 months to gain biochemical control and arrest tumour progression whilst the patient awaited trans-sphenoidal surgery (TSS). Surgery went well with no immediate postoperative concerns. On day 3, the patient developed transient DI followed by a protracted period of SIADH which complicated by CSF leak post-operatively allowing for infection requiring 3-week admission. She recovered well afterward.

Endocrine Abstracts (2023) Vol 91
consistent with a biphasic response following pituitary surgery which is often challenging to manage. History was found consistent with a mixed somatotroph/lactotroph tumour with Ki67 1% and relevant outpatient follow-up was arranged.  

**Table 1** An outline of key post-surgical events and interventions.

<table>
<thead>
<tr>
<th>Events</th>
<th>Serum Na mmol/l</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 2</td>
<td>137</td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>143</td>
<td>DDAVP 1 mg</td>
</tr>
<tr>
<td>Day 4</td>
<td>130-133</td>
<td></td>
</tr>
<tr>
<td>Day 5</td>
<td>131</td>
<td></td>
</tr>
<tr>
<td>Day 6</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>Day 7</td>
<td>124</td>
<td>HTS 1.8%</td>
</tr>
<tr>
<td>Day 8</td>
<td>121</td>
<td>Tolvaptan 7.5 mg</td>
</tr>
<tr>
<td>Day 9</td>
<td>121-125-128</td>
<td>Dextrose 5%</td>
</tr>
<tr>
<td>Day 10</td>
<td>124</td>
<td>HTS 1.8%</td>
</tr>
<tr>
<td>Day 11</td>
<td>121</td>
<td>Tolvaptan 7.5 mg</td>
</tr>
<tr>
<td>Day 12</td>
<td>126-132-134</td>
<td>Dextrose 5%</td>
</tr>
<tr>
<td>Day 13</td>
<td>136-133</td>
<td></td>
</tr>
<tr>
<td>Day 14</td>
<td>133</td>
<td></td>
</tr>
<tr>
<td>Day 16</td>
<td>Return to baseline</td>
<td>143</td>
</tr>
</tbody>
</table>

DOI: 10.1530/endoabs.91.WA4

**WA5**  
A Case of Giant Prolactinoma with pituitary apoplexy and hypopituitarism  
Huzafa Dasood  
 Ninewells Hospital, Dundee, United Kingdom  

42-year-old male with past medical history of intermittent migraines, only 1 episode this year and no known family history was referred by ophthalmology with history of sudden onset of visual loss for 4 weeks. He described having woken up with visual blurring 4 weeks ago and same degree of blurriness has remained since with no improvement or progression. He denies any headaches, nausea, vomiting or limb weakness. He suffered from covid 19 infection 1 week before presentation. On examination visual acuity was limited to hand moment, visual field assessment was limited due to reduced visual acuity, but at least binocular vision was present. Rest of the neurological examination was unremarkable. Urgent MRI head was done which showed large 4.8x5.1x4.4 cm (TR*CC*AP) part cystic part solid central sellar/ suprasellar mass tenting/compressing optic nerves and optic chiasm. Solid component shows contrast enhancement and cystic part cystic part solid. 

A diagnosis of Pituicytoma giant prolactinoma with apoplexy and hypopituitarism was made. Due to social issues patient refused to stay as an inpatient, he was offered both surgical and medical treatment with risks and benefits explained. Patient refused to go for surgery and decided to go for cabergoline 0.5 mg three times/week. He was also started on hydrocortisone and levothyroxine, with weekly ophthalmology assessment and follow up in joint neurosurgery and endocrine clinic. 8 weeks later pituitary hormone profile was repeat which showed prolactin 177, Oestradiol 513, FSH 20, LH 75. He was commenced on Carbegoline 500mcg a week, which was subsequently increased to twice a week, with the aim of suppressing prolactin to undetectable levels as she was planning conception. She struggled to cope with the increased dose and took it in 3 to 4 divided doses a week. On further review in April 2019, she was planning another IVF cycle, and the plan was to increase to 750mcg per week if tolerated. However, by December 2019, Carbegoline was stopped with a plan to re-introduce the prolactin in 6 months. There was no further IVF planned due to her age and the finding of uterine fibroids. A repeat MRI was to be done in 5 years to monitor any growth of the microadenoma. On further review, in Sep 2021, prolactin had increased to 841mIU/L. Carbegoline was restarted at a dose of 500mcg once a week and withdrawn when the prolactin reduced to 76mIU/L. She remained asymptomatic. By November 2022, she had developed irregular periods. A repeat MRI scan showed that there was no change in the size of the adenoma. Repeat prolactin was 177, Oestradiol 513, FSH 20, LH 75. She continues to remain off cabergoline.

DOI: 10.1530/endoabs.91.WA6

**WA7**  
A Rare Presentation of Macroprolactinoma  
Abigail Mula, Sarah Craus & David Coppini  
“Mater LTHospital, Msida, Malta”  

A 41 year-old gentleman, known case of type 2 diabetes, presented to the emergency department after a witnessed episode of jaw clenching followed by unresponsiveness. The patient was amnesic to the event. He was noted to have a lateral tongue bite. He also reported a similar episode 8 months previously. Initial blood investigations including a random blood glucose were normal. A sulphonylurea induced hypoglycaemia was excluded. Brain imaging by means of a Computed Tomography (CT) Brain showed a large sellar lesion measuring 3.7x4.6x5 cm extending suprasellarly in close proximity to the anterior horn of the left lateral ventricle. This was further evaluated via a Magnetic Resonance (MR) scan of the pituitary which demonstrated a cystic macroadenoma extending suprasellarly compressing the hypothalamus and third ventricle, optic chiasm and encasing the internal carotid arteries. A diagnosis of epilepsy secondary to macroadenoma was made. The patient was treated for his epilepsy with sodium valproate and for the prolactinoma via Cabergoline at 0.25 mg twice weekly.

WA5

A Case of Giant Prolactinoma with pituitary apoplexy and hypopituitarism  
Huzafa Dasood  
Ninewells Hospital, Dundee, United Kingdom  

A 47 year old lady referred to the endocrine clinic following raised prolactin levels picked up on investigation for infertility in 2013. She had irregular periods with cycle length up to 50 days. Peak prolactin following diagnosis was 1309nmIU/L. She had no headaches, visual problems or galactorrhea. An MRI head had picked up a 6.3 x 6.9 x 8.3mm right sided pituitary mass in 2013. She was commenced on Bromocriptine. Her periods normalised on treatment to 24 to 25 day cycles. She had a few unsuccessful IVF attempts as at April 2015. At the time of referral to our clinic in April 2018, she was established on Bromocriptine 7.5 mg once day for 5 years, prolactin was 176nmIU/L, nadir prolactin level was 65nmIU/L in 2017. MRI showed no significant change in the size of the adenoma, no suprasellar mass or optic chiasma compression, with very slight bulging into the adjacent cavernous sinuses. By Sep 2018, prolactin rose again to 738nmIU/L. She was switched to Carbegoline 500mcg/week a week, which was subsequently increased to twice a week, with the aim of suppressing prolactin to undetectable levels as she was planning conception. She struggled to cope with the increased dose and took it in 3 to 4 divided doses a week. On further review in April 2019, she was planning another IVF cycle, and the plan was to increase to 750mcg per week if tolerated. However, by December 2019, Carbegoline was stopped with a plan to re-introduce the prolactin in 6 months. There was no further IVF planned due to her age and the finding of uterine fibroids. A repeat MRI was to be done in 5 years to monitor any growth of the microadenoma. On further review, in Sep 2021, prolactin had increased to 841mIU/L. Carbegoline was restarted at a dose of 500mcg once a week and withdrawn when the prolactin reduced to 76mIU/L. She remained asymptomatic. By November 2022, she had developed irregular periods. A repeat MRI scan showed that there was no change in the size of the adenoma. Repeat prolactin was 177, Oestradiol 513, FSH 20, LH 75. She continues to remain off cabergoline.

DOI: 10.1530/endoabs.91.WA4

**WA7**  
A Rare Presentation of Macroprolactinoma  
Abigail Mula, Sarah Craus & David Coppini  
“Mater LTHospital, Msida, Malta”  

A 41 year-old gentleman, known case of type 2 diabetes, presented to the emergency department after a witnessed episode of jaw clenching followed by unresponsiveness. The patient was amnesic to the event. He was noted to have a lateral tongue bite. He also reported a similar episode 8 months previously. Initial blood investigations including a random blood glucose were normal. A sulphonylurea induced hypoglycaemia was excluded. Brain imaging by means of a Computed Tomography (CT) Brain showed a large sellar lesion measuring 3.7x4.6x5 cm extending suprasellarly in close proximity to the anterior horn of the left lateral ventricle. This was further evaluated via a Magnetic Resonance (MR) scan of the pituitary which demonstrated a cystic macroadenoma extending suprasellarly compressing the hypothalamus and third ventricle, optic chiasm and encasing the internal carotid arteries. A diagnosis of epilepsy secondary to macroadenoma was made. The patient was treated for his epilepsy with sodium valproate and for the prolactinoma via Carbegoline at 0.25 mg twice weekly.

Further investigations included;  
- Formal visual field perimetry – surprisingly minimal appreciable bitemporal hemianopia  
- Bone Mineral Density – Osteopenia (T score Lumbar spine -1.8, Hip O.2)  
- Baseline echocardiogram – Normal  

DOI: 10.1530/endoabs.91.WA6

**Endocrine Abstracts (2023) Vol 91**
Within three months the prolactin had decreased to 3841 mIU/l with a minimal change appreciable on imaging. The patient denied further seizures. Cabergoline was increased to 0.25 mg three times per week. An MR pituitary six months later showed a significant reduction in size with a decrease in the degree of cavernous sinus involvement and no compression of the optic chiasm. Latest prolactin levels have gone down to 680 mIU/l. Despite decrease in prolactin levels testosterone levels remained lower than 10 mmol/l. The patient denied any sexual dysfunction, however in view of osteopenia the patient was started on testosterone undecanoate.

DOI: 10.1530/endoabs.91.WA7

WA8

An interesting case of pituitary macroadenoma with/without apoplexy
Muhammad Taqi, Shahzad Akbar & Shiva Mongolu
Hull Royal Infirmary, Hull, United Kingdom

A 52 year old gentleman was referred for an inpatient Endocrinology review. He was admitted after incidental finding of severe hyponatraemia of 119. He felt unwell after having an episode of vomitting at home a few days ago and then had his bloods done at primary care. He denied any headache, dizziness, or visual disturbance. Further investigations were requested which revealed plasma osm 247, urine osm 350, and urine sodium 132. A diagnosis of SIADH was established and he was put on fluid restriction. His sodium level failed to improve over the following days and rather dropped to 114. CT TAP was organised which did not show any pathology. Short synacthen test showed suboptimal cortisol rise. Bloods showed normal prolactin, and low T4 with normal TSH. CT head was requested which showed an incidental finding of pituitary mass. MRI pituitary was organized which showed likely pituitary macroadenoma with internal haemorrhage. Impression of pituitary apoplexy was made and he was started on IV hydrocortisone. A detailed plan was made to discontinue fluid restriction, continue IV hydrocortisone, anterior pituitary profile, neurosurgery opinion, and ophthalmology referral for formal visual field testing. This case was discussed at pituitary MDT where the diagnosis of macroadenoma without apoplexy was established. He underwent trans-sphenoidal surgery to remove the tumour. I followed him up on the neurosurgery ward for Endocrinology input. He was commenced on hydrocortisone, levothyroxine replacement. A plan was made to discharge him with the follow up at Endocrine clinic.

DOI: 10.1530/endoabs.91.WA8

WA9

First presentation of a prolactinoma with Pituitary Apoplexy
Mohammad Salah Uddin, Harshad Deshmukh & Afrin Kabir
Hull Royal Infirmary, Hull, United Kingdom

Pituitary apoplexy is a rare but potentially life-threatening condition that occurs due to sudden hemorrhage or infarction in a pre-existing pituitary adenoma. Here, we present a case study of a 20 year-old girl who presented to the emergency department (ED) with severe headache due to pituitary apoplexy. The patient had a history of one-year intermittent headache, which was diagnosed as migraine/cluster headache in previous ED visits. She was on Mirena coil and had amenorrhea for a year. On her most recent ED presentation, she complained of temporal severe headache, associated with heaviness in the neck and nausea, which had been increasing in intensity and frequency over the past month. Her blood pressure and other vitals were stable at presentation. CT head and MRI pituitary revealed a 15x20x18 mm heterogeneous intra/suprasellar lesion with fluid level on T2 sequence, mainly cystic, with no significant mass effect but contact with the optic chiasma, consistent with macro adenoma and pituitary apoplexy. The patient was managed with hydrocortisone and kept under medical admission for observation and subsequently discharged with oral hydrocortisone. Repeat Pituitary hormone profile was normal except raised prolactin and repeat MRI pituitary showed appearances of the hemorrhagic pituitary macroadenoma. Prolactin levels had risen from 5300 mIU/lat presentation to 7000 mIU/l in two months. She was subsequently started on cabergoline. This case highlights the importance of considering pituitary apoplexy as a differential diagnosis in young patients presenting with severe headache who have contraeptive induced amenorrhoea. Early diagnosis and management can prevent further complications and improve patient outcomes.

DOI: 10.1530/endoabs.91.WA9

WA10

A Young lady with a massive prolactinoma
Pyei Aung & Alexander Lewis
Manchester Royal Infirmary, Manchester, United Kingdom

Introduction
Prolactinoma are the commonest functioning pituitary tumours. Pressure symptoms such as headache and visual field defect are common in patients with macroprolactinoma. Early investigation and intervention can deter permanent visual impairment, pituitary apoplexy and panhypopituitarism.

Case vignette
27-year-old lady presented to ophthalmologist with two months history of headache with visual impairment on the right side. She was found to have Inferior-nasal quadrantopia, reduced colour vision and relative afferent pupillary defect on right side. CT brain showed 29 x 28 x 23 mm sellar and right parasellar hyperdense lesion. Subsequently, MRI pituitary confirmed the sellar mass had appearances in keeping with a macroadenoma occupying the right pre-chiasmatic optic nerve. It also protruded into sphenoid sinus, right cavernous sinus and partially encased cavernous carotid artery. She was referred to Endocrinology team. She did not have any galactorrhoea and was otherwise asymptomatic. She used progesterone only pill continuously to avoid menstruation. Baseline blood tests showed Prolactin of 124250 mIU/ULN - 496mU/l, FSH 0.7 IU/l(Low), LH <0.3 IU/l(Low), Oestradiol 18 pmol/l(Low). IGF-1, cortisol, thyroid function and routine bloods were normal. Cabergoline 500 micrograms twice a week was initiated with the counseling on the risk of CSF rhinorrhoea with rapid tumour regression and risk of disInhibition with dopamine agonist therapy. Her Prolactin level reduced significantly (23 folds) in four weeks. Headache improved significantly but gonadotrophins and oestradiol remained low. After 4 months, her prolactin level normalized and gonadotrophins were starting to rise. Her colour vision and visual field dramatically improved. Repeat MRI demonstrated reduced tumour volume and regression away from the pre-chiasmatic optic nerves and optic chiasm. Her genetic test result for multiple endocrine neoplasia type 1 is still pending but there is no evidence of other clinical manifestation to date.

Discussions
- Macroadenomas can have varying appearance on CT and MRI is the gold standard imaging test to confirm the diagnosis
- Massive macroprolactinoma in a young patient (<30yr) prompts for genetic testing.
- Women of child bearing age taking POP pill could mask menstrual disturbances caused by prolactinoma and may delay early diagnosis
- Although galactorrhoea is a common presentation (80-90%) of prolactinoma, it was not present in our patient despite a large macroprolactinoma with prolactin level more than 250 times above normal range.
- Dopamine agonist therapy is safe and well tolerated by most but patients should be counselled on associated risks of the medication itself and effects on tumour size.

DOI: 10.1530/endoabs.91.WA10

WA11

A case of macroprolactinoma
Arwa Alyamani
Queen Elizabeth Hospital, Birmingham, United Kingdom

A 44 year old man was referred in 2012 to his local endocrine service for headaches and visual deterioration with bi-temporal hemianopia. His prolactin was found at 107.240 mIU/l(85-325) and pituitary MRI demonstrated a 3.1x1.5x3.3 cm adenoma, compressing the optic chiasma. He was commenced on cabergoline 0.5 mg twice per week and hydrocortisone 20 mg and 10 mg empirically and was referred to us. On review in our Pituitary clinic, he reported considerable improvement in his headaches and vision. Formal assessment of his visual fields had shown no deficits. Blood tests showed prolactin 18174 mU/l(85-325), 11: a.m. testosterone 2.3 nmol/l(7.0-27.0), SHBG 17.4 mU/l(19.0-95.0), FSH 3.1 IU/l(1.5-12.4), LH 2.2 IU/l (1.7-8.6), IGF-1:17 nmol/l(13-37) and free T4 15.5 pmol/l(9-20.0). He had normal cortisol response on the short Synacthen test and he was advised to stop hydrocortisone. Baseline echocardiogram showed a good biventricular systolic function and normal valves. During the subsequent follow-up, his prolactin continued to decline slowly with also significant shrinkage of the tumour. In 2014, the dose of cabergoline was increased to 0.5 mg three times per week due to a slight increase in the prolactin levels. This led to a further gradual reduction of the prolactin, as well as normalisation of his testosterone levels. In 2018, follow-up echocardiogram showed normal function and structure of the heart, with no evidence of valve disease. On last assessment in January 2023, he was still on cabergoline 0.5 mg three times a week with no

DOI: 10.1530/endoabs.91.WA11
A 29yrs lady presented to endocrinology clinic with 2-3 stone weight gain over a 3 period which was central in nature, associated with rounding of her face, muscle weakness, fatigue and ease of bruising. She was premenopausal and had a number of violaceous striae since age 22yrs suggesting her Cushing’s syndrome was long-standing. Her past history included renal calculi, liver focal nodular hyperplasia and hradenitis suppurativa. Initial investigations showed LH 5.5iu/l, FSH 6.9iu/l, testosterone 1.9nmol/l, HbA1c 45mmol/mol; ODST on two occasions showed 9am cortisol 491nmol/l and 530nmol/L; Urinary free cortisol 339 (>147) nmol/l. ACTH was raised on two occasions. A diagnosis of ACTH-dependent Cushing’s syndrome was made. MRI pituitary showed minor asymmetry with no discreet nodule but suggested the left aspect of the gland was larger. High-resolution MRI suggested a focal area of hypoenhancement within the midline anterior superior aspect of the adenohypophysis. IPSS confirmed a pituitary source with lateralised to the left. She was commenced on metyrapone whilst awaiting surgery. During pre-assessment she was diagnosed with severe GSA and was commenced on CPAP. Metyrapone was discontinued on the day endonasal transsphenoidal resection. Histology confirmed an ACTH-secreting adenoma. Ki67: 14% with scattered p53 positivity in <5% of cells. The surgery was undertaken in the morning and by the evening she complained of dysuria. Bladder scan showed 500ml of urine. She was catheterised and her urine output in the following hour was >1500ml. Paired blood and urine samples showed serum sodium 142mmol/l, creatinine 60mmol/l, serum osmolality 294mmolkg/kg and urine osmolality 166mmol/kg. Input-output monitoring was undertaken. She was reviewed by the Endocrine team when she complained of thirst and passing clear urine. Serum sodium was 154mmol/l and I/O in the following hour was 6550/4040. Repeated urine osmolality was 42mOsmol/kg and serum osmolality 514nmol/kg. A diagnosis of likely AVP deficiency was made. Her sodium improved to 147mmol/l on IV fluids to compensate for the urinary loss. She received 50 mg desmopressin orally. Six hours after desmopressin her sodium improved to 147mmol/l on IV fluids to compensate for the urinary loss.

The goals of treatment for a prolactinoma are to normalise serum prolactin and decrease the size of the tumour. Dopamine agonists (cabergoline is first-line) represent primary therapy for almost all prolactinomas. Some prolactinomas exhibit resistance to dopamine agonist treatment and require higher doses. Our patient was a 35-year-old male who presented to Ophthalmology in March 2021 with visual disturbance, confirmed to be secondary to a bitemporal hemianopia. OCT showed bilateral reduced RNFL thickness, worse on the right. Initial bloods revealed: prolactin 28 000 mIU/l (c<300), FSH 2.9 IU/L, LH 1.7 IU/l and testosterone 4.6 nmol/l. 9AM cortisol, thyroid function and IGF-1 were normal. MRI Pituitary showed a 3.5x2.5x2.6 cm suprasellar mass compressing the optic nerves and chiasm. He started cabergoline 250 mg twice a week which the dose gradually increased, aiming to reduce prolactin into the reference range and to restore normal gonadal function. Once the weekly cabergoline dose exceeded 2 mg/week, annual echocardiography was organised with close monitoring of behaviour for impulse control disorder throughout. However, further pituitary imaging again showed little reduction in the tumour size with ongoing chiasmal compression. At this stage his serum prolactin remained above the reference range at 744mU/L. To try to achieve further reduction in tumour size and normalise serum prolactin, cabergoline was increased to a weekly dose of 7 mg/week. This was tolerated well by the patient. Surprisingly, subsequent imaging revealed only a marginal reduction in tumour size despite a normal serum prolactin with ongoing mass effect on the optic chiasm. The patient underwent trans-sphenoidal pituitary surgery in March 2023. Post-operative MRI showed an excellent resection and we wait ophthalmology review post-operatively. Histology confirmed staining for GH and prolactin, with a Ki67 index of <3%. Since this histology may reflect a somatotroph adenoma, which is a more aggressive histology with high risk of recurrence, we will monitor this closely with imaging. We are interested why prolactin normalised with dopamine agonists (at high dose) but the tumour size did not change.

A 19-year-old man attended his optician with an 18-month history of decreased visual acuity. Normal visual field testing revealed significant bitemporal hemianopia. On further questioning in hospital, his voice had deepened only 6 months previously. He had no facial hair. He had no difficulty with speech or lability. He had felt fatigued for months, but had no headaches, weight loss or postural dizziness. There was no history of galactorrhoea, gynaecomastia, nocturia, or excessive thirst. Physical examination revealed normal height and weight. He had sparse axillary and pubic hair and decreased testicular volume. There were no features to suggest GH or glucocorticoid excess. Laboratory investigations revealed a normal TSH (0.5mU/L), Free T4 was low for our assay (9.0 pmol/l), with normal TSH (2.29 mU/L). A short Synacthen test demonstrated a blunted cortisol response. Serum osmolality was normal. Prolactin was markedly elevated (248,353 mU/L). An MRI pituitary demonstrated a large (31 x 30 x 48 mm) solid and cystic pituitary mass with suprasellar extension and chiasmal compression. An escalating regimen of cabergoline was commenced, in addition to hydrocortisone replacement. Prolactin levels dropped steadily, and the dose of cabergoline was up-titrated, targeting a prolactin level in the normal range. Over the following months there were steady improvements in serial visual field testing, correlating with MRI improvements. An insulin tolerance test (ITT) confirmed a blunted GH response and blunted cortisol response. A TRH stimulation test showed a normal TSH response. Free T4 remained inadequate, and levothyroxine was commenced. Twelve months after the initial presentation, a repeat ITT showed continued blunting of the GH axis, but recovery of the cortisol axis. Hydrocortisone was weaned. Growth hormone replacement was introduced. One month thereafter, the patient attended outpatients with a 3-week history of anorexia, vomiting, fatigue, and weight loss. He started cabergoline 250 mg twice a week which the dose gradually increased, aiming to reduce prolactin into the reference range and to restore normal gonadal function. Once the weekly cabergoline dose exceeded 2 mg/week, annual echocardiography was organised with close monitoring of behaviour for impulse control disorder throughout. However, further pituitary imaging again showed little reduction in the tumour size with ongoing chiasmal compression. At this stage his serum prolactin remained above the reference range at 744mU/L. To try to achieve further reduction in tumour size and normalise serum prolactin, cabergoline was increased to a weekly dose of 7 mg/week. This was tolerated well by the patient. Surprisingly, subsequent imaging revealed only a marginal reduction in tumour size despite a normal serum prolactin with ongoing mass effect on the optic chiasm. The patient underwent trans-sphenoidal pituitary surgery in March 2023. Post-operative MRI showed an excellent resection and we wait ophthalmology review post-operatively. Histology confirmed staining for GH and prolactin, with a Ki67 index of <3%. Since this histology may reflect a somatotroph adenoma, which is a more aggressive histology with high risk of recurrence, we will monitor this closely with imaging. We are interested why prolactin normalised with dopamine agonists (at high dose) but the tumour size did not change.
A 19 year old male was referred urgently due to a significantly raised Prolactin. He had seen his GP due to a cough, who then noted the patient had not progressed through puberty and organized further testing. On examination he had a BMI of 47. His height was 178 cm with a target of 184.5 cm (range 176-193). He had bilateral gynaecomastia with microopenis and pre-pubertal testes. He had never shaved and his voice was high-pitched. He did not report anosmia. Visual fields were normal. There was no relevant family history and his older brother had gone through puberty normally. He was otherwise healthy working as a car mechanic.

Investigations showed raised Prolactin at 21,036mU/l. Gonadotrophins were suppressed with Testosterone at 1.6nmol/l. The rest of his anterior pituitary profile was normal including a normal short synachten test. Pituitary MRI showed expanded right side of the pituitary fossa with a rounded 11 x 11 x 11 mm mass. There was minimal bulging into the suprasellar system, but no contact with optic nerve or the chiasm. Bone age was calculated as 17.95 (TW2), and 16.48 (TW3). A diagnosis of macroprolactinoma was established and he was commenced initially on Cabergoline 500 mg weekly with the usual precautions for the risk of CSF leak and impulsive behavior. He was reviewed 2 months later and his Prolactin had improved to 8,885mU/l. Then at 4 month review the Cabergoline dose was increased to 500 mg twice weekly as Prolactin had plateaued. He was also started on testosterone replacement with testosterone gel to induce puberty. Current status; He is now 12 months post diagnosis. His Cabergoline dose is 1.5 mg twice weekly and latest Prolactin is 3,804mU/l. Repeat MRI showed decreased volume of the macroadenoma. His testosterone has increased to 13.5nmol/l and he has developed body and facial hair. He also reports sexual drive and erections.

Discussion points:
- Strategies for puberty induction in the context of macroprolactinoma
- Further optimization of Dopamine agonist at this level of Prolactin.

DOI: 10.1530/endoabs.91.WA15

WA16

Recurrent Pituitary Apoplexy in a young male with giant Prolactinoma: A management consternation

Dhulashiha Jegavanthan1, Charles Antonypillai1, Sonali Gunathilake2 & Dinesha Kumaranthus3
1National Hospital Kandy, Kandy, Sri Lanka; 2District Hospital Nuwara Eliya, Nuwara Eliya, Sri Lanka

Introduction
Pituitary apoplexy is an endocrinological emergency that can be life-threatening if treatment is delayed. Apoplexy occurs either due to haemorrhage or infarction of a pituitary tumour.

Case History
A 19-year-old male, presented with a sudden severe headache and visual disturbances. The examination was normal with stable haemodynamic parameters and tanner staging 5. An urgent MRI pituitary revealed a haemorrhagic pituitary macroadenoma compressing the optic chiasm. Neuro-ophthalmology revealed bitemporal hemianopia (Apoplexy score 2). He was commenced on prophylactic steroid replacement. Further investigations were as below.

A diagnosis of prolactinoma with apoplexy was made and he was commenced on Cabergoline. The repeat MRI pituitary after 6 months revealed significant size reduction with no optic chiasma compression. Pituitary levels were normalized.

Unfortunately, he developed a second episode of apoplexy with deterioration of visual acuity and fields. MRI pituitary showed a significant interval upgrade in tumor size with subacute bleeding and compression of the optic chiasm, 3rd ventricle with para-sellar extension. At this point, the pituitary apoplexy score was 4/10, therefore, urgent surgery was offered. He made an excellent recovery.

Discussion
Pituitary apoplexy complicates about 2-12% of pituitary tumours with the majority being previously undiagnosed as in our case. This condition was first described as a haemorrhage into a pituitary tumour by Bailey in 1898 (1). The best management approach is largely controversial between conservative and surgery. To determine a uniform clinical assessment and decision-making, Rajasekaran et al have introduced a pituitary apoplexy score (PAS) based on 4 parameters such as visual acuity, visual field defects, ocular paresis, and Glasgow coma scale (2). A score of ≥ 3 indicates surgery. An early surgical treatment within 7-8 days is associated with a better neuro-ophthalmological and endocrinological outcome.

References

DOI: 10.1530/endoabs.91.WA16
Workshop B: Disorders of growth and development
WB1
Lumps, bumps and organ failure following childhood cancer therapy
Simon Berry & Miguel Debono
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

Background
The late effects of childhood cancer therapy include a higher risk of subsequent primary cancers, fertility issues, and other endocrine dysfunction.

Case
A 47 year old woman was treated at age 9 for acute myeloid leukaemia with chemotherapy (DAT, MACE, and cyclophosphamide), total body irradiation (990 cGy) and allogeneic bone marrow transplantation. Aged 22, a rapidly enlarging right sided thyroid nodule developed in the context of a multinodular goitre. Histology from fine needle aspiration was inconclusive so she underwent total thyroidectomy. Two parathyroid glands were preserved. Histology showed a 9mm papillary thyroid cancer. Aged 33, on investigation for causes of secondary infertility, she was found to have premature ovarian insufficiency with LH 17 IU/l, FSH 31 IU/l, oestradiol 66 pmol/l AMH <1.5 pmol/l. Fertility treatment with donor egg IVF was unsuccessful and hormone replacement therapy was commenced. Aged 40, she developed easy bruising and a marked increase in weight over the course of a few months. A low dose dexamethasone suppression test was carried out showing a baseline ACTH of 5.8 ng/ml with a 48 hour suppressed ACTH of <5.0 ng/ml a non-suppressed cortisol of 99 nmol/lconsistent with ACTH-independent hypercortisolism. CT of the adrenals showed bilateral adrenal gland enlargement and a 1.3 cm right adrenal nodule of 5 Hounsfield units. Given the bilateral enlargement and absence of metabolic complications, the decision was made for conservative management with monitoring of cardiometabolic risk factors. At the age of 42, she developed breast cancer with metastases to the pelvis and was found to have a co-existing lung adenocarcinoma. On annual review blood tests, hypercalcaemia of 2.83 mg/dl was noted with PTH 11.5 pmol/l. Urinary calcium was low. FSH genistein testing was negative. US of the parathyroid gland showed two hyperplastic parathyroid nodules consistent with primary hyperparathyroidism.

Conclusion with points for discussion
This case illustrates the wide spectrum of late effects of childhood cancer therapy and the importance of long-term follow up and screening. Radiation to the neck predisposes to a high risk of thyroid and parathyroid dysfunction. The options for monitoring of cardiometabolic risk factors. At the age of 42, she developed breast cancer with metastases to the pelvis and was found to have a co-existing lung adenocarcinoma. On annual review blood tests, hypercalcaemia of 2.83 mg/dl was noted with PTH 11.5 pmol/l. Urinary calcium was low. FSH genistein testing was negative. US of the parathyroid gland showed two hyperplastic parathyroid nodules consistent with primary hyperparathyroidism.

Questions
1-Can be testosterone deficiency presented as short stature or affect constitutional growth?
2-Transition from pediatric to adult clinic can be done earlier than 17 years.
3-Do we need combined team to assess patients in age 13 to 14 to decide which one to be shifted to adult clinic earlier and what is plan of management.
4-Is there any chance to start Growth hormone if needed.

DOI: 10.1530/endoabs.91.WB2

WB3
Multiple Endocrinopathies associated with Childhood Cancer Treatment- in a patient
Dooshanty Tulsi & Gul Bano
St George’s Hospital, London, United Kingdom

A 48 year old man was reviewed in the late endocrine effect of childhood cancer treatment clinic. He was diagnosed with Acute Lymphoblastic Leukemia back in 1983, at the age of 9 and underwent chemotherapy with UKALL X regime, craniospinal irradiation, followed by total body irradiation and autologous bone marrow transplant the same year. Subsequently he was found to be growth hormone deficient 2 years later and by the age of 21 he developed hypopituitarism. In 2001, by the age of 27, he was also diagnosed with Type 1 DM. He also had an impressive complex background of Dilated Cardiomyopathy secondary to anthracycline therapy, Pulmonary Fibrosis from Sarcoidosis, Recurrent strokes in childhood related to radiation vasculopathy, pancreatic exocrine insufficiency and SMART (Stroke-Like Migration Attacks after Radiation Therapy) Syndrome. When he was seen in clinic in December 2022, he was on the following medications: Levothyroxine 100 mg OD, Nebido 1gr every 12 weeks and on an insulin pump for diabetes. His Growth Hormone (Subcutaneous Genotropin 0.1 mg OD) was ceased in February 2022 as it was felt that the latter could be contributing to his poor glycemic control and possible insulin resistance. Interestingly he was never on hydrocortisone as replacement as his HPA axis remained intact. He was requiring a substantial 300 Units of Insulin via the pump and even then, his blood glucose readings were off target. In clinic, he was mostly concerned about his erratic blood glucose readings and worsening exercise tolerance due to shortness of breath and fatigue. He had evidence of shaving on examination with obvious facial stubble. He reported having early morning erections and a good libido overall. He had his bloods checked on the same day and his endocrine panel was as follows: LH <0.1, FSH <0.1, Testosterone 28.8, TSH 1.16, FT4 15.5, IGF-1 20.2, Prolactin 173, PTH 4.8, Adjusted Ca 2.52. Since his AGHDA score remained unchanged off the growth hormone injection (14/25) and in view of his poor glycemic control, the latter was not restarted and no changes were made to his medications since the rest of his blood tests were unremarkable. Given his persistent high insulin requirement for his diabetes, investigations and genetic tests were sent for possible insulin resistance syndrome.

DOI: 10.1530/endoabs.91.WB3

WB4
A case of Childhood onset GH deficiency being transitioned to adult endocrinology service- Three phases of GH replacement and dose/ device indications
Idowu Olaogun
University College London Hospital, London, United Kingdom

Growth hormone replacement is not essential but it is an important treatment for adult with GH deficiency and for adults with childhood onset GH deficiency, the aim of management changes as they grow which involves testing and retuning, clarification of the replacement aim and adjustments of the dosage accordingly. This is a case of a 29 year old man who presented with short stature during childhood at the age 7 yr old and subsequently found to have growth hormone (GH) deficiency. Other pituitary hormones ares normal and pituitary MRI done twice showed a small anterior pituitary gland with other intracranial appearance reported as normal. He had GH (Zomacton 1.4 mg daily) treatment between age 7-17 and stopped. He was subsequently transitioned to adult endocrinology service a year after and the most prominent symptoms on assessment was excessive tiredness. Repeat pituitary and general screening were essentially normal. He had the end of growth assessment with ITT with peak GH level of 1.0 despite adequate hypoglycaemia achieved. He was therefore restarted on GH (Easypod at the adult dose of 0.4 mg daily) at the age of 18 years. He was reassessed after three months and there was improvement in the energy level. At the age of 25 years, GH was discontinued and he had a repeat assessment with ITT which showed the peak GH of 0.8 and had the AGHDA questionnaire checked off GH with score 24/25 which improved when he was started on Omnitrope to 10/25 the

Endocrine Abstracts (2023) Vol 91
following year. This case illustrate the three phases of GH replacement in childhood onset growth hormone deficiency. This is because the longitudinal growth is the aim during the childhood, between age 18 and 25, growth hormone is important for body composition and well being. However, after the age of 25 years, the only indication for replacement is the quality of life which is assessed by the AGHDA questionnaire and not strictly only the biochemical finding of GH deficiency. The case also highlight the dose and device indications as the dosage changes during this period and in this case, there was also a change of the GH devices from the group 2 products to the cheaper group one product- and this call for review of the indications for those device at each stage of reassessment in order to reduce the service cost.

DOI: 10.1530/endoabs.91.WB4

WBS
Secondary Effects of Childhood Cancer Therapy
Henna Patel, Nadia Osman & William Drake
Bart’s Health Trust, London, United Kingdom

A 31 year old female presented to the Endocrine day ward due to headache and dizziness in 2015. She had a background of childhood acute lymphoblastic leukaemia diagnosed at age 7 treated with chemotherapy. She had a cerebral recurrence at age 10 and underwent cerebral radiotherapy, further chemotherapy and subsequently total body irradiation and bone marrow transplant. Following this treatment she was diagnosed with panhypopituitarism and required hormone replacement therapy with growth hormone, hydrocortisone, levothyroxine, oestrogen, progesterone and desmopressin. She reported severe headaches and dizziness with an episode of collapse, with similar episodes found to be secondary to hyponatraemia. She also reported changes in her right breast, with nipple inversion. On examination there was a mass palpable within the right breast and was referred to her local breast clinic. She was found to have breast cancer and underwent a right-sided mastectomy and axillary node clearance. Her oestrogen was stopped and was started on Letrozole. Her genetic screen was negative. She underwent a prophylactic left mastectomy which subsequently showed an invasive ductal carcinoma. She was advised to continue Letrozole. In 2022 she was found to be hypercalcaemic and following investigation found to have primary hyperparathyroidism. A bone density scan showed significant osteoporosis at the femoral head. She is currently undergoing imaging to guide surgical treatment of primary hyperparathyroidism given high risk of worsening bone health given her oestrogen deprived state. Our patient demonstrates several secondary effects of her childhood cancer treatment. Early on her management plan she received high dose whole brain irradiation. Cerebral irradiation has been long shown to lead to endocrine deficiencies with varying degrees of pituitary dysfunction secondary to the radiation field and the radiation dose. Growth hormone and gonadotrophins are the most sensitive to radiation with abnormalities in TSH and ACTH related to higher doses of radiation. The drop in gonadotrophins appears to be a major contributor in the high rates of osteoporosis in patients following childhood cranial irradiation. Total body irradiation is used in conditions such as lymphoma, leukaemia and multiple myeloma. It provides radiation to the entire body allowing penetration to areas that are often less accessed by chemotherapy. It is also used prior to stem cell transplantation. Following total body irradiation, patients are at 2.8 times higher risk of subsequent malignancy with the highest risk associated with the highest doses. Surveillance programmes for childhood cancer survivors remain difficult given the wide variety of complications.

DOI: 10.1530/endoabs.91.WB5

WB6
Development of Hypopituitarism over a decade of diagnosis of Sheehan syndrome
May Thin Khine
QHEB, Birmingham, United Kingdom

Sheehan is an Interesting disease; post-partum bleeding can cause dangerous pituitary gland necrosis. Sheehan’s syndrome is a well-known condition that is generally diagnosed several years postpartum or can present acutely. Hypopituitarism after diagnosis of Sheehan syndrome can be present in insidious ways and there may be delay to diagnosis of over a decade because symptoms are often vague and pituitary dysfunction progresses gradually. We presented the case of hypopituitarism after a decade of diagnosis of Sheehan syndrome.

Case Presentation
A 75 year- old woman, presented to the clinic for feeling tiredness and lethargy in 1994. She was diagnosed with Sheehan syndrome in 1945 after post-partum haemorrhage with shock and inverted uterus. She was subsequently found to have growth hormone, cortisol deficiency as well as central hypothryroidism in 1994 and on hormonal replacement therapy. She was also treated for hyperlipidaemia with rosuvastatin and fenofibrate. Furthermore,Raloxifene 60 mg daily was given for 4 years to prevent from the effect of the steroid therapy and stopped after satisfactory DEXA scan.

Conclusion
Sheehan syndrome is a rare condition of progressive pituitary dysfunction, which can present with nonspecific symptoms and a myriad of laboratory abnormalities until an adrenal crisis is triggered years after the precipitating event. Screening patients for hypopituitarism by free thyroxine levels and adrenocorticotropic hormone (ACTH) stimulation testing is vital for determining whether hypopituitarism is the cause in the appropriate clinical scenario. Use of thyroid-stimulating hormone levels and morning cortisol testing alone will miss this diagnosis, and free thyroxine levels and ACTH stimulation testing are vital.

DOI: 10.1530/endoabs.91.WB6
Workshop C: Disorders of the thyroid gland
WC1
Beyond the Baby Blues: A Case Report of Postpartum Thyroiditis Presenting with Debilitating Lethargy
Kyle Cilia
Haz˙-Z˙ebbug˙, Malta
Faheem, Umaira Aziz & Gaurav Malhotra
Kiran Sarwar

(Abbreviation WC3)

Li levels 0.4-1 mmol/l (maintenance-
FT3 3.9-6.7 pmol/l 15.2 9.2 6.6 4.3
FT4 12-22 pmol/l 39.6 24.4 18.9 11.6

TSH unit)
FTTs (range & suppressed TSH (confusion
screen thyroid functions were tested which showed thyrotoxicosis with
on amiodarone for last 3 years for atrial fibrillation. Other than confusion
sis, primary hyperparathyroidism, type 2 Diabetes mellitus, severe frailty. He
was admitted with history of recurrent falls. He had past medical history of
on non-
ischemic cardiomyopathy, CRT, atrial fibrillation, vascular dementia, osteoporo-
sis, unremarkable.

TFTs taken 5 days ago by her GP showed suppressed thyroid stimulating
hormone (TSH) at a level of 0.016uIU/mL (reference range 0.3-3) with elevated
free thyroxine (T4) and triiodothyronine (T3) at a level of 42.12 pmol/l(11-18) and
11.3 pmol/l(3.5-6.5) respectively. Previous TFTs during her pregnancy were
normal. Thyroid antibodies were taken and showed a negative TSH receptor
antibody with a positive anti-thyroid peroxidase antibody (80IU/ml, reference
range 0.0-50.0). Thyroid scintigraphy scan showed an enlarged smooth thyroid
gland with decreased tracer uptake. A diagnosis of postpartum thyroiditis was
made. She was started on propranolol 40 mg three times a day and a "watch and
wait" approach was applied. The patient was reviewed 1 month after and she
noticed an improvement in her energy levels. She also noticed decreased in her
palpitations. Biochemically, there was evidence of subclinical hyperthyroidism
with T4 and T3 at a level of 15.42 pmol/l and 4.2 pmol/l respectively and elevated
TSH at 6.68uIU/mL. Propranolol was stopped. During her visits, the patient
remained well and felt back to her normal self. Also reported regular menses after
4 months from her delivery. TFTs continued to improve and euthyroidism was
achieved 8 months postpartum. No thyroid hormone replacement was started as
she was always asymptomatic and with no over hypothyroidism biochemically.

<table>
<thead>
<tr>
<th>Weeks/months post partum</th>
<th>TSH (0.3-3uIU/ml)</th>
<th>FT4 (11-18 pmol/l)</th>
<th>FT3 (3.5-6.5 pmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 weeks</td>
<td>0.016</td>
<td>6.675</td>
<td>4.006</td>
</tr>
<tr>
<td>10 weeks</td>
<td>0.016</td>
<td>6.675</td>
<td>4.006</td>
</tr>
<tr>
<td>3 months</td>
<td>4.212</td>
<td>15.42</td>
<td>17.21</td>
</tr>
<tr>
<td>5 months</td>
<td>4.212</td>
<td>15.42</td>
<td>17.21</td>
</tr>
<tr>
<td>8 months</td>
<td>11.3</td>
<td>4.2</td>
<td>4.3</td>
</tr>
<tr>
<td>13 months</td>
<td>11.3</td>
<td>4.2</td>
<td>4.3</td>
</tr>
</tbody>
</table>

DO: 10.1530/endoabs.91.WC1

WC2
Amiodarone induced thyrotoxicosis- A challenging case to manage
Muhammad Faheem, Umaria Aziz & Gaurav Malhotra
Basildon University Hospital, Basildon, United Kingdom

Amiodarone is commonly prescribed anti-arythmic drug which can lead to
thyroid dysfunction manifesting as either hypothyroidism or hyperthyroidism. This
case of amiodarone induced thyrotoxicosis is being reported to
highlight the challenges faced during its management. A 72-year-old gentleman
was admitted with history of recurrent falls. He had past medical history of
non-
ischemi cardiac myopathy, CRT, atrial fibrillation, vascular dementia, osteopo-
sis, type 2 Diabetes mellitus, severe frailty. He was
was started on carbimazole 20 mg daily by GP
with raised FT4 and FT3 (Table), was started on Carbimazole 20 mg daily by GP
therapeutic range. Four months ago, his thyroid profile showed suppressed TSH
TSH levels remained normal along with Li levels in therapeutic range. Four months ago, his thyroid profile showed suppressed TSH with raised FT4 and FT3 (Table), was started on Carbimazole 20 mg daily by GP
and referred to Endocrinology for further evaluation. 2 months later, when
reviewed by Endocrinology, he reported some heat intolerance, occasional
palpitations, shakiness and restlessness which he co-relates to happen during
anxiety episodes. There were no peripheral signs of hyperthyroidism and thyroid
palpations, shakiness and restlessness which he co-relates to happen during
anxiety episodes. There were no peripheral signs of hyperthyroidism and thyroid
palpations, shakiness and restlessness which he co-relates to happen during
anxiety episodes. There were no peripheral signs of hyperthyroidism and thyroid
tests were confirmed by repeating them. His thyroid antibodies were negative.
Vascular ultrasound of thyroid did not show increased vascularity. Likewise,
technetium uptake scan of thyroid revealed absent uptake on the expected
localization of thyroid. As likely diagnosis in this case was amiodarone induced
thyrotoxicosis type 2, prednisolone was started at 30 mg daily for 2 weeks with
aim of gradual tapering in 2 to 3 months. Cardiologist consultation was taken and
amiodarone was stopped. After 2 weeks there was no improvement in thyroid
functions and with suspicion of mixed Type I and Type I1 AIT, carbimazole was
added on to the treatment regimen. The dose of Prednisolone and carbimazole was
gradually increased to 40 mg and 60 mg respectively. Even after 4 months of the
above treatment thyrotoxicosis persisted (Table 1). Due to other medical
conditions and family’s unwillingness surgical management was not an option in
this case. Afterwards, Cholestyramine was added to treatment regimen and in next
2 months, patient’s confusion state and TFTs started improving and became
euthyroid (Table 2). Further plan of management is made to gradually taper off
steroids and carbimazole with frequent monitoring of TFTs. This case highlights
the challenges in the management of Amiodarone induced thyrotoxicosis. It was
unsual that despite on high dose of steroids and carbimazole patient responded
slowly. It should also be noted that other than steroids and carbimazole,
cholestyramine is also an adjunctive to treat this condition.

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH</td>
</tr>
<tr>
<td>11/01/23</td>
</tr>
<tr>
<td>28/11/22</td>
</tr>
<tr>
<td>10/11/22</td>
</tr>
<tr>
<td>27/9/22</td>
</tr>
<tr>
<td>12/9/22</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH</td>
</tr>
<tr>
<td>24/2/23</td>
</tr>
<tr>
<td>07/02/23</td>
</tr>
</tbody>
</table>

DO: 10.1530/endoabs.91.WC2

WC3
Li-induced Thyrotoxicosis
Anna Kiran Sarwar
Hereford County Hospital, Hereford, United Kingdom

Lithium is commonly used for management of Bipolar disorders. Li-induced
thyroid dysfunction, including hypothyroidism and goitre are the most prevalent
while hyperthyroidism is very infrequent, mainly characterised by transient
painless thyroiditis but it increases the propensity to thyroid autoimmunity in
susceptible individuals. Thyroid profile, thyroid auto-antibodies, assessment of
thyroid size should be performed among patients initiating lithium, at baseline
and later annually.

Case
A 32-year-old gentleman was referred to Endocrinology for evaluation of
thyrotoxicosis. He has a background history of Bipolar psychosis, on long term Li
(Fradian MR tablet 800 mg noxte) for last 7 years. Over previous years (Feb 2016
to March 2022), his TSH levels remained normal along with Li levels in
therapeutic range. Four months ago, his thyroid profile showed suppressed TSH
with raised FT4 and FT3 (Table), was started on Carbimazole 20 mg daily by GP
and referred to Endocrinology for further evaluation. 2 months later, when
reviewed by Endocrinology, he reported some heat intolerance, occasional
palpitations, shakiness and restlessness which he co-relates to happen during
anxiety episodes. There were no peripheral signs of hyperthyroidism and thyroid
was not palpable. Repeated thyroid profiles showed downturn of FT4 and FT3 to
normal; however, TSH remained suppressed at <0.01mU/l after 7 weeks of
treatment. He was advised to decrease Carbimazole to 10 mg daily. His anti-TPO
and anti-TSH receptor antibodies came out to be negative. On further review 6

Endocrine Abstracts (2023) Vol 91
weeks later, he mentioned that he is not taking Carbimazole for last 6 weeks, despite that repeated profile showed hypothyroidism with raised TSH (13.1mU/l) and low FT4 (11.6 pmol/l). He was advised to stop Carbimazole. Thyroid uptake scan with technetium was arranged. No further drug induced thyroiditis vs toxic adenoma. This patient likely have Li-induced transient thyroiditis, hypothyroid phase followed by development of hypothyroidism. Should the hypothyroid phase be treated or monitored with thyroid function testing? In Li-induced thyroiditis, regular follow up is recommended since majority develop hypothyroidism subsequently. No role for anti-thyroid drugs or RAI, thyroid function should be monitored every 4-8 weeks to confirm resolution of hypothyroidism and to detect hypothyroidism.

**Day** | **Remarks** | **TSH** | **Free t4** | **Free t3**
--- | --- | --- | --- | ---
1 | FT4 5.82 ng/dl | 0.23 | 16.4 |
3 | TPE - 1st cycle | 0.05 | 14.7 |
4 | FT4 2.47 ng/dl | <0.05 | 31.3 |
5 | TPE - 2nd cycle | <0.05 | 7.3 |
6 | FT4 2.10 ng/dl | <0.05 | 20.0 |
7 | Total Thyroidectomy | <0.05 | 16.1 |
8 | FT4 2.96 ng/dl | <0.05 | 14.7 |
12 | FT4 0.84 ng/dl | <0.05 | 5.2 |

**References**

**Conclusion**
It is important to identify the transient gestational thyrotoxicosis to avoid any unnecessary treatment of abnormal thyroid functions. Due to the weak thyroid stimulating activity of the beta HCG (human chorionic gonadotrophin) and direct stimulation of the maternal thyroid gland by HCG, changes in thyroid functions including a low or undetectable TSH and rise in total and free t4 are not uncommon. We do not advise treating an isolated low TSH or elevated free T4 in the absence of clinical evidence of hypothyroidism, as in our patient whose thyroid function was monitored during her pregnancy but no treatment was required.

**Discussion**
Resistant thyrotoxicosis can be treated with surgery or radioactive iodine ablation. However, a euthyroid state should be achieved prior to these treatment strategies to minimize the risk of complications including thyroid storm. Therefore, in patients with refractory thyrotoxicosis with maximum tolerable medical management, a therapeutic plasma exchange (TPE) can be offered to reduce the FT4 up to a safer level. TPE is a procedure that involves exchanging a patient’s plasma through an apheresis machine. It can be used in severe hyperthyroidism as it removes active thyroid hormones and thyroid receptor antibodies (1). Therefore, TPE in refractory thyrotoxicosis is an effective treatment option and a crucial bridge to the definitive treatment in challenging cases (2).

**References**

Introduction
Thyroid dysfunction in pregnancy is not uncommon (1). Early recognition and intervention are essential to avoid any adverse pregnancy outcomes however caution must be exercised while interpreting the thyroid functions during pregnancy to avoid any unnecessary treatment.

Case report
32-year female with was referred to the combined antenatal clinic for review following an abnormal thyroid function tests during pregnancy. She had no known medical conditions and was on no regular prescribed or over the counter medications. She had a routine blood test at the GP surgery at around 8 weeks of gestation, which showed thyrotoxicosis. There was no history of recent acute illness or use of iodine contrast medium. There was no family history of thyroid dysfunction. On clinical examination, she had a mild goitre. There were no other clinical signs of hyperthyroidism and no signs of thyroid eye disease. The TSH receptor antibody tested at 8-weeks of gestation was negative (<0.3 IU/l, range 0 - 0.9). She reported ongoing emesis from the first trimester of pregnancy, which continued during the second trimester, but was settling as the pregnancy was advancing. The thyroid hormone levels normalised as the pregnancy advanced without any intervention. The thyroid hormone profile done at various times of gestation was as follows:

**Case report**
A Case of Amiodarone Induced Thyrotoxicosis Type 2
Ciara Kilcoyne & Audrey Melvin
University Hospital Limerick, Limerick, Ireland

55-year-old man referred to the medical assessment unit by GP with weight loss and tachycardia. His past medical history was significant for myocarditis, long-QT syndrome, out of hospital cardiac arrest and an in-situ ICD. On examination the patient was tachycardic but otherwise well. An ECG demonstrated sinus tachycardia and routine blood tests were unremarkable. A clinical diagnosis of thyrotoxicosis was made and confirmed biochemically with TSH <0.01 (0.3-4.2)mU/l and FT4 >100 (10.5-22.8) pmol/l. The patient had no family history of thyroid dysfunction, no recent iodinated contrast, no clinical signs suggestive of Grave’s disease and no goitre, lymphadenopathy or tenderness on neck examination. His medical history was significant for exposure to Amiodarone therapy, although this had been stopped approximately 12 months before his current presentation. The patient was assessed for thyroid autoimmunity, TPO antibodies <15 (0-34)kU/l and TRAb was sent to an external lab with a reporting time of approximately 2 weeks. The patient was commenced on beta blockade for symptom control and Carbimazole. A presumed diagnosis was made of Amiodarone Induced Thyrotoxicosis (AIT), likely type-2 relating to remote amiodarone exposure. Radiological investigations were expedited to aid in the diagnosis. An ultrasound of then thyroid revealed 'Heterogenous appearance to both thyroid lobes with multiple microcystic change present suggestive of thyroiditis no significant increase in vascularity. No large discrete nodule identified'. This was followed by a puncture scan of the thyroid showing ‘Absent thyroid uptake. In the setting of thyrotoxicosis and the given the appearance of diffuse thyroiditis on recent ultrasound. If the patient is on amiodarone, this appearance may relate to amiodarone induced thyrotoxicosis.
most commonly type-2 in the setting of absent uptake. The radiological findings were most in keeping with AIT type-2, specifically an absence of a nodular thyroid, reduced vascularity and absent uptake on nuclear medicine scan, as such the patient was commenced on prednisolone 40 mg daily. The patient’s clinical course is outlined in table 1. TRAb was negative. The patient responded very well to therapy and remains under follow-up in the endocrine clinic.

**Table 1: Clinic follow-up**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>TS &lt;0.01</th>
<th>TS &gt;0.01</th>
<th>FT &lt;0.01</th>
<th>FT &gt;0.01</th>
<th>FT3 &lt;0.01</th>
<th>FT3 &gt;0.01</th>
<th>Carbimazole 40 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start</td>
<td>Prednisolone 40 mg</td>
<td>Prednisolone 10 mg</td>
<td>Carbimazole 40 mg</td>
<td>Carbimazole 10 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continue</td>
<td>Dose reduce to</td>
<td>Prednisolone 10 mg</td>
<td>Carbimazole 10 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slow taper</td>
<td>Prednisolone 40 mg</td>
<td>Stop Carbimazole 40 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FT3 pmol/l** 18.3 17.3 4.6 5.1
**FT4 pmol/l** 0.03 (0.35 - 4.94) **FT4 – 40.7 (9 – 18.1)**

**Diagnosis** 4 weeks 8 weeks 16 weeks

**Notes:**
- Prednisolone 40 mg daily for 8 weeks then reduced to 10 mg and continued for 8 weeks.
- Carbimazole 40 mg stopped after 16 weeks.

A 39-year-old female was referred to the emergency department with a sore throat, fever, myalgia and oedophagia. She had presented to her GP three months previously with palpitations, erratic mood and fatigue and had been diagnosed with hyperthyroidism. She had been started on carbimazole 20 mg od and was awaiting review in endocrinology OPD. She had no other past medical history and was a non-smoker. On examination she was tachycardic with a heart rate of 113. She had cervical lymphadenopathy and oropharyngeal exam revealed tonsillitis with exudate. Laboratory work up showed neutropenia with a total white cell count of 0.8 (ref 4.1-11 x 10^9/l) neutrophils of <0.1 (ref 2.7-5 x 10^9/l). Her thyroid function tests had improved with a TSH of <0.05mU/l (ref 0.3-4.2mU/l) and free thyroxine of 13.6 pmol/l (ref 12-22 pmol/l) which had been 66.8 pmol/l three months prior. TSH receptor antibody was positive- 14.4IU/l (ref <1.8IU/l). She was diagnosed with neutropenic sepsis and agranulocytosis secondary to carbimazole. She was treated with antibiotics and granulocyte colony stimulating factor (GCSF) 30mu once daily as per haematology advice. Thyroid ultrasound showed ‘diffuse thyroid enlargement with increased vascularity in keeping with thyroids’ and technetium 99m pertechnetate scan showed ‘high uptake of radionucide in both lobes, appearances suggest Graves’. Her white cell count returned to normal and GCSF was stopped after 6 days. Her thyroid function tests deteriorated while she was off carbimazole.

She was commenced on lithium 200 mg bd and discharged home with close outpatient follow up to monitor thyroid function tests and lithium levels. Unfortunately, she did not attend her follow up appointments and was poorly compliant with lithium therapy. When she engaged with the service again, she had clinical and biochemical evidence of thyrotoxicosis with a free thyroxine of 80 pmol/l and evidence of thyroid eye disease with left eye proptosis, lid retraction and exophthalmos and mild right eye proptosis. Lithium therapy was restarted and a plan was made for definitive therapy. Surgery was preferred over radioactive iodine treatment given the presence of thyroid eye disease and the patient’s plans for pregnancy in the near future. She was electively admitted prior to surgery for treatment with lugol’s iodine and close monitoring of thyroid function tests. She ultimately had a successful thyroidectomy and is now well on thyroxine replacement therapy.

**WC8**

*Management of alemtuzumab-associated Graves’ disease in pregnancy* Kerrie Thackray, Shakanthala Narayanaswamy & Felicity Kaplan East and North Herts NHS Trust, Stevenage, United Kingdom

A 31 year old female patient initially presented with a two month history of unintentional weight loss. Past medical history included multiple sclerosis, for which she had last received alemtuzumab immunotherapy five months previously. Thyroid function tests (TFTs) demonstrated hyperthyroidism, with Thyroid Stimulating Immunoglobulins (TSI) 5.71 iu/l/NI: <0.56). She was diagnosed with Graves’ disease, possibly induced by alemtuzumab, and commenced on carbimazole. She was strongly advised to avoid pregnancy while hyperthyroid, with a plan to switch to propylthiouracil once stable. Concordance with carbimazole was variable over the next few months requiring frequent changes to her treatment regime, although alemtuzumab-induced thyroid dysfunction is also associated with spontaneous, bidirectional switching between hyperthyroidism and hypothyroidism. Carbimazole was gradually titrated to 15 mg daily after nine months. Six weeks later, repeat TFTs demonstrated profound hypothyroidism. She stopped carbimazole and started levothyroxine, which was titrated to 125 mg daily. Six months later, she presented in the tenth week of pregnancy. Levothyroxine was increased to 150 mg daily at booking then adjusted throughout pregnancy. TSI at 28 weeks gestation was significantly elevated at 31.60 iu/l. Serial growth scans were performed, and a decision was made to deliver her baby at 35 weeks for tailing growth and abnormal Dopplers. The baby required CPAP for 24 hours but was otherwise well. TFTs demonstrated suppressed TSH <0.02 iu/l/Normal FT4 corrected for neonatal age. The baby was discharged at 3 days old and subsequent TFTs normalised. The prevalence of Graves’ disease in pregnancy is estimated at 0.2%. Up to 10% of babies born to mothers with Graves’ disease will develop fetal or neonatal thyrotoxicosis, particularly when TSI is significantly elevated. Alemtuzumab-induced Graves’ disease is particularly associated with a rapid elevation in TSI. Pregnant women with current or previous thyrotoxicosis with raised TSI should be offered growth scans and fetal heart rate monitoring at 28, 32 and 36 weeks. Women with...
hypothyroidism should increase levotiroxine dose by 25 mg on diagnosis of pregnancy with TFTs at least each trimester, aiming TSH <2.0 mIU/L. TSH should be checked at 28 weeks to allow assessment of the risk of neonatal hypothyroidism and antenatal referral to the neonatal team. The baby should have TSI and TPTTs checked on day 3-7, with repeat bloods and anti-thyroid drugs as appropriate. Those caring for women with thyroid disease and their babies should be alert to the increased risks to promote healthy outcomes for both.

DOI: 10.1530/endoabs.91.WC9

WC10

Trials and Tribulations of Management of Amiodarone-Induced Thyroiditis in A Young Patient With Heart Failure
Abigail Mula, Sarah Craig & David Coppini
Mater Dei Hospital, Msida, Malta

A 41 year old female, followed up closely by cardiology in view of grown up congenital heart disease secondary to tricuspid atresia, pulmonary stenosis and atrial septal defect in infancy, and bristle paroxysmal atrial fibrillation (AF) was noted to be progressively lethargic and anorexic. She also developed bilateral lower limb oedema and was admitted for further investigation of decompensated congestive heart failure (CHF). Overt thyrotoxicosis was found on investigation. Since the patient had been on Amiodarone for five years, a diagnosis of Amiodarone-induced thyroiditis (AIT) was made and the endocrinology team was involved. At initial assessment, the patient was noted to be anxious, emotionally labile, tremulous and had a resting sinus tachycardia. Thyroid examination also revealed a goitre. The patient’s main concern was the decompensation in heart failure and the possibility of rebound atrial fibrillation off treatment. There was no past history of thyroid disease. Initial treatment included 40 mg of prednisolone (Pred) and 40 mg of carbimazole (CBZ) daily and 10 mg Propranolol three times daily. Cardiologists were also concerned regarding steroid use in view of the risk of further decompensation of CHF. Autoimmune serology and a thyroid ultrasound were done to better elucidate if AIT Type 1 (antithyroid agent responsive) or AIT Type 2 (steroid responsive) was the cause. Results are shown in table 1 below. Whereas immunology was consistent with AIT Type 1, Ultrasoundography favoured AIT Type 2. The patient was therefore kept on both Carbimazole and Prednisolone with clinical response showing a slow course and therefore favouring AIT Type 1. The patient improved clinically and biochemically over a 4 month period with results shown below in table 2.

Investigation Result AIT Type 1 AIT Type 2
Anti-TSH Receptor Antibody 2 (0.1-1IU/l) X
Anti-Tiroid Antibody Intar-Lisum 6 Antibody Negative X
Thyroid Ultrasound Mild goitre Decreased vascularity.

Weeks from diagnosis Treatment regimen TSH level (mIU/l) T4 level (pmol/l) Free T3 (pmol/l)Free T4 (pmol/l)
0 0.009 93.44 27.2 121.41 17.7
1 CBZ 40 mg BD Pred 40 mg Dy 0.008 132.65 20.2
2 CBZ 50 mg Dy Pred 40 mg Dy 0.008 133.89 19.4
3 CBZ 50 mg Dy Pred 30 mg Dy <0.008 62.3 10.8
6 CBZ 40 mg Dy Pred 30 mg Dy <0.008 40.44 8.4
9 CBZ 35 mg Dy Pred 20 mg Dy <0.008 19.3 5.6
12 CBZ 20 mg Dy Pred 5 mg Dy <0.008 13.32 5.6
15 CBZ 15 mg Dy Off Pred

DOI: 10.1530/endoabs.91.WC11

WC12

Thyrotoxicosis, Neutropenia and Appendicitis and emergency thyroideectomy
Aiyappa Buddhanda & Helen Simpson
UCLH, London, United Kingdom

36F from Hungary with a h/o Graves disease in the past which was in remission since 2017 presented to ED at UCLH with a fast heart rate and acute weight loss. Feb 2020 presented with fast heart rate and FT4 8.49, TSH < 0.01. TPO Negative, TRAB raised at 6.5. Patient was commenced on 20 mg carbimazole and 20 mg TDS propranolol, referred to endocrine clinic. Patient missed her appointment in the endocrine clinic as she was in Hungary during the pandemic. June 2020: 15 weeks pregnant and Carbimazole changed by her GP to Propyl thioracil 50 mg BD. Reviewed in the antenatal clinic by Endocrinology who advised for her to continue PTU 50 mg and repeat TSH, TRAB and FU in Aug 2020. Nov 2020: 34 weeks missed ANC endo appointment in August returned to report stopped PTU Sept 2020. Repeat TSH in Nov 2020: TSH 0.71, FT4 7.5 TRAB neg. TPO Negative. Graves’ disease in Biochemical remission repeat TSH’s 6 weeks post-partum. C section 12/1/21. Nov 2021: Contracted COVID and was admitted to hospital with hypoxia. March 2022: Recovering from COVID 19 infection developed tachycardia and weight loss. TSH 0.010, FT4 21.7 FT3 33.8 pmol/l, fT4 20.7 (0.1-1IU/l), TSI should increase levothyroxine dose by 25 mg on diagnosis of hypothyroidism should increase levotiroxine dose by 25 mg on diagnosis of pregnancy with TFTs at least each trimester, aiming TSH <2.0 mIU/L. TSH should be checked at 28 weeks to allow assessment of the risk of neonatal hypothyroidism and antenatal referral to the neonatal team. The baby should have TSI and TPTTs checked on day 3-7, with repeat bloods and anti-thyroid drugs as appropriate. Those caring for women with thyroid disease and their babies should be alert to the increased risks to promote healthy outcomes for both.

DOI: 10.1530/endoabs.91.WC12

A 25 year old lady initially presented with symptoms of palpitation, irregular menses and unintentional weight loss. She was a non-smoker with no current pregnancy plans or family history of thyroid disease. On examination, she was tachycardic and had a moderate diffuse goitre but no signs of thyroid ophthalmopathy. She was biochemically hyperthyroid (TSH <0.01 mIU/L, FT4 30.7 pmol/l, FT3 >30.7 pmol/l). Carbimazole 30 mg daily was started for likely Graves’ disease, after standard advice on auranofinolysis and rash and the need for contraception. Definitive therapy with radioactive iodine and surgery were discussed and patient information leaflets provided. A clinic review was booked for her decision on radioactive therapy and the TSH receptor antibody result. However, she re-presented in ED 4 weeks later with a 5-day history of sore throat, fever and rash. On examination, she was tachycardic and had a widespread erythematous rash. An urgent FBC showed new and profound neutropaenia (0.12x109/l). TETFs showed ongoing hyperthyroidism (TSH <0.01 mIU/L, T4 15.0 pmol/l, T3 6.9 pmol/l). Her TSH receptor antibodies were elevated at 80 IU/l. She was diagnosed with carbimazole-induced auranofinolysis and rash and underlying Graves’ disease. Carbimazole was stopped immediately. Propranolol was increased from 40 to 80 mg twice daily. An urgent clinic review was booked for consideration of definitive treatment. In clinic 1 week later, her pulsations had improved. TETFs however showed worsened hyperthyroidism (TSH <0.01 mIU/L, FT4 33.8 pmol/l, FT3 >30.7 pmol/l). Her neutrophil count had improved (0.58x109/l). She was counselled about urgent definitive therapy with either radioactive iodine or surgery. She opted for radioactive iodine but did not attend the appointment. After repeatedly changing her mind about radioactive iodine, she eventually declined to proceed. When she came to clinic 6 weeks later, her TFTs showed ongoing hyperthyroidism (TSH <0.01 mIU/L, FT4 30.0 pmol/l, FT3 >30.7 pmol/l). A semi-urgent total thyroideectomy was recommended. She received pre-operative preparation with potassium iodate 65 mg twice daily for 2 weeks. She then underwent a total thyroideectomy. There were no intraoperative complications. Post-operatively, her calcium and PTH levels remained within the normal range but she developed voice hoarseness. Fibreoptic nasendoscopy showed no evidence of vocal cord palsy. The voice hoarseness resolved promptly. Histology showed moderate diffuse hyperplasia, consistent with partially-treated Graves’ disease and no evidence of neoplasia. Thyrotoxicosis was restored after starting lifelong levothyroxine replacement post-operatively.

DOI: 10.1530/endoabs.91.WC11

A case of thyrotoxicosis requiring urgent definitive therapy
Kiran Issure & Kristen Boelaert
Queen Elizabeth Hospital, Birmingham, United Kingdom

Endocrine Abstracts (2023) Vol 91
Graves’ disease in pregnancy with neonatal thyrotoxicosis

Rachel Flynn & Ayesha Siddiqi
Barts Health NHS Trust, London, United Kingdom

Case history
A 30-year-old Afrocaribbean lady with a history of Graves’ thyrotoxicosis (2012) and subsequent thyroidectomy (2013) presented to the antenatal clinic in January 2020 at 9 + 6 weeks gestation. Medication included levothyroxine 125 mg daily. She had a history of neonatal thyrotoxicosis in her first pregnancy in 2017 which required carbimazole therapy due to fetal tachycardia.

Investigations
At booking, thyroid function tests (TFTs) showed a TSH 6.48 mIU/l and free T4 12.8 mIU/l. TSH Receptor antibodies were very high at 34.24 IU/l. Her anomaly scan was normal. A CTG (cardiotocography) showed a rising fetal heart rate (FHR 150-170 bpm) at 32 weeks. The fetal US scan showed a normal thyroid gland with no goitre.

Results and treatment
The levothyroxine dose was initially increased from 125 mg OD to 150/175 mg on alternate days in the second trimester which improved her TFTs at 23 weeks (TSH 1.73 mIU/l, Free T4 15.1 mIU/l). Due to fetal tachycardia, carbimazole 5 mg OD was added at 32 + 3 weeks and plans made for twice weekly CTG monitoring. TFTs at 35 weeks showed TSH 0.33 mIU/l and Total T3 15 pmol/l with FHR of 140-150 bpm. The patient went into spontaneous labour at 36 + 3 weeks. Her infant male (2960 g) was delivered by Caesarean section due to fetal tachycardia and carbimazole was commenced postpartum. The infant was weaned over 2 weeks. At 5 weeks, the weight was 4400g and TFTs normalised (TSH 0.01 mIU/l, Free T4 12.7 mIU/l, TSH receptor antibodies 0.57 IU/l). The mother stopped taking carbimazole at the time of delivery and returned to her normal work and social life. TSH was 1.18 mIU/l, Free T4 12.7 pmol/l; TSH receptor antibodies 0.57 IU/l. Her anomaly scan was normal. A CTG (cardiotocography) showed a rising fetal heart rate (FHR 150-170 bpm) at 32 weeks but the fetal US scan showed a normal thyroid gland with no goitre.

Conclusions
Neonatal thyrotoxicosis is rare but more common with a history of maternal Graves’ disease with high antibody titres requiring treatment in pregnancy. TSH receptor antibodies may continue to be produced after thyroidectomy and can cross the placenta and lead to neonatal thyrotoxicosis. This is a transient disorder where patient didn’t respond to first line anti-thyroid medications and required Lithium and Cholestyramine to achieve euthyroid status prior to surgery.

Case
A 29 years old lady was referred with 1 year history of tiredness, on and off loose stools and weight loss of 26 kg. She also reported getting sweaty easily, shakings of hands and palpitations. She had never smoked and was working as a support worker. On examination, she was tachycardic with heart rate of 110, had a fine tremor and a World Health Organization (WHO) grade 2 smooth goiter with an audible bruit. There were no signs of thyroid eye disease and no neck lymphadenopathy. She had significant family history of thyroid disease on her maternal side (Mother, Aunts, Uncle and Grandfather - hypothyroid). Her initial TFTs showed a FT4 34.1 pmol/l, FT3 > 30 pmol/l and TSH < 0.01 mIU/l. TSH Receptor antibodies (TRAb) level > 68 IU/l and anti-thyroid peroxidase (TPO) antibodies level of 1118 IU/ml. Patient was commenced on carbimazole 30 mg and propranolol for symptomatic relief. After 6 months of treatment, despite being on maximum dose of carbimazole (60 mg) and good compliance, she had fully suppressed TSH, elevated FT3 and FT4 and she remained symptomatic. Patient declined radioactive iodine due to work commitments and agreed for surgery as definitive treatment. To prepare her for surgery, she was started on Lithium and Cholestyramine which showed an improvement in her TFTs. She was also planned to receive Lugol’s iodine 2 weeks before surgery.

Conclusion
Thionamide resistant thyrotoxicosis is uncommon but can be life-threatening. Surgery and/or radio-iodine remains the mainstream of treatment. This case highlights the approach and importance of considering second line treatments to achieve euthyroid status before definitive therapy.

DOI: 10.1530/endoabs.91.WC15

Thionamide Resistant Graves: What are 2nd line options
Hafiz Muhammad Zubair Ullah & Prakash Abraham
Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Background
Conventional management for thyrotoxicosis includes anti-thyroid medications, radioactive iodine and/or surgery. However, in some cases patients are resistant to first line drugs and need second line treatment to normalize thyroid function tests (TFTs) before considering definitive therapy. We present a case of Grave’s disease where patient didn’t respond to first line anti-thyroid medications and required Lithium and Cholestyramine to achieve euthyroid status prior to surgery.

Case
A 56 year old man came to the attention of the endocrine service during an admission with COVID 19. Due to persistent tachycardia he had thyroid function tests (TFTs) which showed TSH < 0.01 mIU/l and free T4 58 pmol/l. He had reported weight loss over the past couple of months and occasional palpitations but no other features of thyrotoxicosis. On examination his pulse was 90 beats per minute, had no goitre or thyroid tenderness and no signs of thyroid eye disease. In addition to COVID 19, he also had acute hepatitis and required NG feeding. His past medical history is of Marfan syndrome, aortic valve replacement, aortic repair complicated by aortic segmental spinal stroke, moderate LVSD, and recurrent ventricular tachycardia with an implantable cardioverter-defibrillator. Of note he had been on amiodarone for 18 years. He had undetectable thyroid receptor antibodies. He was commenced on prednisolone 40 mg once daily for presumed type two amiodarone induced thyrotoxicosis (AIT2). He was not initially commenced on carbimazole due to his acute liver dysfunction. A request for a thyroid uptake scan was rejected by radiology as he was COVID 19 positive. Amiodarone was stopped on discussion with cardiology and dromedarone was commenced. He received alendronic acid for bone protection and required three weeks of gliclazide for steroid induced hyperglycaemia. TFTs improved as below and prednisolone was gradually weaned. Amiodarone has large proportion of iodine and a long half life. It can cause both hypothyroidism and thyrotoxicosis. Amiodarone induced thyrotoxicosis (AIT) can be split into type 1 AIT and type 2 AIT. Type 1 AIT is more common in those with underlying thyroid disease, is due to increased synthesis of thyroid hormones and is usually treated with anti-thyroid drugs. Type 2 AIT is caused by a direct toxic effect of amiodarone on the thyroid cells leading to thyrotoxicosis and release of preformed thyroid hormones. It can be treated with steroids. In practice it can be difficult to distinguish between the type of AIT and some patients have a mixed type.

DOI: 10.1530/endoabs.91.WC16

A case of thyrotoxic hypokalaemic periodic paralysis presenting to the emergency department
Andrew Down & Laura Rich
Royal United Hospitals, Bath, United Kingdom

A 35 year old Asian man presented to the emergency department on several occasions with episodes of severe muscle weakness, affecting his arms and legs, to the point he was unable to walk or stand. He was found to be hypokalaemic on both occasions, at 2.3mmol/l and 3.0mmol/l respectively, and his weakness gradually improved with potassium replacement. He gave a history of two years of intermittent weakness and stiffness of the limbs which typically occurred at night or after long periods of rest. Initially they resolved spontaneously within minutes but the attacks became increasingly severe, lasting hours, to the point he was unable to mobilise. He reported a recent history of weight loss, tremor,
palpitations and significant heat intolerance. He was found to be thyrotoxic with a suppressed TSH, free T4 39.4 pmol/l and free T3 14.4 pmol/l. His TSH receptor antibodies were positive at 4.0 IU/l and the diagnosis of Grave’s disease was made. He was commenced on Carbimazole 40 mg and Propanolol. Looking back at his previous results he had subclinical hyperthyroidism at the time when his symptoms of weakness first presented, but no treatment was given at that stage. Given the presentation of acute painless muscle weakness, in the presence of hypokalaemia and thyroxicosis, a diagnosis of thyrotoxic periodic paralysis was made. This is an extremely rare condition which is most commonly caused by Grave’s disease and occurs more frequently in Asian men between the ages of 20 and 40. It is potentially life-threatening and prompt correction of hypokalaemia is essential in the acute phase. Resolution of the attacks occurs with curative treatment of the thyroxicosis, either with surgery or radioiodine ablation. Our patient’s thyroid function rapidly normalised and his episodes of weakness completely resolved. The Carbimazole was titrated down and his TSH fell below the normal range. This caused his symptoms of weakness to transiently return. Due to his young age and the severity of his weakness in the context of thyrotoxicosis we recommended proceeding to curative thyroidectomy. The risk of radiation induced thyroiditis causing severe paralysis was deemed to be unacceptable.

DOI: 10.1530/endoabs.91.WC16
Workshop D: Disorders of the adrenal gland
**WD1**

Adrenal mass and Cushings’s – lessons to be learned?

Amy Morrison

University Hospitals of Leicester, Leicester, United Kingdom

Case: A 74-year-old female presenting with central weight gain, proximal myopathy, thin skin and bruising. Clinical examination identified central obesity, round facies, dorso-cervical and supra-clavicular fat pads.

Investigations:

Bloods revealed hypokalaemia (3.2mmol/l), elevated cortisol levels (>1000nmol/l) persisted post low dose Dexamethasone suppression test, with a suppressed ACTH (< 5). Urine free cortisol 1842nmol/24hrs (0.165). CT Chest-Abdomen-Pelvis revealed a large heterogeneous left adrenal mass (5.7x3.7 cm) with no disseminated malignancy. She commenced Metyrapone whilst awaiting surgery.

Management:

In July 2021 Laparoscopic left Adrenalectomy was performed. The adrenal was noted to be ragged and distorted, 70x40x38mm weighing 51g. Histology was consistent with an adrenal cortical adenoma, Weiss score 2 (confuent necrosis and capsule invasion). Hydrocortisone replacement was commenced post-operatively. Short Synacthen Test two months later revealed a flat response (Cortisol 90 to 165nmol/l), hydrocortisone was continued. Ten months post-operatively Cushingoid features recurred; bruising, facial and abdominal weight gain, with elevated cortisol (927nmol/l) after 48hrs without Prednisolone. CTCAP revealed disseminated metastatic disease; multiple nodules in the left upper quadrant at the adrenalectomy bed, adjacent to the pancreas and splenic flexure, lung (2.2 cm right lower lobe) and liver metastases. No resectable targets were identified. Metyrapone was re-commenced, she was referred to Cambridge to start Mitotane and EDP Chemotherapy (Etoposide, Doxorubicin, Cisplatin). Urine steroid profile revealed high cortisol metabolites suggestive of Cushing’s recurrence. Repeat urine steroid profile in June 2022 indicated treatment with Metyrapone had improved to cortisol metabolites with a corresponding increase in androgend metabolite levels. The initial histology of the adrenalectomy was re-reviewed in light of the aggressive behaviour clinically. It was found to contain an oncocytic component (dominant) of a higher nuclear grade and more mitotically active than the clear cell component, with resulting challenging assessment of malignant potential. Worrisome features were present; fibrous bands, disruption of reticulin architecture and prominent capsular invasion. Re-review of the initial CT, highlighted a possible tiny lung deposit, suggesting potential metastatic disease prior to the initial operation. Her most recent EDP chemotherapy occurred in October and there has been a partial response. The latest round has been delayed, as she recently presented with expressive dysphasia, an acute right pontine infarct was evident on MRI. Significant hypercholesterolemia (Total Cholesterol 19, LDL 15.5mmol/l) was apparent, likely due to persistent effects of Mitotane on free fatty acid release already stopped for a few months, and Pravastatin was commenced. She is ongoing review to assess regarding the role of further Chemotherapy. DOI: 10.1530/endoabs.91.WD1

**WD2**

Composite Pheochromocytoma with Adrenocortical Carcinoma - a rare coexistence

Ashutosh Kapoor, Ainesh Singh, Erika Vaineri, Rochan Agha-Jaffar

Imperial College Healthcare NHS Trust, London, United Kingdom

A 65-year-old man presenting with urinary symptoms was incidentally discovered to have an adrenal mass on imaging. Abdominal computed tomography (CT) revealed a 9.5 x 8 cm heterogeneous solid right adrenal tumour with no evidence of metastatic disease. Family history included a brother who died from metastatic carcinoid and another brother who died from metastatic neuroendocrine tumour. The initial differential lay between adrenocortical carcinoma (ACC) or a pheochromocytoma. The plasma fractionated normetanephrine was elevated at 14439 pmol/l (0-1180), metanephrine 15202 pmol/l (0-510), 3-MT 415 pmol/l (0-180) led to a presumed preoperative diagnosis of pheochromocytoma. However, there was also evidence of autonomous cortisol secretion with a positive overnight dexamethasone suppression test of 209 nmol/l (suppresses ACTH and an elevated DHEAS of 14.9 umol/l. An I-123 metaiodobenzylguanidine (MIBG) scan demonstrated heterogeneous avidity in the adrenal lesion. Due to his previous surgeries, right adrenalectomy via an open right subcostal approach was opted with a possible capsule breach. Histology of the resected tumour was consistent with an 8 cm, 22g pheochromocytoma with a PASS of 11/20 with areas of atypical mitoses, tumour stain positive for synaptophysin and chromogranin-A, S100, melan-A and inhibin, however calretinin was negative. Ten weeks postoperatively CT scan demonstrated significant disease recurrence in the tumour bed with a 9.4 x 5.2 cm in size mass with encasement of the IVC and other vessels and perinephric tumour deposits and a mass invading a segment of the liver. Plasma metanephrines were normal and the lesions were not MIBG-avid. A significant elevation in DHEAS to >27umol/l with normal plasma metanephrine was highly suggestive of adrenocortical carcinoma. A CT guided biopsy was consistent with adrenocortical carcinoma. Histology demonstrated pleomorphic cells with mitotic rate 12/10 bpf. Immunohistochemistry was positive for adrenocortical markers for Melan A, inhibin and synaptophysin with a Ki67 proliferation 80-90%. On comparison with the previous resected specimen, the appearance was morphologically similar, although elements of medullary neoplasia were also present making this an extremely challenging histological diagnosis. He had negative genetic testing for the MEN1 gene, including DP53, AIP, MEN1, CDKN1B, RET and CDC73. He was diagnosed as metastatic adrenocortical carcinoma with malignant Cushing’s syndrome and commenced on mitostone and received six cycles of Cisplatin/Etoposide/Doxorubicin. His symptoms of Cushing’s improved and serial imaging following the completion of chemotherapy shows an excellent response to treatment, with reduction of the tumour burden in the liver and adrenal bed.

**WD3**

Uncovering the Hidden Link - A Case Report of Cushing’s Syndrome Masquerading as Type 2 Diabetes

Beaumont Hospital, Dublin, Ireland

Mater Dei Hospital, Msida, Malta

A 52-year-old female, newly diagnosed with Type 2 Diabetes during pre-operative assessment for cholecystectomy, was referred to Diabetes clinic. An initial trial of metformin was discontinued in view of intolerable gastrointestinal side effects and the patient was started on low dose glitazide. The patient’s main concern was her struggle to lose weight despite lifestyle measures, a seemingly common issue faced by patients with diabetes on sulphonylurea.

On further examination the patient was noted to be pheotheric, with a centripetal fat distribution and interscapular fat accumulation. Proximal myopathy was also noted. Hypertension was confirmed with a blood pressure of 180/90mmHg at clinic. Given the above investigations were consistent with Cushing’s syndrome, a non-contrast Computed Tomography (CT) Scan of the adrenal glands was done. This showed a 2.7 cm right adrenal nodule with an attenuation of 9 HU, compatible with an adenoma whereas the left adrenal gland was normal in size. The endocrine surgeons were subsequently involved and the patient underwent a laparoscopic right adrenalectomy three months later. In the interim she was optimised with adequate glycaemic and blood pressure control. Throughout this period the patient complained of worsening proximal myopathy, and was thus given a trial of metyrapone. At induction of surgery the patient was given 100 mg of Hydrocortisone and subsequently kept on 50 mg Hydrocortisone 6 hourly while nil by mouth. At day 2 after surgery, 9am cortisol was repeated (having omitted last evening and first morning hydrocortisone doses) in order to ensure the adenoma had been excised. A cortisol level of 62 nmol/l meant that although an appreciable difference was notable the patient will need to be surveilled closely for recurrence. Histology later confirmed an adenoma with no suspicious features. Oral hydrocortisone at a dose of 20 mg-10 mg-10 mg was started once the patient was tolerating oral intake. This was tailed down gradually with decrements of 5 mg of hydrocortisone per month. The patient is currently on antihypertensive therapy and demonstrates improved glycaemic control with a single daily dose of glitazide.

**WD4**

Cushing’s syndrome: keep searching, and then search for more!

Ashutosh Kapoor, Ainesh Singh, Erika Vaineri, Rochan Agha-Jaffar, Ben Jones, Jeremy Cox, Florian Wernig, Stephen Robinson & May Al-Sahaf

Imperial College Healthcare NHS Trust, London, United Kingdom

The patient was investigated as follows:

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Result</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 hour urinary Cortisol</td>
<td>938</td>
<td>57.4-806.8 nmol/24hrs</td>
</tr>
<tr>
<td>9am Cortisol</td>
<td>462 nmol/l</td>
<td>145.4-619.4 nmol/l</td>
</tr>
<tr>
<td>9am Cortisol post Overnight Dexamethasone Suppression Test (ODST)</td>
<td>418 nmol/l</td>
<td>&lt; 50 nmol/l</td>
</tr>
<tr>
<td>Adrenocorticotropic Hormone (ACTH)</td>
<td>&lt; 5 pg/ml</td>
<td>10-48 pg/ml</td>
</tr>
</tbody>
</table>

DOI: 10.1530/endoabs.91.WD3

The patient was investigated as follows:
We present the case of a 53-year-old lady who was recently diagnosed with Type 2 Diabetes, Hypertension and Dyslipidaemia. She was referred by the lipid clinic with a 3-month history of progressive facial swelling, hyperpigmentation and proximal myopathy. Clinical history and examination were highly suspicious of endogenous hypercortisolism. An initial overnight dexamethasone suppression test yielded an elevated morning cortisol (752 nmol/l, normal < 500 nmol/l). Two 24-hour urine collections revealed markedly elevated urinary free cortisol values (1917nmol/day, 1511 nmol/day). The low-dose dexamethasone suppression test demonstrated an incomplete suppression of cortisol (basal 606 nmol/l, Time = 48 hours 642 nmol/l), accompanied by a high ACTH (basal 48.5 ng/l, Time = 48 hours 49.5 ng/l) indicating ACTH-dependent Cushing’s disease. Ketoconazole therapy was commenced to alleviate hypercortisolism, alongside anti-hypertensive and glycaemic agents. This was beneficial for blood pressure and glycaemic management.

An MRI adrenal scan revealed bulky adrenal glands with no discrete lesion. An MRI pituitary showed increased size and heterogeneity of the signal at the left lateral aspect, with infundibulum deviation to the left; however, no discrete lesion or contrast-enhancing characteristics were identified. The patient underwent inferior petrosus sinus sampling which did not show a central-to-peripheral ACTH gradient, in keeping with an ectopic source of ACTH. Upon review of previous imaging performed to look for unrelated coronary artery calcification, the presence of a small 6mm lesion was noted in the Lingula of the lung. In light of the clinical, radiological, and IPSS findings, a Gallium-68 DOTATATE PET scan was performed, confirming the presence of an 8mm tracer-avid carcinoid nodule in the lingula believed to be the source of the ectopic ACTH production (not amenable to biopsy but resectable). Ketoconazole was stopped prior to surgery and the patient underwent a left VATS lingulectomy and lymphadenectomy for resection of the nodule, staged as T1a N0 P1.0 R0, with histology findings consistent with Carcinoid. Postoperatively, the hypercortisolism improved (morning cortisol of 45 nmol/l). She was provided with steroid cover and the prednisolone was weaned following surgery. She has remained stable with satisfactory blood pressure and glycaemic control; her symptomatology has additionally improved. Ectopic ACTH secretion is a rare condition which accounts for approximately 10% of ACTH-dependent Cushing cases. This case illustrates the importance of a methodical diagnostic approach in an individual with overt clinical and biochemical hypercortisolism and highlights the need of an MDT approach for prompt intervention.

References


4. DOI: 10.1530/endoabs.91.WD6

WD7

Hang in there; be patient!

Hema Patel, Nadia Osman & William Drake

The University of Manchester, United Kingdom

In 2009 a 39 year old gentleman presented to the Endocrine clinic with symptoms, signs and biochemistry consistent with severe glucocorticoid excess (urinary free cortisol level was significantly raised at >1380mol/24 hours, normal up to 124;
early morning cortisol levels varying between 760nmol/l and 1225nmol/l (with failure of suppression on a low dose dexamethasone suppression test). An ACTH level taken at this time was 43ng/l. He underwent an MRI pituitary gland which showed a normal gland with no evidence of an adenoma. He also underwent inferior petrosal sinus sampling; this showed consistent ACTH level several minutes following CRH stimulation; confirming ectopic ACTH secretion. Cross-sectional and nuclear medicine imaging showed no evidence of an ectopic source of ACTH. He was started on a combination of metyrapone, ketoconazole and hydrocortisone, via a block and replace regimen, to manage his hypercortisolaemia symptoms as discussions and decisions were made about definitive intervention. Although initially hesitant, hypercortisolaemic complications (including vertebral crush fractures, reduced mobility and difficult glycaemic control) were important in the patient agreeing to a bilateral adrenalectomy. This was performed with good outcome at the end of 2009. He was started on hydrocortisone and fludrocortisone replacement and made significant improvement in his physical symptoms. He returned to work and remains well, active on maintenance SSRI therapy for mood.

Between 2010 and 2022 he had intermittent imaging, recognising the issue of radiation exposure, but no source of ACTH production was identified. In December 2022, 13 years after the original diagnosis, a Dotate scan identified a 9mm left lower lobe lung nodule demonstrating somatostatin receptor activity. He has subsequently been referred to the thoracic surgeons for removal. Ectopic ACTH secretion accounts for around 10% of cases of ACTH-dependent Cushing’s disease. The clinical features are similar to that of a pituitary source of Cushing’s, but frequently more severe. Having confirmed ACTH-mediated cortisol excess, the gold standard investigation to differentiate a pituitary from an ectopic source is inferior petrosal sinus sampling before and after injection of CRH. Ideally the definitive management plan would be to remove the source of ectopic ACTH however as seen in this case the identification of this ectopic source can be difficult and given debilitating symptoms of Cushing’s this may be time sensitive. Bilateral adrenalectomy is an excellent treatment in this situation but efforts should continue to locate the primary source of ACTH excess.

DOI: 10.1530/endoabs.91.WD7

WD8
Can serum ACTH level be reliably interpreted in the diagnostic work-up for Cushing in adrenal incidentaloma?

Irfan Iqbal Khan1, Abuzar Awadelkareem2, Catherine Napier1 & Yasir Mamoojee1
1Royal Victoria Infirmary Hospital, Newcastle, United Kingdom; 2Darlington Memorial Hospital, Darlington, United Kingdom

Diagnostic work-up for Cushing Syndrome (CS) can be challenging and is based on clinical and biochemical assessment. Biochemical evidence of endogenous steroid excess is demonstrated through overnight dexamethasone suppression test (ODST), low dose dexamethasone suppression test and/or 24-hour urinary free cortisol estimation (UFC). Once endogenous steroid excess is confirmed, random serum ACTH measurement is in determining the suspected source of steroid excess: ACTH-independent (adrenal cause) or ACTH-dependent Cushing (pituitary or ectopic ACTH secretion). We report a case of CS where the serum ACTH caused diagnostic confusion during work-up for adrenal incidentalomas. 55-year-old female with history of Type II diabetes mellitus, Hypertension, psychosis and Iliac bone lesion was seen for an incidental finding of Left adrenal mass. She was on medication for ischemic heart disease, diabetes, and centrally acting drugs in the form of Quetiapine, gabapentin, Duloxetine. She was seen 5 years back at another hospital for same and discharged labelled as normal hormonal work up. She reported Ongoing weight gain, Excessive hair growth and she had Cushingoid features Flushed face, thinning of skin, abdominal striae, Central adiposity, Proximal myopathy and diabetes was poorly controlled despite been on insulin. Her Random ACTH were 13 and 17. Her cortisol didn’t suppress on Low dose and high dose dexamethasone suppression test. Her urinary steroid profile was supportive of Cushing’s. The reason for ACTH not being fully suppressed was unclear. We reviewed imaging in MDT and it was found that there was Left adrenal adenoma which was static in size but there was hyperplasia of right adrenal on retrospective review. DDAVP was positive with Increase in ACTH and cortisol. MRI pituitary was discussed in MDT and there was debate whether it is normal or there is small adenoma. IPSS was positive with lateralization to one side confirming pituitary Cushing. ACTH was low despite being pituitary Cushing likely due to centrally acting drugs. This leads to discussion around the Cushing’s work-up in patients presenting through the adrenal incidentaloma pathway:

- Clinical assessment of pretest probability is very important
- ACTH levels and Dex suppression testing should be interpreted carefully
- We should take into consideration centrally-acting drugs
- Review CT adrenals in MDT – is it the ‘normal’ adrenal normal looking?

DOI: 10.1530/endoabs.91.WD8

WD9
White hair and loss of eyebrows: An unusual presentation of ACC

Layla Thurston, Aimee Di Marco, Michael Seckl & Florian Wernig
Imperial College Healthcare NHS Trust, London, United Kingdom

A 57-year-old gentleman presented with a very sudden change in hair colour to bright white and eyebrow loss. On further questioning, he had been shaving much less and had not had any getting erections. On examination he had gynaecomastia. Initial blood tests showed hypogonadotropic hypogonadism (LH 0.6 IU/l, FSH 0.1 IU/l, testosterone 1.6 nmol/l) with an otherwise normal anterior pituitary hormonal profile. Oestradiol was found to be significantly elevated at 582 pmol/l. He was investigated for a possible testicular tumour which proved negative. He went on to have MRI of his adrenal glands which elucidated a large and suspicious mass in the right retroperitoneum. CT scanning confirmed this mass, of approximately 11 cm, was most likely to be adrenal in nature with concerns of invasion of the liver, right kidney, renal vein and inferior vena cava. FDG-PET showed that the adrenal lesion was FDG avid with no evidence of other sites of disease. A provisional diagnosis of adrenocortical carcinoma (ACC) ENSAT stage II was made. The adrenal MDT reviewed a scan from three years previously which showed a 10 mm right adrenal indeterminate lesion at that time. He underwent a right open adrenalectomy for removal of the adrenal lesion. The tumour was carefully dissected out without any spillage or capsular breach. Histology showed the tumour had a high Weiss score of 8 with a mitotic count of 10/50 HPF and Ki67 proliferation index was 20–25%. The lesion showed extra adrenal extension with vascular and perineural invasion. Post-operative oestriol levels normalised to 182 pmol/l, and testosterone recovered to 21 nmol/l. As the risk of recurrence was high, he completed six cycles of adjuvant EDP chemotherapy (etoposide, doxorubicin and cisplatin). He was also started on mitotane post-operatively which was uptitrated to 1.5 g twice daily plus prednisolone 4 mg daily. Nine months after surgery, his oestradiol began to increase again. On a CT thorax he was found to have pulmonary nodules and underwent VATS wedge resections. Histopathology confirmed metastatic ACC and genomic testing did not identify actionable mutations. Following MDT discussion, he was commenced on sunibinti and after three months of treatment, oestradiol remained elevated and a trial of letrozole was added. He went on to have radiofrequency ablation for liver metastases with subsequent gemcitabine and cepecabatine chemotherapy for further disease progression. This case illustrates the challenges of managing a case of an aggressive oestrogen-secreting metastatic ACC.

DOI: 10.1530/endoabs.91.WD9

WD10
Adrenocortical carcinoma, a rare but aggressive tumour

Maria Omer & Pallavi Hegde
Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom

Case summary
A 40-year-old lady, who has a background of asthma, presented to emergency department with back pain radiated down to her left leg with associated foot drop. She also complained of 2 months history of weight gain, hirsutism, and menstrual disturbance. Clinical examination confirmed that she had some cushingoid features. Further assessment and investigations revealed that her acute disc prolapse on MRI as well as an incidental finding of right adrenal gland and some indeterminate lesions in the iliac bones. Further CT-TAP confirmed that she had a large tumour in the right adrenal gland, 7.4 x 12.2 cm, highly suspicious of malignancy with multiple pleural-based intrathoracic nodules suggesting metastases. Following discussion at the adrenal MDT, further investigations such as PET CT, adrenal biopsy and secretion studies which were arranged on the back of high suspicion for adrenal cortical carcinoma (ACC). Secretion studies confirmed hyperandrogenism with high androstenedione at 27 (0.3-12.0 umol/l). Cortisol was 728nmol/l with ACTH of 0.7 1.9 ng/ml. Rest of the biochemistry, renin and aldosterone ratio and plasma metadrenalines were unremarkable. PET scan showed high uptake in the right adrenal mass with some areas of calcification in keeping with malignancy, multiple pleural nodules bilaterally consistent with metastatic lesions and no evidence of definite FDG avid destructive bone lesion. US guided biopsy confirmed an adrenal cortical origin Systemic chemotherapy was started for ACC under Oncology service and genetic screening was organised.

Conclusion
ACC tumours are rare, but often aggressive in nature. It is important to have high index of suspicion for these lesions whenever it is relevant like in this case. ACC could be functional and cause Cushing’s syndrome and/or virilization, or non-functional and could present with manifestations related to tumour growth (e.g. abdominal or flank pain). It is not uncommon for these lesions to present as
incidentaloma especially if the subtle clinical signs are overlooked in an otherwise fit and young patient like ours. This also highlights the importance of having a dedicated adrenal MDT service for these patients through which investigations and referrals to appropriate specialties could be arranged without any undue delay and timely treatment could be initiated.

DOI: 10.1530/endoabs.91.WD10

WD11
Desmopressin Test – any use in Cushing’s?
Kirsty Wood & Prakash Abraham
Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Identifying the cause of hypercortisolism is vital in ensuring the correct treatment plan for a patient. I present the case of a patient in whom the desmopressin test, an adjunct to the CRH test, proved helpful in determining the cause. A 27 year old man who initially presented with weight gain, abdominal striae and sweating was admitted with low mood, anxiety and suicidal ideation. Tests showed elevated 24 hour urinary cortisol (highest 1446 nmol/24 hours), random cortisol (624 nmol/l) and ACTH (98 ng/l). Cortisol did not suppress after low dose dexamethasone suppression test (DST:625 nmol/l). Cortisol suppressed by 60% to 259 nmol/l in high dose DST. MRI pituitary showed a 5mm adenoma and CT thorax, abdomen and pelvis was normal. He commenced on Metyrapone. There was a rise in cortisol and ACTH during CRH and desmopresin tests consistent with pituitary Cushing’s disease and he proceeded to transphenoidal surgery (TSS), achieving biochemical cure with day 2 morning cortisol of 46 nmol/l.

Discussion
It is imperative to identify the cause of ACTH dependent hypercortisolism before proceeding to TSS but this can be challenging as biochemical and imaging tests have limitations. MRI fails to identify a surgical target in up to 40% of patients with Cushing’s disease and may incorrectly implicate an incidentaloma. Bilateral inferior petrosal sinus sampling is more invasive, availability can be limited and success depends on surgical expertise. Methionine PET can effectively locate a corticotroph adenoma but is not yet widely available. The 2008 Endocrine Society Guideline advises confirming endogenous hypercortisolism with screening tests and then proceeding to CRH test but advised against using the desmopressin test until additional data validates it. Since then, research has established an adjunctive role of desmopressin testing in the diagnostic workup of ACTH dependent hypercortisolism. In the presented case, the combination of CRH and desmopresin tests, both consistent with pituitary Cushing’s disease provided the confidence with proceeding to TSS, resulting in cure. Given the recent announcement of a shortage of ICRH in the UK, the guidance around investigating hypercortisolism will be reviewed and more data on the desmopressin test could clarify its role.

Table: Desmopressin test results

<table>
<thead>
<tr>
<th>Time (mins)</th>
<th>Cortisol (pmol/l)</th>
<th>ACTH (ng/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>584</td>
<td>88</td>
</tr>
<tr>
<td>15</td>
<td>601</td>
<td>96</td>
</tr>
<tr>
<td>30</td>
<td>706</td>
<td>158</td>
</tr>
<tr>
<td>45</td>
<td>717</td>
<td>133</td>
</tr>
<tr>
<td>60</td>
<td>639</td>
<td>113</td>
</tr>
<tr>
<td>90</td>
<td>644</td>
<td>104</td>
</tr>
<tr>
<td>120</td>
<td>597</td>
<td>93</td>
</tr>
</tbody>
</table>

DOI: 10.1530/endoabs.91.WD11

WD12
Primary bilateral macronodular adrenal adenocarcinoma as a cause for Cushing syndrome
Mohammed Shamaldeen & Junki Panicker
Royal Liverpool Hospital, Liverpool, United Kingdom

Introduction
Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of Cushing’s syndrome and is more often diagnosed as bilateral adrenal incidentalomas with subclinical cortisol production. It is mainly a heterogeneous disease, but familial cases have been reported. Treatment of PBMAH with overt Cushing’s syndrome is usually bilateral adrenalectomy with unilateral adrenalectomy occasionally used to normalize urinary free cortisol (UFC) in patients with less severe Cushing’s syndrome. Case summary

51-year-old male, known to have migraine, hypertension, dyslipidaemia and generalized anxiety disorder for which he takes topiramate 100 mg bd, Lisinopril 20 mg od, Lipitamide 2.5 mg od, and Atorvastatin 20 mgs od. He was investigated for chest pain with CT scan which showed incidentally multiple bilateral intermediate adrenal lesions (Bilateral nodular adrenal hyperplasia, right > left). Further assessment in Endocrine clinic revealed central obesity, plethoric face and emotional liability, otherwise unremarkable history and examination. Investigations showed 24-hour urinary cortisol was 117 nmol (Normal value <165nmol/24hours) and his urine was negative for catecholamines. Overnight Dexamethasone suppression test was unsuppressed at 370 nmol/l starting at 570 nmol/l and his ACTH was suppressed at 0.4 pmol/l(2.0 – 11.0 pmol/l). His cortisol failed to suppress with high dose Dexamethasone suppression test (day 1 cortisol 500 nmol/l, day 3 cortisol 561 nmol/l, day 5 cortisol 508 nmol/l). MRI scan of his pituitary showed a normal enhancing pituitary with no evidence of any pituitary tumour. Adrenal Venous sampling did not reveal any lateralization. Bilateral laparoscopic adrenalectomy was performed, and post-operative Hydrocortisone and fludrocortisone were started. Histology has shown Primary Bilateral Macronodular Adrenal hyperplasia (PBMAH). Furthermore, Genetic testing consists with a ‘genetic diagnosis of ARMC5-related ACTH-independent macronodular adrenal hyperplasia type2’ with recommendation to refer the offspring to clinical genetics as would be 50% change of inheritance.

Conclusion
A significant proportion of what is thought to be sporadic cases of bilateral macronodular adrenal hyperplasia are due to ARMC5 genetic mutations and family history is not a reliable indicator. Patients with large multinodular adrenal gland and cortisol excess may be more likely to harbour ARMC5 germline mutation and there may be a low threshold for genetic testing.

DOI: 10.1530/endoabs.91.WD12

WD13
Adrenal Cortical Carcinoma
Isuri Kurera & Sabysachi Roy
Frimley Park Hospital, Frimley, United Kingdom

Adrenal cortical carcinoma (ACC) is extremely rare, the incidence is 0.5 - 2 cases per million populations per year. Most ACCs occur as sporadic tumours. It is more common in females and can occur at any age with a peak in fifth and sixth decades of life. We present a 45-year-old otherwise well and fit lady presented with headache, lethargy, and two stone rapid weight gain over a period of 6 months. She also had associated nocturia, insomnia, night sweats, hirsutism, and acne. Her initial clinical examination revealed new onset of hypertension 190/120 mmHg and spontaneous hypokalaemia required attendance to ambulatory care unit for intravenous potassium replacement. She had raised aldosterone at 1600, suppressed renin with low potassium of 2.5. Her overnight dexamethasone suppression test failed to suppress cortisol this was 730. Her ACTH was suppressed < 3 and a 24-hour urine cortisol was high at 729 (150-350). Her testosterone was raised at 4.5 pmol and adrenal androgens were also raised. She did not have diabetes or osteoporosis. Hba1c was 41mmol/mol. Urgent adrenal imaging revealed a 15 cm large heterogeneous left adrenal mass radiologically keeping in with likely ACC. Her urine steroid profile revealed the metabolites confirming the diagnosis of ACC. Overall biochemical findings were keeping in with multiple hormones producing ACC (producing glucocorticoids, mineralocorticoids and androgens). Her completion staging CT has not confirmed any distant metastasis. She was commenced on Amlodipine, Spironolactone and Ketoconazole for preoperative optimisation. Then she underwent radical left adrenalectomy, left nephrectomy, distal pancreatectomy, and splenectomy. She had an uneventful recovery and remained on hydrocortisone replacement and was commenced on Mitotane for a planned two year course. Her initial imaging 3 months after surgery was satisfactory, however her repeat PET scan in 6 months revealed PET avid lesion in adrenal bed this was thought to be incomplete clearance rather than recurrence. MDT decision was to commence on systemic EDP chemotherapy for 6 months and repeat PET to consider redo surgery. Her latest imaging following completion EDP chemotherapy revealed complete metabolic remission. She is to continue mitotane for 2 years and to continue monthly imaging. She has developed a left ovarian cyst now under surveillance and primary hypothyroidism requiring Levothyroxine replacement thought to be secondary to effects of chemotherapy. She currently also remains on Hydrocortisone replacement until she completes Mitotane thereafter short synacthen test to review her adrenal reserves.

DOI: 10.1530/endoabs.91.WD13

WD14
Life-threatening hypokalaemia heralding the diagnosis of metastatic Adrenocortical Cancer (ACC) with 11-deoxycorticisol hypersecretion
Tara McDonnell1, Cussen Leanne1, Clare Miller1, Carla Moran2, Neil Dugai1, Mark Sherlock1 & Michael O’Reilly1

Endocrine Abstracts (2023) Vol 91
A 51 year old presented with headaches, fatigue and generalised weakness. She had a background history of hypertension diagnosed one year prior to presentation. Initial laboratory evaluation demonstrated life-threatening hypokalaemia, potassium 0.9mmol/l (R.1.35-5.3). This profound hypokalaemia required ICU admission for replacement of potassium and monitoring. Management of subsequent fluid overload necessitated a brief period of hemofiltration. During the course of evaluation a 20 cm adrenal mass was discovered with nodal, hepatic and pulmonary lesions, which were FDG avid on PET imaging. Radiology was concerning for metastatic ACC and hormonal evaluation reported elevated 11-deoxycortisol (DOC) levels, 100 times higher than the upper limit of the reference. Overnight dexamethasone suppression test cortisol was 127nmol/l (with low adrenal androgens DHEAS 0.4umol/l (1.0-7.0), DHEA 2.1nmol/l (3.1-53)), Androstenedione 1.05 nmol/l (0.39-7.77) and low testosterone <0.4nmol/l. Aldosterone was 825 pmol/l (0-1179) with renin 8.5 mIU/l. Following multidisciplinary input, open cytoreductive & bilateral nephrectomy was planned. Pre-operatively hypokalaemia and hypertension were managed with oral potassium replacement, spironolactone, ramipril, amiodipine and doxazosin. Subsequent histology confirmed metastatic ACC with hepatic and nodal involvement. Weiss score 5/9, K67 score 20%. Her post-operative course has been complicated by decompensated heart failure aggravated by tumour related mineralocorticoid and glucocorticoid excess. Mitotane and replacement hydrocortisone have been initiated post-operatively with systemic chemotherapy planned in light of disease progression. First post-operative 11-DOC levels are suppressed. Persistent PTH-dependent hypercalcemia has prompted genetic evaluation for MEN-1, results are awaited. This complex case highlights the complications of hormonal hyperscretion associated with ACC and the profound hypokalaemia that can result from 11-DOC hypersecretion.

**Conclusion**

The patient was pre-treated with Metyrapone followed by trans-sphenoidal resection of pituitary microadenoma. Histology revealed densely granulated corticotroph adenoma with Ki-67 of <4% . Her 6-week postoperative morning ACTH was 9 ng/l and cortisol 43 nmol/l, consistent with biochemical cure. A 3-month postoperative MRI of the pituitary showed no tumour remnant. She remains on hydrocortisone replacement but is otherwise eupituitary.

The presence of an adrenal adenoma in a patient with biochemically confirmed hypercortisolism suggests adrenal Cushing’s syndrome. However, the non-suppressed ACTH and non-atrophied contralateral adrenal gland were clues to the diagnosis of pituitary Cushing’s disease.

**Table 1 PPIS**

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Peripheral ACTH</th>
<th>Right-sided ACTH</th>
<th>Left-sided ACTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>-10</td>
<td>28</td>
<td>377</td>
<td>30</td>
</tr>
<tr>
<td>-5</td>
<td>30</td>
<td>400</td>
<td>33</td>
</tr>
<tr>
<td>0</td>
<td>363</td>
<td>&gt;1250</td>
<td>&gt;1250</td>
</tr>
<tr>
<td>administered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>&gt;1250</td>
<td>&gt;1250</td>
</tr>
<tr>
<td>5</td>
<td>49</td>
<td>&gt;1250</td>
<td>77</td>
</tr>
<tr>
<td>10</td>
<td>88</td>
<td>&gt;1250</td>
<td>121</td>
</tr>
<tr>
<td>20</td>
<td>144</td>
<td>&gt;1250</td>
<td>&gt;1250</td>
</tr>
</tbody>
</table>

*ACTH, adrenocorticotropic hormone (ng/l)*

**DOE:** 10.1530/endoabs.91.WD15

**WD15**

**Uncovering the Rare: Managing a case of ‘Cushing’s Crisis’**


Royal Free Hospital, London, United Kingdom

**Introduction**

Cushing’s syndrome is a rare endocrine disorder characterized by excess cortisol secretion. It can be caused by various etiologies, including ACTH-dependent and ACTH-independent forms. We report a case of a 78-year-old male who presented with severe hypertension, refractory hypokalemia, and severe hypercortisolism, diagnosed with ACTH-dependent Cushing’s syndrome with bilateral adrenal hyperplasia.

**Case Presentation**

A 78-year-old male presented to emergency department with severe hypertension of 215/125 mmHg and refractory hypokalemia of 2.4 mmol/l (Normal: 3.5 - 5.1) not normalizing after 120 mmol of IV potassium chloride replacement. Serum cortisol level was significantly elevated at 2394 nmol/l (Normal: 172 - 497), with a paired ACTH level of 250 ng/l (Normal: 7.2 - 63.3) confirming ACTH-dependent Cushing’s disease.

Imaging studies, including CT adrenals, MRI pituitary, CT Chest abdomen and pelvis, Ga68 Dotatate and FDG PET scan, failed to demonstrate an ectopic source of ACTH or a pituitary adenoma. With the clinical suspicion of ACTH-independent forms. We report a case of a 78-year-old male who presented with severe hypertension, refractory hypokalemia, and severe hypercortisolism, suggesting adrenal Cushing’s syndrome. However, the non-suppressed ACTH and non-atrophied contralateral adrenal gland were clues to the diagnosis of pituitary Cushing’s disease.

**Treatment and Outcome**

During admission, he developed recurrent infections including atypical pneumonia, C. diff and CoVID-19, likely due to his immunosuppressed state resulting from prolonged hypercortisolism. He was stabilized with ketoconazole, metyrapone and prednisolone as a block-and-replace regimen. Following treatment, his cortisol level gradually decreased to 162 nmol/l. He was planned for inferior petrosal sinus sampling (IPSS) to assess pituitary source of ACTH. Because of anatomical difficulties in cannulation of right jugular vein, his IPSS was unsuccessful, and the procedure was abandoned. Bilateral adrenalectomy was considered, but after achieving clinical stability on metyrapone and prednisolone as block-and-replace, this was not carried out.

**Discussion**

This case highlights the diagnostic and therapeutic challenges of managing ACTH-dependent Cushing’s syndrome. Imaging studies are essential to identify the underlying cause of Cushing’s syndrome, and bilateral adrenal enlargement can be challenging to diagnose due to its rarity. The use of Etomidate infusion in the management of Cushing’s crisis has been well established in the literature in managing severe hypercortisolism by inhibiting steroidogenesis.

**Conclusion**

In conclusion, this case report emphasizes the importance of timely diagnosis and management of Cushing’s Crisis, which is a rare endocrine emergency. Severe hypercortisolism can lead to multiple complications, including severe hypertension, refractory hypokalemia, high risk infection, venous thromboembolism, and GI bleed with high mortality. High index of clinical suspicion and prompt management with IV Etomidate infusion remains pivotal managing Cushing’s crisis.

**DOI:** 10.1530/endoabs.91.WD16

**WD16**

**Diagnosis of Cushing’s in the presence of unilateral adrenal adenoma: not always what it seems**

Xiao ying Khor1, Waseem Majeed1,2 & Akheel Syed1,2

1Department of Diabetes, Endocrinology and Obesity Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom; 2Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom

**Case presentation**

A 34-year-old woman was diagnosed with hypertension from the age of 26 years. She had been investigated in Canada previously and discovered to have a small left adrenal nodule, satisfactory aldosterone and renin levels, but raised urinary free cortisol levels and non-suppressed cortisol levels on overnight 1 mg dexamethasone suppression test. Upon assessment in our service, the patient reported a history of easy bruising and insomnia. Her BMI was 28.1 kg/m² but not atrophied. ACTH was 9 ng/l and cortisol 43 nmol/l, consistent with biochemical cure. A diagnosis of pituitary Cushing’s disease.

**Investigations**

Two sets of 9 a.m. ACTH levels were 17–20 (reference range, 0–46) ng/l with cortisol of 517–673 (200–500) nmol/l. The nadir cortisol following overnight and 48-hour low dose dexamethasone suppression tests were 318 and 285 nmol/l, respectively. Paired midnight and morning salivary cortisol levels demonstrated loss of diurnal variation. Aldosterone-renin, plasma metanephrines, androgen profile and DHEA sulfate levels were satisfactory. MRI of the adrenals confirmed a left-sided adrenal adenoma measuring 2.9 x 2.2 cm. The contralateral adrenal was not atrophied. As ACTH was unsuppressed, a dynamic MRI of the pituitary was performed which showed a 4 mm right-sided microadenoma and a central cystic lesion. Pituitary profile was otherwise normal apart from a mildly raised IGF-1 at 312 (71.2–234 ng/ml) with growth hormone nadir at <0.1 ng/l on an oral glucose tolerance test. Genetic screening for multiple endocrine neoplasia was negative. Inferior petrosal sinus (IPSS) sampling demonstrated a raised central-to-peripheral ratio consistent with Cushing’s disease, lateralising to the right side (Table 1).

**Management**

The patient was pre-treated with Metyrapone followed by trans-sphenoidal resection of pituitary microadenoma. Histology revealed densely granulated corticotroph adenoma with Ki-67 of < 4%. Her 6-week postoperative morning ACTH was 9 ng/l and cortisol 43 nmol/l, consistent with biochemical cure. A 3-month postoperative MRI of the pituitary showed no tumour remnant. She remains on hydrocortisone replacement but is otherwise eutopiatric.

**Conclusion**

The presence of an adrenal adenoma in a patient with biochemically confirmed hypercortisolism suggests adenial Cushing’s syndrome. However, the non-suppressed ACTH and non-atrophied contralateral adrenal gland were clues to the diagnosis of pituitary Cushing’s disease.

**Table 1**

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Peripheral ACTH</th>
<th>Right-sided ACTH</th>
<th>Left-sided ACTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>-10</td>
<td>28</td>
<td>377</td>
<td>30</td>
</tr>
<tr>
<td>-5</td>
<td>30</td>
<td>400</td>
<td>33</td>
</tr>
<tr>
<td>0</td>
<td>363</td>
<td>&gt;1250</td>
<td>&gt;1250</td>
</tr>
<tr>
<td>administered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>&gt;1250</td>
<td>&gt;1250</td>
</tr>
<tr>
<td>5</td>
<td>49</td>
<td>&gt;1250</td>
<td>77</td>
</tr>
<tr>
<td>10</td>
<td>88</td>
<td>&gt;1250</td>
<td>121</td>
</tr>
<tr>
<td>20</td>
<td>144</td>
<td>&gt;1250</td>
<td>&gt;1250</td>
</tr>
</tbody>
</table>

*ACTH, adrenocorticotropic hormone (ng/l)*

**DOI:** 10.1530/endoabs.91.WD16
Workshop E: Disorders of the gonads
WE1
Infertile Couple: Spermatogenesis in Congenital Gonadotropin Urinary Syrian
Lydia Grixiti & Richard Quinton
Northumbria NHS Trust, Newcastle Upon Tyne, United Kingdom; 2Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom

A 31-year-old gentleman presented to our Endocrine Services with his 20-year-old fiancée with plans for marriage and to conceive. He was diagnosed with congenital gonadotropinuria and absent pituitary stalk at the age of 13 years. He was noticed to have bilateral cryptorchidism that failed to descend with 6 months of ICG monotherapy and underwent successful orchiectomy at the age of 15. His fiancée was a healthy, young lady with normal reproductive hormones and tubal patency confirmed on investigation. On examination he was well virilised, had a well-developed phallus and a normal BMI. Testicular examination showed small testicular volume at 2mls on the right and 5mls on the left. He reported normal libido and erectile function. Clinic discussions were held and the possibility of passing on the congenital condition to the offspring was accepted. Following baseline investigations, he proceeded to spermatogenesis induction with subcutaneous gonadotrophin injections starting as human menopausal gonadotrophin (hMG) 150UI three times weekly and recombinant human chorionic gonadotrophin (r-hCG) 2000UI twice weekly, monitored by 3-6 monthly visits. A sperm analysis around 20 months into treatment encouraged showed evidence of sperm although the count was low. The couple preferred to continue to try for natural fertilisation methods. Approaching the end of the third year, there was no improvement in testicular volume or sperm analysis. There was a hint of a positive pregnancy line on one occasion which faded after some days indicating the pregnancy was not successful. On starting the fourth year, they had stored sperm of sufficient quality to give them an estimated 45% chance of pregnancy as they had been taking testosterone undecanoate injections every 12 weeks. His partner is 34 years old fiancee with plans for marriage and to conceive. He was diagnosed with normosmic congenital HH had been made. He had been initially treated with testosterone injections. He has two children aged 13 and 8 years following successful sperm induction with gonadotrophins. Since then, he had been taking testosterone undecanoate injections every 12 weeks. His partner is 34 years old and has no fertility problems. This time he presented seeking fertility treatment. He had small-volume testes (Prader orchidometer: 6 ml) with low libido with intact morning erections referred to Endocrinology clinic after being seen by psychologist and private endocrinologist who started 3 years before for infertility. Puberty was early, normal, at around 9-10 years old age. Previous fathered a pregnancy. He has no history of testicular damage of any sort - torsion or trauma or radiotherapy or surgery. No headache, visual impairments or any pituitary hypo or hyper functioning symptoms. He had no history of androgen or anabolic steroid use or supplements and not on any medication. Significant alcohol intake in the past 20 units/day. Recent abuse of MDMA and Canabinoid (once monthly) to improve sexual functions. Previously tried on testosterone which improved his symptoms but due to infertility, stopped and started on Sildenafil which is not very effective for him. Female infertility factors excluded by the fertility clinic. Examination showed a BMI of 24 with normal external genitalia and testicular volumes of 25 ml bilaterally. No eunuchoidal or mooseman pacey habitus, no gynecomastia. Investigations showed high SHBG 102-133, morning testosterone of 27.1, free testosterone using vernacular equation is 0.248. Normal prolactin, estradiol 120, TSH 1.29, FT4 21, prolactin 122, LH 4.9, FSH 3.8, normal LFT, ferritin 188. Semen analysis pending. This case illustrates some difficulties sometimes encountered in infertility in which the numbers are alright but subjective and other objective patient’s experience is different from this. The question is what is the right explanation for the seemingly normal free testosterone level but differential spermatogenesis. How do we approach infertility in this patient with normal gonadotropins and testosterone.

DO: 10.1530/endoabs.91.WE1

WE2
Clinically symptomatic hypogonadism with High SHBH of unknown aetiology and normal free testosterone in an infertile man
Idowa Olaguwu
University College London Hospital, London, United Kingdom

The relationship between male infertility and plasma testosterone level is not linear and sometimes there could be discordance in the association. This is a case of 41 year old investment banker presented with erectile dysfunction and low libido with intact morning erections referred to Endocrinology clinic after being seen by psychologist and private endocrinologist who started 3 years before for infertility. Puberty was early, normal, at around 9-10 years old age. Previous fathered a pregnancy. He has no history of testicular damage of any sort - torsion or trauma or radiotherapy or surgery. No headache, visual impairments or any pituitary hypo or hyper functioning symptoms. He had no history of androgen or anabolic steroid use or supplements and not on any medication. Significant alcohol intake in the past 20 units/day. Recent abuse of MDMA and Canabinoid (once monthly) to improve sexual functions. Previously tried on testosterone which improved his symptoms but due to infertility, stopped and started on Sildenafil which is not very effective for him. Female infertility factors excluded by the fertility clinic. Examination showed a BMI of 24 with normal external genitalia and testicular volumes of 25 ml bilaterally. No eunuchoidal or mooseman pacey habitus, no gynecomastia. Investigations showed high SHBG 102-133, morning testosterone of 27.1, free testosterone using vernacular equation is 0.248. Normal prolactin, estradiol 120, TSH 1.29, FT4 21, prolactin 122, LH 4.9, FSH 3.8, normal LFT, ferritin 188. Semen analysis pending. This case illustrates some difficulties sometimes encountered in infertility in which the numbers are alright but subjective and other objective patient’s experience is different from this. The question is what is the right explanation for the seemingly normal free testosterone level but differential spermatogenesis. How do we approach infertility in this patient with normal gonadotropins and testosterone.

DO: 10.1530/endoabs.91.WE2

WE3
Primary amenorrhea? Cause
Sagen Zac-Varghese
East and North Herts NHS Trust, Stevenage, United Kingdom

26-year-old referred with primary amenorrhea. Described puberty aged 11 years with breast and axillary hair development. One day of a menstrual period in secondary school. She has a partner and would like to start a family.

PMH
T2DM on metformin and tiraglutide Undiagnosed but possible learning disability/ autism Increased BMI, 57.5 kg/m2

Investigations
Normal TV scan – normal ovaries, endometrium 3 mm FSH 3.9 U/LH 4.8 U/Lestradiol 281 pmol/LBeta HCG negative SHBG 15.8 nmol/lPro-lactin 120 mLU/l17-OH progesterone < 1.6 nmol/lTestosterone 2.2 DHEA sulphate 7.7 nmol/lTSH 1.53 T4 -19.5 Overight dexmethylsome suppression test – cortisol < 25 nmol/lChromosome analysis XX Progesterone challenge - Medroxyprogesterone – withdrawal bleed Pituitary MRI – normal appearance

Impression
Possible functional amenorrhea secondary to obesity

Management
Patient referred to tertiary centre for further management of weight

DO: 10.1530/endoabs.91.WE3

WE4
Fertility induction in a man with congenital hypogonadotropic hypogonadism
Nipun Lakshitha de Silva, Nikoleta Papanikolaou, Karim Meeran & Channa Jayasena
Imperial College Healthcare NHS Trust, London, United Kingdom

Background
Hypogonadotropic hypogonadism (HH) is one of the few treatable causes of male infertility; spermatogenesis induction can be achieved with gonadotrophins or pulsatile GnRH. Treatment protocols are normally long, and outcome varies according to the underlying aetiology, age of onset and history of undescended testes. Regular follow-ups are needed to assess the response and monitor for adverse effects of therapy that could make the management challenging.

Case presentation
A 39-year-old male was reviewed in the clinic for fertility management. He had normal childhood growth and development but had no secondary sexual characteristics up to his late teenage years. There was no evidence of other pituitary hormone deficiencies and the pituitary MRI had been normal. There was no history of recreational drugs including opioid or anabolic steroid use. The diagnosis of normosmic congenital HH had been made. He had been initially treated with testosterone injections. He has two children aged 13 and 8 years following successful sperm induction with gonadotrophins. Since then, he had been taking testosterone undecanoate injections every 12 weeks. His partner is 34 years old and has no fertility problems. This time he presented seeking fertility treatment. He had small-volume testes (Prader orchidometer: 6 ml) with otherwise normal secondary sexual characteristics. He occasionally smoked and was at low risk for obstructive sleep apnoea. His weight was 100 kg and his height was 190 cm (BMI: 27.7 kg/m²). Blood results revealed a raised haematocrit, testosterone, and suppressed LH and FSH (<0.1 U/L) consistent with testosterone therapy. He was azoospermic. Testosterone replacement was withheld, and he was started on subcutaneous injections of human chorionic gonadotrophin 2500 IU twice weekly. Since he remained azoospermic after one year of treatment, subcutaneous menstrin 75 IU twice weekly was added. There was a spermatogenic response, but haematoctrit increased again (Table 1)

Table 1 Summary of investigation results during gonadotrophin treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Reference range</th>
<th>Before gonadotrophin</th>
<th>6 months</th>
<th>12 months</th>
<th>18 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haematocrit</td>
<td>0.39-0.5</td>
<td>0.516</td>
<td>0.501</td>
<td>0.498</td>
<td>0.535</td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td>10-30</td>
<td>36.1</td>
<td>22.4</td>
<td>20.6</td>
<td>24.4</td>
</tr>
<tr>
<td>Sperm concentration (million/ml)</td>
<td>&gt; 15</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>&lt; 0.1</td>
</tr>
</tbody>
</table>

Conclusions
Response to gonadotrophins in male HH is variable with the need for prolonged and intensive treatment in some; yet, adverse effects could limit treatment intensification.

DO: 10.1530/endoabs.91.WE4
WE5
Is normal not enough?
Anna Malik & Gurmit Gill
Royal Stoke University Hospital, Stoke On Trent, United Kingdom

A 36 M seen in endocrinology clinic October 2022 with 9/12 history of reduced testicular size and hypo gonadal symptoms. He has a past medical history of suicidal ideation and urinary incontinence. On review of previous GP records from 2003 he was seen for delayed puberty, although the patient denied this in clinic. There was no history of testicular trauma or infection and he denied any history of exogenous steroid or recreational drug use. There was no significant family history. His partner did have a positive pregnancy in 2021 although miscarried this at an early gestation. The initial biochemical workup following his clinic visit revealed elevated FSH of 56.4 IU/l (RR 1.4 - 18.1) and LH 23.6 IU/l (RR 1.5 - 9.3) and testosterone of 8 nmol/l (RR 6.83 - 23.25). The remaining pituitary profile was unremarkable. His clinical examination and radiological USS confirmed bilaterally small testicular volume and mild varicoceles. His height in clinic was 163 cm, weight, 62 kg and BMI 23.34 kg/m2. On review of the above results suggestive of primary hypogonadism he was subsequently consented for genetic chromosomal analysis. The results of this were consistent with male mosaic karyotype with 2 cell lines. 50/62 cells displayed XY chromosome analysis and 12/62 X analysis with short arm of Y chromosome. He was subsequently referred to the specialist genetic clinic to discuss the implications of the results on fertility. The questions to discuss with this case is should we consider testosterone replacement as low end of normal results and with positive symptoms. What would be the impacts on fertility for this couple and the explanation of previous positive pregnancy?

DOI: 10.1530/endoabs.91.WE5

WE6
Interesting case of Sertoli cell Injury of unknown cause with normal testosterone and ultrasound
Kyaw Zin Hnin
North West Anglia, Peterborough, United Kingdom

A 45-year-old Caucasian man with BMI of 34 presented with a few years’ history of low libido and premature ejaculation. He had azoospermia in the past for infertility investigation 4 years ago with his previous relationship. His LH and FSH were high at 18 U/l (2-13 U/l) and 10 U/l (2-9 U/l) while his 9 amtestosterone level was 19.2 nmol/l (10-38 nmol/l) along with normal prolactin and TSH. The testicular examination is unremarkable. His repeat semen analysis shows azoospermia and ultrasound testes is normal. There is no history of chemotherapy, radiotherapy, mumps, orchitis, or testicular injury. His chromosomal analysis is in process. He is not planning to father a child in the future. This case demonstrates Sertoli cell injury and brings the challenges of how to investigate the causes if chromosomal analysis is normal and how to manage low libido with normal testosterone.

DOI: 10.1530/endoabs.91.WE6

WE7
High testosterone in a young man preserving his hairline
Christo Albor
Whittington Hospital, London, United Kingdom

A 36 year old man was referred to the Endocrine clinic from his GP practice due to an accidental finding of high Testosterone (44.3 nmol/l). He is an actor who has been under a private Trichologist for a number of years, and had been on Finasteride and topical Mixonidil. Under the Trichologist he has had his Testosterone levels periodically monitored, which had been persistently elevated since at least 2018 (39-44 nmol/l). The patient was otherwise well. He has Type 1 Diabetes, Coeliac Disease, and Gilbert’s Syndrome. He had normal puberty, and has normal genitalia, sexual function, arousal and ejaculation. At the time of first presenting in clinic he had stopped Finasteride for at least 3 months, but was still on Mixonidil. He had occasionally been using protein powder shakes, bought from his private members’ club. He has never tried to have children but plans to soon with his wife. On examination he is of medium build, with no increased pigmentation in his creases, and no visual field deficits. Bloods from clinic showed raised total testosterone (39.3 nmol/l) with raised SHBG (91 nmol/l), raised LH (13.7 u/l) and FSH (21.4 u/l), with otherwise normal pituitary function and no polycythaemia. Further bloods showed both 17OH Progesterone and Androstenedione within normal range. Mass spectrometry confirmed raised Testosterone. Calculated free Testosterone was 0.443 nmol/l, within the normal range. US testes, MRI adrenal and pituitary were all reassuringly normal. The exact cause of the raised LH, FSH and total Testosterone remain unclear. The possibility of longstanding up-regulation of gonadotropins due to previous persistent reduced negative feedback from suppressed dihydrotestosterone has been considered. Current systemic levels of free testosterone have been normal due to abnormally high SHBG. Aberrations in testicular free testosterone have not been ruled out, and we are currently awaiting semenalysis. The patient has been told that he can start trying for a baby with his wife. He has also been counselled regarding the use of Finasteride and Moxonidil. Given the patient’s strong desire to preserve his hairline for his work and livelihood, he is considering his options.

DOI: 10.1530/endoabs.91.WE7

WE8
A case of non obstructive azoospermia
P A D M Kumaranthaunga, Vindya Wellalal, George Yovos, Puja Thadani & Harpal Randeva
University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

Introduction
Infertility is a common medical condition affecting 50 million couples worldwide and azoospermia account for around 10 % of cases of male infertility. Non-obstructive azoospermia is one of the most severe forms of male infertility and aetiology could be due to primary testicular failure, secondary testicular failure and those with incomplete or ambiguous picture of testicular failure.

Case report
A 34-year-old patient referred to endocrine clinic for further evaluation for primary subfertility. The couple was unable to conceive after 5 years of regular unprotected intercourse. He denied reduced libido or sexual dysfunction. He had uneventful childhood and puberty development. He denied previous inguinal/-testicular surgeries, testicular trauma or infections or toxic exposures and denied any history of anabolic androgen abuse. There was no family history of male infertility. He was treated for depression 4 years back but had no other illnesses. On examination his height was 168 cm with BMI of 34 and had normal adult male facial and body hair distribution with no gynecomastia. Genital examination revealed bilateral soft, small testes; 6 ml on right side and 4 ml on left side, with normal penile length. His blood investigations (table 1) revealed evidence of normo-gonadotrophic hypogonadism and MRI pituitary was within normal limits. USS testes confirmed bilaterally small testes with normal perfusion and otherwise normal epididymis. His seminal fluid analysis revealed azoospermia on two sperm samples. Subsequent evaluation revealed 46 XY karyotype, negative for copy number AZF microdeletions and CFTG gene variant was not identified. He was referred to subfertility clinic and was planned for surgical sperm retrieval and IVF.

Conclusion
Patients with azoospermia needs to be evaluated for chromosomal and genetic abnormalities. However underlying aetiology and genetic mechanisms remain largely unclear. Combination of sperm extraction with in vitro fertilization and intra-cytoplasmic sperm injection gives these patients an opportunity to father children with the sperm retrieval rate is around 40 to 50%.

Table 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>6.4 nmol/l</td>
</tr>
<tr>
<td>SHBG</td>
<td>15.6 nmol/l</td>
</tr>
<tr>
<td>LH</td>
<td>5 IU/l</td>
</tr>
<tr>
<td>FSH</td>
<td>8 IU/l</td>
</tr>
<tr>
<td>prolactin</td>
<td>198 mIU/l</td>
</tr>
<tr>
<td>TSH</td>
<td>0.98 mIU/l</td>
</tr>
<tr>
<td>FT4</td>
<td>13.2 pmol/l</td>
</tr>
<tr>
<td>IGF1</td>
<td>25.4 nmol/l</td>
</tr>
<tr>
<td>HbA1c</td>
<td>47 mmol/mol</td>
</tr>
<tr>
<td>ODTB</td>
<td>29 nmol/l</td>
</tr>
<tr>
<td>ferritin</td>
<td>87 mg/l</td>
</tr>
<tr>
<td>Renal Functions</td>
<td>normal</td>
</tr>
<tr>
<td>Liver functions</td>
<td>normal</td>
</tr>
<tr>
<td>Semen analysis</td>
<td>Volume 1.5 ml Concentration 0 mll/ml</td>
</tr>
</tbody>
</table>

DOI: 10.1530/endoabs.91.WE8
Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone
WF1
Hypercalleaemia in granulomatous disease
Maria Omer & Tejpal Purewal
Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom

Introduction
Hypercalleaemia has been described in patients with granulomatous disorders. Most commonly sarcoidosis (10% of patients) and tuberculosis with three-fold increase in hypercalcemia. It’s due to production of calcidiol from calcitriol in the lung and lymph nodes that is independent of PTH. Main modalities of therapy are low-calcium diet, glucocorticoids, and treatment of the underlying disease.

The Case
A 48-year-old male, referred to endocrine team with hypercalcemia (calcium 2.96 mmol/l). He had background of Type 2 DM, low mood and hypercholesterolemia. He was under respiratory team for suspected diagnosis of sarcoidosis for several years with suggestive x-ray and CT findings, elevated Serum ACE and recurrent anterior uveitis which has been managed by ophthalmology. No histological proof of sarcoidosis. He was on Metformin 1g bd, Simvastatin 40 mg, Sitaglaptin 100 mg od, and Citalopram 40 mg od. His calcium was high at 2.96 mmol/l on routine investigations and admission was arranged. Investigations revealed impaired renal function with urea 8mmol/l, Cr 118 umol/l, and eGFR of 58 mL/min/1.73m2 (>60mL/min/1.73m2). He expressed symptoms of polyuria and polydipsia, and otherwise had no significant finding on history or examinations. With hydration his Calcium dropped to 2.68 mmol/l but increased again to 2.92 after 2 days. He was commenced on prednisolone 40 mg. As a result, his calcium level normalized within 10 days.

Investigations revealed
Suppressed PTH: 1.0(1.6-6.9), Vit D2: <12 <nmol/l, Vit D3: 29 nmol/l with Total vit D of 29 nmol/l. Negative Myeloma screening. ACE was 183 U/l. It was noted that ACE level was high at 156 U/l on August 2020, return to normal at 48 U/l on December 2020, then increased to 183 U/l at this presentation. The patient was discharge home with steroid tapering regimen when his calcium level dropped to 2.65 with follow up with respiratory team in the OP clinic.

Conclusion
Hypercalleaemia and hypercalciuria have been described in patients with sarcoidosis and should be borne in mind in differential diagnosis. If undetected, it can cause nephrocalcinosis, renal stones, and renal failure. Serum concentrations of vitamin D metabolites, 25-hydroxyvitamin D (calcidiol) and 1,25-dihydroxyvitamin D (calcitriol) should be measured if there is no obvious malignancy and PTH is not elevated. High 25(OH)D is indicative of vitamin D intoxication while increased levels of 1,25-dihydroxyvitamin D may be induced by direct intake of this metabolite, extrarenal production as in granulomatous diseases or lymphoma.

DOI: 10.1530/endoabs.91.WF1

WF2
A case of hungry bone syndrome following denosumab administration with an unfortunate outcome
Sheela Sathyarnarayan, Paul Carroll, Anand Velusamy & Aaisha Saqib
Guy’s and St Thomas Hospital, London, United Kingdom

A 71 year old gentleman, known to have Renal Cell Carcinoma with metastasis to lung, mediastinum, spine and liver, was transferred to our services for management of T2/T3 Spinal root impingement. On admission he was noted to have severe hypercalcaemia of 3.33mmol/l, mild hypophosphataemia 0.8mmol/l and an ongoing acute kidney injury. He had appropriate initial management with intravenous fluids, and was started on dexamethasone 8 mg with PPI cover for the spinal metastasis. His imaging was reviewed in the spinal MDT and medical management and radiotherapy was advised. The patient went on to have spinal radio therapy subsequently. The patient was also prescribed Denosumab at admission which he had not yet received due to availability. With the fluids his Calcium levels had appropriately started improving. On day 4 of admission his calcium had reduced to 2.8mmol/l, while his phosphate was 0.7mmol/l. His Parathormone and vitamin D3 levels were not checked. Unfortunately, at this point he went on to receive Denosumab. On day 10 of admission patient developed symptoms of tingling, numbness and fasciculations. He was found to be profoundly hypercalcaemic at 1.68mmol/l with characteristic corresponding ECG changes of QTc prolongation. He was then referred to Endocrinology for evaluation, and was managed with multiple Calcium Gluconate infusions, alfalcacidol, and high dose cholecalciferol in Level 2-3 care. He went on to have his Parathormone and vitamin D levels checked, which were 174ng/l and 30nmol/l respectively. His calcium levels normalised and stabilised on day 17, and his Alfalcacidol was stopped. He was switched to maintenance dose Vitamin D and oral calcium replacement. Unfortunately, the patient’s general condition deteriorated significantly during the admission and he passed away. This case demonstrates a classic presentation of Hungry Bone syndrome (HBS) secondary to Denosumab administration on background of low vitamin D and phosphate levels, post hypercalcaemia treatment. It highlights the importance of trying to determine the cause of hypercalcaemia during resuscitation and ensuring replete vitamin D levels prior to use of bisphosphonates or denosumab, though this might seem counterintuitive. Low prevailing vitamin D, magnesium and phosphate levels while administering these medications can precipitate large calcium shifts from the blood to the bone, hence the term ‘Hungry Bone Syndrome’. HBS can cause refractory hypercalcaemia, unnecessarily prolonging hospital stay and has the potential to cause significant change in electrolyte homeostasis.

DOI: 10.1530/endoabs.91.WF2

WF3
Differentiating Primary Hyperparathyroidism from Familial Hypocalciuric Hypercalcaemia Can Be Difficult: A Misleading Urinary Calcium to Creatinine Clearance Ratio
Edouard G Mills1,2, Dimitri J Hadjiminas1, Ali Abbura1,2
Preethi Cox3,4, Jeremy Cox3,4 & Alexander N Cummins3,4
1Section of Endocrinology and Investigative Medicine, Imperial College London, London, United Kingdom; 2Department of Endocrinology, Imperial College Healthcare NHS Trust, London, United Kingdom; 3Department of Breast Surgery, Imperial College Healthcare NHS Trust, London, United Kingdom; 4Endocrine Bone Unit, Imperial College Healthcare NHS Trust, London, United Kingdom

Case
We report a 79-year-old female who was referred to our Endocrine Bone Unit with osteoporosis, which was initially treated with Alendronate (but poorly tolerated due to dyspepsia) followed by annual Zoledronate infusions. Her bone history was significant for a proximal humeral fragility fracture 30-years previously. She was an ex-smoker, had limited dietary calcium intake, and had a history of osteopenia. DEXA demonstrated T scores at lumbar spine -1.8, total hip -2.0, and distal radius -2.8, corresponding to 4.6% reduction in lumbar spine BMD from the assessment two years earlier. Thoracolumbar X-rays revealed multiple silent vertebral fractures. However, serial measurements revealed persistent PTH-dependent hypercalcaemia (adjusted calcium range 2.73-2.84mmol/l, PTH 15.7-21.8 pmol/l, 25 OH vitamin D 69 nmol/l and eGFR 79). 24-hour urinary calcium to creatinine clearance ratio (CCCR) was 0.0056, suggesting that Familial Hypocalciuric Hypercalcaemia (FHH) should be considered. However, genetic testing for FHH did not identify known pathogenic variants of the AP2S1, GNa11 or CASR genes. Repeat 24-hour urinary CCCR was slightly higher at 0.012, raising a suspicion for Primary Hyperparathyroidism (PHPT). Parathyroid USS revealed a possible 5mm left inferior parathyroid adenoma (also noted on 4D CT), but without strong evidence of uptake on sestamibi. Renal USS demonstrated a 4mm non-obstructing renal cortical calculus of the left kidney.

Outcome
Owing to non-concordant localisation studies, she underwent a four-gland exploration of the parathyroids, with the left inferior gland removed. Post-operative histology was consistent with an adenoma, and she is now cured with corrected calcium values 2.72-2.39mmol/l. Repeat DEXA at 24-months post-parathyroidectomy has been arranged to re-assess her BMD.

Discussion
Differentiating between FHH and PHPT is essential for correct management, as FHH usually necessitates no intervention, whereas PHPT may require parathyroidectomy. Discrimination is usually based on a 24-hour urinary CCCR with values <0.01 suggestive of FHH. This is based on data highlighting that 80% of individuals with FHH will have a CCCR of <0.01, while 20% have values between 0.01-0.02 and so can overlap with PHPT. However, as noted in this case, a falsely low CCCR can be observed in PHPT with concurrent use of medications that affect calcium metabolism or renal calcium handling, such as bisphosphonates (as in our patient), lithium and thiazide diuretics, as well as vitamin D deficiency/insufficiency, low dietary calcium intake, Afro-Caribbean ethnicity, and chronic kidney disease. As shown here, a combination of clinical suspicion, biochemical testing and genetic analysis may be required to differentiate PHPT from FHH.

DOI: 10.1530/endoabs.91.WF3
WF4
Asymptomatic severe hypercalcaemia and renal impairment following vitamin-D replacement in a patient with military and CNS tuberculosis
Ananthi Anandakrishnan1,2 & Kirun Gunganah1,2
Chopra & Shivshankar Seechurn
Dewdney & Anna Dover

Case history
A 49-year-old male was readmitted with asymptomatic hypercalcaemia and renal impairment following a recent admission where he was diagnosed and commenced on treatment for miliary tuberculosis. He was on month 6 of standard anti-tuberculous therapy (ATT) and one month off glucocorticoids commenced for CNS-involvement. High dose cholecalciferol was started on initial admission when he was found to be normocalcaemic but vitamin-D deficient, and continued. The clinical concern was of hypervitaminosis-D.

Investigations
Calcium on initial admission was 2.29 mmol/l (2.2-2.6 mmol/l) and serum phosphate 1.31 mmol/l (0.8-1.5 mmol/l) with serum 25(OH)D3 21 mmol/l (> 50 mmol/l). Creatinine was 30-40 umol/l.

Results and treatment
Cholecalciferol was commenced at 4000 units/day on initial admission. Synaechen stimulated cortisol at 60 minutes was 526 nmol/l after 16 weeks exposure to glucocorticoids, and weaning prednisolone stopped. Improved radiology and weight gain (BMI 17.18 kg/m2 from 13.19 kg/m2) suggested reduced disease burden. The patient was discharged following 16 weeks' inpatient stay to respiratory follow-up. Calcium 2.76 mmol/l, phosphate 1.4 mmol/l and creatinine 70 mmol/l were detected on outpatient bloods 4 months after 4000 units/day vitamin-D3, and one month off glucocorticoids. Vitamin-D3 was stopped, and increased oral fluids advised. Two weeks later, a serum calcium 3.67 mmol/l and creatinine 123 umol/l prompted readmission. Serum-ACE was 75 ul/l (20-70), PTH suppressed (2.2 pmol/l) and serum 25(OH)D3 95.9 nmol/l. Calcium 3.64 mmol/l on day 3 despite 2.3 litres/24hrs 0.9% sodium chloride prompted starting 30 mg prednisolone. Zolendronate was administered on day 7 due to ongoing hypercalcaemia (3.53 mmol/l) and rising creatinine (158 mmol/l). Normocalcaemia (calcium 2.57 mmol/l) and downtrending creatinine (98 mmol/l) was seen on day 12, and the patient discharged on 15 mg prednisolone. On 15 mg prednisolone, normocalcaemia (2.34 mmol/l) with improved creatinine 61 umol/l was seen at 2 months. Serum 1.25-dihydroxy-vitamin-D3 from the second admission returned at 149 pmol/l (55-139 pmol/l).

Discussion
Hypervitaminosis-D with hypercalcaemia occurs secondary to excess vitamin-D consumption or extrarenal 1-alpha-hydroxylase activity and is a rare but well-cited complication of tuberculosis. With the toxic effects of vitamin-D supplementation thought not to occur until 25(OH)D3 levels exceed 150 ng/ml (.374 nmol/l), elevated 1.25(OH)2-D3 and improved hypercalcaemia following glucocorticoids favour granulomatous hypercalcaemia in our patient. Efficacy data on the use of adjunctive vitamin-D supplementation to standard ATT on improved tuberculosis outcomes is conflicting. Vitamin-D deficiency is common in patients with tuberculosis however, and replacement in those deficient is reasonable. Close monitoring of serum calcium and using more conservative vitamin-D3 doses could ameliorate the dangers of hypercalcaemia seen to occur in these patients more often following supplementation.

DOI: 10.1530/endoabs.91.WF4

WF6
COVID-19 delayed diagnosis resulting in severe hyperparathyroidism with evidence of brown tumours and parathyroid adenoma
Venkataram Subramanian1, Hasinta Bhayat1 & Irfanulla Baig2

A 47-year-old female was referred and presented with generalised aches and pains and her calcium level was found to be elevated with a corresponding raised PTH level. She had previously had a parathyroid hormone level in excess of 212.000 pmol/l (the upper limit for our assay is 212 pmol/l). Interestingly, she has had a mildly elevated calcium level in 2017, rechecked in 2018 and lost to follow up until December 2021. At this juncture, she sustained a closed fracture of her metacarpal which prompted further assessment due to the nature of the report from the Xray which suggested significant osteopenia and bone resorption. Other blood tests also showed persistent hypercalcaemia, severe deficiency in Vitamin D and a high ALP in the range 2300-2400. Once admitted, due to her going bone pain, she had multiple X-rays including that of her lumbar spine, pelvis and right knee. The common finding reported evidence of bony resorption particularly to the femoral shafts bilaterally and several luencies were noted within the femoral shafts bilaterally in keeping with brown tumours. Fortunately, no fractures were demonstrated. Additionally, a CT thorax, abdomen and pelvis was requested to rule out a malignancy and this, too, confirmed innumerable lytic lesions seen throughout the entire skeleton with no vertebral collapse and further subperiosteal resorption noted at the sacroiliac joints and pubic symphysis. These lytic lesions were thought to represent multiple brown tumours on the background of hyperparathyroidism. Furthermore, her ultrasound neck revealed a small vascular mass in the lower pole of the left thyroid gland suspicious for parathyroid adenoma. The subsequent Tc-99 MIBI nuclear medicine scan suggested there is a solitary focus of intense tracer activity present in the lower right position at the level just immediately above the right sternoclavicular joint.Appearances are entirely consistent with an autonomous solitary parathyroid adenoma. She has had an ENT review for consideration of surgical intervention which is currently awaited. We have therefore concluded that she has Primary hyperparathyroidism caused by likely a single adenoma. She has had surgical treatment of the lesion and is now starting to recover with close monitoring from the team in hospital.

DOI: 10.1530/endoabs.91.WF6

WF7
A case of familial hypocalciuric hypercalcaemia
Charlotte Dewdney & Anna Dover
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Endocrine Abstracts (2023) Vol 91
Introduction

Familial hypocalciuric hypercalcaemia (FHH) is an autosomal dominant disorder affecting the calcium-sensing receptor (CaSR) expressed in the chief cells of the parathyroid glands and in the renal tubules. The CaSR permits the parathyroid gland to sense variations in serum calcium thus regulating parathyroid hormone (PTH) secretion; it also regulates calcium excretion in the kidneys. In FHH, loss-of-function mutations in the CaSR result in a higher serum calcium due to enhanced PTH secretion, and hypocalciuria due to higher tubular reabsorption of calcium in the nephrons. It can sometimes be difficult to differentiate between primary hyperparathyroidism (PHPT) and FHH.

Case Presentation

A 26-year-old woman was referred to the endocrine clinic with longstanding severe asymptomatic hypercalcaemia. She has a background of emotionally unstable personality disorder (EUPD) and anorexia nervosa. Her most recent biochemistry demonstrated an adjusted calcium of 3.23 mmol/l (2.2-2.6 mmol/l) with normal albumin, PTH 61 pmol/l (1.6-6.9 pmol/l), vitamin D 27 nmol/l (25-162 nmol/l), and phosphate 0.7 mmol/l (2.2-2.6 mmol/l). A neck ultrasound was normal. A family history of hypercalcaemia was noted. Genetic blood tests confirmed a mutation in the CASR gene in keeping with autosomal dominant FHH.

Discussion

Despite usually having a benign prognosis FHH can be associated with nephrolithiasis, chondrocalcinosis and pancreatitis. Interestingly it can also be linked to behavioural disorders and this lady has EUPD. Cinacalcet was ineffective and achieved a sustained benefit on calcium, PTH, and CaSR. In the absence of CaSR gene mutations, FHH can be linked to a hypothalamic or pituitary tumour. The patient would benefit from re-imaging the sella turcica.

Case Presentation

A 23 year old male patient with a background of insulin dependent diabetes, diabetic nephropathy (chronic kidney disease stage 1) was admitted feeling acutely unwell. Clinical and bed side investigations identified he was in severe dehydration and was not able to manage oral fluid intake. He was not on any bowel discomfort. His blood pressure was within normal range. He did not have any significant family medical history. He was started on vitamin D3 1000 units daily, with a plan of measuring the urine calcium creatinine clearance ratio and repeat the calcium levels. He was further treated for electrolyte imbalance. His urine and fluid intake were monitored closely.

Conclusion

It is vital to fully investigate for all the causes of hypercalcaemia before concluding hypercalcaemia of immobilisation. This was a complicated case in which one expects patient to develop hypercalcaemia from chronic kidney disease.
A 37 year old woman presented to A&E with symptoms of hyperemesis gravidarum. She was 9 weeks pregnant, in her third pregnancy. It was noted that her calcium level was 3.13mmol/l, PTH 12.1 pmol/l, vitamin D 42nmol/l. She was treated with IV fluids and discharged with endocrine follow up. The endocrine and obstetric teams arranged for an urgent review on the antenatal ward the next week. Calcium was still raised at 3mmol/l. She was admitted overnight for antiemetics and IV fluids until calcium was 2.79mmol/l. She had been recently diagnosed with likely primary hyperparathyroidism at a different hospital but had only undergone part of the necessary investigations before moving to a new area. Hypercalcaemia likely exacerbated her nausea and was itself exacerbated by the dehydration from vomiting. She required weekly blood tests and IV hydration as calcium levels rose quickly between admissions. The option of parathyroid surgery was discussed as it was difficult to maintain the calcium in a normal range with hydration alone. Ultrasound of the parathyroids showed two likely adenomas in the left inferior and right inferior parathyroid glands. The patient agreed to surgery in the second trimester. Hypercalcaemia in pregnancy is associated with complications for both the mother and the foetus. The mother can develop hyperemesis gravidarum, nephrolithiasis, osteoporosis, pancreatitis, as well as other complications for both the mother and the foetus. The mother can develop hyperemesis gravidarum, nephrolithiasis, osteoporosis, pancreatitis, as well as having a higher risk of pre-eclampsia. The foetal complication rate has been shown to be up to 80%, including growth restriction, preterm delivery and miscarriage. Postpartum, up to 50% of neonates have transient hypocalcaemia. If medical management is insufficient in pregnancy, parathyroid surgery can be considered and is usually performed in the second trimester due to the potential impact on organogenesis in the first trimester and risk of preterm labour in third trimester. These decisions require a multidisciplinary approach and discussion with the patient regarding risks and benefits of medical and surgical treatments.

DOI: 10.1530/endoabs.91.WF12
Workshop G: Disorders of appetite and weight
A 46-year-old lady with background of type 2 DM with severe insulin resistance, hyperandrogenism, bipolar disorder, glaucoma, diabetic neuropathy, hypertension, GERD, necrobiotic lipodiosis, PCOS and hypercholesterolaemia is followed up in complex type 2 diabetes clinic for severe insulin resistance. Her BMI is 25.7, she has freestyle libre with blood glucose readings around 15mmol/L85% of the time. Hba1c is 11% on June 2022, she is on humalog 265units 7 times/day and 285units at bedtime, dapagliflozin 10 mg OD, iraglutide 1.8 mg OD, metformin 1g BD. Lab tests: eGFR > 90, U&A, LFTs, BFC were normal. Blood pressure in the clinic 167/103mmbh. She is checking the insulin injection sites and rotating the sites of injections. She had extensive work up at Manchester diabetes centre and Addenbrooks Hospital, however, no identified genetic syndrome to explain her severe insulin resistance could be found. She was on pioglitazone in the past with little success. Tresiba 60 units OD was added to her medications and her follow up Hba1c improved to 9.1mmol/mol on October 2022. Her other medications are gabapentin 600 mg TDS, pentoxyfylline 400 mg TDS, pantoprazole 40 mg BD, atorvastatin 40 mg ON, mirtazapine 45 mg ON, ramipril 10 mg OD, bendroflumethiazide 2.5 mg OD. I am curious if there is any work up or change in the management plan that can improve her diabetes control.

DOI: 10.1530/endoabs.91.WG1

**WG2**

**Severe hyperandrogenism due to ovarian hyperthecosis in a young woman**

Shafatna Ahamed Sadig1, Neha Jeyaka1, Giuseppe Maltese1, Nikhil Johri1, Mamta Joshi1 & Steve Hyer2

1Epsom St Helier University Hospitals NHS FT, Carshalton, United Kingdom; 2Epsom and St Helier University Hospitals NHS FT, Carshalton, United Kingdom

**Case History**

Hyperandrogenism is a relatively common clinical problem. However, severe hyperandrogenism causing virilisation is rare. A 22-year-old lady with no significant past medical history, presented with oligomenorrhoea, hirsutism and male pattern hair loss over last 3 years duration. She has no acne or change in voice or clitoromegaly. She was also noted to be having high BP on clinic visit and grade 1 acanthosis nigricans. Investigations

Her total testosterone was elevated to 5.9 mmol/l with elevated free testosterone index of 28.9 and low SHBG at 18nmol/l, normal FSH, LH and oestradiol (152pmol/l) with normal prolactin. Trans abdominal ultrasound pelvis was normal, MRI Pelvis revealed enlarged ovaries with thickening of the ovarian stroma and multiple small peripheral follicles. The appearances were suggestive of PCOS. This excluded any suspicious adnexal mass. CT/adenal was normal with no evidence of soft tissue enhancement. Her Hba1C was 39nmol/mol. Treatment

We discussed lifestyle modification ensuring stable weight and avoiding weight gain. She was prescribed metformin to maximum tolerable dose and the combined oral contraceptive pill. We considered spironolactone at some stage in the future.

**Discussion**

Ovarian hyperthecosis or ovarian stromal hyperplasia is a non-neoplastic functional disorder resulting from the presence of luteinized thecal cells within a hyperplastic ovarian stroma. The condition is more common in postmenopausal women than in those of reproductive age and leads to substantial clinical and laboratory alterations, principally androgenic alopecia, progressive hirsutism, and elevated testosterone levels. Investigation should include clinical evaluation, laboratory tests, and imaging tests to differentiate between the principal diagnostic hypotheses. The standard goal for diagnosis is histopathology of the ovarian tissue which is not often possible in young women. Medical treatment with GnRH analogue and combined oral contraceptive pills usually has an excellent clinical and biochemical response resulting in suppression of testosterone levels. Treatment with long term GnRH analogue has its own side effects, worsening metabolic abnormalities. PCOS per se is closely linked to metabolic disorders such as obesity and insulin resistance which were seen in our patient too. This case highlights a rare presentation of ovarian hyperthecosis in a young woman with severe hyperandrogenism mimicking a virilising neoplasm.

DOI: 10.1530/endoabs.91.WG2

**WG3**

Clinical utility of GnRH analogues in female androgen excess due to severe insulin resistance

Leanne Cussen1,2, Tara McDonnell1,3, Claire Miller1,2, Lauren Madden1

1Endocrinology Department, Beaumont Hospital, Dublin, Ireland; 2Department of Medicine, Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, Dublin, Ireland

Lipodystrophy represents a broad spectrum of disorders, subdivided depending on aetiology (congenital or acquired) or the extent of adipose tissue absence (generalised or partial). A lack of adipose tissue results in systemic insulin resistance and ectopic fat deposition, which predisposes patients to metabolic syndrome and associated conditions such as non-alcoholic fatty liver disease and diabetes mellitus. Additionally, severe hyperinsulininaemia can generate ovarian androgen production, resulting in an incorrect diagnosis of polycystic ovary syndrome (PCOS) due to a combination of ovulatory dysfunction, androgen excess and severe polycystic ovaries on ultrasound. Juvenile dermatomyositis is a rare autoimmune inflammatory myositis that is associated with lipodystrophy. We present a case of a severe insulin resistance disorder in the setting of juvenile dermatomyositis referred to endocrinology with PCOS features. 25-year-old female diagnosed with juvenile dermatomyositis in childhood, presenting with rashes, joint pains and muscle weakness, which developed into contractures. She had a background history of steroid-induced hyperglycaemia, hypertension and recurrent calcinosis with JJ stents inserted. She was diagnosed with PCOS at age 15 and had been referred to Endocrinology by Rheumatology colleagues due to worsening symptoms of anovulation for over a year and significant hirsutism. On exam, she was a wheelchair user with severe acanthosis nigricans around her neck, axillae and antecubital fossae bilaterally. In addition, there was evidence of partial lipodystrophy affecting her arms and legs and relatively sparing her face and abdomen. Her initial investigations revealed profound insulin resistance with a HOMA insulin ratio of 41.5 based on a glucose of 5.4 mmol/l, a insulin of 15.2 and insulin level of 174nmol/l (>1,000 pmol/l). There was biochemical evidence of androgen excess with elevated testosterone of 4.6nmol/land androstenedione of 15nmol/l. At this juncture, she was commenced on Provera, which she had a partial response to and metformin and spironolactone. She underwent a gonadotropin-releasing hormone (GnRH) suppression test to confirm gonadotropin-driven ovarian hyperandrogenism and explore potentially as a therapeutic option with add back oestrogen. After administration of triptorelin 3mg, androgens were completely suppressed, with significant clinical improvement in symptoms. She continues on maintenance GnRH therapy with add-back oestrogen and progesterone. This case highlights severe insulin resistance syndromes as a non-PCOS form of androgen excess and the clinical utility of GnRH analogues.

**WG4**

**Extreme hyperandrogenism secondary to PCOS with weight gain**

Kefah Bashir, Giridhar Tarigopula, Catherine Mitchell, Mustafa Al-Ansari, Yong Ling & Raisa Minhaz

The Hillingdon Hospital, London, United Kingdom

A 45-year-old female presented with secondary amenorrhea. Since menarche, her period has been irregular, which she initially managed with oral pills, which were discontinued in 2009. Subsequently, she does have complete secondary amenorrhea. She has hirsutism at the age of 20. Which was initially well controlled with oral contraceptive pills but has been getting worse over the years. Ferriman-Gallway’s score was high. She also stated that her weight had been steadily increasing over the years. Her weight was 105 kg when she first visited the clinic in 2018, and it is now 112.7 kg, with a BMI of more than 40. She has schizophrenia, and she is on Risperidone and Mirtazapine, which prompted her to gain more weight. She has no family history of note, particularly no history of diabetes. She has a clinically high BMI of more than 40, and her BP 130/80. She does have extensive hirsutism, and the Ferriman-Gallway score was 31. She also...
does have acanthosis nigricans and multiple skin tags around her face, but no
classical cushingoid and not virilised. She had investigations that revealed
extremely high levels of testosterone was 13 nmol/l, normal DHEA, and
marginally raised androstenedione making the ovariain source more likely. She
had an overnight dexamethasone suppression test, the cortisol level was supressed
and the testosterone level was still high, suggesting a possible ovarian source of
testosterone. She also underwent an MRI and US scans of the ovaries, both of
which revealed polycystic ovaries. Other than that, no other sinister pathology
was noted. Additionally, the CT adrenals were normal. We did start her on a trial
of Zoladex GnRH agonist injection due to the risk of thrombosis. She was referred
to the weight management team. She also referred for ovarian venous sampling to
determine the source of the testosterone. Subsequently, she may require an
oophorectomy. She is quite keen to take this route.

Conclusion
- PCOS is a common disorder of young women and can rarely have extreme
  presentation.
- This patient’s case was unusual in that the presenting symptoms of severe
  hirsutism, and significantly elevated androgens raised concern for a non-PCOS
  pathology
- Approach to such patients involves suppression testing with Dexamethasone to
differentiate between adrenal and ovarian sources.
- Dexamethasone suppression test was in favour of ovarian source, and MRI
  imaging excluded ovarian and adrenal tumour
- Certain imaging may not reveal smaller masses, and ovarian/adrenal vein
  sampling may be needed.

DOI: 10.1530/endoabs.91.WG4

WG5
A Case of non-diabetes hypoglycaemia: A dual diagnostic challenge
Komal Zia Rao, Jasmine Tharma, Sara Haboosh, Pyra Sen Gupta,
Paul Carroll & Aaisha Saqib
Guy’s and St Thomas’ NHS Trust, London, United Kingdom

A 47-year-old female presented to the Emergency department following an
episode of loss of consciousness at home that her daughter had identified as due to
hypoglycaemia (using her husband’s capillary blood glucose meter 1.1 mmol/l)
and treated. She reported several episodes of fainting, sweating and generalised
weakness over 6 months which improved after eating snacks. There was no
previous history of diabetes; she had been diagnosed with Graves’ disease 6
months previously, following unintentional weight loss of 7 kg over 4 months,
treated with carbimazole. Her past medical history included hypertension,
arthritis, functional neurological disorder and migraine. She lived with her family
from which it was noted her husband and sister were on oral medications for
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
diabetes. On clinical examination, her BMI was 24 kg/m². Pigmentation was
noted on the dorsal aspect of her neck but overt acanthosis nigricans or features of
acanthosis nigricans and multiple skin tags around her face, but no
classical cushingoid and not virilised. She had investigations that revealed
extremely high levels of testosterone was 13 nmol/l, normal DHEA, and
marginally raised androstenedione making the ovariain source more likely. She
had an overnight dexamethasone suppression test, the cortisol level was supressed
and the testosterone level was still high, suggesting a possible ovarian source of
testosterone. She also underwent an MRI and US scans of the ovaries, both of
which revealed polycystic ovaries. Other than that, no other sinister pathology
was noted. Additionally, the CT adrenals were normal. We did start her on a trial
of Zoladex GnRH agonist injection due to the risk of thrombosis. She was referred
to the weight management team. She also referred for ovarian venous sampling to
determine the source of the testosterone. Subsequently, she may require an
oophorectomy. She is quite keen to take this route.

Conclusion
- PCOS is a common disorder of young women and can rarely have extreme
  presentation.
- This patient’s case was unusual in that the presenting symptoms of severe
  hirsutism, and significantly elevated androgens raised concern for a non-PCOS
  pathology
- Approach to such patients involves suppression testing with Dexamethasone to
differentiate between adrenal and ovarian sources.
- Dexamethasone suppression test was in favour of ovarian source, and MRI
  imaging excluded ovarian and adrenal tumour
- Certain imaging may not reveal smaller masses, and ovarian/adrenal vein
  sampling may be needed.

DOI: 10.1530/endoabs.91.WG4

WG6
Post-prandial hypoglycaemia of unknown origin
Vaios Koutroukas1, Ketan Dhaturiya2 & Antonia Brooke3
1Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom;
2Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

Introduction
A 19-year-old female patient with no past medical history presented with multiple
collapses following exercise due to hypoglycaemia. From the history it transpired
that she had previous symptoms consistent with hypoglycaemia on multiple
occasions, with no relation to fasting or food or a specific diurnal or nocturnal
pattern. The two most severe episodes (requiring paramedic treatment) were in
the recovery period from anaerobic exercise. Her body mass index (BMI) is 23.4
kg/m². She does not drink alcohol or take any illicit medications. Her half-brother
has type 1 diabetes (T1DM) but lives away; no other family member has diabetes
or known hypoglycaemia-related disease.

Investigations
Her pituitary screen, fasting gut peptides and prolonged oral glucose test (OGTT)
were normal. Her 72-hr fast achieved hypoglycaemia with low insulin and C-peptide
levels, excluding insulinoma. She had amino acids sent off for organic
acids and this was reported as normal excluding aminoacidopathy, with a normal
IgF1/ IgG2 ratio and normal zinc 8 transporters, GAD and IA2 antibodies, too.
Finally, genetic causes of hyperinsulinemia (ABCC8, AKT2, CACNA1D, CREBBP, EP300, FOXA2, GCK, GLUD1, GPCR, HADH, HKI1, HNF1A, HNF4A, INS, KCNJ11, KDM6A, KMT2D, MAFA, NSD1, PHOX2B, PPM2, SLC16A1 and TRMT10A genes) were also negative. An ultrasound of her liver
was of normal echogenicity and appearance. A repeat 72-hr fast to check insulin, C-peptide, insulin analogues, sulphonyluria screen, pH, lactate, pyruvate/factate
ratio when plasma glucose < 2.5 mmol/l was abandoned due to influenza A within
12 hours of admission. A further 72-hr fast is planned. At this point, it was
theorised her symptoms could be explained by exercise-induced hyperinsulinae-
mia or a genetic defect in various metabolic pathways (glucosegenesis,
ketogenesis, or fatty acid oxidation disorder). To that end, an exercise test was
organised with pH, lactate, pyruvate and glucose measurements; however, the
patient did not develop hypoglycaemia. A continuous glucose monitoring system
with an integrated low glucose alarm (Dexcom) has shown considerable
variability with some days without hypoglycaemia, and others regularly < 3
mmol/l despite regular carbohydrate and sugar intake. The patient avoids
anaerobic exercise for fear of hypoglycaemia, which means she cannot do
lifeguarding, her main hobby.

Conclusion
This is a rare case of disabling hypoglycaemia without a confirmed cause. It
highlights the merits of continuous glucose monitoring outside of diabetes and
places emphasis on the need to consider additional metabolic causes; a pragmatic
approach to treatment is likely to be needed.

DOI: 10.1530/endoabs.91.WG6

Endocrine Abstracts (2023) Vol 91
Workshop H: Miscellaneous endocrine and metabolic disorders
WH1
Crisis Looming Large- Endocrine Dysfunction with Cancer Immunotherapy
Angel Mary Joseph, Ryan Vernon D’ Costa & Tolulope Shomihare
The Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom

Background
Immunotherapy with checkpoint inhibitors (CPI) [CTLA4 and PD-1 inhibitors] have significantly improved outcomes and survival rates in patients with a number of cancers. In the UK, Ipilimumab and Nivolumab are approved for the treatment of advanced malignant melanoma. These are often long term therapies and are associated with immune mediated endocrinopathies.

Case
A 70 year old male presented to the Medical Admissions Unit with a history of lethargy, nausea, postural dizziness and reduced urine output since 4 days. He had a background history of Type 2 Diabetes Mellitus (on Metformin); and Stage IV malignant melanoma of the lower back diagnosed in March 2021 and was initiated on Ipilimumab and Nivolumab combination therapy in July 2022 for progressive disease. He was a non smoker and occasionally consumed alcohol. He had no known drug allergies and denied any significant family history. On examination, he had significant orthostatic hypotension and clinical signs of hypothyroidism. Visual fields were normal on confrontation, he had no peripheral hyperyperpigmentation and was well virilized. Rest of his systemic examination was unremarkable. Investigations were notable for acute kidney injury with normal electrolytes, a raised TSH (40), low FT4 (< 3) and markedly reduced cortisol (11). An endocrine opinion was sought in view of severe primary hypothyroidism and low cortisol. In light of his background history, a diagnosis of CPI associated endocrine dysfunction was made. He was started on stress dose oral hydrocortisone and further initiated on levothyroxine three days after. Blood tests to screen for other endocrinopathies (LH, FSH, Testosterone, Prolactin) were requested. On follow up in the endocrine clinic, he was detected to have low free testosterone (100) with raised LH (19.3) and FSH (34.7). Prolactin was normal. He responded well to thyroxine and cortisol replacement and is due to start testosterone replacement. Stimulatory testing is planned, but is delayed due to short term tapering Prednisolone course that was initiated for hepatotoxicity associated with CPI. His CT scan 6 months post initiation of immunotherapy showed treatment response and he is planned to continue on treatment for the long term. He is also being closely follow up by the endocrine team.

Conclusion
Clinical manifestations of immune mediated endocrinopathies can be non specific and can overlap with multi-organ involvement in the acute care setting. A clinician must consider endocrine dysfunction as a possibility while managing these patients, thus preventing potential life threatening consequences when recognised early and treated appropriately.

DOI: 10.1530/endoabs.91.WH1

WH2
Post-COVID-19 male hypogonadism: an area of endocrine concern?
Nyan Lin, Anneke Graf, Parnami De Sliva, Devesh Sennik & Ellie Panteliou
Princess’Alexandra Hospital, Harlow, United Kingdom

A 48-year-old gentleman, father of 3 children, was referred to our endocrinology clinic, with sexual dysfunction and hypergonadotropic hypogonadism. He had a history of severe Coronavirus-Disease-2019 (COVID-19) pneumonia for which he received prolonged ventilatory support. Post extubation, he experienced testicular pain and swelling. A testicular ultrasound showed a left-sided hydrocele, multiloculated epididymal-cyst and a right testicular cyst. He also described new symptoms of lethargy and poor sexual function, since discharged from hospital. He had a past medical history of Type-2 Diabetes on oral agents, Polycystic-Kidney Disease, a post-COVID-19 occipital haemorrhagic infarct and class-1 obesity. Endocrine testing revealed total testosterone:4.7nmol/l, FSH:11.7u/l, LH:6.1u/l, SHBG:9nmol/l, Free-Androgen-Index:58.7, prolactin:187mU/l, cortisol:187mU/l, ferritin:161ug/l, PSA:0.26ug/l, HbA1c:82mmol/mol. This biochemical picture was consistent with primary hypogonadism, contrary to the profile that might have been expected in an obese man with metabolic syndrome, who had survived critical illness. Magnetic-Resonance-Imaging (MRI) of the head did not show any pituitary pathology. Transdermal testosterone was initiated and on follow-up, testosterone levels as well sexual function had improved. A number of case-reports and small studies have demonstrated the presence of male-hypogonadism in the acute phase and during recovery from COVID-19. The male reproductive system can be affected by the Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), causing COVID-19, in numerous ways. SARS-CoV-2 uses angiotensin-converting-Enzyme-2 (ACE-2) receptor and Trans-Membrane-Serine protease-2 (TMPRSS-2) to infect host cells. ACE-2 and TMPRSS-2 are co-expressed in the testes. The development of hypogonadism can also be attributed to increased pro-inflammatory cytokines. Severe inflammation can disrupt the Blood-Testicular-Barrier (BTB), allowing direct damage of the seminiferous epithelium and spermatogonial stem cells. Possible effects of COVID-19 on the Hypothalamic-Pituitary-Gonadal (HPG) axis have also been proposed, with a declined testosterone:LH ratio. Small studies of patients with moderate to severe COVID-19 reported that epididymo-orchitis can be present in 10-25% of this cohort. Although this seems to be more common at the moderate to severe spectrum of Covid-19, recent studies have demonstrated that this might also be the case for patients at the milder end of the spectrum too. Virus-induced endocrine disorders, including male-hypogonadism, have been implicated in the pathogenesis, of the “post-COVID condition”, as defined by the World-Health-Organization (WHO), which can affect up to 1/3 of patients having contracted COVID-19. In the post pandemic era, concerns over the long-term sequelae of COVID-19 on the male reproductive health have been raised by a number of fertility societies, something that could also be reflected on the male-hypogonadism workload of our endocrine practice.

DOI: 10.1530/endoabs.91.WH2

WH3
Diagnosing Adrenal insufficiency
Janine MusseLwhite
East Kent Hospitals NHS Foundation Trust, Margate, Kent, United Kingdom

Patient referred to us for Short Synacthen test following, low baseline cortisol in the community, symptoms of fatigue, background history of neck pain on mild opioids, Paracetamol, codeine and Tamadol. Asthmatic on prn salbutamol inhalers. Before attending for Synacthen test patient asked to withhold inhalers and any steroid based medications. Synacthen performed at 08:30am: Pre Cortisol level: 96nmol/l/Post Synacthen administration: 388nmol/l/Inadequate response to synacthen (adequate response is > 480 nmol/lat 30 mins post synacthen). ACHT: negative Medically, the patient was started on hydrocortisone, 10/5 but this had little effect on the original symptoms of fatigue. She was also advised to reduce her mild opioid medication, as this should have a positive effect on the adrenal glands and in time should mean we can reduce the hydrocortisone medication. Two months later the patient had a hydrocortisone day curve test, mainly because she was reporting a 1.5 stone weight gain. HDC are preformed using the Imperial college hospital guidelines, pre medication and one hour after medication.

Pre levels less than 30nmol/l, 10 mg hydrocortisone given post blood test 579nmol/l/Post lunchtime levels was 317nmol/l, 5 mg hydrocortisone given post blood test 731nmol/l/It was suggested we reduce the 4pm dosage slightly to 2.5 mg. Other than that there was no changes were made. A further two months post and the patient contacted us to say she had stopped her hydrocortisone medication as the weight gain was getting worse. She reports she did not feel any different and she also informed us she had stopped her Tamadol medication. At the point the best option was to start again with a synacthen test. Pre cortisol level: 69nmol/l/Post synacthen cortisol level: 357nmol/l/The patient was encouraged to restart hydrocortisone at a lower dosage 5 mg twice daily. We are now at present day and the plan to date is do a day curve again after a further few weeks.

DOI: 10.1530/endoabs.91.WH3

WH4
A patient with known Langerhans cell histiocytosis presents with polyuria and polydipsia
Moe Kyaw1,2 & Amit Banerjee1
1St Helens and Knowsley Teaching Hospitals NHS Trust, Prescott, United Kingdom; 2Furness General Hospital, Barrow-in-Furness, United Kingdom

A 41 year old lady was referred to the endocrine clinic by her respiratory physician. She is known to have Langerhans cell histiocytosis (LCH) with lung involvement. She is having yearly follow up under respiratory team and not needing any treatment for LCH. In endocrine clinic she confirmed that she is drinking around 9 to 10L of water / day and having quite significant polyuria. She works in Tesco. She does not have any other medical condition and not taking any regular medication. There is no history of change in body weight, lethargy, oral or genital thrush, cough or abdominal pain. Her Hba1c was 37 and Na 148 with normal eGFR. Her early morning cortisol 430. She had a water deprivation test patient asked to withhold inhalers which confirmed central diabetes insipidus (CDI). Her MRI pituitary showed hypoplasia. CT Neck, thorax, abdomen and pelvis: was unremarkable. Other autoimmune, infiltrative and infections were ruled out. Her rest of pituitary profile

Endocrine Abstracts (2023) Vol 91
was checked and it was normal. A clinical diagnosis of central diabetes insipidus secondary to LCH was made. She was started on desmopressin nasal spray. Symptoms dramatically improved with desmopressin nasal spray 5 mg in the morning and 10 mg at night. Appropriate follow up arranged in endocrine clinic to monitor her electrolytes. LCH is a rare and probably underdiagnosed disease with a wide range of presentation. Due to infiltration of the hypothalamic pituitary axis, CDI can even be the first manifestation, even before LCH is diagnosed. Therefore, LCH should be considered in the diagnostic workup of CDI.

DOI: 10.1530/endoabs.91.WH5

WH5

Transient Severe Hypothyroidism of Uncertain Aetiology
Chinaza Nwachukwu, Gui Rubab & Amutha Krishnan
Manx Centre for Diabetes, Endocrinology and Metabolism Noble’s Hospital, Douglas, Isle of Man

32 year old male patient admitted to A&E with 3 days history of confusion and generalised oedema. History from the mother revealed long standing self-neglect, poor nutrition and prolonged immobility due to abnormal painful sensation and weakness in the lower limbs. This is preceded by a post traumatic drastic change in character of the patient, with resultant agoraphobia and excess consumption of alcohol. Investigations on admission include: TSH 128 ulu/ml (0.27-4.20), T4 < 0.5 pmol/l(11.1-22.6); HB 170g/l(135-175), WBC 10.40 x109 (4-11), Neutrophils 8.14x 109 (2.0-7.5); AKI- eGFR 22 (>90), creatinine 306umol/l(59-104), urea 32.7mmol/l(2.5-7.8); ALT 58U/l(10-20), bilirubin 34umol/l(0-21), GOT 313U/l(10-71; sodium 129mmol/l(133-146), magnesium 0.66mmol/l(0.7-1.0), phosphate 0.50mmol/l(0.80-1.50); Vitamin D level <7.5nmol/l (<50 deficient); albumin 34.6g/l(35-50), globulin 23g/l(19-35); normal iron studies and 0.5 - Started

Date
TSH (ulu/l) (0.27-4.20)
T4 ( pmol/l) (11.1-22.6)
T3 ( pmol/l) (0.3- 6.8)
Treatment with thyroid hormone
Sept 2021
128
<0.5

Starved
Nov 2021
2.07
32.1
4.8
Ongoing treatment
May 2022
1.31
26.6
4.5
Ongoing
Sept 2022
1.09
23.5
4.6
Stopped
November 2022
1.54
21.9
4.8
No treatment
Jan 2023
1.70
21.6
5.4
No treatment

DOE: 10.1530/endoabs.91.WH5

WH6

A case of bilateral adrenal infarction of uncommon aetiology
Orighomisan Awala, Shivangi Shah & Harit Buch
Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom

Background
We present a case of a 33 year old female with a background of Turner’s syndrome, adequately managed with growth hormone and oestrogen supplementation. Cronh’s disease, horse shoe kidney and subclinical hypothyroidism
Case details
She presented to the emergency team with high-grade fever and right sided hemiplegia 10 days following Astra Zeneca COVID vaccination. Initial blood tests showed mildly raised CRP of 49, thrombocytopenia with platelet count of 54 and a normal plain CT head. MRI head showed bilateral multifocal acute infarcts in MCA territory and watershed areas on the left raising a suspicion of a thromboembolic source. She was seen by multiple teams with a working diagnosis of COVID vaccine-induced thrombotic thrombocytopenic thrombosis. Abdominal and pelvic CT scan was arranged on day 15 of admission on account of persistent pyrexia and raised inflammatory markers. It did not identify focal sepsis but showed ill-defined and enlarged adrenal glands. Soon after the scan she deteriorated acutely with hypotenison, hyponatraemia and hyperkalaemia, requiring ITU admission. She was treated for suspected acute hypocortisolism with intravenous hydrocortisone and after stabilisation she was initiated on oral hydrocortisone and fludrocortisone. A short synacthen test performed after acute illness, along with ACTH level, confirmed the diagnosis of primary hypocortisolism secondary to bilateral adrenal infarction most likely to be secondary to vaccine-induced thrombocytopenic thrombosis. Repeat CT scan showed resolution of adrenal gland enlargement. She has made moderate recovery from the cerebrovascular episode and continues to be managed with a multidisciplinary team approach in the community. She has received the standard advice regarding long-term steroid use. Oral contraceptive pills were initially stopped as a result of the recent stroke although as she experienced menopausal symptoms she was re-instated on topical HRT patches. There is no plan to withdraw steroids and retest.

Summary
Vaccine related immune thrombocytopenia and thrombosis is a syndrome that has been reported in rare cases after COVID-19 vaccination although this entity is not yet fully understood. Cerebral venous thrombosis is the most common site of thrombosis, with remaining cases affecting a range of sites such as the splanchic system, heart, lungs, limbs and other solid organs such as adrenal glands and in many cases two or more vascular beds are involved simultaneously. This case highlights the limitation of imaging and importance of clinical signs and symptoms, high index of suspicion in the diagnosis of hypocortisolism.

DOE: 10.1530/endoabs.91.WH6

WH7

Erdheim Chester disease as a cause of Diabetes Insipidus
Soe Nyi Nyi Htet, Kagabo Hirwa & Jamie Smith
Torbay Hospital, Torquay, United Kingdom

Case Summary
A 53-year-old lady who was normally fit and well, presented with a 3 months history of polydipsia and excessive polyuria up to 13 litres a day. A water deprivation test confirmed a cranial diabetes insipidus, and she was started on desmopressin. Apart from hypothyroidism that was well controlled with levothyroxine replacement, the rest of her pituitary profile was unremarkable

DOE: 10.1530/endoabs.91.WH7

Endocrine Abstracts (2023) Vol 91
Additional Cases
C81
Non-classical presentation of Graves' disease during the postpartum period with idiopathic intracranial hypertension (IIH): A cause or a red herring
Idowu Olaogun
University College London Hospital, London, United Kingdom

Graves' disease relapse is a common occurrence during the postpartum period which is due to resurgence of immune system after pregnancy. In most cases, overt clinical symptoms are seen and the timing of its occurrence varies from 4 to 8 months. This is a case of a 33 year old lady referred after an MTOP with bilateral papilloedema and subsequently diagnosed with Graves relapse. She had a background of Graves' disease 7 years ago initially treated medically and had two previous relapses. Pregnancy was unplanned and eventually had Medical termination of pregnancy (MTOP) at 20 weeks of gestation for Down’s syndrome on fetal scans. The Thyroid function test was monitored during the antenatal clinic and normal a month before the MTOP. She developed headache about 12 hours after the use of misoprostol which progressively worsened with associated progressive visual impairments. Of note is the rapid weight gain previously before and during the pregnancy, has gained about 20 kg in the previous 2 years. Fundoscopy revealed bilateral papilloedema and MRI showed raised intracranial pressure with no structural brain disease. She had an LP with opening pressure of 35 cm and closing pressure of 12 cm H2O. Blood subsequently showed TSH <0.01 and FT4 44 two months after which necessitated Endocrinology referral. No other discriminatory features of hyperthyroidism apart from tachycardia and she was more concerned with the progressive visual loss and headache that is not controlled by simple analgesics impacting her quality of life. Literature was reviewed which confirmed previous case reports, she was advised that hyperthyroidism may be the cause of the IIH. While treatment of hyperthyroidism might work if it is responsible for the IIH, it might make it more difficult to lose weight which is the treatment for the weight gain as another possible risk factor. We therefore offered the treatment for hyperthyroidism and encouraged the Neurologists to start the treatment of IIH. She however chose not to take any of these medications but started lifestyle modification for weight loss which improved her IIH symptoms significantly and after 12 weeks, she started a low dose of PTU. This case illustrates the dilemma faced when thyrotoxicosis presents with non classical signs and symptoms and in this case, hyperthyroidism co-existed with other risks factors for IIH and it was difficult to know the risk factor responsible initially. However, the dominant risks was not the thyrotoxicosis but excessive weight gain.

DOI: 10.1530/endoabs.91.CB1

C82
Subclinical hyperthyroidism in pregnancy
David Hope
Imperial College, London, United Kingdom

33 year old female who is 5 months pregnant, referred to Endocrinology clinic with TFT’s in keeping with sub clinical hyperthyroidism. Previously also had a USS showing large 5 cm nodules both lobes, both indeterminate in appearance (US) which preceded pregnancy. Symptomatic with sweating and palpitations. No family history of thyroid disease and no ‘red flag’ symptoms. Clinical examination showed palpable thyroid nodules with no evidence of thyrotoxicosis. TSH 0.09mU/l, 14 and 13 within normal range. Discussed further investigation for both nodules and best management for SCHyperthyroidism in pregnancy. This patient is awaiting a further US thyroid +/- FNA.

DOI: 10.1530/endoabs.91.CB2

C83
A case of Graves’ disease relapse with high immunologic activity and recurrent refractory course precipitated by poor drug compliance - influence of carbimazole compliance on immunogenic activity
Idowu Olaogun
University College London Hospital, London, United Kingdom

Graves’ disease is a very common cause of thyrotoxicosis and it runs a relapsing remitting course due to varying immunogenicity of the pathogenic autoantibodies. Medical treatment is the preferred means of treatment by patients especially in the uncomplicated and non relapsing cases. Few studies have established the additional benefit of thionamides on immunogenic characteristics in Graves’ disease. This is a case of a 30 year old lady diagnosed with Graves’ disease 10 years ago during the peripuerium and treated medically in India for 6 months. She had a relapse 4 years after initial treatment when she was referred to our thyroid clinic with weight loss, tremor and palpitations. On examination, she had diffuse goitre with no orbitopathy and high TRAb of 97.8 with FT4 of 67.1. She initially opted for medical therapy after discussing risks of further relapses and in the course of treatment, noticed fluctuating course while on carbimazole in terms of the TFT and TRAb levels. We reiterated the need for compliance and need for definitive treatment due to inability to achieve remission while on medical therapy. She eventually opted for thyroidectomy (as she had small children at home). Due to the very poor control, the surgery was delayed and eventually when she was scheduled 3 years ago, she cancelled it with no documented reasons and continued on medical treatment. Her FT4 in the last six years has ranged between 35.4 and > 100 (normal range 12-22) with suppressed TSH <0.01 (normal 1-5) and TRAb 12.4 and >100. She has had several episodes of severe thyrotoxicosis with unrecordable high FT4 above 100 and high immunologic activity TRAb above 100 while on standard dose of carbimazole. However, during hospital admissions, she had reasonable response to high dose Carbimazole and prednisolone which confirmed poor drug compliance. The cause of her non compliance may be related to fatigue (long term medical treatment for which she was not insightful), no underlined psychopathology. Despite reiterating the needs for compliance and clarifying complications of poorly controlled thyrotoxicosis, she is still having unsteady TFT and persistently unrecordable high TRAB. This case illustrate the vicious cycle of poor drug compliance leading to upsurge of immunogenicity which continued to trigger recurrent refractory Graves’ disease leading to multiple hospital admissions- which suggests the possible benefits of carbimazole on immunogenicity.

DOI: 10.1530/endoabs.91.CB3

CB4
Amiodarone-Induced Thyrotoxicosis: Case Report
Chinedu Amazor & Jesse Kumar
 Maidstone Hospital, Hermitage Lane, Maidstone, Kent, United Kingdom

Introduction
Amiodarone is a widely used antiarrhythmic drug for refractory atrial or ventricular tachyarrhythmias. Amiodarone-induced thyrotoxicosis (AIT) occurs in up to 6% of patients taking this medication in iodine-sufficient areas of the world and in up to 10% in iodine deficient areas. AIT is of two types: type 1 is a form of iodine-induced hyperthyroidism whereas type 2 is a drug-induced destructive thyroiditis. Type 1 AIT tends to occur in patients with underlying thyroid autonomy in a nodular goitre, or Graves’ disease, while type 2 AIT appears because of direct damage or induction of apoptosis in thyocytes by amiodarone. Case report
A 68-year-old man presented to our emergency department with worsening atrial fibrillation. He denied previous personal or familiar history of thyroid dysfunction. On examination, he was tachycardic with a heart rate of 150 bpm. An ECG showed in was in a fast atrial fibrillation. Thyroid function tests showed a TSH <0.02 μU/l, FT3 9.1 pmol/l, FT4 71.0 pmol/l. Given the previous medical history of amiodarone use, a diagnosis of amiodarone-induced thyrotoxicosis was made. He was started on bisoprolol by the Cardiologist for rate control. He was then started on Carbimazole 40 mg mg and 30 mg of prednisolone daily. An iodine uptake scan was not performed as patient had already been started on carbimazole. His TSH-receptor antibody result came later to be < 0.3U/l. We stopped carbimazole as this was likely a Type 2 AIT, while he continued prednisolone. Prednisolone was gradually tapered and stopped over the next three months while monitoring his thyroid function. About four months post-steroid cessation, biochemical re-evaluation showed TSH 16.2 mU/l and FT4 11.4 pmol/l and similar picture persisted on a repeat follow up sample. He was then started on Levotirothyronine replacement. He is presently under endocrine follow up
Conclusion
This case highlights the effects of Amiodarone on the thyroid gland and demonstrates the possible spontaneous evolution of amiodarone induced thyrotoxicosis into hypothyroidism.

DOI: 10.1530/endoabs.91.CB4
A 72-year-old man with a past medical history of hypertension, atrial fibrillation and ischemic heart disease presented to cardiology outpatients for his routine visit. His regular medications included atorvastatin 80 mg daily, enalapril 5 mg daily, amiodipine 5 mg daily, aspirin 75 mg daily and amiodarone 200 mg daily. Endocrinologists were involved after noticing abnormal thyroid function tests (TFTs) on his routine check. TFTs showed a suppressed thyroid stimulating hormone (TSH) at a level of 0.001 mIU/ml (reference range 0.3-3) and elevated free thyroxine (T4) and triiodothyronine (T3) at a level of 47.58 pmol/l (11-18) and 7 pmol/l (3.5-6.5) respectively. Previous TFTs over the years were always normal. The patient was completely asymptomatic and denied any recent illness or neck pain or swelling. He has no family history of thyroid disorders and was a non-smoker. Physical examination was unremarkable with a resting heart rate of 80 beats per minute, irregularly irregular. A diagnosis of amiodarone-induced hyperthyroidism (AIT) was made. He was initially started on carbimazole (CBZ) 20 mg daily and prednisolone 20 mg daily. Amiodarone was stopped and atenolol at a dose of 12.5 mg daily was started after discussion with his caring cardiologist. TSH receptor antibodies came back negative and an ultrasound doppler of the thyroid gland showed a normal size gland with reduced vascularity. A diagnosis of type 2 AIT was made. Patient was reviewed after 3 weeks of treatment. He remained clinically well. Biochemically there was a slight decrease in T4, down to 36.49 pmol/l and T3 down to 6.2 pmol/l. TSH suppressed at 0.008 mIU/ml. CBZ was stopped and kept on the same dose of prednisolone. After 7 weeks of treatment, there was worsening in his TFTs, with T4 level of 52.18 pmol/l and T3 of 9.4 pmol/l. Prednisolone was increased to 30 mg daily and kept off CBZ. After 16 weeks of treatment, T4 came down to 26.77 pmol/l and T3 to 6.9 pmol/l, with TSH still suppressed at 0.008 mIU/ml. During this visit, prednisolone was decreased to 20 mg daily. TFTs continued to improve gradually and became euthyroid after 5 months of treatment (TSH 0.382 mIU/ml, T4 14.43 pmol/l and T3 4.9 pmol/l, currently on prednisolone 5 mg daily). A morning serum cortisol was taken more than 24 hours after his last dose of prednisolone and showed normal adrenal response with a cortisol level of 511 nmol/l. Prednisolone was stop completely after a total of 26 weeks of treatment. During follow-up visits the patient remained well and TFTs remained within range.

DOI: 10.1530/endoabs.91.CB6

Type 2 Amiodarone-induced Thyrotoxicosis
Kye-Cia Cilia
Male Dei Hospital, Msida, Malta

2 cases of Amiodarone induced thyroiditis. 1. 60 years old gentleman on haemodialysis, secondary to diabetes related kidney failure, on Insulin for diabetes, also on treatment for active pulmonary tuberculosis and on amiodarone for non-sustained VTs for one year and had left ventricular systolic dysfunction. He went into atrial fibrillation during a dialysis session and his thyroid function tests were done along with other blood tests. He was discussed with cardiology who advised to stop amiodarone and switch to bisoprolol. His TFTs were:
- TSH 0.16 mIU/l (0.27-4.2)
- T4 37.6 pmol/l (12.22)
- T3 2.8 pmol/l (3.1-6.6)

At this point he was referred to endocrine team. Clinically there was no thyroid swelling or peripheral signs of hyperthyroidism. The patient was started on carbimazole and tapering dose of prednisolone as the type of AIT was not known,
thyroid antibodies, thyroid ultrasound scan and Tc thyroid uptake scan was requested. The Thyroid antibodies came back negative, carbimazole dose was reduced and tapering dose of steroids was continued. Thyroid ultrasound came back as normal. Tc Thyroid scan showed homogeneous uptake, and the latest TFTs were normal. 2. 70 years old lady admitted with a fall. Background history of pulmonary embolism, atrial fibrillation, previous multiple cardiovascular, anxiety and depression, hypertension and osteoarthritis. Medications included rivaroxaban and amiodarone for 5 years. She was referred to the endocrine team for abnormal thyroid function tests. T4 > 100 pmol/land TSH < 0.02 mU/l. On examination, she had a normal thyroid and no signs of hyperthyroidism. Cardiology advised to switch amiodarone to bisoprolol. She was started on 40 mg of carbimazole and a tapering dose of steroids. Thyroid antibodies, thyroid ultrasound, and Tc thyroid uptake scan were requested. Thyroid stimulating Immunoglobulins were 0.95 IU/l (<0.56), ultrasound neck showed: mildly enlarged multinodular goiter, background chronic thyroiditis, several benign U2 nodules. Thyroid uptake scan showed, no uptake in the neck, however, this was done after being on carbimazole. The serial thyroid functions showed improvement.

DOI: 10.1530/endoabs.91.CB8

CB9
A case of Thyroid Hormones resistance causing symptoms in a young woman
Aftiz Nizami, Astra Khan & Khwaja Nizamuddin
Royal Blackburn Hospital, Blackburn, United Kingdom

This case report describes a 26-year-old presented with having regular shakes, including tremulous arms, feeling hot and cold, mood swings, increased sweating, constantly feeling hungry, being itching all the time and having stomach-ache. She felt easily bloated with certain types of food. She was investigated and found to have thyroid hormone dysfunction. Symptoms were suggestive of Thyrototoxicosis with Biochemical evidence of Thyrotoxicosis. She had further investigations including genetic studies which confirmed resistance to thyroid hormone. TSH Secretion adenoma is a differential but due pattern of inheritance with positive family history in the first degree relative (father RTH) investigations to differentiate between the two won’t be needed and genetic test could be more cost effective. TSH 1.1 mU/l(0.30-6.00) Normal since 2011 FreeT4 26.6 pmol/l(10.4-24.5) Fluctuating between high and normal since 2011 but persistent High Since 2021 FreeT3 6.2 pmol/l(3.0-7.1) but in 2020 high twice 7.8 & 7.6 pmol/l/CRP < 5 ESR 5 mm/hr Genetic Testing: heterozygous familial THR3 pathogenic variant RTH is autosomal dominant defect in 1 of the 2-thyroid hormone receptors, resulting in decreased end organ responsiveness/sensitivity to thyroid hormones. THR can be classified based on tissue resistance into pituitary, peripheral or generalized (both pituitary and peripheral) types. Mutations in the TR-beta gene, cell membrane transporter and genes controlling intracellular metabolism of thyroid hormone have been implicated in 85% of cases. It is characterized by elevated Thyroid Hormone Levels but the thyroid stimulating hormone (TSH) level is not suppressed, or not completely suppressed as would be expected. Many a times RTH can be mismanaged as hyper/hypothyroidism or there can be a delay in diagnosis due to lack of proper history and investigations. The diagnosis helps in appropriate treatment approach for the patient and genetic counselling of the family.

DOI: 10.1530/endoabs.91.CB9

CB10
Relapse of Graves’ Disease
Arline Deli & Sandro Vella
Malter Dei Hospital, Msida, Malta

A 23-year-old female presented with a three-month history of palpitations, tremors and recent anxiety. This was associated with hot flushes in the morning, heat intolerance and increase in appetite. Otherwise, bowel habits were normal and the patient suffered from long-standing menorrhagia with regular menstrual cycles. She denied a recent viral illness, neck pain or swelling, dysphagia, shortness of breath or dysphonia. She denied thyroid eye disease symptoms. She denied a past history of radiation or family history of thyroid cancer. The patient had no other medical or surgical history and denied smoking or alcohol intake. On examination, the patient appeared clinically hyperthyroid with an evident tremor of the out-stretched hands, sinus tachycardia and a palpable goitre, however there was no associated lymphadenopathy, thyroid bruits or thyroid eye signs.

Complete blood count and Liver Function Tests were normal at baseline. Ultrasound of the Neck and Thyroid showed a swollen and hyperaemic thyroid gland. The parenchyma was diffusely inhomogeneous in echotexture and mostly hypo-echoic with overall increase in Doppler signal in-keeping with Graves’ Disease. Seven years ago, the patient presented to her paediatric endocrinologist with fever, pharyngitis and thyroid hormone function tests. She was diagnosed with acute Epstein-Barr virus confirmed on PCR and treated conservatively. Anti-TSH Receptor Antibody and anti-TPO Antibody were negative and US Neck/Thyroid was in-keeping with a subacute thyroiditis. However, on-being reviewed more than one month after the viral infection, the patient remained clinically hyperthyroid, retained thyrotoxic thyroid function tests and was presumed to have Graves’ Disease. She was therefore started on Carbimazole 5 mg 8-hourly and titrated down over the span of a year. The patient was started on Propranolol 10 mg 8-hourly and Carbimazole 20 mg 12-hourly, and advised to start contraception. Risks of becoming pregnant while on Carbimazole and in the current thyrototoxic phase explained. Side effects of Carbimazole, including agranulocytosis and hepatitis, were also explained. She was counselled on radioactive iodine therapy (RAIDT) vs total thyroidectomy as a form of definitive treatment as this was a relapse of Graves’. Risks and benefits of both were explained and patient chose to undergo RAIDT once euthyroid on Carbimazole. Thyroid function tests were repeated every 6 weeks and Carbimazole down-titrated accordingly.

DOI: 10.1530/endoabs.91.CB10

CB11
Late Onset Amiodarone Induced Thyrotoxicosis
Delano Bramble, Sawsan Hamdan & Sherif Ghieth
University Hospitals Plymouth, Plymouth, United Kingdom

A 60-year-old engineer was reviewed in the Endocrinology clinic on 07/05/2021. He reported weight loss, palpitations, disturbed sleep, and fatigue over the previous four (4) months. He denied any neck pain or swelling. There were no symptoms consistent with thyroid eye disease. He had no pre-existing history of thyroid disease. TFT’s in March 2021 confirmed primary hyperthyroidism (TSH < 0.004 (0.35-4.94 pmol/l), FT4 19.8 (9.19-20.3 pmol/l), FT3 7.4 (2.9-4.9 pmol/l). Anti-TSH receptor antibodies 0.43 (0-2 IU/l) and TPO antibodies were negative. His GP had started carbimazole 20 mg once daily at the end of March 2021 after discussion with the Endocrinology team. A thyroid uptake scan was requested to rule out toxic nodular disease. There was a long delay in obtaining the uptake scan but eventually he received an appointment from the nuclear medicine team approximately 5 months after the clinic appointment. In preparation for the scan his carbimazole was discontinued (September 2021) and serial repeat TFT’s revealed that his thyroid function had completely normalised despite remaining off carbimazole. Hence, he received a total of six (6) months of carbimazole treatment. The nuclear medicine team decided against proceeding with the scan as the diagnostic yield would be low. A thyroid ultrasound scan was normal, revealing no evidence of nodular thyroid disease. He had a history of atrial fibrillation and had been treated with amiodarone 200 mg once daily for approximately 15 months (13/03/2018 – 01/07/2019). He underwent successful DC cardioversion during this time, but there was recurrence of his atrial fibrillation when he developed thyrotoxicosis. He had normal TFT’s during treatment with amiodarone and one (1) year after stopping the drug. Amiodarone had been discontinued eighteen (18) months prior to presentation with thyrotoxicosis. At follow up he remained clinically and biochemically euthyroid, off antithyroid medication. A diagnosis of late onset Amiodarone Induced Thyrotoxicosis (AIT) was considered. He had not been treated with steroids.

Discussion
Amiodarone is an effective anti-arrhythmic drug with recognised toxic effects. There are case reports describing the onset of thyrotoxicosis long after the discontinuation of amiodarone. This case highlights the need to consider the diagnosis of AIT in patients previously treated with this drug.

DOI: 10.1530/endoabs.91.CB11
CB12

Graves’ Disease and Cerebral Vasculopathy
Kasi Subbah1, Sam undeeshwari Perumal2 & Jacqueline Gilbert1
1King’s College Hospital, London, United Kingdom; 2University of Medicine and Pharmacy “Gregoire T. Popa”, Iaşi, Romania

A 20-year-old lady of Vietnamese origin presented with increasing frequency of headaches and worsening right sided weakness over 4 days. There was no other significant past medical illness, and she was not on any regular medication. She was not a smoker, and there was a history of thyrototoxicosis in her mother. Her heart rate was 110 beats per minute, and she was in sinus rhythm. On examination there was right sided weakness (MRC grade 4/5), expressive dysphasia, tremor of her extended fingers and smooth thyromegaly. CT angiogram showed smooth moderate narrowing throughout the course of the left internal carotid artery (ICA) and narrowing of the intracranial right ICA, right MCA and ACA. MRI showed ischaemic changes involving the left ICA territory. She was started on dual anti-platelets. Subsequent investigations revealed the following: FT3 41.7 pmol/l(3.1-6.8), FT4 >100 pmol/l(11.21.2) and TSH suppressed, TSH receptor antibody: 16.1 U/l(0-1.75), anti-TPO ab: 110 IU/ml (0-35). She was commenced on Carbimazole 40 mg once daily and Propranolol 80 mg three times a day (which was later switched to Verapamil to address any potential cerebral vasospasm).

Repeat CT angiogram done 5 days later, for worsening right sided weakness (MRC grade 0/5) showed worsening changes affecting the proximal major intracranial vessels with complete occlusion of the distal left ICA. An extensive vasculitis and thrombophlebitis scan did not reveal any abnormalities. An FDG PET-CT and MRA to assess extra-cranial vasculature did not show any evidence of large vessel vasculitis. Upper and lower limb arterial duplex study revealed triphasic waveforms throughout. CSF biochemistry and microbiology were unremarkable. There was no surgical target or indication for vascular bypass and medical treatment was advised. Differentials include Graves’ disease associated cerebral vasculopathy and Moyamoya syndrome, both of which are uncommon. She exhibited a limited responsive to Carbimazole and therefore switched to Propylthiouracil 200 mg four times a day. She received 3 doses of intravenous methylprednisolone 1000 mg and then was switched to oral prednisolone 50 mg titrating down by 5 mg weekly to a maintenance dose of 10 mg daily and was started on Methotrexate 15 mg subcutaneous weekly to be continued for 1 year. At the time of discharge, the weakness and expressive dysphasia had considerably improved. FT4 was 40.7 pmol/l, FT3 9.1 pmol/l and TSH remained suppressed.

Benefits of long-term immunosuppression are still unclear, with any treatment likely to prevent further stenosis rather than reverse changes already present.

DOI: 10.1530/endoabs.91.CB12

CB13

 Persistent Hyperthyroidism Secondary to Ectopic Autonomous Thyroid Tissue
Kasi Subbah, Samundeeshwari Perumal, Sheela Sathyarayan & Georgios Diffentiadis
King’s College Hospital, London, United Kingdom

A 28 year old lady presented with a 4 month history of anxiety, palpitations, weight loss and a pressure sensation in the neck. On examination she had fine tremor of her outstretched fingers and no palpable goitre with a regular heart rate. FT4 was 22 pmol/l(10.3-24.5), FT3 7.9 pmol/l(3.5-6.5), TSH 0.02 mIU/l(0.3-5.5), TSH receptor antibodies (TRAb) <0.9 U/l(0-1.75) and TPO antibodies <4 IU/ml(0-35). She was started on Carbimazole 20 mg daily and after being well controlled this was eventually weaned off. She was also referred with clinical and biochemical thyrotoxicosis when 34 weeks pregnant and was treated medically with low dose thionamides. TRAb’s were again undetectable and delivery was uneventful. Anticipating the next planned pregnancy, she was referred for thyroidectomy. Histology showed hyperplastic thyroid follicles consistent with Graves’ disease. Post-surgery she continued to be thyrotoxic on 150 mg of L-thyroxine. She was again referred at 26 weeks gestation with biochemical thyrotoxicosis after having stopped L-thyroxine for 2 weeks, with a suspicion of relapsed Graves’ disease secondary to remnant tissue. TRAb’s were again undetectable and there was detectable thyroglobulin 29.8 mg/l(0-40). She was restarted on Carbimazole and thyroid ultrasound showed two possible areas of focal thyroid remnant tissue. Pregnancy was again uneventful. Prior to revision neck surgery, a Tc99 uptake scan showed an ectopic large focus of tracer concentration in the left mediastinum with an uptake of 3.5% (Normal <3%) and at this point an older Tc99 scan from eight years ago which was unavailable to the endocrine team initially, was revisited and demonstrated a toxic right thyroid nodule with suppression elsewhere in the thyroid and a retrosternal focus of uptake. CT showed a rounded soft-tissue density mass in the anterior mediastinum measuring 4 x 6.5 cm. Her case was discussed in the southeast London Network thyroid MDM. The consensus was that this is more likely in keeping with seronegative Graves’ disease and either high dose radioactive iodine therapy or thoracic surgery was advised. The ectopic mediastinal autonomous thyroid tissue was successfully removed with thoracotomy as per patient’s wish. Histology showed nodular hyperplastic thyroid tissue.

Discussion
The coexistence of both Graves’ disease and toxic nodules (Marine-Lenhart syndrome) is uncommon. It is even rarer to see ectopic thyroid tissue in this setting. The diagnosis was further complicated by Graves’ disease being TRAb negative.

DOI: 10.1530/endoabs.91.CB13

CB14

Familial dysalbuminemic hyperthyroxinemia (FDH)
Mohammed Sha msaldene & Janki Panicker
Royal Liverpool Hospital, Liverpool, United Kingdom

Introduction
Familial dysalbuminemic hyperthyroxinemia (FDH) is a familial autosomal dominant condition that first was reported in 1979. It is caused by a mutant albumin molecule with an increased affinity for serum thyroxine (T4), despite the serum albumin level being normal. FDH causes increase in total T4 and T3 level with normal TSH level. As FDH patients are clinically euthyroid and asymptomatic, they do not require treatment.

Case report
68-year-old female, with no past medical history first seen in 2015 in the clinic following referral from the general practitioner with abnormal Thyroid function test (Normal TSH (3.9mU/l) with elevated T4 (24.9 pmol/l) and T3 (6.5 pmol/l)). There were no any symptoms to suggest hyperthyroidism at that point apart from change in bowel habit and occasional palpitations. There was no headaches or visual disturbances, no family history of thyroid illness and bed side examination was normal. Initial work ups was design to exclude or confirm TSH secreting pituitary adenoma (TSHoma) and thyroid hormone resistant. Hence, she underwent whole pituitary profile hormone check (Prolactin 151U/L, LH 21.5U/L, FSH 32.5U/L, Testosterone 1.0nmol/L, IGF-1 1nmol/L), TRH test, alpha subunit (0.51 IU/l) and thyroxine binding protein which all came back withing normal range. Different lab has been used to check for assay interference which had the similar result. Then suspicion of FDH has been raised for which bloods sent to Addenbrooke’s hospital, Cambridge to check TFT via different method which confirms the diagnosis of FDH. Furthermore, genetic test was conducted using fluorescent sequencing analysis of exon 7 of the albumin (ALB) gene using Mutation Surveyor with the result showed ‘This patient is heterozygous for the common c.725G>A (Arg242His) pathogenic variant in the ALB gene, which is known to cause elevated serum thyroxine levels associated with autosomal dominant FDH’ with the recommendation of no further TFT or genetic testing needed as finding explain the abnormal TFT.

Discussion
FDH is cause of discordant TFT due to interference in FT4 assays and can be diagnosed by assessing gene variants in the albumin (ALB) gene using Mutation Surveyor with the result showed ‘This patient is heterozygous for the common c.725G>A (Arg242His) pathogenic variant in the ALB gene, which is known to cause elevated serum thyroxine levels associated with autosomal dominant FDH’. The report was used as a part of patient’s genetic test results.

DOI: 10.1530/endoabs.91.CB14

CB15

Thyroid hyperplasia in Graves’ Disease – a not so uncommon occurrence
Herpreet Chagger
University Hospital of Coventry and Warwickshire, Coventry, United Kingdom

Thyroid hyperplasia (TH) in Grave’s Disease (GD) is not uncommon. It was first described in 1914 by William Halstead, however incidence has been difficult to establish as most patients remain asymptomatic from the TH and do not routinely undergo chest imaging when managing GD. We present a 49-year-old female with a background of rheumatoid arthritis and hypothyroidism, who presented to Rheumatology with proximal and distal muscle weakness, absent reflexes and weight loss. MRI scan reported widespread myositis in the thighs muscles, and EMG confirmed myopathy for all muscle groups. CT TAP was performed to investigate for malignancy and revealed a thymic mass measuring 2.3x2.6x5 cm and an enlarged thyroid. A PET scan was performed to rule-out metastatic disease
CB16

Abstract Withdrawn
DOI: 10.1530/endoabs.91.CB16

CB17

Thyrotoxicosis presenting as Stroke
Soo Yee Phang
Wrexham Maenor Hospital, Wrexham, United Kingdom

We have been seeing an 82 year old lady in endocrine clinic since 2017. She was initially admitted via ED in September 2017 with sudden onset confusion and left sided weakness. MRI confirmed ischaemic stroke with evidence of an acute right sided posterior cerebral artery infarct affecting right occipital and superior cerebellar regions. She was also noted to be in atrial fibrillation, and was also found to have significant thyrotoxicosis with a supressed TSH, free T4 32.0 pmol/l(11.5-22.7 pmol/l); free T3 17.1 pmol/l(3.5-6.5 pmol/l); thyrotropin receptors antibodies (TRAb) 38.8 U/I(< 1.0), and thyroid peroxidase antibodies > 1300IU/l(< 61). Despite stopping levothyroxine therapy, the patient remained hyperthyroid, and carimbazole was started. Surgery was halted in view of the likely possibility of TH secondary to GD. Multiple studies describe regression of TH with treatment of hyperthyroidism. If the thymic mass is non-cystic and homogenous, with no calcification or invasion of surrounding structures, TH is likely in the presence of GD. Anti-thyroid treatment should be started for at least 6 months before a follow-up CT is performed. If there is less than 50% regression, a biopsy or thymectomy should be considered to rule out malignancy. Our patient awaits repeat thoracic imaging.

A 70-year-old male, with background of hypertension and atrial fibrillation, presents with 6-week history of palpitation, 1.5 stone weight loss and syncope. He was on amiodarone since 14 years, with previous failed cardioversions. Thyroid function tests on presentation showed thyrotoxicosis TSH < 0.01 munit/l, T4:64.35 pmol/l, T3:17.2 pmol/l. All historic TFT were normal. TRAB was < 0.4 IU/l, TPO < 35IU/ml. He also had exertional dyspnoea and was in decompensated heart failure with bilateral limb edema. He was noted to have goitre but no thyroid eye disease. He was initiated on carbimazole 40 mg od. He proceeded to have a doppler ultrasound scan which showed increased vascularity indicating AIT 1. He was reviewed by cardiology team who stopped amiodarone and echocardiogram showed EF > 55%. His TFT slowly improved within 2 weeks of initiation of carbimazole, TSH < 0.01 munit/l, T4 30.2 pmol/l, T3: 9.4pmol/l. His case was discussed in MDT and the plan is to offer definitive treatment once euthyroidism achieved.

A case of Amiodarone induced thyrotoxicosis Type 1
Huma Humayun Khan
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Introduction
Amiodarone, a drug with high iodine content, is commonly associated with thyroid dysfunction. There are two well-recognized forms of amiodarone induced thyrotoxicosis. Thyrotoxicosis due to iodine excess leading to increased thyroid hormone synthesis is referred to as Amiodarone induced thyrotoxicosis type 1 (AIT type 1) whilst thyrotoxicosis due to direct toxic effect (thyroiditis) is known as Amiodarone induced thyrotoxicosis Type 2 (AIT type 2). The aim in both is to achieve euthyroidism, achieved by thionamides in AIT type 1 and glucocorticoid in AIT Type 2. Mixed or uncertain cases are treated with combination trial of both. The table from European thyroid association guideline highlights comparison.

Case
A 70-year-old male, with background of hypertension and atrial fibrillation, presents with 6-week history of palpitation, 1.5 stone weight loss and syncope. He has been on amiodarone since 14 years, with previous failed cardioversions. Thyroid function tests on presentation showed thyrotoxicosis TSH < 0.01 munit/l, T4:64.35 pmol/l, T3:17.2 pmol/l. All historic TFT were normal. TRAB was < 0.4 IU/l, TPO < 35IU/ml. He also had exertional dyspnoea and was in decompensated heart failure with bilateral limb edema. He was noted to have goitre but no thyroid eye disease. He was initiated on carbimazole 40 mg od. He proceeded to have a doppler ultrasound scan which showed increased vascularity indicating AIT 1. He was reviewed by cardiology team who stopped amiodarone and echocardiogram showed EF > 55%. His TFT slowly improved within 2 weeks of initiation of carbimazole, TSH < 0.01 munit/l, T4 30.2 pmol/l, T3: 9.4pmol/l. His case was discussed in MDT and the plan is to offer definitive treatment once euthyroidism achieved.

Discussion
The above case is unique as the presentation is 14 years post initiation of amiodarone with no underlying autoimmune thyroid dysfunction. Normally the effect of amiodarone on thyroid is seen as early as few weeks post-initiation and up to several months post-discontinuation due to long half-life. There was also reluctance in initiating combined therapy with prednisolone due to concern of worsening heart failure with fluid retention. Doppler ultrasound proved the most useful diagnostic aid.

<table>
<thead>
<tr>
<th>AIT Type 1</th>
<th>AIT Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour flow doppler sonography</td>
<td>Increased vascularity</td>
</tr>
<tr>
<td>Thyroid Radio iodine uptake</td>
<td>High/normal/low</td>
</tr>
<tr>
<td>Thyroid antibodies</td>
<td>Yes</td>
</tr>
<tr>
<td>Goitre</td>
<td>Usually, present</td>
</tr>
<tr>
<td>Onset time after starting amiodarone</td>
<td>Short</td>
</tr>
<tr>
<td>Spontaneous remission</td>
<td>No</td>
</tr>
<tr>
<td>Subsequent hypothyroidism</td>
<td>No</td>
</tr>
<tr>
<td>First line medical treatment</td>
<td>Anti-thyroid medication</td>
</tr>
<tr>
<td>Subsequent definitive treatment</td>
<td>Generally, yes</td>
</tr>
</tbody>
</table>

CB19

A case of Amiodarone induced thyrotoxicosis Type 1
Huma Humayun Khan
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Introduction
Amiodarone, a drug with high iodine content, is commonly associated with thyroid dysfunction. There are two well-recognized forms of amiodarone induced thyrotoxicosis. Thyrotoxicosis due to iodine excess leading to increased thyroid hormone synthesis is referred to as Amiodarone induced thyrotoxicosis type 1 (AIT type 1) whilst thyrotoxicosis due to direct toxic effect (thyroiditis) is known as amiodarone induced thyrotoxicosis Type 2 (AIT type 2). The aim in both is to achieve euthyroidism, achieved by thionamides in AIT type 1 and glucocorticoid in AIT Type 2. Mixed or uncertain cases are treated with combination trial of both. The table from European thyroid association guideline highlights comparison.

Case
A 70-year-old male, with background of hypertension and atrial fibrillation, presents with 6-week history of palpitation, 1.5 stone weight loss and syncope. He has been on amiodarone since 14 years, with previous failed cardioversions. Thyroid function tests on presentation showed thyrotoxicosis TSH < 0.01 munit/l, T4:64.35 pmol/l, T3:17.2 pmol/l. All historic TFT were normal. TRAB was < 0.4 IU/l, TPO < 35IU/ml. He also had exertional dyspnoea and was in decompensated heart failure with bilateral limb edema. He was noted to have goitre but no thyroid eye disease. He was initiated on carbimazole 40 mg od. He proceeded to have a doppler ultrasound scan which showed increased vascularity indicating AIT 1. He was reviewed by cardiology team who stopped amiodarone and echocardiogram showed EF > 55%. His TFT slowly improved within 2 weeks of initiation of carbimazole, TSH < 0.01 munit/l, T4 30.2 pmol/l, T3: 9.4pmol/l. His case was discussed in MDT and the plan is to offer definitive treatment once euthyroidism achieved.

Discussion
The above case is unique as the presentation is 14 years post initiation of amiodarone with no underlying autoimmune thyroid dysfunction. Normally the effect of amiodarone on thyroid is seen as early as few weeks post-initiation and up to several months post-discontinuation due to long half-life. There was also reluctance in initiating combined therapy with prednisolone due to concern of worsening heart failure with fluid retention. Doppler ultrasound proved the most useful diagnostic aid.

<table>
<thead>
<tr>
<th>AIT Type 1</th>
<th>AIT Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour flow doppler sonography</td>
<td>Increased vascularity</td>
</tr>
<tr>
<td>Thyroid Radio iodine uptake</td>
<td>High/normal/low</td>
</tr>
<tr>
<td>Thyroid antibodies</td>
<td>Yes</td>
</tr>
<tr>
<td>Goitre</td>
<td>Usually, present</td>
</tr>
<tr>
<td>Onset time after starting amiodarone</td>
<td>Short</td>
</tr>
<tr>
<td>Spontaneous remission</td>
<td>No</td>
</tr>
<tr>
<td>Subsequent hypothyroidism</td>
<td>No</td>
</tr>
<tr>
<td>First line medical treatment</td>
<td>Anti-thyroid medication</td>
</tr>
<tr>
<td>Subsequent definitive treatment</td>
<td>Generally, yes</td>
</tr>
</tbody>
</table>
**CB20**

Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves’ Disease

May Thin Khine

University Hospital Birmingham, Birmingham, United Kingdom

**Background**

Autoimmune thyroid conditions such as Hashimoto’s thyroiditis and Graves’ disease are more common in women than men. Both conditions are characterized by symptoms and signs on the opposite spectrum of the scale. Although cases of conversion from hyperthyroidism to hypothyroidism are often encountered in clinical practice, the exact incidence of this conversion is not known - it is possible that such conversion may be due to development of blocking and stimulating antibodies. Treatment is straightforward with anti-thyroid medications once the diagnosis is suspected and confirmed. It is important to get the correct diagnosis to be able to treat such patients appropriately.

**Case Presentation**

A 57-year-old man was referred with complaining of feeling hot and sweaty with palpitation and found to be thyrotoxicosis. He was then treated for thyrotoxicosis with ATD but found to have positive antibodies so diagnosis of graves’ disease was made. He was then developed the symptoms of hypothyroidism while on the lowest maintenance dose of ATD. He was then found to be overt hypothyroidism which needs a period of replacement treatment. He then redeveloped the overt active symptoms causing thyrotoxicosis pictures again. He completed the 18 months of ATD treatment with biochemical resolution of euthyroid status but then he developed severe thyroid eye disease. He eventually planned for total thyroidectomy for his Graves’ disease and ongoing ophthalmology input.

**Conclusions**

Although Graves’ thyrotoxicosis is common thyroid manifestation in day-to-day thyroid clinic, it is important to be aware of the nature of TRAb can be switching from stimulating to blocking activities and it makes the case to be challenging to manage in order to avoid the over hyper or hypothyroidism.

**DOE:** 10.1530/endobas.91.CB20

---

**CB21**

The Swinging Sixties: Drug-fuelled Highs and Lows

Xiao Ying Khor & Akheel Syed

Department of Diabetes, Endocrinology and Obesity Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom

A man in his sixties, with no previous history of thyroid dysfunction (Table 1), was commenced on Amiodarone for atrial fibrillation at the age of 64 years. 24 months after starting on Amiodarone, the patient was found to have a low TSH with markedly elevated fT4 but normal free T3 (fT3). He was asymptomatic, there was no goitre, thyrotoxicosis and TSH-receptor antibodies were negative.

The thyroid dysfunction was managed by non-interventional observation with gradual resolution (Table 2).

**Table 1** Thyroid function tests (TFTs) prior to commencement of Amiodarone

<table>
<thead>
<tr>
<th>Age</th>
<th>TSH (0.35-5.50 mU/l)</th>
<th>fT4 (10-20 pmol/l)</th>
<th>fT3 (3.5-6.5 pmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>58+</td>
<td>2.7</td>
<td>21.0</td>
<td>3.4</td>
</tr>
<tr>
<td>62+</td>
<td>2.5</td>
<td>21.0</td>
<td>3.4</td>
</tr>
<tr>
<td>64+</td>
<td>3.4</td>
<td>21.0</td>
<td>3.4</td>
</tr>
</tbody>
</table>

Intriguingly, his TSH has now risen above the upper limit of normal with mildly elevated fT4 (Table 3). To exclude assay interference, thyroid function was rechecked on a different laboratory platform (Table 4).

**Table 4** TFTs checked on a different laboratory platform

<table>
<thead>
<tr>
<th>Age</th>
<th>TSH (0.35-5.94 mU/l)</th>
<th>fT4 (0.9-19.0 pmol/l)</th>
<th>fT3 (2.43-6.01 pmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>70+</td>
<td>6.04</td>
<td>18.4</td>
<td>3.18</td>
</tr>
</tbody>
</table>

An ultrasound scan of the thyroid revealed a slightly bulky thyroid gland with mild heterogeneity and no increased vascularity, suggestive of chronic or subacute thyroiditis.

**Points for discussion**

- Amiodarone-induced thyroid dysfunction?
- Laboratory assay interference?
- Other thoughts?

**DOE:** 10.1530/endobas.91.CB22

---

**CB22**

Recurrence of Graves’ disease in remnant Thyroid tissue after Total Thyroidectomy

Anna Zeeshan & Ira AhmedMohamed

Cambridge University Hospital, Cambridge, Cambridge, United Kingdom

**Case Report**

We reported a case of 54 year old lady who presented with symptomatic hyperthyroidism 11 years after total Thyroidectomy. She remained well controlled on average 100 mg of Levothyroxine until presented with persistently suppressed TSH despite weaning off and later withdrawal of levothyroxine (T4 16 pmol/land TSH <0.03 pmol/l) and elevated Thyroid Stimulating Antibodies (TST) (>40 iu/l). Her Thyroid ultrasonography showed remnants of thyroid tissue in the thyroid surgical bed. Peri-prosthesis scintigraphy showed multiple foci of active thyroid tissue; 13 mm nodule anterior to thyroid cartilage, 5 mm right paratracheal nodule and 2 small left thyroid nodules. Her Fine needle aspiration confirmed benign thyroid tissue (Thy2). She also developed mild Thyroid eye Disease managed with eye drops and selenium 200 mg. She was commenced on carbimazole 10 mg once a day. Although surgery will be challenging, she has been referred to surgeons for consideration of removal of remnant thyroid tissue.

Radioactive Iodine Treatment is best definitive treatment option as MRI Orbit did not show any active thyroid eye disease but she will likely need steroid cover to prevent progression of Thyroid eye symptoms.

**Discussion**

Graves’ Disease is an autoimmune condition characterized by production of auto antibodies against thyroid-stimulating hormone receptor (TRAb). Total Thyroidectomy removes target tissue for TRAb and controls hyperthyroidism. Surgical Thyroid resection reduces TRAb levels in variable degrees. The median half-life of TRAb has been estimated 93.5 days after total thyroidectomy in patients without Graves Ophthalmopathy(GO)or smoking and 357.4 days in patients with GO and smoking.

**Conclusion**

This case therefore demonstrates recurrence of thyrotoxicosis in remnant thyroid tissue stimulated by TRAb presenting years after Total Thyroidectomy.

**DOE:** 10.1530/endobas.91.CB22

---

**CB23**

A story of resistance: When Graves’ disease isn’t just Graves’ disease

Aisha Aslam & Alexander Lewis

Manchester Royal Infirmary, Manchester, United Kingdom

A 32-year-old female was referred with abnormal thyroid function tests after investigation for nonspecific joint symptoms and exhaustion in 2010. Initial biochemistry showed TSH 0.03 mU/l(0.2-5), Free T4 75 pmol/l(9-24). At her endocrine appointment she reported loose stools, tremors, exertional dyspnea and a peculiar sensation in neck in keeping with thyrotoxicosis. Since puberty, she had problems acquiring weight. Repeat thyroid function demonstrated TSH <0.01 mU/land Free T4 97.6 pmol/l. Carbimazole was initiated alongside propranolol and she felt marginally better after taking the prescription for a few days, so she stopped taking it and ceased follow up. Due to several unsuccessful appointments, she was discharged from the service. She returned to the service eight years later with the same symptoms. She was now experiencing ophthalmic issues. TSH was 1.2 mu/l and Free T4 was 35.4 pmol/l. Thyroid peroxidase antibodies and TSH Receptor antibodies were positive in keeping with autoimmune thyroid disease. Thyroid US was normal. There was a family history of thyroid disorders, with her mother and maternal grandmother having thyrotoxicosis. Two of her children had type 1 diabetes and one was reported to have a thyroid problem. Carbimazole and propranolol were prescribed for Graves’ disease. Despite significant carbimazole...
doses her symptoms persisted. She switched to propylthiouracil after believing she had issues with carbimazole but later reported varied compliance. She represented in 2022 with palpitations, hot flushes, tremor, insomnia, amniorrhhea and altered bowel habit, predominantly diarrhoea. She had continued propranolol but was intermittently taking propylthiouracil. She reported dry, gritty eyes but clinical activity score was 0/7. Smoking cessation and eye lubricants were advised. Investigations revealed TSH 0.64 mIU/L, Free T4 37.0 pmol/L. This pattern had persisted over several years and TSH hadn’t been suppressed since initial presentation. History was in keeping with Graves’ disease but underlying thyroid hormone resistance was also suspected. Propylthiouracil was ceased and symptoms were managed with titration of propranolol. Subsequent testing confirmed a pathogenic missense mutation in TRHB gene.

Conclusion

Graves’ disease is common and strong family history alongside positive antibody titres and clinical features are supportive of the diagnosis. Variable compliance with medications can make interpretation of results difficult but careful assessment of trends and spotting anomalies is vital to ensure alternate diagnoses aren’t missed, particularly when dual pathologies can co-exist. Thyroid hormone resistance is rare and treatment revolves around symptomatic management.

DOI: 10.1530/endoabs.91.CB23

**CB24**

**Acute decompensated heart failure in a patient with longstanding uncontrolled Graves’ thyrotoxicosis**

Ananthi Anandhakrishnan,1,2 & Kirun Gunganah,1,2

1Newham University Hospital, London, United Kingdom; 2Barts Health NHS Trust, London, United Kingdom

Case history

A 69-year-old female was referred acutely from the community with 4 weeks of progressive breathlessness. Initially exertional, she was now also breathless at rest with orthopnoea and paroxysmal nocturnal dyspnoea. She had a background of antibody-positive thyrotoxicosis diagnosed 33 years ago, managed solely in primary care on carbimazole 20 mg, with good compliance. On examination, she was dyspnoeic with an irregularly-irregular tachycardia and fine tremor to the outstretched hands. There was no ophthalmoplegia or palpable goitre. She had fine bibasal crackles with mild bilateral pitting oedema. She reported 10 kg of peripheral oedema, but ongoing thyrotoxicosis (fT4 15.9, TSH 0.01) prompted investigations.

Discussion

Radio-active iodine (RAI) therapy is effective in managing hyperthyroidism due to solitary toxic thyroid nodule, in which 90% efficacy is observed. The most common side effects of RAI include hypothyroidism, transient neck pain and dry mouth and eyes. Occasionally, transient worsening of hyperthyroidism or the development of Graves’ orbitopathy occurring after radioiodine therapy for toxic nodular goitre

Japhet Olaremi

Queen Elizabeth Hospital, Gateshead, Gateshead, United Kingdom

Radio-active iodine (RAI) therapy is effective in managing hyperthyroidism due to solitary toxic thyroid nodule, in which 90% efficacy is observed. The most common side effects of RAI include hypothyroidism, transient neck pain and dry mouth and eyes. Occasionally, transient worsening of hyperthyroidism or the development of Graves’ orbitopathy occurring after radioiodine therapy for toxic nodular goitre

Japhet Olaremi

Queen Elizabeth Hospital, Gateshead, Gateshead, United Kingdom

Radio-active iodine (RAI) therapy is effective in managing hyperthyroidism due to solitary toxic thyroid nodule, in which 90% efficacy is observed. The most common side effects of RAI include hypothyroidism, transient neck pain and dry mouth and eyes. Occasionally, transient worsening of hyperthyroidism or the development of Graves’ orbitopathy occurring after radioiodine therapy for toxic nodular goitre

Japhet Olaremi

Queen Elizabeth Hospital, Gateshead, Gateshead, United Kingdom

Radio-active iodine (RAI) therapy is effective in managing hyperthyroidism due to solitary toxic thyroid nodule, in which 90% efficacy is observed. The most common side effects of RAI include hypothyroidism, transient neck pain and dry mouth and eyes. Occasionally, transient worsening of hyperthyroidism or the development of Graves’ orbitopathy occurring after radioiodine therapy for toxic nodular goitre
Hyperthyroidism is a pathological state characterized by increased synthesis and secretion of thyroid hormones (thyroxine (T4) and triiodothyronine (T3)) by the thyroid gland. Subclinical hyperthyroidism – a milder form – is defined as a low or suppressed TSH (<0.4 mIU/L), but serum free T4 (FT4) and free T3 (FT3) within the reference interval.

Case
76 years old lady seen in endocrine clinic. She was referred by GP because of concerns regarding subclinical hyperthyroidism. She has background history of COPD, Psoriasis, and Osteoarthritis. Her usual medications included Salbutamol inhaler, Feastinal inhaler and Oceola (Aprimelast-for psoriasis). She has been having periodic bloods with the GP and found out to have subclinical hyperthyroidism. On assessment in the clinic patient has mentioned that she is generally lethargic and tired. There has been no change in her weight. She has occasional palpitations that mainly occur during the night. There was no history to suggest of fractures or low trauma fractures. She mentioned that she was previously diagnosed as having hypothyroidism and was on Levothyroxine tablets. She stopped taking those tablets 10 years ago. On clinical examination there were no signs of thyroid disease and no thyroid enlargement. Her heart sounds were normal to auscultations and there were no tremors too. She had been feeling unwell from psoriasis recently but there were no features of hyperthyroidism on history and clinical examination. TPO Antibodies were negative. Her Thyroid Receptor antibodies have been sent and awaiting results. She was started on low dose. Bloods for central hypothyroidism were done and were normal too. Considering that she has grade II subclinical hyperthyroidism, her age and potential complications, she has now been started on low dose Carbimazole 5 mg per day and will be followed up in clinic in due course for further review plus consideration of radioactive iodine if needed.

### Discussion
Treating subclinical hyperthyroidism is an open question amongst the endocrinologists. However, individualised treatment is necessary and the aim of the treatment is to restore thyroid state and avoid complications.

**Table 1.**

<table>
<thead>
<tr>
<th>Year</th>
<th>TSH</th>
<th>FT4</th>
<th>FT3</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/2022</td>
<td>&lt;0.02</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>16/01/23</td>
<td>&lt;0.02</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>30/11/2022</td>
<td>0.05</td>
<td>0.07</td>
<td>0.07</td>
</tr>
<tr>
<td>21/6/2018</td>
<td>11</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>02/11/2016</td>
<td>9.5</td>
<td>11</td>
<td>11</td>
</tr>
</tbody>
</table>

DOI: 10.1530/endoabs.91.CB29

---

**Case of persistent grade II subclinical hyperthyroidism without any overt complications**

Shahzad Akbar, Muhammad Taqi & Shiva Mongolu

Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom

Introduction
Hyperthyroidism is a pathological state characterized by increased synthesis and secretion of thyroid hormones (thyroxine (T4) and triiodothyronine (T3)) by the thyroid gland. Treatment of hyperthyroidism is usually undertaken in two phases: the first aim is to restore normal thyroid state and avoid complications. There are few reported cases of radioiodine induced de novo Graves’ disease in the literature. This case highlights the dual importance of clinicians being aware of and informing patients that RAI may induce Graves’ disease in a small group of patients.

**Discussion**
Treating subclinical hyperthyroidism is an open question amongst the endocrinologists. However, individualised treatment is necessary and the aim of the treatment is to restore thyroid state and avoid complications.

DOI: 10.1530/endoabs.91.CB29
CB31
Graves’ disease in ITU: Thyroid Storm vs Thyrotoxicosis
Vikram Ajit Rajan Thirupathirajan, Sawsan Hamdan, Delanos Bramble, Nishchil Patel & Ioannis Dimitropoulos
University Hospital Plymouth NHS Trust, Plymouth, United Kingdom

A 28-year-old female presented to ED with one week history of flu-like symptoms, palpitations, increasing breathlessness, and productive cough with copious sputum, of two days duration. There was h/o some weight loss over the last year, with episodic palpitations over the last 8-10 years that increased in frequency over the last one year. She had a family history of hyperthyroidism paternally and maternally. On examination, there was mild lid-lag and proptosis. She was tachypnoeic, tachycardic and had a low SO2 of 70% on room air. There were widespread bilateral crackles on lung auscultation. Routine blood tests showed an infective picture with an elevated CRP and White Cell Count. She tested positive for influenza A and Haemophilus influenzae, CT thorax confirmed pneumonitis. She was admitted to ITU and was managed with non-invasive ventilation, nebulisers, IV antibiotics, IV hydrocortisone and fluids. In ITU, her TFTs were deranged, with TSH < 0.004mIU/l(0.35-4.94mIU/l), free T3 - 21.5 pmol/l(2.9-4.9 pmol/l), and free thyroxine - 47.7 pmol/l(9.19 pmol/l). Anti-TSH receptor and TPO antibodies were positive. She was given propylthiouracil (PTU) and IV hydrocortisone. Whilst this improved the TFTs, she developed neutropenia - 0.6x10^9/l(1.76-2x10^9/l). PTU was stopped and after the neutropaenia resolved, carbimazole was commenced. At this point, the patient improved clinically from an infection point of view. However, she subsequently developed neutropenia on carbimazole too - 0.6x10^9/l. She was therefore posted for thyroideectomy and received seven days of Lugol’s iodine prior to this. This was an interesting case as there was debate about whether this lady had long-term undiagnosed thyrotoxicosis from Grave’s disease contributing to severe infection, or a thyroid storm. Thyroid storm is a clinical diagnosis, and use of the Burch-Wartoﬁsky Point Scale can help. For our patient, there were various positive signs to suggest thyroid storm, such as a tachycarrhythmia, breathlessness, and productive cough. However, on review, it was determined that these clinical signs were likely due to her severe pneumonia alone. In addition to this and her past history of thyrotoxicosis symptoms, it was concluded that our patient presented with pneumonitis, on a background long standing thyrotoxicosis from untreated Graves’ disease that was diagnosed in this admission, which may have exacerbated her infection and symptoms.

DOE: 10.1530/endoabs.91.CB31

CB32
Medical and surgical management of thyrotoxicosis
Beenish Zaki & Paul Carroll
Guy’s & St Thomas Hospital, London, United Kingdom

A 25-year old lady was referred to GSTT for further management of thyrotoxicosis as she had relocated to London. The patient developed thyrotoxicosis during her pregnancy at the age of 23. During her pregnancy, she had signiﬁcant weight loss. Her thyroid function test in September 2020 showed TSH <0.01 mIU/l; FT4 of 24.1 pmol/l; and TSH receptor antibody of 1.35 IU/l. Hence she was started on propylthiouracil (PTU) during pregnancy. PTU was titrated down based on biochemical response. However, she relapsed in the post-partum period in April 2021. Her TSH <0.01 mIU/l; FT4 of 41.5 pmol/l. Carbimazole was initiated at 40 mg per day. However, she developed swelling of her joints, thought to be carbimazole-related, and PTU was restarted. Nausea and vomiting were problematic, and therefore PTU was discontinued promptly. On review at GSTT in March 2022, she was found to have clinical features of thyrotoxicosis, with a body weight of 44 kg. There was a smooth goitre and no thyroid eye disease. Her thyroid function test showed TSH <0.01 mIU/l; FT4 of 77.0 pmol/l; FT3 of 28.2 pmol/l; TSH receptor antibodies at 8.222 IU/l; TPO antibodies at 175 U/ml. US examination: Heterogeneous hypervascular thyroid gland. No suspicious discrete nodules are identiﬁed. As it was uncertain whether PTU had resulted in adverse effects, PTU 150 mg TDS was re-initiated. She complained of ongoing palpitation and was started on beta-blocker. However, she had an allergic reaction following the commencement of the beta-blocker. Hence her medications were stopped, and she was offered surgery as a deﬁnitive treatment option for her thyrotoxicosis. As she remained thyrotoxic before surgery, she was pre-operatively started on Lugol’s iodine at a dose of ten drops TDS. This was commenced ten days before surgery to prevent thyroid storm. The patient had thyroid surgery on the 13th of June, 2022. The histopathological examination of the thyroid specimen demonstrated no evidence of malignancy. There were features consistent with treated Graves’ thyrotoxicosis.

CB33
Management of thyrotoxicosis complicated by neutropenia
Beenish Zaki & Anand Velusamy
Guy’s & St Thomas Hospital, London, United Kingdom

A 40-year-old female was referred for further management of thyrotoxicosis to GSTT. She worked as a nanny and had Graves’ thyrotoxicosis since October 2019. Her presenting symptoms were weight gain, hair loss, insomnia, and increasing anxiety. She had a large palpable goitre on examination with no eye disease. Ultrasound of the thyroid showed a diffusely enlarged thyroid with a normal echotexture, reﬂectivity and vascular ﬂow. Benign subcentimeter nodules were seen in each lobe, consistent with U2 nodules. No retrosternal extension was seen. ECG: Rate-controlled AF She was started on Carbimazole 60 mg OD in November 2019. This was tapered to 40 mg OD as the patient suffered from ﬂu-like symptoms. However, due to ongoing thyrotoxicosis, it was subsequently increased to 60 mg OD. She became pregnant in April 2020 and was started on PTU 100 mg. The patient medically terminated the pregnancy in September 2020. She had to be restarted on Carbimazole 40 mg due to an isolated increase in alkaline phosphate. In September 2021, she developed coryzal symptoms and stopped carbimazole. Carbimazole was again restarted at the lower dose of 20 mg OD which continued till August 2022. She stopped her treatment in August 2022 because she disagreed with the management plan of her local endocrinology team and was referred to GSTT. At GSTT, she was started on PTU 50 mg BD after reporting an adverse reaction to Carbimazole. In February 2023, she developed severe neutropenia with PTU, so the anti-thyroid medications had to be discontinued. She also received three doses of G-CSF. She is now awaiting a thyroideectomy.

Blood test results

<table>
<thead>
<tr>
<th>Dates</th>
<th>Nov 2019</th>
<th>Sep 2020</th>
<th>Sep 2021</th>
<th>Oct 2022</th>
<th>Feb 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophil</td>
<td>1.5</td>
<td>1.4</td>
<td>1.4</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Platelets</td>
<td>218</td>
<td>205</td>
<td>165</td>
<td>209</td>
<td></td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>T3 (pmol/l)</td>
<td>25.1</td>
<td>48.2</td>
<td>25.5</td>
<td>19.8</td>
<td>13.9</td>
</tr>
<tr>
<td>T4 (pmol/l)</td>
<td>46.3</td>
<td>89.7</td>
<td>46.3</td>
<td>36.6</td>
<td>27.1</td>
</tr>
<tr>
<td>Alk Phos</td>
<td>344</td>
<td>280</td>
<td>169</td>
<td>156</td>
<td></td>
</tr>
</tbody>
</table>

DOE: 10.1530/endoabs.91.CB33

CB34
Immunotherapy induced Thyrotoxicosis and adrenal insufﬁciency
Abuzar Awadelkareem, Irfan Khan, Thanda Hnin, Nitin Shekar, Muhammad Asam & Sanjana Masinghe
CDDFT, Darlington, United Kingdom

Introduction
Immune-checkpoint inhibitors are used in patients with advanced cancers. They are associated with a wide array of side effects known as immune-related adverse events (irAEs). These can affect skin, gastrointestinal tract, multiple endocrine glands, liver and other systems. We report a 69-year-old male with a past medical history of Chronic Obstructive Pulmonary Disease and Lung cancer who was referred by the oncology team with a clinical and biochemical picture of thyrotoxicosis (TSH < 0.5, T4 38). His symptoms started 3 weeks following the second cycle of immunotherapy in the form of palpitation, tiredness, loss of weight and hand tremors. His thyroid function spontaneously recovered but he was having ongoing tiredness and feeling unwell and dizzy when reviewed in clinic, hence, further blood tests including random cortisol were arranged and the result of cortisol was 27, subsequently, a short Synacthen test was performed and the result as follow; baseline cortisol was 106 and after 30 minutes it was 336 . Rest of pituitary hormones were unremarkable. He started him on steroids replacement and planned to repeat the short Synacthen test in 3 months. The patient’s symptoms did improve signiﬁcantly following the steroids use.

Learning points:
1. Immunotherapy induced adrenal insufﬁciency is rare and needs a high index of suspicion to diagnose.

Endocrine Abstracts (2023) Vol 91
2. When reviewing a patient following immunotherapy, it is important to think of other autoimmune endocrine problems when the patient has one especially if the patient’s symptoms have not improved with treatment.

DOI: 10.1530/endoabs.91.CB34

CB35
A Case of Thyrotoxicosis refractory to medical management
Venkatram Subramaniam & Richard Bell
Stepping Hill Hospital, Stockport, United Kingdom

A 39-year-old lady with background history of autoimmune hypothyroidism diagnosed over 10 years ago, established on Levothyroxine 100 mg once daily, was referred by the GP with unusual sweating, palpitations, tiredness, anxiety, tremors and weight loss of around one stone over last few months. The thyroid function tests were suggestive of thyrotoxicosis with TSH of less than 0.05 mU/l, FT4 60 pmol/l, hence the dose of levothyroxine was gradually reduced and ultimately stopped. Despite all this she remained symptomatic. She was commenced on Carbimazole 20 mg once daily and Propranolol 40 mg thrice daily. Her symptoms gradually improved. On examination there was no goitre or thyroid enlargement. She had family history of thyroid disease. The thyroid uptake scan and the TRAb result which was available later (raised at 24 U/l) confirmed autoimmune Graves’ disease. She had radioactive iodine therapy (530 MBq), following which she developed of thyroiditis with thyroid gland swelling and painful swallowing. She was started on tab Prednisolone 30 mg once daily for 5 days which improved her symptoms. When she was reviewed again after five weeks, the TTFs were suggestive of hypothyroidism (TSH of 131.5 mU/l, FT4 less than 1 pmol/l), hence she was started on tab Levothyroxine 100 mg once daily. She was closely monitored with repeat TTFs and after a period of 4-6 weeks her TTFs improved significantly (TSH 1.69 mU/l, FT3 4.5 and FT4 19 pmol/lrespectively). She still complained of tiredness and low energy levels, hence vitamin D level was done which was very low and she was started on replacement. We explained to her that around 10% of patients with hypothyroidism still have symptoms of feeling tired and lethargic despite achieving target range of FT4, FT3 and TSH level. For completion purpose she was referred to rheumatologist to look into the possibility of fibromyalgia causing her symptoms.

Conclusion
This case highlights the fact that occasionally patients labelled with diagnosis of hypothyroidism may actually have blocking thyroid antibodies, and later they may present as thyrotoxicosis when producing stimulating antibodies. Hence physician or GP need to be aware of this switching antibodies in Graves’ disease to manage the patient properly and prevent any thyrotoxicosis related complications. Such cases are clinically challenging hence block and replace regimen is ideal until definitive treatment is done.

DOI: 10.1530/endoabs.91.CB36

CB37
A Case of severe hypothyroidism in an elderly patient with Hashimoto’s Disease
Margaret White
NHS, Dundee, United Kingdom

85 yo presenting with collapse, found to be hypothermic, bradycardic, hypotensive and hypoglycaemic, decreased GCS, on admission. TSH 155. T4 unrecordable. Prescribed IV liothyronine and hydrocortisone as per guidelines. Managed in Medical HDU. Careful management of hypothermia to avoid vasodilatation and hypotension- blankets rather than active warming. Close management of blood sugars for hypoglycaemia. PI responded well to therapy. Oral levothyroxine started once pt alert and swallowing. The trigger was thought to be non compliance with medication.

DOI: 10.1530/endoabs.91.CB37

CB38
A Rare Occurrence of Solitary Pheochromocytoma in an Adolescent Presenting with Cholestatic Liver Derangement
Preehivn Pillai Gopalakrishnan1, Yong Ming2 & Serena Sert Khim Kho2
1 Lahad Datu General Hospital, Sabah, Malaysia; 2 Queen Elizabeth II General Hospital, Sabah, Malaysia

A 16-year-old male, previously well, presented with 3 days history of non-specific body ache and headache. His blood pressure was 194/127 mmHg, heart rate 115 beats/minute but had normal examination findings otherwise. His BP was high throughout his admission and his BMI was 20 kg/m2. Drug history was unremarkable. He had noted he had transaminitis with predominately elevated alkaline phosphatase (ALP), His ALP was 397 U/l, Alanine transaminase (ALT) 124 U/l, Aspartate transaminase (AST) 140 U/l, 3-Methoxytyramine: 4.20 umol/day (0.10 - 1.79 umol/day) and Normetanephrine: 56.50 umol/day (0.50 - 2.49 umol/day) and 3-Methoxytyramine: 4.20 umol/day (0.10 - 1.79 umol/day). The diagnosis of pheochromocytoma was made and he was started on alpha then subsequently beta blockade with high salt diet. Interestingly we noted his cholestasis resolved in 4 weeks after starting on antihypertensives. Surgery was delayed for 2 months due to socioeconomic constraints. Post surgery, histopathological examination revealed findings consistent with pheochromocytoma with no evidence of necrosis. It is reported this is likely due to effects of excessive interleukin-6 (IL-6). Catecholamines can increase IL-6 production which is shown to cause intrahepatic cholestasis. Besides, it is also shown alpha adrenergic receptors have significant influence in the increased expression and secretion of IL-6. Hence alpha blockade may reduce IL-6 secretion. However, reports vary on when IL-6 reduces in patients with pheochromocytoma. Some case reports have shown that it reduces with alpha and beta adrenergic blockade and hence the improvement in liver injury. Others have shown IL-6 level normalised only after adrenalectomy. This difference could be due to severity of adrenal tumour necrosis as it is postulated the bigger the necrosis, the higher the IL-6 production. This may possibly explain why our patient’s liver function test normalised after commencing antihypertensives as there was no evidence of tumour necrosis on either CT scan or HPE examination. Hence early pharmacological treatment and definitive surgery should be instituted as soon as possible once the diagnosis is confirmed.

DOI: 10.1530/endoabs.91.CB38

Endocrine Abstracts (2023) Vol 91
CB39
Case of Adrenocortical Tumour
Sangita Sharma
NHS Trust, London, United Kingdom

Background
Mrs X had experienced severe right sided abdominal pain. Brought to hospital by ambulance from the residential home. In Accident and Emergency, she was confused and the accuracy of her history was difficult to confirm. Mrs X had a CT abdomen and pelvis with contrast. This had reported a 3.8 cm enhancing, well defined left adrenal mass, this needed to be assessed with adrenal protocol CT. Referred to Nurse-Led Adrenal Incidentaloma clinic for investigations.

Past Medical History
History of falls. New diagnosed hypertension Current Medication: Nitrofurantoit 100 mg MR 1 BD Codeine 15 mg 1-2 up to 4 x daily as required Paracetamol Newly Commenced on Amlodipine in view of elevated BP

Investigations following clinic appointment
1. Plasma renin aldosterone measurement:
   Aldosterone renin ratio = 463 pmol/l, Renin: 0.3 nmol/L/hr
2. Plasma metanephrines (after being in the recumbent position for 30 minutes)
   Plasma metanephrine: 156 pmol/l(151)
   Plasma normetanephrine: 346 pmol/l(180)
3. Plasma 3-Methoxytyramine: < 75 pmol/l(180)
4. Urine free cortisol measurement.
   This had demonstrated a raised 24hr urine free cortisol levels significantly elevated at 618 (1-124)
5. Overnight dexamethasone suppression test
   Result was 81 nmol/l, non-suppressed level.
6. low dose dexamethasone suppression test (LDSST)-
   Baseline cortisol day 1: 661 nmol/l
   Day 2 48hr: 78 nmol/l, non-suppressed level
7. ACTH: 12.9 ng/l(7-63)
8. CT Adrenal with contrast-
   Left adrenal lesion in keeping with a benign adrenal adenoma.
9. Adrenal MDT Mrs X case was discussed amongst our MDT and this will be investigated further at a tertiary centre.
10. The new working diagnosis

Discussion
Interestingly, this patient does not have cushingoid features and she is not obese. It has been difficult to interpret the ACTH level given that it is not fully suppressed. One may even consider a case of ectopic ACTH. Making a diagnosis has been difficult to interpret the ACTH level given that it is not fully suppressed. One may even consider a case of ectopic ACTH. Making a diagnosis may not always be straightforward. However, given the ACTH is low, cortisol levels are not suppressed, and she has an adrenal adenoma this may be in keeping with a diagnosis of adrenal incidentaloma.

DOI: 10.1530/endoabs.91.CB39

CB40
Adrenocortical Carcinoma Presenting with flank pain: A Case Report
Mili Dhar
King’s College Hospital, London, United Kingdom

A 52-year-old female presented with acute left flank pain after experiencing intermittent pain, weight gain, mood disturbances and hirsutism for six months. A CT scan of the abdomen and pelvis revealed a large heterogeneous 10x7x15 cm mass in the left adrenal gland with local invasion. The patient had a past medical history of right invasive ductal carcinoma and had undergone a wide local excision. She was referred to the Endocrine team.

Biochemical Investigations:

The initial biochemical investigations revealed unsuppressed cortisol levels on ONDST and elevated serum androgens.

Pre-operative Biochemical tests:

<table>
<thead>
<tr>
<th>Test</th>
<th>Normal range</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overnight dexamethasone</td>
<td>&lt;50</td>
<td></td>
</tr>
<tr>
<td>Cortisol 217 nmol/l</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Androgens:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-Hydroxyprogesterone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.0 nmol/l</td>
<td>(0.0-5.0)</td>
<td></td>
</tr>
<tr>
<td>Androstenedione</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 nmol/l</td>
<td>(1.1-7.7)</td>
<td></td>
</tr>
<tr>
<td>DHEAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.7 nmol/l</td>
<td>(0.9-11.6)</td>
<td></td>
</tr>
<tr>
<td>Serum Testosterone</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Blood test

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overnight dexamethasone</td>
<td>406 nmol/l(&lt;50)</td>
</tr>
<tr>
<td>suppression test</td>
<td></td>
</tr>
<tr>
<td>24-hour urine cortisol</td>
<td>94 nmol(24 Hours: 10 - 147)</td>
</tr>
<tr>
<td>ACTH</td>
<td>7 ng/l(&lt;47)</td>
</tr>
<tr>
<td>Renin</td>
<td>0.6 nmol/L(0.5 - 3.5)</td>
</tr>
<tr>
<td>Aldosterone</td>
<td>88 pmol/l(100 – 890)</td>
</tr>
<tr>
<td>Plasma metanephrines</td>
<td>119 pmol/l(1180)</td>
</tr>
<tr>
<td>Plasma normetanephrines</td>
<td>384 pmol/l(510)</td>
</tr>
<tr>
<td>17 OH progesterone</td>
<td>3.5 nmol/l(&lt;5.0)</td>
</tr>
<tr>
<td>DHEAS</td>
<td>&gt; 27.1 nmol/l(10 – 8.0)</td>
</tr>
<tr>
<td>Androstenedione</td>
<td>4.5 nmol/l(1.3 – 5.8)</td>
</tr>
<tr>
<td>FSH</td>
<td>3.1 IU/l(1.4 - 18.1)</td>
</tr>
<tr>
<td>LH</td>
<td>5.5 IU/l(1.5 - 9.3)</td>
</tr>
<tr>
<td>Oestradiol</td>
<td>115 pmol/l(28 – 156)</td>
</tr>
<tr>
<td>Testosterone</td>
<td>19.8 nmol/l(8.0 – 30.0)</td>
</tr>
<tr>
<td>SHBG</td>
<td>52.00 nmol/l(14.56 - 113.3)</td>
</tr>
</tbody>
</table>

Staging and Treatment:

As part of tumour staging, an FDG-PET scan was performed, which showed an intensely FDG-avid left adrenal mass consistent with a primary adrenal malignancy. There was no evidence of distant metastasis. Following discussion in the Adrenal Multidisciplinary meeting (MDT), the patient underwent a left oncological adrenalectomy. The surgery was complicated by haemorrhage due to left kidney blood vessels infiltrating the mass, and part of mesocolon and left kidney were attached to the mass, requiring resection. She was commenced on hydrocortisone 10 mg twice daily post-operatively. Histology confirmed ACC with a Ki67 of 80-90%. A genetic panel was completed, which came back negative for Li Fraumeni syndrome.

Post-operative Biochemical Investigations:

Following surgery, repeat biochemical assessment revealed undetectable DHEAs and androgen metabolites. Repeat USP showed previous androgen metabolite levels were low (and appropriate for age), whilst DHA metabolites and 17-hydroxyprogrenolone metabolite pregnenisol were not detected.

DOI: 10.1530/endoabs.91.CB40
CB42
A case of Phaeochromocytoma crisis precipitated by biliary sepsis
Nihad Elsayed Mohamed Ali1, Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom
Background Phaeochromocytoma is a rare tumour that arise from chromaffin cells in the adrenal medulla and produces signs and symptoms due to excessive catecholamines secretion from tumour. Presenting symptoms can vary but often they classically present with headaches, sweating and palpitations in the setting of paroxysmal hypertension. Phaeochromocytoma crisis results from the sudden release of large quantities of catecholamines and leads to progressive multiple organ dysfunction.
Case presentation 54 years old gentleman with a history of phaeochromocytoma not for surgical resection as high anaesthetics risk, obesity, IHD, CABG, DM type2, toes amputations bilaterally and PVD. Presented with biliary sepsis precipitating phaeochromocytoma crisis. The patient admitted to ED with right upper quadrant abdominal pain, jaundice, vomiting and pyrexia. Repeat CT scans revealed acute necrosis, compatible with an adrenocortical carcinoma and no FDG avid metastatic disease demonstrated. The patient was planned for adrenalectomy. He did not need medical therapy for hypercortisolism prior to surgery as he was completely asymptomatic and blood pressure was well controlled. He underwent an open right adrenalectomy with no immediate complications. The histopathology showed oncocytic adrenal cortical carcinoma with vascular invasion, PT2 gN2 (TNMv8), no capsular invasion, Ki 67 8.7%. He was started on hydrocortisone tablets post-surgery. Short synacthen test 6 weeks post-surgery showed an adequate cortisol response. He was reviewed in Oncology clinic in view of histopathology finding. After discussion with Histopathology for tumour grading, it was regarded as very low grade by Helsinki scoring system (Helsinki score 13) and no adjuvant therapy is needed. He will be closely monitored with surveillance CT scans. He remains well and is waiting for the surveillance CT scan. Further plan from Endocrinology includes testing of 9 am cortisol off morning hydrocortisone to assess his adrenal axis. Oncocytic variant is a rare subtype of adrenocortical cancer and there is less guidance available for post operative period care. Helsinki scoring system is used for prognosis and a score more than 17 is associated with adverse prognosis.
DOI: 10.1530/endoabs.91.CB42

CB43
Cushing’s Syndrome of Unknown Aetiology
Wuyee Win
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Endocrine Abstracts (2023) Vol 91

PET CT scan showed large right suprarenal mass with intense FDG activity and necrosis, compatible with an adrenocortical carcinoma and no FDG avid metastatic disease demonstrated. He was planned for adrenalectomy. He did not need medical therapy for hypercortisolism prior to surgery as he was completely asymptomatic and blood pressure was well controlled. He underwent an open right adrenalectomy with no immediate complications. The histopathology showed oncocytic adrenal cortical carcinoma with vascular invasion, PT2 gN2 (TNMv8), no capsular invasion, Ki 67 8.7%. He was started on hydrocortisone tablets post-surgery. Short synacthen test 6 weeks post-surgery showed an adequate cortisol response. He was reviewed in Oncology clinic in view of histopathology finding. After discussion with Histopathology for tumour grading, it was regarded as very low grade by Helsinki scoring system (Helsinki score 13) and no adjuvant therapy is needed. He will be closely monitored with surveillance CT scans. He remains well and is waiting for the surveillance CT scan. Further plan from Endocrinology includes testing of 9 am cortisol off morning hydrocortisone to assess his adrenal axis. Oncocytic variant is a rare subtype of adrenocortical cancer and there is less guidance available for post operative period care. Helsinki scoring system is used for prognosis and a score more than 17 is associated with adverse prognosis.
DOI: 10.1530/endoabs.91.CB42

CB44
Severe Cushing’s Syndrome in a 24 year old female
Gordon Sloan1,2, Ruth Macinerney1, Anita Pillai1, Robert Robinson1, Shillo Pallai3 & Ibrahim Shabuddin2
1Chesterfield Royal Hospital, Chesterfield, United Kingdom; 2University of Sheffield, Sheffield, United Kingdom; 3University of Sheffield, Sheffield, United Kingdom
A 24 year old female presented to her general practitioner with general malaise. She had a genetic diagnosis of hereditary non-polyposis colorectal cancer (Lynch syndrome), with no colonic lesions detected on screening. Routine biochemistry revealed usual laboratory abnormalities with the exception of an elevated alkaline phosphatase and hypercalcaemia (BM 33). On admission he was dehydrated, flushed and sweaty. Repeat ABG showed acidosis, ketones were normal and lactate increased to10. Management was guided by medical registrar and intensive care team, treated with multimodality therapy including IV fluids, alpha-blockers (Phenoxybenzamine and Doxazosin) and variable rate intravenous insulin infusion. Good response to adequate fluid resuscitation and alpha adrenergic blockade, patient was stabilized and BP regains to normal range. Blood glucose levels improved, vomiting settled and he was able to eat and drink therefore the insulin infusion stopped and restarted on his regular insulin regimen. The Patient improved significantly and discharged home after 5 days.
Conclusion Phaeochromocytoma crisis is a life-threatening medical emergency that necessitates cross-disciplinary expertise and management to ensure the best clinical outcome. If crisis is suspected, an n-blocker treatment with adequate fluid replacement therapy should be initiated as soon as possible. Good history taking and assessment on admission is crucial as if a known diagnosis of phaeochromocytoma is overlooked or treatment delayed the consequences could be catastrophic or even fatal; however, prognosis in usually very good if treated appropriately. This case highlights challenges with Phaeochromocytoma management when patients are not fit for surgical intervention.
DOI: 10.1530/endoabs.91.CB42

CB45
ECTOPIC ACTH DEPENDENT CUSHING’S SYNDROME
Shakil Safi
Aneurin Bevan University Health Board, Wales, United Kingdom
History 57 years old gentleman presented with no significant history. He was diagnosed with a left adrenocortical cancer (~8 cm). His metyrapone was titrated to attempt to control his hypercortisolemia and he was referred for surgery.
DOI: 10.1530/endoabs.91.CB44

CB46
Ectopic ACTH Dependent Cushing’s Syndrome
Shahid Safi
Aneurin Bevan University Health Board, Wales, United Kingdom
DOI: 10.1530/endoabs.91.CB44
A histopathology report in the meantime confirmed an adrenocortical adenoma. Hydrocortisone progressively over the next 10 weeks until she was on 10 mg OD. She was uneventful and she was started on IV hydrocortisone post op day 1 which was switched to Doxazosin for 2 weeks. She then had a low dose dexamethasone (0.1 mg) 3 times a day aiming for 5 mg TDS. A plasma metanephrine and parathyroid hormone normal. Calciumitonin 73,000 ng/3October 2019; Calciumitonin 75,000 ng/July 2020 Investigations-CT Thorax, Abd and Pelvis 15/11/2022 CTAP-Large Pleural effusion. There is a large left pleural effusion encasing the lung, which has developed since August 2021. In addition, there is a mass encasing the aorta extending in a preaortic position and related to the left hilum extending into the left upper lobe. Left adrenal mass likely as a result of metastatic medullary thyroid cancer.

Case Management during Hospitalisation
Admitted with shortness of breath and confusion on 15/11/2022 secondary to left sided pleural effusion. Effusion was drained and tachypleudous was performed. Pleural effusion was transudate with no malignant cells and was likely secondary to ongoing malignancy. Incidentally was found to have hypokalaemia and hypocalcemia on admission. Was on furosemide for his chronic pericardial effusion. Electrolytes replacement were refractory to IV replacement and serum cortisol levels were high raising suspicion of ectopic ACTH. Psychosis was noted. Was admitted in ITU for refractory hypokalemia, hypocalcemia and hypogonadism. Free cortisol [Urine] 11392 nmol/L: Free cortisol output [24hr urine] 27764 nmol/24h H < 146

Treatment
Furosemide was replaced by Spironolactone to minimise renal losses. Metyrapone was started and dose was titrated up without any complications 500 mg TDS aiming cortisol of 300-500. Electrolytes were corrected. Cortisol levels dropped. Also the chronic diarrhoea due to calcitonin producing tumor was controlled with loperamid and cholestyramine.

Block and Replace Regimen
Ketokonazole 400 mg TDS (inc from 200 mg TDS on 10/12/23), Metyrapone 5 caps TDS (inc from 4 caps 10/12/23), Spironolactone 100 mg OD, Dexamethasone 500mg BD.

Diagnoses
1. MEN 2A syndrome (634 mutation).
2. Metastatic medullary thyroid cancer with extensive bone metastases.
3. Ectopic ACTH Dependent Cushing’s Syndrome

Definitive Management-
Scheduled for bilateral Adrenalectomy

Genetics
His father-carrier, sister-positive MEN2A, Sister’s son-MEN2A, his daughter-positive MEN2A.

DOI: 10.1530/endoabs.91.CB45

CB46
A case of Adrenal Hypercortisolism: A timeline
Dooshayah Tuil, Gul Bano & Christina Triantafyllou
St George’s Hospital, London, United Kingdom

A 69 year old lady was initially seen in clinic in August 2020 for a right adrenal incidentaloma which was discovered after she had a CT abdomen for diverticulitis related symptoms. She subsequently had a dedicated CT Adrenal in January 2019 before she was seen in clinic which showed a 25 x 32 mm right adrenal adenoma labelled as lipid poor with an absolute & relative washout of 67% and 47% respectively. Her past medical history included hypertension and anxiety labelled as lipid poor with an absolute & relative washout of 67% and 47% respectively. Her other comorbidities included chronic obstructive lung disease, ischaemic heart disease, valvular heart disease, obstructive sleep apnoea and rheumatoid arthritis. She was on a number of regular medications including centrally acting agents for pain control and antipsychotic agents. She underwent Cushingoid features on examination and her random serum ACTH levels ranged between 7 and 17 ng/L (NR <42). She failed her overnight dexamethasone suppression test (ODST) with a cortisol level of 107 nmol/l/post-dexamethasone and her Low Dose Dexamethasone Suppression Test was also positive. Although her 24-hour urine free cortisol estimation was normal, her unstimulated urine steroid profile demonstrated relatively increased proportions of cortisol metabolites in the direction of Cushing’s. A peripheral dexamethasone test (IV dexamethasone 10 μg) was positive with an ACTH increase of 85% and a serum cortisol increase of 40%. Her pituitary MRI did not reveal a discrete adenoma.

She underwent Inferior Petrosal Sinus Sampling which confirmed a pituitary source of ACTH excess (ACTH IPPS: peripheral >3). Given her adverse anaesthetic risk profile she is currently being managed on medical therapy with metyrapone and fluconazole therapy.

Conclusion
Diagnosis of ACTH dependent Cushing’s in patients presenting through the adrenal incidentaloma pathway can be challenging, especially in the presence of suppressed serum ACTH levels from centrally acting medications. The presence of Cushingoid features and radiological suggestion of a hyperplastic-looking contralateral adrenal gland should trigger investigations for ACTH-dependent CS in those with proven hypercortisolism. A multidisciplinary approach to investigation and interpretation is advised.

DOI: 10.1530/endoabs.91.CB47

CB47
ACTH-dependent Cushing with low ACTH levels: a diagnostic conundrum
Razan Ali Rashid, Catherine Napijer, Simon Pearce & Yaasir Mamoojee
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom

Background
Diagnostic work-up for Cushing Syndrome (CS) can be challenging and is based on clinical and biochemical assessments. Biochemical evidence of endogenous steroid excess is demonstrated through overnight dexamethasone suppression test (ODST), low dose dexamethasone suppression test and/or 24-hour urinary free cortisol estimation (UFC). Once endogenous steroid excess is confirmed, random serum ACTH measurement is key in determining the suspected source of steroid excess: ACTH-independent (adrenal cause) or ACTH-dependent Cushing (pituitary or ectopic ACTH secretion). We report a case of ACTH-dependent CS where the serum ACTH level remains persistently low.

Case report
A 55-year-old female patient was referred with a 3 cm left adrenal adenoma, first discovered 8 years prior. She had type 2 diabetes, hypertension and a history of psychosis. Her other comorbidities included chronic obstructive lung disease, ischaemic heart disease, valvular heart disease, obstructive sleep apnoea and rheumatoid arthritis. She was on a number of regular medications including centrally acting agents for pain control and antipsychotic agents. She underwent dexamethasone suppression test and random serum ACTH levels ranged between 7 and 17 ng/L (NR <42). She failed her overnight dexamethasone suppression test (ODST) with a cortisol level of 107 nmol/l/post-dexamethasone and her Low Dose Dexamethasone Suppression Test was also positive. Although her 24-hour urine free cortisol estimation was normal, her unstimulated urine steroid profile demonstrated relatively increased proportions of cortisol metabolites in the direction of Cushing’s. A peripheral dexamethasone test (IV dexamethasone 10 μg) was positive with an ACTH increase of 85% and a serum cortisol increase of 40%. Her pituitary MRI did not reveal a discrete adenoma.

She underwent Inferior Petrosal Sinus Sampling which confirmed a pituitary source of ACTH excess (ACTH IPPS: peripheral >3). Given her adverse anaesthetic risk profile she is currently being managed on medical therapy with metyrapone and fluconazole therapy.

Conclusion
Diagnosis of ACTH dependent Cushing’s in patients presenting through the adrenal incidentaloma pathway can be challenging, especially in the presence of suppressed serum ACTH levels from centrally acting medications. The presence of Cushingoid features and radiological suggestion of a hyperplastic-looking contralateral adrenal gland should trigger investigations for ACTH-dependent CS in those with proven hypercortisolism. A multidisciplinary approach to investigation and interpretation is advised.

DOI: 10.1530/endoabs.91.CB47

CB48
Hunting for the source of ACTH
Lisa Yang & Florian Wernig
Imperial Healthcare NHS Trust, London, United Kingdom

A 64 year old female presented to A&E with a 3 month history of general decline, low mood and 8 kg weight loss. On examination there was facial plethora, thin skin with generalised bruising and peripheral oedema. Initial blood tests showed raised inflammatory markers, low potassium (2.6 mmol/l) and deranged liver function tests. A CT chest/abdomen/pelvis found a 2 cm lesion in the left lung with extensive liver metastases but no nodal deposits in the abdomen so this was felt to be a lung primary with liver metastases. A liver biopsy showed grade 2 neuroendocrine tumour (NET) with Ki67 3-5%. In the interim the patient went to Germany where she was started on chemotherapy. The patient returned to the UK one month later and presented to A&E with general malaise. She was found to be profoundly hypokalaemic with worsening liver function. A pituitary scan showed secondary hypothyroidism, hyperprolactinemia and hypogonadotropic hypogonadism. She had a raised ACTH with 9am cortisol of 1350 nmol/l which
did not suppress on dexamethasone testing. 24 hr urine free cortisol was also raised at 1730 nmol/l. MRI pituitary showed a 1 mm mass closely associated with the infundibulum and elevating the chiasm but appeared to be separate from pituitary gland. After discussion in pituitary and NET MDT meetings, she was started on prophylactic rivaroxaban, lanreotide and metyrapone. Functional imaging was carried out which showed that the lung lesion was FDG positive but did not take up Gallium which is unusual for a NET. Two attempts at lung biopsy were unsuccessful and the patient was deemed to be too frail for inferior petrosal sinus sampling. The decision was made to go ahead with medical management to stabilise the patient without confirmation of source of ACTH. She was commenced on metyrapone but was unable to normalise cortisol as she could not tolerate higher doses of metyrapone. An application was approved to use the novel agent Osilodrostat on compassionate grounds. This led to a marked reduction in cortisol levels and she was quickly established on a block and replace regime. She has remained well on osilodrostat therapy for 6 months and has been able to tolerate several cycles of chemotherapy with good effect. We have been monitoring her pituitary lesion which has marginally increased in size and further review in pituitary MDT have concluded that it is most likely to be a pituitary metastasis.

**CB50**
Cushing’s syndrome due to ectopic ACTH secretion
Muhammad Faheem, Gaurav Malhotra & Umaira Aziz
Basingstoke University Hospital, Basingstoke, United Kingdom

Ectopic ACTH is an infrequent cause of Cushing’s syndrome which can be severe in its presentation and needs immediate management to in order to prevent the complications associated with severe hypercortisolism. This case of ectopic ACTH secretion is being reported who presented clinically as Cushing’s syndrome and later diagnosed to have small cell carcinoma of lung. A 62-year-old previously healthy female was referred to Endocrinology in another hospital [December 2012] regarding possible PCOS but was lost to follow up after one appointment. Clinic enquiry established daily face shaving and frequent waxing. Menarche at 17 years old. Current periods were irregular. Examination showed generalised muscle wasting with lower limbs weakness started after chemotherapy. Her symptoms were progressive, with hemoptysis, weight loss and chest pain. She had further investigations for relatively acute presentation of Cushing’s syndrome. Her Overnight dexamethasone and low dose dexamethasone suppression tests revealed unsuspressed cortisol. Her ACTH levels were markedly raised. Radiograph of chest revealed left hilar mass which was followed by CT scan chest abdomen and pelvis which revealed left hilar lymph node, mediastinal and hilar adenopathy. Cortisol day curve showed blunted response. She also had aldosterone renin ratio, plasma metanephrines and MRI pituitary done which were normal. Her Blood glucose and HBA1c were normal. She was managed with IV potassium chloride infusion, anti-hypertensive and potassium sparing diuretics and heparin for prophylaxis. She was subsequently referred to tertiary care hospital for management. She was also started on metyrapone for high burden of cortisol. She had PET CT scan and EUS guided biopsy of hilar lymph node confirmed small cell carcinoma of lung. She was discussed in oncology MDT and was started on chemotherapy and radiotherapy for lung cancer. Ectopic ACTH related Cushing’s syndrome though rare; however, it should be taken as endocrine emergency as it is usually associated with severe complications of hypercortisolism. It should be urgently evaluated with diagnostic tests for Cushing’s and to localize the ectopic source of ACTH secretion. The strategies to manage these cases are the treatment of source of ACTH and to manage hypercortisolism and the complications associated with it, including hypertension, hypokalemia, thromboembolic prevention, and prevention of opportunistic infections especially P. Jirovecii. Furthermore, these patients should be managed under multidisciplinary settings.

DOI: 10.1530/endoabs.91.CB50
proximal more than distal. She had no sensory or cerebellar signs. She needed a walking stick and the assistance of 1 to mobilise and had low mood. Examination otherwise unremarkable.

Work up:
- HB 132g/dl, WBC 10.7 x 10^9/L, PLT 264 x 10^9/L
- CA 2.25 mg/dl, ALBUMIN 26g/dl, CRP 10, BLILIRUBIN 50 mg/dl, ALT 68u/l, ALP 631u/l
- K 3.8mmol/l, NA 142mmol/l, HCO3-32mmol/l, CK 68units/l
- CORTISOL 1388, TSH 1.5, VITAMIN D <20, HBA1C 7.1

Neurologist investigations:
- MRI Brain- no abnormality
- MRI whole spine: no metastatic spinal cord compression. acute osteoporotic
- Nerve conduction study: no sensory or motor polyneuropathy or myopathy. No evidence of motor neuron disease.
- Paraneoplastic antibodies screen was negative.

Endocrinology assessment showed no typical cushingoid appearance, however the possibility needed to be ruled out. Overnight dexamethasone suppression test which failed to suppress her cortisol suggesting excessive secretion, her serum cortisol was 784. Her 24 hr urine cortisol was >1790nmol/d, ACTH 141pg/ml. Treatment was started – Metyrapone started 1 week and a 5-point cortisol test was done to assess treatment response, it showed serum cortisol of 1097, 889, 1073, 902 and 933. Metapyrone was increased to 1g tds a repeat 5-point cortisol curve showed serum cortisol of 375, 441,449,487 and 346. Patient readmitted with hypoglycaemia and progressive weakness, insulin stopped and is being assessed currently for possibility of concomitant neurological dysfunction in view of ongoing muscle weakness. She underwent muscle biopsy to exclude Lambert Eaton myasthenic syndrome as an additional paraneoplastic phenomenon in this case.

DOI: 10.1530/endoabs.91.CB51

---

CB52
Cyclical Cushing’s disease – challenges in diagnosis and management
Natasha Sawhney & Prakash Abraham
Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Background
The case is a 64 year old patient referred by the GP who noticed she looked ‘cushingoid’. She gave an approximately 4 year history of a change in facial complexion, central weight gain, unsteadiness and poor wound healing. There was a history of depression, essential hypertension and previous back surgery. On examination she was plethoric, had pedal oedema, thin skin and central obesity (BMI 32).

Investigations
Initial overnight dexamethasone suppression test (DST) did not suppress cortisol (500nmol/l). Two 24 hour urine free cortisol (24UFC) tests were raised at 439 and 346nmol/24hours (55-284), confirming the diagnosis of Cushing’s syndrome. Pituitary profile showed normal IGF-1, prolactin, post-menopausal gonado-trophins and hypothyroidism. Repeat low dose DST gave a similar high cortisol level of 527nmol/l. High dose DST again failed to fully suppress, with cortisol 118nmol/l and ACTH 34ng/l, suggesting either a pituitary or an ectopic source. Corticotropic releasing hormone test was suggestive of pituitary rather than ectopic disease, with ACTH ranging 28 to 47ng/land cortisol ranging 365 to 698nmol/l. MRI pituitary gland suggested a possible 3mm pituitary adenoma. A plan was made for a methionine PET scan prior to surgery. One year following presentation however, 24UFC was normal at 236nmol/l, and symptoms had improved. A diagnosis of cyclical Cushing’s disease was made. Following biochemical recurrence in 2021, the patient declined the option of either pituitary or adrenal surgery and has opted to ‘watch and wait’. Her preference would be for adrenal surgery and has opted to ‘watch and wait’. Her preference would be for any intervention currently for possibility of concomitant neurological dysfunction in view of ongoing muscle weakness. She underwent muscle biopsy to exclude Lambert Eaton myasthenic syndrome as an additional paraneoplastic phenomenon in this case.

DOI: 10.1530/endoabs.91.CB52

---

CB53
Co-existence of an adrenal mass and Cushing’s disease: a diagnostic challenge
Buljoo Al Radhi¹, Yaasir Mamoojee² & Ahmed Al-Sharefi³
South Tyne Side Hospital, Newcastle Upon Tyne, United Kingdom; ²The Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom

Introduction
Adrenal tumors are commonly discovered incidentally on cross-sectional abdominal imaging. The Incidence of adrenal tumors increased 10-fold in the past 2 decades, with most diagnosed in older adults. In any patient with a newly discovered adrenal mass, determining whether it is functioning adenoma or non-functioning and identifying whether it is ACTH dependent or not is crucial to avoid missing the real underlying pathology.

Clinical case
A 40 years old female was referred to Endocrinology team by surgeons after having assessment for incisional hernia around the umbilical area and was found to have an incidental right adrenal adenoma of 4 cm size. She has past medical history of polycystic ovaries and reported excessive hair growth, acne and weight gain [ 133 Kg ]. Her pre clinic screening investigations showed normal urinary cortisol and normal baseline ACTH but with significantly raised Androgens. Her Testosterone and DHEAS levels were reducing with dexamethasone suppression test but post Dexamethasone cortisol was 71 nmol/l confirming cortisol excess. Subsequent clinical examination and further assessment confirmed the presence of Cushing’s disease and currently she is awaiting pituitary surgery.

Outcome
In presence of large adrenal mass, it is important not to miss a co-existence of pituitary dependent Cushion’s disease. The utilisation of urine cortisol and ACTH as a screening for autonomous cortisol secretion in adrenal mass work up can be falsely reassuring and a high index of suspicion is needed especially in symptomatic patients.

DOI: 10.1530/endoabs.91.CB53

---

CB54
Complexities in the diagnosing of Cushing’s syndrome
Vindya Wellala, Rao Rangarathana, Dineshka Kumarathunga, Puja Thadani & Givos Georgios
University Hospital Coventry and Warwickshire, Coventry, United Kingdom

Diagnosis of Cushing’s syndrome is challenging in the absence of cardinal features. But still, they have the same metabolic risk due to the presence of biochemical hypercortisolism. A 35-year lady was referred to the tertiary care endocrine unit following an incidental finding of high cortisol levels while on treatment for covid in 2021. She also had some weight gain, slow healing of wounds, and easy bruising. She did not have any features of hyperandrogenism and hypertension, or diabetes. Her periods were regular. On examination, BMI 32. She had no history of polycystic ovaries and reported excessive hair growth, acne and weight gain { 133 Kg }. Her pre clinic screening investigations showed normal urinary cortisol and normal baseline ACTH and cortisol 116nmol/d, ACTH 34ng/ml. Overtime dexamethasone suppression test but post Dexamethasone cortisol was 71 nmol/l confirming cortisol excess. Subsequent clinical examination and further assessment confirmed the presence of Cushing’s disease and currently she is awaiting pituitary surgery.

Table 1. Monitoring of cortisol excess.

<table>
<thead>
<tr>
<th>Laboratory value</th>
<th>24hr urine free cortisol (mg/dl)</th>
<th>Urine cortisol/creatinine ratio (mg/mmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td>439</td>
<td>127</td>
</tr>
<tr>
<td>1 week later</td>
<td>346</td>
<td>116</td>
</tr>
<tr>
<td>3 months</td>
<td>236</td>
<td>116</td>
</tr>
<tr>
<td>6 months</td>
<td>186</td>
<td>71</td>
</tr>
<tr>
<td>9 months</td>
<td>261</td>
<td>71</td>
</tr>
<tr>
<td>12 months</td>
<td>505</td>
<td>112</td>
</tr>
<tr>
<td>14 months</td>
<td>257</td>
<td>5.9</td>
</tr>
</tbody>
</table>

DOI: 10.1530/endoabs.91.CB54
A complex case of Cushing’s disease from an evasive source
Nosheen Sattar & Miguel Debono
Sheffield Teaching Hospitals, Sheffield, United Kingdom

Diagnosis of Cushing’s disease can be a difficult and lengthy process with repeated and dynamic testing required to ensure the correct diagnosis is made prior to invasive intervention such as surgery. This case demonstrates that even with meticulous investigation the underlying cause of the disease can still be evasive. A 43-year-old female presented with a history of hypertension since age 20, managed with Amlodipine (10 mg) and Ramipril (10 mg). She was investigated for secondary causes and an overnight Dexamethasone Suppression Test (DST) revealed a raised cortisol of 168nmol/l which was supported by a 24-hour urinary free cortisol result of 398nmol/24hour (< 199nmol/24hour). A low dose DST found baseline cortisol 320nmol/l with ACTH 40ng/l, and an almost doubling of cortisol at 45minutes (454nmol/l- 771nmol/l). A CT-CAP showed no other potential sources of ectopic ACTH. The patient was commenced on Metyrapone (250 mg BD) and VTE prophylaxis with low molecular weight heparin pending surgery. Following trans-sphenoidal surgery, histology found the adenoma to be a Gonadotrophinoma. Macroscopically no other lesions had been seen in the pituitary gland. Post-surgery the patient remained asymptomatic, with a cortisol of 329nmol/l at 15 min post-contrast washout was 35HU. Absolute washout was 96 % consistent with adenoma. The patent has successful surgery led to the resolution of hypercortisolism and symptoms. This case highlights the challenges in the diagnosis of Cushing’s in the absence of cardinal features. This problem occurs because there is an increasing global prevalence of obesity and diabetes, and the increasing use of exogenous glucocorticoids, leads to pseudo Cushing’s. And there is uncertainty about the best screening test for Cushing’s and how to individualize the choice of tests to prevent false positives. There is difficulty in identifying pathologic hypercortisolism in certain conditions: when it is extremely mild or cyclic. These difficulties are mitigated in part by the availability of assays for synthetic glucocorticoids, an increased understanding of the caveats and confounding factors that can cause false-positive and false-negative tests, and an increased understanding of the physiologic underpinning of pseudo-Cushings.

CB5

A complex case of Cushing’s disease from an evasive source
Nosheen Sattar & Miguel Debono
Sheffield Teaching Hospitals, Sheffield, United Kingdom

Diagnosis of Cushing’s disease can be a difficult and lengthy process with repeated and dynamic testing required to ensure the correct diagnosis is made prior to invasive intervention such as surgery. This case demonstrates that even with meticulous investigation the underlying cause of the disease can still be evasive. A 43-year-old female presented with a history of hypertension since age 20, managed with Amlodipine (10 mg) and Ramipril (10 mg). She was investigated for secondary causes and an overnight Dexamethasone Suppression Test (DST) revealed a raised cortisol of 168nmol/l which was supported by a 24-hour urinary free cortisol result of 398nmol/24hour (< 199nmol/24hour). A low dose DST found baseline cortisol 320nmol/l with ACTH 40ng/l, and an almost doubling of cortisol at 45minutes (454nmol/l - 771nmol/l). A CT-CAP showed no other potential sources of ectopic ACTH. The patient was commenced on Metyrapone (250 mg BD) and VTE prophylaxis with low molecular weight heparin pending surgery. Following trans-sphenoidal surgery, histology found the adenoma to be a Gonadotrophinoma. Macroscopically no other lesions had been seen in the pituitary gland. Post-surgery the patient remained asymptomatic, with a cortisol of 329nmol/l at 15 min post-contrast washout was 35HU. Absolute washout was 96 % consistent with adenoma. The patent has successful surgery led to the resolution of hypercortisolism and symptoms. This case highlights the challenges in the diagnosis of Cushing’s in the absence of cardinal features. This problem occurs because there is an increasing global prevalence of obesity and diabetes, and the increasing use of exogenous glucocorticoids, leads to pseudo Cushing’s. And there is uncertainty about the best screening test for Cushing’s and how to individualize the choice of tests to prevent false positives. There is difficulty in identifying pathologic hypercortisolism in certain conditions: when it is extremely mild or cyclic. These difficulties are mitigated in part by the availability of assays for synthetic glucocorticoids, an increased understanding of the caveats and confounding factors that can cause false-positive and false-negative tests, and an increased understanding of the physiologic underpinning of pseudo-Cushings.

CB56

A journey through Cushing’s Syndrome – “From Discovery till Recovery.”
Sadia Zafar, Ridhi Bhati & Sharmistha Roy Chowdhury
Princess of Wales Hospital, Bridgend, United Kingdom

Background
Cushing’s syndrome (10-15 million people diagnosed/year) is quite rare with Cushing’s disease accounting for >70% of cases in adults. Spinal epidural lipomatosis (SEl) secondary to endogenous Cushing’s syndrome is even more rare condition (8 reported cases so far) of which 3 cases are secondary to Cushing’s disease. Here, we highlight a case of ACTH-dependent Cushing disease with resultant spinal epidural lipomatosis (SEl) that was treated with complete hypophysectomy leading to post-operative cranial Diabetes Insipidus. Case
A 36-years old gentleman, background of asthma and ETOH abuse presented with sudden onset palpitations. He appeared cushingoid with moon face, facial plethora, central adiposity and purple abdominal striae and was referred to Endocrinology.

Investigations
Unsuppressed cortisol: 466nmol/l(1 mg overnight dexamethasone suppression test and 24hours urinary cortisol concentration was raised (928nmol/l/day). LDDST failed to suppress serum cortisol and confirmed Cushing’s Syndrome (CS). Unsuppressed random ACTH level: 190ng/l indicated ACTH dependent CS. MRI pituitary, rest of pituitary profile and CT adrenal was normal. Inferior Petrosal Sinus Sampling (IPSS) revealed central source with left sided gradient.

Management
He was commenced on block and replace therapy initially: metyrapone 250 mg TDS and dexamethasone 0.25 mg BD. During investigation, he developed lower limb weakness worsening over 4-5 weeks with no bowel/bladder symptoms. Being wheel-chair bound, he had features of thoracic myelopathy with grade 3/5 power, hyper-reflexia and clonus bilaterally. Sensations were reduced below T10-11 level with intact perianal sensation. MRI spine demonstrated diffuse excessive epidural fatty tissue posteriorly over his thoracic cord with spondylodiscitis at T11-T12. Generalised narrowing of thecal dimension, old superior end plate compression fracture at T11 and significant cord compression in thoracic spine was noted. Diagnosis was paraparesis secondary to Spinal Epidural Lipomatosis (SEl). Spinal MDT suggested treating conservatively with optimization of his Cushing disease, weight-bearing exercises and DLSO brace. Transfer-sphenoidal complete hypophysectomy was performed as curative procedure. Post-operatively he developed polyuria (8 litres/day) and was commenced on DDAVP (Desmopressin 50 mg BD-100 mg BD) along with Hydrocortisone 20 mg and thyroxine 50 mg OD. Currently he has post-operative pan hypopituitarism (Desmopressin 50 mg BD-100 mg BD) along with Hydrocortisone 20 mg and thyroxine 50 mg OD. Currently he has post-operative pan hypopituitarism.

Conclusion
Early diagnosis and management of Cushing syndrome is imperative to prevent long term metabolic complications leading to increased morbidity and mortality. Spinal epidural lipomatosis is a very rare complication of Cushing syndrome and early optimization of Cushing syndrome remains vital to reduce neurological sequelae in these rare cases.

DOI: 10.1530/endoabs.91.CB56

CB57

Can serum ACTH level be reliably interpreted in the diagnostic work-up for Cushing in adrenal incidentalomas?
Mudassir Ali, Jason Ramsingh & Yasir Mannoojee
Royal Victoria Infirmary, Newcastle, United Kingdom

Background
Diagnostic work-up for Cushing Syndrome (CS) can be challenging and is based on clinical and biochemical assessments. Biochemical evidence of endogenous steroid excess is demonstrated through overnight dexamethasone suppression test (ODST), low dose dexamethasone suppression test and/or 24-hour urinary free cortisol estimation (UFC). Once endogenous steroid excess is confirmed, random serum ACTH measurement is key in determining the suspected source of steroid excess: ACTH-independent (adrenal cause) or ACTH-dependent Cushing (pituitary or ectopic ACTH secretion). We report a case of CS where the serum ACTH caused diagnostic confusion during work-up for an adrenal incidentaloma.

Case report
A 42-year-old female was referred with a 2.6 cm left adrenal adenoma, discovered on CT-PHA when she presented with bilateral massive pulmonary embolisms necessitating thrombolysis. She had a history of anxiety and was newly diagnosed with type 2 diabetes. Her BMI was 38 kg/m2 and she displayed Cushingoid features on clinical examination. Random serum ACTH levels ranged from 5 to...
A 79-year-old female was admitted with general decline, polydipsia, polyuria, decreased appetite and constipation. Her family reported mobility decline over past six months and confusion over past few days with weight loss. She had hypertension on Amlodipine and renal impairment was only detected when she recently moved to UK from Jamaica. An incidental finding of hypercalcaemia was found with an adjusted calcium of 3.03, PTH 79.8, vitamin D 33 and phosphate 0.41. The initial impression was tertiary hyperparathyroidism secondary to chronic kidney disease. This was managed with intravenous hydration and furosemide aiming for a urinary output of 1.00-1.50ml/hour. Her low eGFR of 17 was a contraindication for bisphosphonates treatment. Her Vitamin D was replaced & her calcium improved with hydration but rose up to 3.15 a week later with a marked increase in PTH level to 172. She was reviewed by Endocrine team, and patient had a 3 cm right sided neck mass felt on palpation. She had a high urine calcium: creatinine ratio of 0.71 with normal thyroid function tests, serum ACE and negative myeloma screening. A Neck USS showed a well-defined 2.9 cm right thyroid lobe U3 nodule and 2.4 cm left side lesion likely to be parathyroid in origin while a SESTAMIBI scan suggested a left sided parathyroid adenoma and intense uptake in the right thyroid lobe. FNA performed revealed right thyroid oncocyotic neoplasm with microfollicles, Thy3f. The left nodule was consistent with parathyroid lesion. Her calcium increased again despite satisfactory hydration and furosemide. She was thus commenced on Predisolone with PPI cover alongside intravenous hydration. Cinacalcet was subsequently started following SESTAMIBI with good response, with her Calcium level going down to 2.70 & staying within the normal range. She was discussed at the Endocrine MDT, total thyroidectomy with level 6 dissection on the left was planned with a suspicion of parathyroid cancer. Histology pending, to discuss results. Points for discussion: Parathyroid carcinoma despite being a rare endocrine malignancy and an uncommon cause of PTH-dependent hypercalcaemia needs to be considered in the setting of refractory hypercalcemia and very high PTH levels. It is difficult to distinguish between atypical parathyroid adenomas and parathyroid carcinomas and surgery is indicated for tissue diagnosis.

Treatment of hypercalcaemia and role of glucocorticoids; prednisolone is very effective acting within 2-4 days. Bisphosphonate use is limited in patients with renal impairment. Calciumpyrokinetics can be used if poor response to other treatments.

DOI: 10.1530/endoabs.91.CB59
CB61
Asymptomatic hyperparathyroidism with Hip fracture- Primary Hyperparathyroidism
Aisha Irfan
East and North Hertfordshire NHS trust, Lister Hospital, Stevenage, United Kingdom

78 years old lady admitted with fall and right hip fracture under the orthopaedic team was referred to endocrinology with high calcium levels (2.8 mmol/l). Patient was mobile and independent, had a mechanical fall, no preceding symptoms. She had no symptoms of hyperparathyroidism. She had background history of osteoarthritis and previous history of removal of skin cancer. She was taking calcium supplements, but they were stopped at the time of admission. She was a non-smoker. Her mother had a hip fracture but there was no family history of hyperparathyroidism. Her clinical examination didn’t reveal any neck swelling, no breast lump, or any lymphadenopathy or organomegaly. Her hyperparathyroidism work up showed PTH of 22.37 pmol/l, normal renal function, myeloma screen was normal, full blood count was normal, and CRP was raised post operatively. Initially she was treated with intravenous fluids, and she received bisphosphonates. Further work up showed normal chest X-ray and no evidence of malignancy on chest, abdomen, and pelvis CT scan. She was discharged from the hospital after her blood calcium levels were below 2.80 mmol/l and started to mobilize. Further tests were done as an outpatient. DEXA scan showed BMD Lumbar spine, T Score: -2.6 BMD Total Hip, T Score: -2.5 BMD Femoral Neck, T Score: -3.7. Her calcium levels started to creep up, so she was started on cinacalcet in Outpatient clinic. Her Urine calcium creatinine clearance ratio was 0.0175. Vitamin D levels were 49.2 nmol/l. Urinary 25-calcium was 10.14 nmol/24h (2.5-7.5). TFFS, ACE levels and anti-TTG were within normal range. Ultrasound neck showed a 11 x 6 x 15 mm isoechogenic nodule with polar vascularity in right thyroid lobe inferiorly, likely a parathyroid lesion. SPECT CT scan of parathyroid showed 8x13x15 mm SPECT avid right nodule. She was discussed in parathyroid multidisciplinary team and the outcome was to offer urgently right inferior targeted parathyroidectomy.

CB62
Diagnosis and Management of Primary Hyperparathyroidism
Arline Gatt & Sandro Vella
Mater Dei Hospital, Msida, Malta

A 57-year-old gentleman presented with severe hypercalcaemia (Corrected Calcium 3.48 mmol/l) associated with polyuria and polydipsia. He denied pruritus, nausea, vomiting, abdominal pain, constipation or other aches and pains. He denied syncope, seizures, haematuria or recent urinary tract infections. He had a past history of bilateral urolithiasis as well as right pyelonephritis and hydronephrosis requiring nephrostomy. He had a past history of removal of skin cancer. He was taking omeprazole 20 mg daily, omeprazole and vitamin B12 and folic acid. The above results suggested familial hypercalciuric hypercalcaemia. She was referred for genetic testing and asked to undergo testing for MEN syndrome.

CB63
A Young Woman with Symptomatic Primary Hyperparathyroidism and a Renal Stone
Shaila Khan, Fausto Palazzo, Sara Habboosh, Preshela Behary, Florian Wernig, Jeremy Cox & Alexander Comninos
Imperial College Healthcare NHS Trust, London, United Kingdom

A 27-year old Caucasian woman was referred to the Endocrine Bone Clinic after investigations for general malaise revealed hypercalcaemia and elevated parathyroid hormone levels. She had no history of constellation, abdominal pain, bone pain, or other related symptoms. She had no history of renal stones or fractures and no change in weight. In her past medical history included asthma and she took a salbutamol inhaler as required. She had no family history of endocrine pathology. General examination was remarkable. Her adjusted calcium level was 3.01 mmol/l (RR 2.2-2.6), phosphate level was 0.61 mmol/l (RR 0.8-1.5), parathyroid hormone level was elevated at 14 pmol/l (RR 1.6-7.2) with low vitamin D levels 18.9 nmol/l (RR 70-150). She had normal renal function and normal thyroid function. 24 hour urinary collection was taken which excluded familial hypercalcemic hyperparathyroidism (24h urine calcium 8.49 mmol/24h (RR 2.5-7.5), urine calcium:creatinine ratio 0.03). She had a normal pituitary profile, normal gut hormone profile and genetics did not identify any familial cause (genes tested: CASR, CDC73, CDKN1A/1B/2B/2C, MEN1, RET). An initial Sestamibi scan did not localise any clear adenoma. A neck ultrasound revealed a 14mm lesion bulging out of the posterior aspect of the right thyroid lobe. Given the uncertainty as to the origin, an FNA was performed with non-diagnostic histology but a PTH level of 861 pmol/l. A renal ultrasound revealed bilateral unobstructing renal calculi with the largest stone measuring 6.2 mm. A bone densitometry scan showed normal bone density including at the distal radius. She was referred for parathyroid surgery and was advised to increase her fluid intake. Due to her work as a delivery driver, she found it difficult to adhere to this due to lack of toilet facilities. Her malaise continued with development of nausea and constipation. Therefore, cinacalcet was introduced while awaiting surgery, with symptomatic relief. At parathyroidectomy, an abnormal right superior parathyroid was excised with subsequent normalisation of calcium and parathyroid hormone levels and symptomatic resolution. The histology revealed hypercellular parathyroid tissue and so she continues under follow-up. She remains normocalcaemic and her previous renal stones are no longer present on imaging.

CB64
An atypical case of hyperparathyroidism
Ahmad Eyaddeh & Kiyatisha Seejoo

Examination was unremarkable with a normal neck exam.

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corrected Calcium</td>
<td>3.48</td>
<td>2.15-2.55 mmol/l</td>
</tr>
<tr>
<td>Phosphate</td>
<td>0.86</td>
<td>0.87-1.45 mmol/l</td>
</tr>
<tr>
<td>Albunin</td>
<td>37</td>
<td>30-52 g/l</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.95</td>
<td>0.65-1.05 mmol/l</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>82</td>
<td>40-129 U/l</td>
</tr>
<tr>
<td>Parathyroid Hormone (PTH)</td>
<td>83</td>
<td>15-45 pg/ml</td>
</tr>
<tr>
<td>PTHrP</td>
<td>&lt;1.5 pmol/l</td>
<td></td>
</tr>
</tbody>
</table>

Total 25(OH) Vitamin D | 38 | 30-100 ng/ml |
24hr Urinary Calcium | 8.73 | 2.5-8 mmol/24hr |
Calcium/Creatinine excretion ratio | 0.03 | In-keeping with PHEPT |
Thyroid Stimulating Hormone | 0.179 | 0.3-3 mU/ml |
Free Thyroxine | 15.85 | 11.0-20.3 mU/ml |
Serum Protein Electro phosphorysis | No monoclonal band detected |
Coelec screen (anti-Tissue TG Ab) | 1.8 | 0.9-9.0 x 10^3 |
Corfsool | 359 | 164-419.4 nmol/l |
Angiotensin Converting Enzyme | 46 | 20-70 U/l |
Sodium | 143 | 136-145 mmol/l |
Potassium | 4.38 | 3.5-5.1 mmol/l |
Urea | 7.3 | 3.5-7.4 mmol/l |
Creatinine | 728 | 58-104 mc mol/l |
κsTFR | 57 | maximum 173 mmol |

DOI: 10.1530/endoabs.91.CB60
DOI: 10.1530/endoabs.91.CB61
DOI: 10.1530/endoabs.91.CB62
DOI: 10.1530/endoabs.91.CB63
DOI: 10.1530/endoabs.91.CB64

Endocrine Abstracts (2023) Vol 91
A 70-year old female patient was referred to the Endocrine clinic after incidental finding of significant hypercalcaemia (3.19 mmol/l, NR: 2.20-2.60 mmol/l) during work-up for cognitive decline. She had a known background of T2DM, hyperlipidaemia, osteoarthritis with a previous right total hip replacement and a laparoscopic cholecystectomy. She was first reviewed in clinic in June 2022 and was almost asymptomatic, except for memory issues. She denied previous history of renal calculi and had no fragility fractures in the past. There was no family history of hypercalcaemia or endocrinopathy. On clinical examination, she had a normal blood pressure. There were no palpable neck masses. Screening into end organ complications of hypercalcaemia revealed no nephrolithiasis and the bone density scan (DEXA) showed normal bone density. Calcium-creatinine clearance ratio was 0.02, thereby excluding familial hypocalciuric hypercalcaemia and confirming primary hyperparathyroidism. Parathyroid localisation studies demonstrated a solitary 2.3 cm right superior parathyroid lesion on SPECT-CT. She suffered a rapid decline in cognitive function and was urgently referred for surgical management in view of rising hypercalcaemia. There was an increased risk of hungry bone syndrome in view of significant hypercalcaemia and PTH levels. She was started on vitamin D replacement and calciumcitrate titrated to 90 mg twice daily with no significant improvement in her calcium levels which remained persistently above 3.0 mmol/l. She underwent parathyroidectomy in December 2022 with no immediate complications. The histology showed atypical features, including a prominent trabecular growth pattern and fibrous band formation, suggestive of an atypical parathyroid adenoma (APA). She is currently stable with normal calcium levels and will be closely monitored biochemically and radiologically in view of the uncertain malignant potential of APA. Of note, no specific guidelines for the surveillance of patients with APA after parathyroid surgery exist so far.

DOB: 10.1530/endoabs.91.CB64

CB65

The familial hypocalciuric hypercalcaemic mask
Stefano Busti
Royal Lancaster Infirmary, Lancaster, United Kingdom

Background
Primary hyperparathyroidism is a relatively common endocrine disorder. Familial hypocalciuric hypercalcaemia is an important differential diagnosis but is much less prevalent. We examine a case of hypercalcaemia where there was some initial diagnostic uncertainty.

Case report
A 55-year-old lady was referred from primary care with mild hypercalcaemia, low mood, constipation and urinary frequency. She had a previous history of renal stones at the age of 38, a previous clavicular fracture and no history of renal disease. Her mother has a history of osteoporosis but there is no other family history of calcium-related disorders. She was not on any diuretics or any calcium supplements. Initial blood tests from primary care showed an adjusted calcium of 2.64 with a PTH of 14 and a Vitamin D level of 60.5. An initial calcium creatinine clearance ratio in secondary care came back at 0.0049, a result more consistent with familial hypocalciuric hypercalcaemia than primary hyperparathyroidism. A renal tract ultrasound as well as a DEXA scan showed no abnormalities. A repeat calcium creatinine clearance ratio came back as inconclusive (< 0.014), with a repeat adjusted calcium of 2.69, a PTH of 11.9 and a Vitamin D level of 51. The clinical suspicion of primary hyperparathyroidism remained, so an ultrasound of the parathyroid gland and a SestaMIBI SPECT scan were requested. These both showed evidence of a left-sided inferior parathyroid adenoma. A third calcium creatinine clearance ratio was positive at 0.021 and primary hyperparathyroidism was finally diagnosed.

DOB: 10.1530/endoabs.91.CB65

CB66

Primary hyperparathyroidism vs Familial hypocalciuric hypercalcaemia
Lisa Chin-Hatty
Hereford County Hospital, Hereford, United Kingdom

A 61-year-old male was referred for hypercalcaemia. He was experiencing generalized fatigue and underwent several investigations which included serum calcium. He had recently been treated for two episodes of chest infections. At that time, he was also experiencing weight loss and night sweats. His symptoms have since resolved. He had no symptoms of hypercalcaemia-polyuria, polydipsia, abdominal pain, constipation, bone pain, or headaches. He was not taking calcium supplements. He had no chronic illnesses. There was no family history of hypercalcaemia or hyperparathyroidism. Physical examination was normal except for an elevated BMI of 33.6. His initial investigations showed mild hypercalcaemia, hypophosphataemia, and elevated PTH (see table). Urine BJP and serum ACE levels were normal. There were no previous calcium levels prior to his initial presentation to suggest longstanding hypercalcaemia. His bone density scan was normal. Imaging did not show any renal calculi. His calcium: creatinine clearance ratio (CCCR) was 0.0083 which suggested familial hypocalciuric hypercalcaemia. Genetic testing for FHH was negative. At subsequent review, repeat studies show a CCCR of 0.0129 with corresponding serum calcium of 2.83 mmol/l, phosphate 0.68 mmol/l (0.8-1.43), and PTH of 96.3 nmol/l. While familial hypocalciuric hypercalcaemia is a rare entity, it is important to differentiate it from primary hyperparathyroidism to prevent unnecessary surgery. There are several clinical features that can be used to discern between the two pathologies, but urinary calcium excretion is primarily used to determine the likely diagnosis and further investigation. However, what are the sensitivity and specificity of this test? Additionally, is there a parathyroid hormone level that makes primary hyperparathyroidism more likely in spite of the calcium creatinine clearance ratio?

DOB: 10.1530/endoabs.91.CB66

CB67

Recurrent primary hyperparathyroidism
Faroug Ahmed
MidYorkshire Hospital Trust, Wakefield, United Kingdom

Introduction
- Primary hyperparathyroidism is a relatively common disorder affecting 1 in 500 women and 1 in 2000 men aged over 40 years.
- Diagnosis of primary hyperparathyroidism is confirmed biochemically with synchronous elevation of serum calcium and inappropriate elevation of parathyroid hormone.
- Parathyroid adenomas are the most common aetiology. Around 80% are a single, benign adenoma, which in most cases is sporadic. Multiple adenomas and hypertrophy of all 4 glands are less common.

Case presentation
A 78-year-old male with previous history of Primary hyperparathyroidism in 2018, Basal cell carcinoma, CKD 3 and IHD. He was diagnosed with primary hyperparathyroidism in 2018 after he had had high calcium during routine blood. Renal USS did not show no renal stones. Bone Mineral density revealed osteopenia. Parathyroid US, difficult to identify any parathyroid adenoma. Sestamibi scan: demonstrates intensely sestamibi avid prolapsed right superior parathyroid gland.

DOB: 10.1530/endoabs.91.CB67
adenoma 2.3 cm inferior to the lower border of the criocoid cartilage. There is a further low grade seutamibi avid 2.9 cm prolapsed left superior adenoma 2.1 cm inferior to the lower border of the criocoid cartilage. For that he underwent parathyroidectomy and the two adenomas had been removed and confirmed to be parathyroid adenomas. After the surgery he had normal calcium Level till Jul 2022 when he was admitted to the hospital. He was not on any medications that can cause hypercalcemia. MM screening was negative. Vitamin D Level was normal. During the hospital admission he was managed with hydration, bisphosphonate and Cinacalcet. Given that he has hypercalcemia after normal level calcium more than 6 months after the surgery, the impression was recurrent primary hyperparathyroidism. Further plan included parathyroid Ultrasound, Sestamibi scan, 24 hours urinary calcium excretion and discussion regarding possible parathyroidectomy. Unfortunately, the patient died before completion of the investigation with un-related issue.

Discussion and Learning point
Recurrent primary hyperparathyroidism is defined as a recurrence of hypercalcemia after a normocalcaemic interval of greater than 6 months post-parathyroidectomy. It is more common in patients with double parathyroid adenomas compared with those with a single adenoma or hyperplasia.

DOI: 10.1530/endoabs.91.CB68

CB69

A pt bed bound diabetic patient presents with unexplained drowsiness
Moe Kyaw & Amit Banerjee
St Helens and Knowsley NHS Trust, Prescot, United Kingdom

A 71 year lady, who has past history of acute (ischaemic stroke (now bed bound and can only get out of bed with the help of a hoist) Type 2 diabetes mellitus, HTN, CKD and high lipid. She is on Metformin 1 gm twice daily, Ramipril 5 mg at night, Clopidogrel 75 mg od, Atorvastatin 80 mg od. She was brought to hospital by unexplained drowsiness and poor oral intake. Her blood sugar was 72, ketone 5.2, Ph: 7.21, Na: 165, Urea 14 and calculated osmolality of 412. Her chest xray and ct head were unremarkable. Mildly high inflammatory markers. She was showing features of both Diabetic ketoacidosis (DKA) and euglycaemic Diabetic ketoacidosis (eDKA). She was initially managed with DKA protocol (fixed rate insulin) with 10 units of Tresiba (basal insulin) cover. Her DKA resolved in 4 hours into the treatment but her Blood sugar remained 37 with an osmolality of 412. Then DKA protocol stopped and she was started on HHS pathway (insulin infusion rate halved) and fluid replacement. Her HHS resolved in 24 hrs time. Her fixed rate of insulin infusion was switched to variable rate and observed for 24 hrs more (she remained on Tresiba 10 units). When her oral intake got better, Her Tresiba and Variable rate stopped and she was started on Novomix 30 bd. She was observed in hospital for 24 hr more and then got discharged back to home. Community nurse referral sent for administration of insulin. It is important to remember that when feature of of DKA and HHS presents together, then to treat DKA first.

DOI: 10.1530/endoabs.91.CB69

CB68

‘Changing faces’ - A new diagnosis of acromegaly presenting with euglycaemic DKA
Nadia Osman, Henna Patel & Kirun Gunganah
Barts Health NHS Trust, London, United Kingdom

A 43-year-old Bangladeshi lady was seen in the endocrinology clinic after recent admission to hospital with vomiting and headaches. Her past medical history included Type 2 diabetes, hypertension, ischaemic heart disease and goitre. During admission, a diagnosis of euglycaemic diabetic ketoacidosis (DKA) was made (pH 7.31, bicarbonate 18.3, glucose 7.8 and ketones 6.1) secondary to SGLT-2 inhibitor. This was managed with a fixed rate insulin infusion, intravenous fluid hydration and cessation of SGLT-2 inhibitor. Brain imaging was arranged for further assessment of her persistent headaches and vomiting. An incidental left sided pituitary macroadenoma, measuring 17 x 11 x 8 mm, with grade II cavernous involvement, was confirmed on MRI imaging. On resolution of DKA, the patient was discharged home on a basal bolus insulin regime. In clinic, review of the history revealed a 5-year history of worsening intermittent headaches associated with visual blurring, increasing nose, jaw and hand size, splayed teeth and two-year history neck swelling with hoarse voice. On systems enquiry, there was a one-year history of oligomenorrhoea, significant hair loss and polyarthralgia with no change in bowel habit. On examination, features of acromegaly were noted including coarse features, spade-like hands, splayed teeth and macrognlossia. She was hypertensive with a BP of 150/98 mmHg. Cardiovascular, respiratory, and abdominal examinations were unremarkable. Visual fields were intact to red pin with no focal neurology. Further investigations showed: HbA1c 70mmol/l, C-peptide 574, Triple Ab negative, elevated IGF-1 411 mg/l(65.6-249.2), Free T4 13.8 pmol/l, TSH 1.05mU/l, ACTH 4ng/l, Cortisol 348nmol/l, prolactin 125pmol/l, oestradiol < 19 pmol/l, LH 42amol/l, FSH 68unit/l and Testosterone <0.5nmol/l. A new diagnosis of acromegaly was made after she failed to suppress her GH levels on an oral glucose tolerance test and she has been referred to tertiary endocrinology services. DKA as the presenting feature of acromegaly is a rare occurrence but nonetheless an important diagnosis to not overlook as can be life-threatening if left untreated. Proposed mechanisms for the development of DKA in patients with acromegaly include increased insulin resistance, inhibition of fatty acid metabolism and increasing lipolysis leading to ketosis, due to GH and IGF-1 excess. Glucagon has also been considered as a possible contributing factor to DKA development and may be increased in acromegaly. Excessive glucagon reduces hepatic fructose 2,6 biphosphate, a metabolite that inhibits gluconeogenesis in the liver and induces hepatic ketogenesis.

DOI: 10.1530/endoabs.91.CB69
Society for Endocrinology
National Clinical Cases 2023
Endocrine Abstracts

Volume 91
April 2023

Society for Endocrinology National Clinical Update 2023
Friday 24 March 2023, Royal Society of Medicine
London, United Kingdom

Programme Chair:
Dr Miles Levy (Leicester)
Dr Helen Turner (Oxford)

Abstract Markers:
Dr Karin Bradley (Bristol)
Dr Antonia Brooke (Exeter)
Professor William Drake (London)
Dr Simon Howell (Preston)
Dr Abdulfattah Lakhdar (London)
Professor Karim Meeran (London)
Dr Daniel Morganstein (London)
Professor Michael O’Reilly (Dublin)
Dr Julia Ostberg (Watford)
Professor Aled Rees (Cardiff)
Professor Peter Taylor (Cardiff)
Dr Nicola Zammitt (Edinburgh)

CONTENTS

Oral Communications ................................................ O C 1 – O C 10
Poster Presentations ......................................................... P 1 – P 4 8
Oral Communications
Case history
A previously well 45-year-old lady presented with a 3-year history of hypertension initially diagnosed at a routine health check. Her blood pressure (BP) was 170-180/90-100 mmHg. Investigations showed hypokalaemia (K+ 3 mmol/l; NR 3.5-5.3 mmol/l), raised aldosterone (976 pmol/l; NR 100-500 pmol/l) and suppressed renin activity (<0.2 nmol/l/h), meeting criteria for diagnosing primary aldosteronism (PA). CT adrenals demonstrated a 2.5 cm left adrenal nodule. Her cortisol was unsuppressed (171 nmol/l) following dexamethasone 1 mg overnight. ACTH was 8 ng/l (NR 0-46 ng/l). She was referred to our centre following unsuccessful cannulation of her right adrenal vein on adrenal vein sampling (AVS) locally. She was enrolled into the MATCH trial, designed to compare the accuracy of [11C]metomidate positron emission tomography computed tomography (MTO) scanning, with AVS in predicting outcomes of PA after surgery(1). MTO demonstrated a left SUVmax ratio of 1.32 indicating a high probability of unilateral left-sided disease. The ACTH-stimulated AVS found the left adrenal vein was cannulated but the selectivity index on the right was 2.6 (threshold >3). Retrospective inspection of the venogram found likely cannulation of both adrenal veins. Her urinary hybrid steroid 18-hydroxycortisol to cortisol ratio was 6.5.

Results and treatment
A left laparoscopic adrenalectomy was performed. Post-operatively she was prescribed hydrocortisone and persistent biochemical abnormality led to a year’s treatment with hydrocortisone. Her BP fell to 110/72 mmHg on no treatment and there was correction of electrolytes, aldosterone (226 pmol/l) and renin (3.3 nmol/l/h). Histology confirmed an aldosterone producing adenoma (APA) and Sanger sequencing of cDNA from tumour and adjacent adrenal found a somatic KCNJ5 mutation, p.Gly151Arg.

Conclusions
Both AVS studies concluded that the right adrenal vein was not cannulated. Her KCNJ5-mutant APA was co-secreting cortisol, as is often the case. It is likely that there was suppression of cortisol secretion from the right gland which led to a reduced cortisol ratio between the right adrenal vein and inferior vena cava. MTO scanning permitted the diagnosis of unilateral PA in this patient. MATCH considered predictors of complete vs partial or absent clinical success following adrenalectomy. In multivariate analysis on genotype, age, sex and ancestry, KCNJ5-genotype was the major independent variable. Furthermore, urine multi-steroid profiling identified higher 18-hydroxycortisol levels in patients with KCNJ5-mutant adenomas, with almost no overlap between them and other patients. Our patient illustrates how adoption of urinary steroid profiles into preoperative workup can select the minority of PA patients most likely to enjoy complete clinical success.

1. Wu X.2023. DOI: 10.1530/endoabs.91.OC1

Conclusions
Both AVS studies concluded that the right adrenal vein was not cannulated. Her KCNJ5-mutant APA was co-secreting cortisol, as is often the case. It is likely that there was suppression of cortisol secretion from the right gland which led to a reduced cortisol ratio between the right adrenal vein and inferior vena cava. MTO scanning permitted the diagnosis of unilateral PA in this patient. MATCH considered predictors of complete vs partial or absent clinical success following adrenalectomy. In multivariate analysis on genotype, age, sex and ancestry, KCNJ5-genotype was the major independent variable. Furthermore, urine multi-steroid profiling identified higher 18-hydroxycortisol levels in patients with KCNJ5-mutant adenomas, with almost no overlap between them and other patients. Our patient illustrates how adoption of urinary steroid profiles into preoperative workup can select the minority of PA patients most likely to enjoy complete clinical success.

1. Wu X.2023. DOI: 10.1530/endoabs.91.OC1

Conclusions
Both AVS studies concluded that the right adrenal vein was not cannulated. Her KCNJ5-mutant APA was co-secreting cortisol, as is often the case. It is likely that there was suppression of cortisol secretion from the right gland which led to a reduced cortisol ratio between the right adrenal vein and inferior vena cava. MTO scanning permitted the diagnosis of unilateral PA in this patient. MATCH considered predictors of complete vs partial or absent clinical success following adrenalectomy. In multivariate analysis on genotype, age, sex and ancestry, KCNJ5-genotype was the major independent variable. Furthermore, urine multi-steroid profiling identified higher 18-hydroxycortisol levels in patients with KCNJ5-mutant adenomas, with almost no overlap between them and other patients. Our patient illustrates how adoption of urinary steroid profiles into preoperative workup can select the minority of PA patients most likely to enjoy complete clinical success.

1. Wu X.2023. DOI: 10.1530/endoabs.91.OC1

Conclusions
Both AVS studies concluded that the right adrenal vein was not cannulated. Her KCNJ5-mutant APA was co-secreting cortisol, as is often the case. It is likely that there was suppression of cortisol secretion from the right gland which led to a reduced cortisol ratio between the right adrenal vein and inferior vena cava. MTO scanning permitted the diagnosis of unilateral PA in this patient. MATCH considered predictors of complete vs partial or absent clinical success following adrenalectomy. In multivariate analysis on genotype, age, sex and ancestry, KCNJ5-genotype was the major independent variable. Furthermore, urine multi-steroid profiling identified higher 18-hydroxycortisol levels in patients with KCNJ5-mutant adenomas, with almost no overlap between them and other patients. Our patient illustrates how adoption of urinary steroid profiles into preoperative workup can select the minority of PA patients most likely to enjoy complete clinical success.

1. Wu X.2023. DOI: 10.1530/endoabs.91.OC1

Section 1: Case history
Persistent hyperinsulinemic hypoglycemia may be caused by either a solitary tumour of the pancreas secreting excessive insulin, i.e. an insulinoma, or, rarely by neondioblastosis. A 70-year-old man was referred with symptoms of hypoglycemia. He had a positive 72-hour-fast with episodes of hypoglycemia and high insulin levels.

Section 2: Investigations
EUS showed a small 3 x 4 mm hyperechoic lesion in the body of the pancreas. His Octreotide scan and calcium stimulation test failed to locate any other discreet lesions. He was started on trial of Diazoxide and somatostatin analogue but didn’t tolerate them due to GI side effects. Routine genetic screening for causes of congenital hyperinsulinism did not identify a pathogenic variant.

Section 3: Results and treatment
Following NET MDT, he had a laparotomy and underwent a distal or subtotal pancreatectomy for the treatment of suspected insulinoma. The histopathology showed a 3mm well differentiated NET grade 1, consistent with an Insulinoma. Mitotic activity was 1 per 20 HPF and the Ki67 was <2%. The remaining pancreas showed focal prominent islets and ductuloinsular complexes. On screening, 3 other family members had positive 72-hour-fasts. They all had octreotide scans, MRI Pancreas and 68Ga-DOTA-exendin-4 PET/CT localisation scans, that reported no insulinoma. Following NET MDT, they all had either distal or subtotal pancreatectomies. Their symptoms have now improved but not fully resolved. The histopathology on these patients revealed 3 of 4 major criteria and 1 of 4 minor criteria for a histopathological diagnosis of diffuse adult neidiblastosis.

Section 4: Conclusions and points for discussion
We describe a unique case of a family with insulinoma associated with symptoms of hyperinsulinemic hypoglycemia. Insulin mediated hypoglycemia can be difficult to characterise and the source difficult to localise. However, when no discrete abnormality is found, other diagnoses should be considered. In our family, an insulinoma was found in only one of the patients while findings consistent with neidiblastosis, were found in the others. Whole genome sequencing is ongoing on affected family members.

DOI: 10.1530/endoabs.91.OC3

Endocrine Abstracts (2023) Vol 91
A rare case of hypergonadotropic hypergondism due to mild androgen insensitivity syndrome (MAIS)
Adhithya Sankar & Mohit Kumar
Royal Albert Edward Infirmary, Manchester, United Kingdom

A 29-year-old man presented with an 18-month history of reduced libido and lethargy. His symptoms started after cessation of anabolic steroids for three years. His childhood and development history were unremarkable with normal onset of puberty and development of secondary sexual characteristics. He had no past medical or family history of note. Clinical examination demonstrated normal BMI, musculature, distribution of body hair, testicular volume, and genital size. Biochemical investigations revealed elevated fasting early morning testosterone 42.9 nmol/l (8.4-28.7), elevated LH 11.7 U/L (2.0-9.0), FSH 2.7 U/L (1.0-18.0), DHT 4.20 nmol/l, DHEA 6.7 µmol/l, SHBG 53 nmol/l, androstenedione 4.3 nmol/l, albumin 47 g/l, RBC 1.7T/Hp/prolactin all normal. Elevated testosterone was re-tested at a different centre to rule out assay interference and measured separately with mass spectrometry (36.4 nmol/l and 35.4 nmol/l, respectively). Similarly, LH remained elevated on re-testing, confirming hypergonadotropic hypergonadism. An MRI pituitary and CT thorax, abdomen and pelvis were both normal, excluding pituitary and neuroendocrine tumours. Subsequently, he was referred to genetic services for investigation. Genetic sequencing identified a hemizygous pathogenic missense variant c.2270A>G p.(Asn757Ser) in the androgen receptor (AR) gene. Combining the genetics with the clinical phenotype, a diagnosis of mild androgen insensitivity syndrome (MAIS) was reached. The patient was educated on the potential impact of MAIS on fertility and referred to the fertility services. Genetic counselling and testing were offered to his female relatives and the patient was subsequently commenced on a trial of testosterone therapy for symptom relief. Androgen insensitivity syndrome (AIS) is a rare x-linked recessive condition, resulting from AR gene mutations, with a prevalence of 2-5 cases per 100,000. Over 1000 unique AR gene mutations have been identified, which result in a spectrum of phenotypes, including complete, partial, or mild androgen insensitivity syndrome. In this case, symptoms initially suspicious for hypogonadism were unmasked following cessation of hormone self-medication. The normal male clinical phenotype, with elevated gonadotrophins and testosterone, prompted initial investigation for a neuroendocrine tumour. Subsequently, genetic testing identified an AR gene mutation, clinching the diagnosis of MAIS. The prevalence of MAIS remains unclear; however, its subtle clinical and biochemical features may cause under-reporting. MAIS should be considered in patients presenting with a normal male phenotype, elevated gonadotrophins and normal/high testosterone and may present with infertility as the sole symptom. The role of testosterone replacement in MAIS remains a subject of debate.

DOI: 10.1530/endoabs.91.OC4

The success story of Osilodrostat for optimisation of severe Cushing’s Disease
Yuvana Subramaniam1, Neil Dorward2, William M Drake1 & Antonia Nwokoro3
1Department of Endocrinology, St Bartholomew’s Hospital, London, United Kingdom. 2Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom. 3Department of Endocrinology, Royal Devon University Healthcare Foundation Trust, Exeter, United Kingdom

A 51-year-old gentleman presented in June 2022 with pneumobilia, staph liver abscesses and rapidly conducted atraumatic biliarectomy requiring ITU admission. He had a 2-year history of typical Cushingoid features and hypogonadism, 4 agent hypertension since 2012, fragility fractures, previous renal calculi, pulmonary emboli and diabetes. He had not been able to walk unaided for a year (was mobilising with crutches on admission). In retrospect, he had previously had a cortisol of 726nmol/l at 1pm in 2017. His past medical history included type A thoracic aortic aneurysm dissection, open repair (and cardiac arrest) in 2016. His admission was complicated by pneumonia, Covid and Influenza and he became bed-bound. He was noted to be hypokalaemic with a cortisol >1750nmol/l, ACHT of 78ng/L. His cortisol levels post-8mg dexamethasone suppression test was 1590nmol/l. MR pituitary showed a 9mm hyper-enhancing lesion in the anterior pituitary which on retrospect had been visible on previous CT imaging in 2011. CT adrenals showed diffuse enlarged adrenal glands. He was unable to tolerate sufficient metyrapone and ketoconazole to achieve biochemical control of his Cushing’s syndrome and so he was commenced on intravenous etomidate and transferred to St Bartholomew’s Hospital (Nov 22). In order to facilitate outpatient medical preparation for pituitary surgery, compassionate use of Osilodrostat was obtained, titrating from a starting dose of 2mg bd to 30mg twice a day over several weeks whilst continuing with maximally tolerated ketoconazole. Osilodrostat was well tolerated. He walked out of hospital for respite over Christmas, with good control of his cortisol, returning in January 23 for pre-transphenoidal surgery. His post-operative Day 1 cortisol was 12nmol/l. Osilodrostat, a novel steroidogenic inhibitor targeting the 11β-hydroxylase, is now approved for the treatment of Cushing’s disease (CD) in the United States and Cushing syndrome in Europe. Although the mainstay of treatment for CD is surgery, medical therapy is often required, to control hypercortisolism to minimise pre, peri and post-operative complications. Osilodrostat works similarly to metyrapone and a study comparing metyrapone and Osilodrostat showed that Osilodrostat works faster in achieving target cortisol levels and controlling blood pressure. The long-term outcomes of Osilodrostat in CD showed good tolerability with a small proportion of adverse effects. Hence, Osilodrostat proves to be a good alternative to metyrapone in optimising Cushing’s when cortisol levels need to be reduced rapidly and for patients intolerant to metyrapone although more head-to-head clinical trials are needed to analyse this in a larger cohort.

 DOI: 10.1530/endoabs.91.OC5

A miraculous case of muscle weakness and bone pain: the jaw-dropping factor.
Imperial College Healthcare NHS Trust, London, United Kingdom

Case History
A 47-year-old female was referred to the Endocrine Bone Unit with worsening back, rib and leg pain associated with significantly reduced mobility. In the preceding year, she had repeatedly presented to healthcare providers with no clear neurological deficit, no fractures identified on X-Ray and normal MRI appearances of the whole spine. Aside from well-controlled asthma and gestational diabetes, she had no significant past medical, medication, social or family history of note. Investigations:
Her bloods revealed hypophosphataemia for over three years, reaching a nadir of 0.32mmol/l (0.80-1.50), and which persisted despite oral phosphate replacement alongside Vitamin D repletion. The remainder of her routine biochemistry was unremarkable. A DEXA scan demonstrated low bone density of L2-L4 (Z score -4.1) and hips (Z score -3.5). On assessment of urinary phosphate excretion, she had significantly reduced tubular reabsorption (TRP) 38.7% (>85%) and tubular maximum reabsorption of phosphate to GFR ratio (TmP/GFR) 0.14mmol/l (0.84-1.23). Further testing detected no abnormality in retinol binding protein or urinary amino acids, and thus excluded renal tubular injury or Fanconi syndrome. A 1.25 Vitamin D level was 66pmol/l (RR 55-139), and she notably had an inappropriate raised Fibroblast Growth Factor 23 (FGF23) level of 105 RU/mL (<100).

Results and Treatment
A Ga68 DOTATATE PET CT demonstrated focal intense uptake within the right lower mandible. An MRI mandible characterised a smooth well-circumscribed nodule 11x7mm in the right buccogingival sulcus, correlating to the focus of intense DOTATATE uptake. An ultrasound delineated a submucosal nodule over the right mandibular body, also identified on oral examination. Collectively, the biochemical, radiological and clinical findings suggested an FGF23-secreting tumour and the patient proceeded to local excision of the lesion with wide margins. The histopathology was consistent with a phosphaturic mesenchymal tumour. Her bloods subsequently demonstrated biochemical cure with a normal phosphate and FGF23 level, without supplements. Her bone density improved by 89.9% in the lumbar spine (Z score 1.7) and 60.2% in the hips (Z score 0.3).

Conclusion
Tumour induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by an FGF23-secreting lesion in the bone or soft tissue. It is characterised by FGF23-releasing tumour and the patient proceeded to local excision of the lesion with wide margins. The long-term outcomes of Osilodrostat in CD showed good tolerability with a small proportion of adverse effects. Hence, Osilodrostat proves to be a good alternative to metyrapone in optimising Cushing’s when cortisol levels need to be reduced rapidly and for patients intolerant to metyrapone although more head-to-head clinical trials are needed to analyse this in a larger cohort.

DOI: 10.1530/endoabs.91.OC6
OC7

Hypokalaemia: An unusual feature of pseudohypoparathyroidism
Type 1b
Ananthi Anandhakrishnan1, Rachel Flynn1, Jansher Khan1,2,2
Kumbhir Dodzo2, Galántihware Gaoatse2, John P Monson1,3,1 & Kurnir Gunganah1
1Department of Endocrinology, Newham University Hospital, Barts Health NHS Trust, London, United Kingdom. 2Professor Emeritus Barts and the London NHS Trust, London, United Kingdom

Section 1: Case history
A 23-year-old female presented to the Emergency Department with a 3-month history of intermittent chest pain and palpitations. She was found to be hypokalaemic and hypocalcaemic. On direct-questioning she reported 3 weeks of perioral parasthesia and muscle spasms. She had an unrestricted diet and no other personal or family history of note. She was normotensive with a sinus tachycardia and normal QT-interval, Chvostek’s negative, with no features to suggest growth retardation. She was admitted for intravenous electrolyte replacement.

Section 2: Investigations
Hypocalcaemia 1.58mmol/l, normal serum phosphate 1.29mmol/l and elevated parathyroid hormone (PTH) levels 127pmol/l were detected on admission. 25-OH Vitamin-D3 was deficient (22nmol/l) with a normal serum magnesium 0.8mmol/l and elevated ALP 944U/L. A spot urine calcium:creatinine ratio was low (0.0028).

She was osteoporotic at the lumbar spine (T-score -1.4). With a hypokalaemia (2.9-3.3mmol/l), there was kaliuria (urine potassium 68mmol/l), a detectable aldosterone (226pmol/l) and elevated renin (7nmol/l). Renal function was preserved with normal serum bicarbonate 24mmol/l. An ultrasound renal tract was normal.

Section 3: Results and treatment
Despite vitamin-D loading, an ongoing requirement for electrolyte replacement with highly elevated PTH levels prompted genetic and epigenetic testing for syndromes associated with PTH-resistance and renal tubulopathies. A loss of maternal methylation pattern in GNAS was detected. This, alongside a negative family history was consistent with the diagnosis of sporadic pseudohypoparathyroidism type-1b. A renal tubulopathy screen was negative. The patient was commenced on alfalcaldiol, Vitamin-D3 and oral potassium. A sustained resolution of her symptoms and improvement in her biochemistry was seen at 4-months; PTH 34.1pmol/l, Ca 2.32mmol/l, Phosphate 0.9mmol/l, ALP 377U/L, K 4.3mmol/l.

Section 4: Conclusions and points for discussion
Pseudohypoparathyroidism type-1b is characterised by PTH-resistance in proximal renal tubules due to epigenetic changes in the differential methylated regions in the GNAS gene (chromosome 20q13.2). The loss of maternal-specific methylation of GNAS has been associated with downregulation of Gs expression and CAMP dependent signalling pathways necessary for PTH action. Interestingly, our patient was normophosphataemic and hypokalaemic on presentation which is very unusual with only 2 other reported cases. It is possible that renal peritubular potassium channels are also governed by Gs pathways, and downregulation may promote renal potassium loss. More research into epigenetic regulation of GNAS/Gs/cAMP related pathways is required to elucidate the intricate relationship between PTH-dependent calcium, phosphate and potassium handling in the kidneys.

DOI: 10.1530/endoaobs.91.OC7

OC8

Brungs-Garland syndrome (diabetic amyotrophy) associated with SGLT2 inhibitor and its rapid HbA1c improvement: a case-report
Kalyani Nagarajah, Grigorios Panagioutou & Julia Platts
University Hospital Llandough, Penarth, United Kingdom

Background
Brungs Garland syndrome is a rare disorder in people living with diabetes, manifesting as unilateral or bilateral muscle pain, weakness and atrophy in the proximal region of the lower limbs. Herein, we present the case of a patient with Brungs-Garland syndrome caused by sodium/glucose co-transporter 2 inhibitors (SGLT2s).

Case description
A 55-year-old male with background of type 2 diabetes for 5 years, and currently on oral therapy, presented to the emergency admissions unit with ketosis, acidosis and borderline hyperglycaemia (ketones 6 mmol/l, pH 7.21 and blood glucose of 11.1 mmol/l, respectively). On further questioning, his diabetes control was suboptimal with some mild tingling sensation in his lower limbs first noticed a year ago; Empagliflozin was added to his therapy at that time, resulting in significant weight loss of about 8 kgs over 6 weeks and a substantial reduction in HbA1c from 10.3 to 48 mmol/mol in less than 6 months. On examination, he had widespread vitiligo, and proximal muscle wasting with bilateral lower limb weakness, reduced reflexes and paraesthesia, suggestive of peripheral neuropathy. Baseline myopathy screening was negative. Imaging studies were negative for sinister causes of weight loss. MRI spine was inconclusive, suggesting mild degenerative changes with multifocal disc prolapses and nerve root impingements, but no spinal canal stenosis. Nerve conduction studies of upper and lower limbs revealed a moderately severe, length dependent sensorimotor axonal neuropathy. This was confirmed with electromyography indicating an axonal peripheral neuropathy, with superimposed bilateral lumbar plexopathy/femoral neuropathy, suggestive of acute on ongoing neurogenic changes in bilateral lower limbs distally and proximally. Despite HbA1c improvement, his symptoms further progressed to debilitating proximal myopathy, with severe paraesthesia and burning sensation over his thighs in the next few months, despite Vitamin B12 levels replacement therapy.

Conclusion
Rapid improvement of HbA1c with SGLT2i or a direct effect of SGLT2i can significantly worsen background neuropathic changes leading to Bruns-Garland type diabetic amyotrophy. With the widespread use of SGLT2i, it is important that physicians treating patients with diabetes recognise these symptoms and consider this association in patients developing fatigue and weakness.

DOI: 10.1530/endoaobs.91.OC8

OC9

ACTH-producing pheochromocytoma
Sahar Hikhar1, Simon Aylwin2, Benjamin Whitelaw2 & Klaus-Martin Schulte3
1Royal Surrey County Hospital, Guildford, United Kingdom. 2Kings College London, London, United Kingdom

Case history
We present a case of 36Y old male who presented with worsening leg edema, leg ulceration and poor mobility leading to admission in intensive care due to sepsis and hemodynamic instability. Found to have metabolic alkalosis with hypokalemia. Clinically, moon-like facies, low proximal muscle mass, skin hyppigmentation (mainly hands), broken skin fingers and legs, abdominal fat distribution. Investigations:Random cortisol 2348nmol/l, post 1mg dexamethasone cortisol 348nmol/l, ACTH 443 ng/l, testosterone 4.0nmol/l. Plasma metadrenalines and normetadrenalines were >25000 pmol/l. CT CAP/Adrenals – Left 7.3 cm adrenal mass consistent with ACC with multiple lung metastases lung lesions were investigated and found to be inflammatory. MRI Pituitary normal. FDG PET showed metabolically active left adrenal malignancy. The new bilateral pulmonary changes are likely inflammatory/infecitive. The pulmonary nodules which were seen on CT CAP were thought to be likely metastasis. MIBG was consistent with a diagnosis of Phaeochromocytoma. Treatment: Was initiated on metyrapone and alpha blockade. He improved markedly after starting metyrapone. Underwent left open adrenalectomy. Histology was in keeping with Pheochromocytoma with capsular irregularities. Ki67 = 7.4%. Capsular and lymphovascular invasion. PASS score was 10. Immunohistochemistry SDHB preserved. Post-operatively showed normal ONDST and plasma metadrenalines. SST demonstrated adrenal insufficiency and remains on hydrocortisone. Genetic testing did not reveal a genetic cause of pheochromocytoma.

Conclusion and points of discussion
ACTH secreting pheochromocytoma is extremely rare but should be considered in the differential diagnosis.

References
1. Clinical, biochemical, and tumour characteristics in patients with ectopic ACTH
2. The utilisation of different imaging modalities.
3. Role of drugs such as Metyrapone, alpha blockade pre-operatively.
4. Review of literature

DOI: 10.1530/endoaobs.91.OC9

OC10

Recurrent painful ovarian cysts: what should an endocrinologist be aware of?
Mayuri Agarwal1, Cornelius Fernandez2 & Dilip Eapen2
1Nottingham University Hospital NHS Trust, Nottingham, United Kingdom. 2United Lincolnshire Hospital NHS Trust, Boston, United Kingdom

Case history
A 33 year old lady with irregular menstrual cycles and infertility presented to gynaecologist with recurrent abdominal pain and bloating. Her pain was found
secondary to bilateral ovarian cysts. She had repeated laparoscopic ovarian cystectomies since 2018. In December 2021, modest hyperprolactinemia (1065 MIU/L, RR 102-496) with negative macroprolactin test was noted, and MRI pituitary revealed 18x17x13mm pituitary macroadenoma. Cabergoline was started and she was referred to endocrine team. A diagnosis of non-functioning pituitary macroadenoma unrelated to ovarian cysts was initially considered. However, on further review of pituitary profile, inappropriately normal FSH levels (even with raised 17-β oestradiol) and suppressed LH levels were noted. Therefore, FSH secreting pituitary tumor (FSHoma) was considered, and it was concluded that recurrent ovarian cysts were attributed to spontaneous ovarian hyperstimulation syndrome in absence of using ovulation inducing agent.

Investigations
MRI pituitary (December 2021) - 18x17x13mm pituitary macroadenoma with mild suprasellar extension indenting the optic chiasm along with deviation of the pituitary stalk towards left. Visual fields- normal.

Results and treatment
With cabergoline, her abdominal symptoms along with estrogen and prolactin levels settled. However, interval MRI pituitary 6 months later revealed no change in size of pituitary macroadenoma. After discussion in pituitary MDT, transsphenoidal surgery with hope of preventing ovarian cyst recurrence was recommended.

Conclusion and point of discussion
FSHomas are usually non-functioning rare pituitary tumors, with no clinical evidence of hormonal hypersecretion. When functioning, the continuous FSH exposure from FSHoma can cause ovarian hyperstimulation syndrome due to associated raised estrogen levels. The characteristics of FSHoma in reproductive-aged women are enlarged multicystic ovaries, elevated serum 17-β oestradiol, normal to mildly raised FSH, suppressed LH, menstrual disorder, infertility, and ovarian hyperstimulation. In this case normal FSH level in setting of raised estrogen and suppressed LH was overlooked at first instance. Diagnosis of FSHoma is further supported by elevated serum alpha subunit levels. In many patients with FSHoma, accurate diagnosis is often delayed by several years and many women might have undergone repeated ovarian procedures that are detrimental to the ovarian function of infertile patients.

DOI: 10.1530/endoabs.91.OC10

Results of pituitary profile blood test:

<table>
<thead>
<tr>
<th></th>
<th>Prolactin (MIU/L)</th>
<th>17-β oestradiol (pmol/l)</th>
<th>FSH (IU/L)</th>
<th>LH (IU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 2020</td>
<td>633</td>
<td>1993</td>
<td>12.7</td>
<td>0.8</td>
</tr>
<tr>
<td>September 2021</td>
<td>1065</td>
<td>2723</td>
<td>12.4</td>
<td>0.5</td>
</tr>
<tr>
<td>December 2021</td>
<td>1237</td>
<td>4385</td>
<td>9.1</td>
<td>0.4</td>
</tr>
<tr>
<td>January 2022</td>
<td>39</td>
<td>316</td>
<td>7</td>
<td>3</td>
</tr>
</tbody>
</table>

Other tests:
- 9 am cortisol 452
- IGF-1 10
- TSH 3
- free T4 13.6
- Alpha subunit of FSH - elevated
- 2.12 IU/L (normal range <1)

Endocrine Abstracts (2023) Vol 91
Poster Presentations
P1 Hereditary Paraganglioma-Phaeochromocytoma Syndrome: A case of malignant paraganglioma discovered following surgery for breast carcinoma
Shaiful Khan, Fatima Bahowairath, Fausto Palazzo & Jeannie Todd
1Department of Endocrinology, St Bartholomew’s Hospital, London, United Kingdom

Section 1: Case
A 42-year-old woman developed central chest pain four hours after undergoing right mastectomy for intraductal breast carcinoma. Serial blood pressures were recorded as significantly elevated, up to 240/130mmHg. There was no history of new-onset headaches, palpitations, anxiety, hirsutism, change in weight or easy bruising. She had no other significant past medical history or family history.

Section 2: Investigations
An electrocardiogram was normal and troponin levels were not elevated. A computer tomography pulmonary angiogram was performed which excluded pulmonary embolism (PE), but also revealed a large (12 cm x 6.6 cm) left-sided retroperitoneal mass. Plasma normetanephrine and metanephrine levels were not elevated. Renin and aldosterone levels were raised at 24 ng/l and 1490pmol/l respectively, ratio 2pmol/mg (RRs: 0.5-3ng/l and 90-700pmol/l). FDG-PET scan showed an intensely avid area within the lesion, with no other sites of FDG uptake. Repeat measurement of plasma metanephrines included 3-methoxytyramine levels which were significantly raised at 21 906pmol/l (RR <180pmol/l).

Section 3: Results and treatment
The results primarily raised concern for adrenocortical carcinoma. Initial imaging showed central necrosis within the suspected tumour with marked peripheral vascularity, with no obvious mass encasing the renal artery. The renin:aldosterone ratio did not indicate primary aldosteronism. However, 3-methoxytyramine levels were strongly indicative of phaeochromocytoma or paraganglioma. The patient underwent left adrenalectomy and nephrectomy. Histology confirmed a moderately differentiated paraganglioma with evidence of capsular and vascular invasion with a Ki-67 index of between 18-20%, which was excised completely.

The patient’s hypertension was treated successfully with alpha blockade using doxazocin. A Gallium Dototate PET-CT scan was carried out four weeks after surgery. This showed no tracer avid disease. Genetic testing confirmed succinate dehydrogenase gene subunit A (SDHA) related Hereditary Paraganglioma-Phaeochromocytoma Syndrome (HPPS). Future imaging surveillance will consist of annual whole body and neck MRI. The patient underwent genetic counselling to discuss screening and surveillance for her brother and two primary school-aged children.

Section 4: Conclusions and points for discussion
We describe a case of HPPS and malignant paraganglioma, diagnosed during active treatment of a separate primary malignancy. The case illustrates the challenges in diagnosis at varying stages of investigation. Here, a hypertensive crisis, which is well-known to occur with paraganglioma and phaeochromocytoma, occurred as an index event, but the incidental finding on imaging for PE was key to elucidating the diagnosis. This case also highlights the diagnostic value of 3-methoxytyramine and issues that may arise around genetic counselling.

DOI: 10.1530/endoabs.91.P1

P2 Is it MEN2B or not? That is The Question
Yuvana Subramaniam1, Jessica Lee1, Laura de Benito-Llopis2 & Aditi Sharm1
1Department of Endocrinology, St Bartholomew’s Hospital, London, United Kingdom. 2Department of Ophthalmology, Moorfields Eye Hospital, London, United Kingdom

A 35-year-old gentleman was referred to our Endocrinology department by Moorfields Eye Hospital. He reported a one-year history of visual decline in his right eye, which led to prescription glasses, and incidental finding of bilateral conjunctival nodules. He had reduced visual acuity (pinhole right eye: 6/24 and 6/30 left eye) and prominent corneal nerves on slit-lamp examination. He underwent an excisional biopsy of the conjunctival nodules confirming bilateral conjunctival nevromas; prompting an urgent Endocrinology referral due to the known association with MEN2B syndrome. He denied any symptoms related to phaeochromocytoma or medullary thyroid cancer. His past medical history included complex Crohn’s disease resistant to biological treatment and infective endocarditis of the pulmonary valve related to his Hickman line which was inserted for nutritional optimisation. His other medical history included renal stones and recent cholecystectomy for a perforated gallbladder. There was no personal or family history of endocrinopathies. He recently had a 7-month-old son, conceived by IVF, due to oligozoospermia. On examination he was tall (height of 183.1 cm), with a marfanoid habitus. His BMI was 16 kg/m2. His BP was 114/70mmHg. He had a high arched palate, tongue, and conjunctival nevi. He had evidence of previous abdominal surgeries. The rest of his systems examination was unremarkable including neck and visual fields. His serum adjusted calcium, phosphate, parathyroid hormone, thyroid function, calcitonin, carcino-embryonal antigen, and plasma and urinary metanephrines were unremarkable. Genetic testing did not reveal a pathogenicity in the RET proto-oncogene associated with MEN2B. Exome sequencing revealed a heterozygous pathogenic SOST (spondylopathy of sevenless-1, suggestive of pure mucosal neuroma syndrome (MNS)). This is the second ever reported case in literature of a patient with pure MNS associated with ocular manifestations. Pure MNS is a recently described clinical entity distinct from MEN2B with typical physical features of MEN2B including marfanoid habitus and mucosal neuromas, but without the associated endocrinopathies (medullary thyroid carcinoma or phaeochromocytoma) and RET mutation. Due to the rarity of MNS, the implications on long term screening, management and genetic counselling remain uncertain. As endocrinologists, it is important to be aware and distinguish between pure MNS from MEN2B to avoid unnecessary prophylactic treatments such as thyroidectomy, as the offspring is at 50% risk of inheriting this variant.

DOI: 10.1530/endoabs.91.P2

P3 A rare case of hypergonadotropic hypogonadism: A combination of two rare entities
Emmanuel Ssemmondo1, Thozhukat Sathyapalan1,2,3, Mo Aye4, Shivu Mongolu2 & Harshal Deshmukh1,4
1University of Hull, Hull, United Kingdom. 2Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom

Case History
This 19-year-old Caucasian female was seen in the Endocrine clinic with history of primary amenorrhea. She had a low sexual drive, no breast development but reported presence of axillary and pubic hair growth. Her main concern was whether she would be able to conceive. She had no comorbidities and took no prophylactic treatments such as thyroidectomy, as the offspring is at 50% risk of inheriting this variant. She reported a one-year history of visual decline in her right eye, which led to prescription glasses, and incidental finding of bilateral conjunctival nevromas. He had reduced visual acuity (pinhole right eye: 6/24 and 6/30 left eye) and prominent corneal nerves on slit-lamp examination. He underwent an excisional biopsy of the conjunctival nodules confirming bilateral conjunctival nevromas; prompting an urgent Endocrinology referral due to the known association with MEN2B syndrome. He denied any symptoms related to phaeochromocytoma or medullary thyroid cancer. His past medical history included complex Crohn’s disease resistant to biological treatment and infective endocarditis of the pulmonary valve related to his Hickman line which was inserted for nutritional optimisation. His other medical history included renal stones and recent cholecystectomy for a perforated gallbladder. There was no personal or family history of endocrinopathies. He recently had a 7-month-old son, conceived by IVF, due to oligozoospermia. On examination he was tall (height of 183.1 cm), with a marfanoid habitus. His BMI was 16 kg/m2. His BP was 114/70mmHg. He had a high arched palate, tongue, and conjunctival nevi. He had evidence of previous abdominal surgeries. The rest of his systems examination was unremarkable including neck and visual fields. His serum adjusted calcium, phosphate, parathyroid hormone, thyroid function, calcitonin, carcino-embryonal antigen, and plasma and urinary metanephrines were unremarkable. Genetic testing did not reveal a pathogenicity in the RET proto-oncogene associated with MEN2B. Exome sequencing revealed a heterozygous pathogenic SOST (spondylopathy of sevenless-1, suggestive of pure mucosal neuroma syndrome (MNS)). This is the second ever reported case in literature of a patient with pure MNS associated with ocular manifestations. Pure MNS is a recently described clinical entity distinct from MEN2B with typical physical features of MEN2B including marfanoid habitus and mucosal neuromas, but without the associated endocrinopathies (medullary thyroid carcinoma or phaeochromocytoma) and RET mutation. Due to the rarity of MNS, the implications on long term screening, management and genetic counselling remain uncertain. As endocrinologists, it is important to be aware and distinguish between pure MNS from MEN2B to avoid unnecessary prophylactic treatments such as thyroidectomy, as the offspring is at 50% risk of inheriting this variant.

DOI: 10.1530/endoabs.91.P3
P4
A case of acute intermittent porphyria in a pregnant lady with hyponatraemia

Rizwan Hay, Emma Murray, Paul Hamilton, Helen Wallace & Karen Mallin
1 Regional Centre for Endocrinology & Diabetes, Royal Victoria Hospital, Belfast, United Kingdom. 2 Clinical Biochemistry, Royal Victoria Hospital, Belfast, United Kingdom

Case History
A 27 year-old lady, seven weeks gestation presented to ED during her second pregnancy with abdominal pain, vomiting, constipation and hyponatraemia (Na = 114 mmol/l). She had attended twice earlier during her pregnancy with presumed hyperemesis gravidarum. Because urinary sodium was elevated at 181 mmol/l, dehydration was deemed unlikely and she was initially treated as SIADH with 1.2L fluid restriction and 2.7% 200mLs of hypertonic saline. Sertraline was held. Repeat sodium next day had dropped further to 112mmol/l, following which a further 2.7% NS bolus was given. Sodium remained refractory to this, despite being followed up by a 500mL 1.8% saline infusion at 50mL/hr. An abdominal ultrasound was obtained for persistent generalised abdominal pain which was unremarkable. Laxatives were given as bowelts hadn’t opened in more than one day. Starvation ketosis without acidosis was noted and dietetic input was requested. Intravenous Pabrinex was given. A porphyria screen was requested at this stage, which was suggestive of acute intermittent porphyria.

Biochemistry was consulted and the patient was sent to HDU for haem arginate infusion 3 mg/kg daily for 4 days. Fluid restriction was lifted and the patient was given 0.9% NaCl for the remainder of her admission and sodium normalised. No neurological or respiratory deficit was noted during her admission.

Investigations
Abdominal Ultrasound: Biliary sludge Chist X-ray: Normal

Results and Treatment
Osmolality (serum): 237 mOsm/kg [Ref: 275.295 (mOsm/kg)] Osmolality (urine): 587 mOsm/kg Urea = 1.4mmol/l (2.5-7.8mmol/l) Urine (Na) = 181 mmol/l Ketones = 3.6 mmol/l Urine porphobilinogen = 559.8 (0-10.7 umol/l) PBG/Creatinine = 64 (<1.5 umol/mmol) Porphyrin/Creatinine = 796 (0-40umol/mmol)

Conclusion and Points for Discussion
Acute intermittent porphyria is rare autosomal dominant condition characterised by partial deficiency of the enzyme hydroxymethylbilane synthase, which results in the accumulation of porphyrin precursors in the body. It can be triggered by various factors such as pregnancy and other hormonal changes, fasting, infections, medications and alcohol consumption. It can present with abdominal pain, constipation, tachycardia, hypertension, behavioural changes, seizures and peripheral neuropathy or paralysis. Drugs that may precipitate acute intermittent porphyria include: anabolic steroids, antidepressants (MAOL TCA), hormonal contraceptives, antifungals, sulphonylureas and taxanes. A safe drug list can be found on the UKPMS website. Although acute intermittent porphyria is a very rare disorder, this case highlights the need to consider porphyria as a differential diagnosis in a patient with abdominal pain and refractory or unexplained hyponatraemia.

DOI: 10.1530/endoabs.91.P4

P5
An unusual case of adrenal mass

Lauran Noel, Dominic Cavlan & David Randall
Barts Health NHS Trust, London, United Kingdom

Case history
A 59 year old woman presented to hospital with severe abdominal pain, diarrhoea and vomiting. Her past medical history included stage end renal failure of unknown cause, renal transplant with antithymocyte globulin (ATG) induction ten years prior, treated pulmonary tuberculosis, hypertension and new onset diabetes after transplant (NODAT).

Investigations
A CT scan of the abdomen demonstrated an 85 x 74 x 69mm heterogeneous mass arising from the right adrenal gland and infiltrating the liver. This was suspicious for adrenocortical carcinoma or phaeochromocytoma and she was referred to the endocrinology team. The patient had hypertension which was well controlled on a single oral agent, but she described paroxysmal episodes of anxiety associated with flushing and headache. There were no clinical features of cortisol or androgen excess. 24hour urine cortisol levels were normal (21nmol/day), and plasma and urine metanephrine levels were all within normal limits. The potential for an additional differential for her adrenal mass was considered on the basis of her history of immunosuppression and a very high serum level of Epstein Barr Virus (>200,000 copies): post-transplant lymphoproliferative disorder. An US-guided biopsy was undertaken to establish a histological diagnosis. She received alpha-blockade with doxasosin in preparation for this.

Results and treatment
Histology from the adrenal biopsy demonstrated an EBV positive high grade lymphoma, consistent with post transplant lymphoproliferative disease. No adrenal tissue was identified in the mass. Immunochemistry was positive for CD20 and CD79a. There was no evidence of metabolically active nodal disease or metastases above or below the diaphragm on FDG-PET CT. She was initiated on R-CHOP chemotherapy following oncology review.

Conclusions and points for discussion
This case demonstrates a rare cause of adrenal mass. Post transplant lymphoproliferative disorder is a common cause of malignancy in solid organ transplant patients, although a rare cause of isolated adrenal mass. Biopsy of adrenal masses is rarely undertaken due to the risk of seeding or causing hypertensive crises. However, this patient had a history of renal transplant, high cumulative immunosuppressive dosing and a high EBV titre. This in conjunction with normal metanephrines justified the biopsy in this case, and was imperative for confirming the diagnosis.

DOI: 10.1530/endoabs.91.P5

P6
Hypercalcaemia in a patient with sarcoidosis and a positive functional parathyroid scan

Muna Guma, Yaasir Mamoojee, Richard Quinton, Catherine Napier & Ian Forrest
Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom

Introduction
Hypercalcaemia diagnosed in hospital setting is most commonly PTH-independent and malignancy related, whilst hypercalcaemia discovered in community setting is commonly secondary to Primary Hyperparathyroidism (PHPT). Other rare causes include granulomatous diseases such as sarcoidosis and familial hypercalcaemic hyperparathyroidism (FHH).

Case Summary
A 73-year-old male with a background of hypertension and chronic kidney disease stage 3 was found to be hypercalcaemic on routine blood tests by his GP. He had no symptoms of hypercalcaemia and his CXR demonstrated bilateral lower zone opacifications. He was admitted to hospital with an adjusted serum calcium of 3.03 mmol/L (NR 2.2 – 2.6) and an eGFR of 53 mL/min/1.73m2. He received intravenous Zoledronic acid and was referred to the Endocrine team for follow-up. His serum vitamin D level was low at 35 nmol/L and his PTH was 5.6 pmol/L (NR 1.1 – 6.4). He received a loading dose of oral vitamin D (100,000 units) followed by daily replacement dosing. His adjusted serum calcium level remained elevated, varying between 2.87 and 3.13 mmol/L, with a suppressed serum phosphate level at 0.51 mmol/L (NR 0.8 – 1.5). His fractional urine calcium excretion, based on a 24 hour urine collection, remained low at 1%, despite vitamin D supplementation. By that time CT imaging of his chest demonstrated features suggestive of pulmonary sarcoidosis. His serum angiotensin converting enzyme level was normal. Given the level of persistent hypercalcaemia, functional imaging of the parathyroid was undertaken which demonstrated a 1.1 cm enhancing nodule posterior to the lower pole of the right lobe of the thyroid suggestive of a parathyroid adenoma. His persistently low urine calcium excretion prompted genetic testing for FHH which revealed a novel pathogenic calcium-sensing receptor (CASK) variant on chromosome 3.

Discussion
Our case highlights the importance of investigating for FHH in patients with PTH-dependent hypercalcaemia and persistently low urine calcium excretion despite replete vitamin D levels. What is unique in our patient is the coexistence of sarcoidosis and probable PHPT. To what extent these two diagnoses are influencing his serum calcium level remain unclear. Nevertheless our patient remains asymptomatic from his hypercalcaemia with no evidence of end-organ damage on bone density scan and renal imaging.

DOI: 10.1530/endoabs.91.P6

P7
Calciphylaxis in a patient with hypoparathyroidism complicated by hyperparathyroidism secondary to immobility

Isabelle van Heeswijk, Lynsey Havill, Rebecca Kinton, Antonia Ugur & David Hughes
Royal Derby Hospital, Derby, United Kingdom

Section 1: Case history
The case concerns a 53-year-old gentleman who developed calciphylaxis following a bioprosthetic aortic valve replacement. His past medical history...
Munisamy, Nur Azman & Kimberley Lambert

FGF23 was identified as causative humoral factor for tumour induced osteomalacia. She is currently awaiting for a 68-Gallium DOTATE PET scan in February 2023.

**P8**

A rare case of FGF23 producing tumour

Narmadha Munisamy, Nur Azman & Kimberley Lambert
Royal Hampshire County Hospital, Winchester, United Kingdom

**Case history**
A 67-year-old lady was referred to endocrinology with an 8-year history of mild hyperparathyroidism with Parathyroid hormone of 7.1 - 15.3 pmol/l (Normal - 1.05 - 4.9). Her corrected calcium ranged from 2.47-2.66 mmol/l (Normal 2.2 - 2.62), phosphate 0.63 - 1.0 mmol/l (normal 0.8-1.5), normal renal function and normal vitamin D. Her urine calcium to creatinine ratio was 0.7 mmol/mmol (Normal 0.0-4.0).

**Investigations and treatment**
She had myalgia due to severe osteoporosis and her DEXA scan showed T-score of -2.8 (hip), -4.5 (spine). She had lost about 1.5 cm from maximal adult height, despite Alendronic acid treatment. She had a negative sestimibi scan and was referred to the tertiary metabolic bone centre to identify the cause for her severe osteoporosis. She was ex-smoker, quit smoking at 54 years of age, attained menarche at 11 years and menopause at the age of 48 by hysterectomy. Tertiary team recommended genetic testing to look for familial hypercalcaemia and hypocalciuria which came back as negative. On review back in endocrinology clinic it was noted she had an intermittent mild hypophosphatemia and on further investigation she had 24-hour urine calcium 0.2 mmol/24hr (Normal 0.6-2.6). Her urine calcium to creatinine ratio was 0.7 mmol/mmol (Normal 0.0-4.0).

She was treated with infusions of pamidronate and total cessation of alfacalcidol and calcium supplements. Her corrected calcium was 2.62 mmol/l and phosphate level 1.88 mmol/l, in-keeping with overtreatment of hyperparathyroidism. Her FGF23 was elevated at 2.62 pmol/l (Normal 0.0-1.95). She was diagnosed with FGF23 producing tumour. She was referred to surgical team and was discharged home where she has now regained his mobility and remains under close monitoring.

**Conclusions and points for discussion**
Calciphylaxis is a rare life threatening disorder characterised by painful necrotic lesions of the skin. Ex-oesosseous soft tissue calcification leading to occlusion of cutaneous arterioles resulting in tissue necrosis. It has an exceptionally high mortality – up to 80% - with most deaths occurring due to sepsis. The vast majority of cases occur in patients with chronic renal disease with only a handful ever reported in the context of hyperparathyroidism. Management of calciphylaxis centres on controlling calcium and phosphate levels, wound care, pain management and prevention of sepsis. In conclusion, this case describes an often-fatal condition occurring in unusual circumstances and the management that led to the patient’s survival against the odds!

DOI: 10.1530/endoabs.91.P8

**P9**

Spontaneous haemorrhage into parathyroid adenoma masquerading as parathyroid carcinoma

Matthew North, Yogesh Bhatt & Mark Cohen
Barnt Hospital, Royal Free London NHS Foundation Trust, London, United Kingdom

**Case history**
A 63-year-old female was admitted to our hospital in January 2022 with neck swelling that had developed over five days with associated dysphagia to fluids. Biochemistry revealed severe hypercalcaemia with a corrected calcium of 3.82 mmol/l (2.20 - 2.60 mmol/l) and PTH of 78.7 pmol/l (1.5 - 6.9 pmol/l), and an associated AKI (creatinine of 174 umol/l from a baseline of 80). Ultrasound initially showed a left-sided 3 x 2 cm nodule suggestive of a large parathyroid adenoma / carcinoma. The patient subsequently developed a significant amount of bruising over the chest wall, originating from the anterior neck, consistent with haemorrhage.

**Investigations**
CT imaging of the neck and chest showed a 4.7 x 3.8 cm soft tissue mass posterior to the left lobe of the thyroid associated with subcutaneous inflammatory change, and an associated 7.2 x 4 cm contiguous soft tissue mass encasing the oropharynx and upper oesophagus with an appearance highly suspicious of malignancy. Due to the significantly elevated PTH level there was a high index of suspicion for parathyroid carcinoma therefore MIBI imaging was performed, which showed a mass of indeterminate appearance likely to represent a parathyroid lesion (adenoma / carcinoma) with surrounding soft tissues suggestive of haemorrhage from the lesion or severe inflammatory changes. A MIBI scan identified two mildly tracer avid soft tissue nodules posterior to the upper and lower poles of the left hemithyroid, and the left soft tissue density lesion posterior to left lobe was not tracer avid, compatible with haemorrhage.

**Results and treatment**
Hypercalcaemia was treated with continuous IV fluids, zoledronate and cinacalcet. Neck swelling was initially managed with IV steroids. There were no airway concerns, but an NG tube was inserted to allow for feeding. Serum calcium level and PTH levels fell, and she was discharged after 10 month inpatient stay. She was referred to the ENT team for evaluation of pain but was diagnosed with laryngitis. On review, she was noted to have a large mass at the upper pole of the right parathyroid gland with mild tracer avid soft tissue nodules posterior to the upper pole of the left parathyroid gland.

**Conclusions and points for discussion**
Haemorrhage into a large parathyroid adenoma can mimic parathyroid carcinoma with severe symptomatic hypercalcaemia, very high PTH levels and dysphagia.

DOI: 10.1530/endoabs.91.P9

**P10**

A case of hypothalamic lipoma causing Hyperprolactinemia in a patient with a family history of Birt-Hogg-Dubé syndrome

Geethika Thota & Natalia Bratis
St. Peter’s University Hospital, New Brunswick, USA

**Case Presentation**
A 41-year old female with a medical history significant for depression presented to the clinic for evaluation of bilateral nipple discharge for 5 months. The patient reported that for the last 5 months she started noticing expressible nipple discharge. She reported no associated headaches, vision changes. She denies the use of vitamins, supplements, herbal remedies. She had no associated fatigue, changes in the shoe/ring size, heat/cold intolerance, tremors, recent weight changes. She had been on Sertraline for the last 4 years with no recent dose changes.

**InVESTIGATIONS**
Initial labs showed Hb 13.3 g/dl (11.1-15.9 g/dl), WBC 6.8 x10^3 /UL (4.1-11 x 10^3 /UL), Platelet 218 x10^3 /UL (150-450 x10^3/UL). Comprehensive metabolic panel was within limits. Hormonal analysis revealed TSH 1.185muU/ml (0.45-4.50muU/ml), T4 1.975muU/ml (0.85-1.80muU/ml), T3 3.8muU/ml (2.9-4.5muU/ml), PRL 2.52 mmol/l.

**Section 4: Conclusions and points for discussion**
Spontaneous haemorrhage into parathyroid adenoma masquerading as parathyroid carcinoma

Matthew North, Yogesh Bhatt & Mark Cohen
Barnt Hospital, Royal Free London NHS Foundation Trust, London, United Kingdom

**Case history**
A 63-year-old female was admitted to our hospital in January 2022 with neck swelling that had developed over five days with associated dysphagia to fluids. Biochemistry revealed severe hypercalcaemia with a corrected calcium of 3.82 mmol/l (2.20 - 2.60 mmol/l) and PTH of 78.7 pmol/l (1.5 - 6.9 pmol/l), and an associated AKI (creatinine of 174 umol/l from a baseline of 80). Ultrasound initially showed a left-sided 3 x 2 cm nodule suggestive of a large parathyroid adenoma / carcinoma. The patient subsequently developed a significant amount of bruising over the chest wall, originating from the anterior neck, consistent with haemorrhage.

**Investigations**
CT imaging of the neck and chest showed a 4.7 x 3.8 cm soft tissue mass posterior to the left lobe of the thyroid associated with subcutaneous inflammatory change, and an associated 7.2 x 4 cm contiguous soft tissue mass encasing the oropharynx and upper oesophagus with an appearance highly suspicious of malignancy. Due to the significantly elevated PTH level there was a high index of suspicion for parathyroid carcinoma therefore MRI imaging was performed, which showed a mass of indeterminate appearance likely to represent a parathyroid lesion (adenoma / carcinoma) with surrounding soft tissues suggestive of haemorrhage from the lesion or severe inflammatory changes. A MIBI scan identified two mildly tracer avid soft tissue nodules posterior to the upper and lower poles of the left hemithyroid, and the left soft tissue density lesion posterior to left lobe was not tracer avid, compatible with haemorrhage.

**Results and treatment**
Hypercalcaemia was treated with continuous IV fluids, zoledronate and cinacalcet. Neck swelling was initially managed with IV steroids. There were no airway concerns, but an NG tube was inserted to allow for feeding. Serum calcium level and PTH levels fell, and she was discharged after 10 month inpatient stay. She was referred to the ENT team for evaluation of pain but was diagnosed with laryngitis. On review, she was noted to have a large mass at the upper pole of the right parathyroid gland with mild tracer avid soft tissue nodules posterior to the upper pole of the left parathyroid gland.

**Conclusions and points for discussion**
Haemorrhage into a large parathyroid adenoma can mimic parathyroid carcinoma with severe symptomatic hypercalcaemia, very high PTH levels and dysphagia.

DOI: 10.1530/endoabs.91.P9

**Endocrine Abstracts (2023) Vol 91**
A rare case of Hyperparathyroidism Jaw Tumour Syndrome without jaw tumours
Sarah Mulholland1 & Alex Lewis2
1University Hospitals North Midlands, Stoke, United Kingdom. 2Manchester University NHS Foundation Trust, Manchester, United Kingdom

Case history
A 19-year-old female presented with painful left shoulder after slipping whilst doing press-ups. Plain x-ray showed a proximal humeral fracture, as well as a large bone cyst raising concerns of a pathological fracture. She had no past medical history and was not taking any regular medications. On further questioning she did complain of a 2 year history of bilateral painful shoulders and left knee pain. Family history was significant for her father suffering primary hyperparathyroidism aged 27 which resolved spontaneously. Paternal grandmother had recently been diagnosed with primary hyperparathyroidism aged 27 which resolved spontaneously. She was referred to the local fracture clinic, and due to the x-ray appearances she was also referred to the sarcoma service.

Investigations
MRI of both shoulders suggested bilateral proximal humeral metaphyseal aneurysmal bone cysts (ABC). Subsequent whole body MRI showed cystic lesions in both proximal humeri, as well as within the left ilium, right fibula and left distal femur. Fluoroscopic guided biopsy of the left distal femur lesion showed giant cell-rich tumour of bone, with no evidence of malignancy. Further genetic analysis in our case may link the possible presentation of intracranial lipomas in BHD syndrome.

Results and treatment
Biochemistry showed parathyroid hormone 82.8 pmol/l (1.6-6.9), corrected calcium 3.33 mmol/l (2.2-2.6), phosphate 0.61 mmol/l (0.8-1.5), Vitamin D 41.7 nmol/l (> 50). On review there was a previously unreported lesion in her right lower parathyroid gland on the whole body MRI and MIBI SPECT scan confirmed increased tracer uptake in this area, in keeping with a right inferior parathyroid adenoma. A diagnosis of pHPT was made and cinacalcet was commenced. She was also referred to the sarcoma service.

Conclusion
Intracranial lipomas are rare and mostly asymptomatic. Our case demonstrates a rare presentation of hypophalamic lipoma in a patient with family history of BHD causing hyperprolactinemia probably resulting from compression of dopaminergic neurons of the hypophalumus. BHD is an autosomal dominant condition presenting with multiple benign skin tumours like lipoma, fibrofolliculocomas, lung cysts, kidney lesions, etc. To our knowledge, intracranial lipomas have not been reported in patients with this syndrome. Further genetic analysis in our case may link the possible presentation of intracranial lipomas in BHD syndrome.
His past medical history was of vitamin D deficiency and arthritis of the spine. Regular medications were Lansoprazole, Senna, and Flecainide. He was a non-smoker and had no relevant family history. Neck examination was unremarkable.

Investigations
Corrected serum calcium (cCa) was initially 4.54 mmol/l, parathyroid hormone (PTH) 104.5 pmol/l, phosphate 0.52 mmol/l, potassium 2.9 mmol/l. 24-hour urinal calcium was 10.1 mmol/l and calcium:creatinine clearance ratio 2.24. Early morning cortisol was 957 mmol/l, thyroid and liver function were within reference ranges. Initial intravenous fluid therapy lowered cCa to 4.12 mmol/l. A Te-99m Sestamibi scan identified an oophoron-like paraortic adenoma related to the left upper lobe of the thyroid, later confirmed on ultrasound as a well-defined 17x8x14 mm oval parathyroid lesion with peripheral cystic change.

Results and treatment:
His frailty precluded parathyroidectomy. Management with intravenous fluids, pamidronate, cinacalcet, and denosumab failed to normalise cCa or PTH. Ultrasound-guided ethanol ablation of his paraortic adenoma was performed. Under local anaesthetic and ultrasound guidance, a 23-gauge needle was inserted into the parathyroid adenoma and 0.2mls 100% ethanol was injected into the lesion. The procedure was well tolerated with no immediate complications. PTH decreased from 104.5 pmol/l to 20.0 pmol/l and cCa decreased from 3.33 mmol/l to 2.94 mmol/l. The procedure was repeated twice, at 19 and 28 days. Although cCa briefly normalised to 2.49 mmol/l after the third ablation, it returned to a peak of 4.94 mmol/l, and the nadir of PTH was 24.0 pmol/l. The patient died as a result of poor oral intake and hypotension, two months after the first ablation.

Conclusions and points for discussion:
Ultrasound-guided ethanol ablation of a parathyroid adenoma is an alternative to surgery in resistant hyperparathyroidism. Results elsewhere showed significant reduction in adenoma size, PTH, and cCa in a comparable patient population (Yazdani, Khaliti, Slanavch, et al., 2020). This technique carries a relatively small side effect profile and the resources required to perform it are available in district general hospitals. In this case, the procedure was technically successful and showed measurable biochemical improvement. It offered some hope to the patient and his carers, despite events revealing that the improvement was not sustained.

The process may help others in this difficult position.

P15
What is the role of 11C Methionine PET-CT in the clinical evaluation of ACTH-dependent Cushing’s disease?
Adeotokunbo Idowu, Mon Hla & Sheharyar Qureshi
West Middlesex University Hospital, London, United Kingdom

Case History
26 year old man with uncontrolled hypertension and weight gain over the last 10 – 15 years associated with abdominal stretch marks. His past medical history includes hypertension managed with four oral anti-hypertensive agents and a BMI of 36.74 kg/m2 (with centripetal obesity). There is no family history of hypertension.

Investigations
There was historical biochemical evidence of hypercalcaemia (between 2.6 – 3.2mmol/l) in the past year but his serum aldosterone levels was not elevated (renin 1.2 mmol/l/h, serum aldosterone <60 pmol/l). Further investigations include 24 hour urine free cortisol (774 mmol/day), post ONSDT serum cortisol (807 mmol/l) with serum ACTH 56.7 ng/dl. These were suggestive of possible Cushing’s disease. His enhanced MRI of the pituitary gland did not identify a discrete lesion and there was no enlargement of the pituitary gland noted. His CT scan of the abdomen revealed bilateral adrenal enlargements.

Results and Treatment
Given the high suspicion of ACTH-dependent Cushing’s syndrome, his case was discussed at our regional pituitary multi-disciplinary team meeting and further tests performed. These are: i) cortisol day curve that identified persistently elevated serum cortisol levels with non-suppressed ACTH; ii) elevated salivary cortisol levels taken on three occasions; iii) an elevated 9am serum cortisol level following repeat ONSDT (380nmol/l); as well as iv) IPSS that revealed a central to peripheral ACTH gradient that excluded ectopic ACTH. He was then commenced on metyrapone 500mg BD and further cortisol day curves were performed to guide the titration of his metyrapone dose. His whole body DEXA scan revealed a BMD that is below the expected range for age at the lumbar spine and hips. NM Methionine PET/CT demonstrated heterogeneous tracer activity in pituitary gland with slightly higher activity towards the right and minor left lateral extension.

Conclusions and Points for discussion
Different imaging modalities having been utilised to evaluate ACTH dependent Cushing syndrome. We advocate the use of 11C Methionine PET CT in the evaluation of pituitary adenomas due to its high sensitivity and ability to detect lesions that may be difficult to identify on cross-sectional MRI sequences. Our case also highlights the importance of multidisciplinary approach in the timely diagnosis and management of patients with high suspicion of Cushing’s disease.

References
DOI: 10.1530/endoabs.91.P15

P16
Oncocytic parathyroid adenoma presenting with refractory hypercalcaemia and multiple incidental Brown tumours
Nur Azman, Narmadha Munisamy, Dana Le Carpentier, Maria Syed, Paul Spraggs, Jimmy Li Voon Chong, Kimberley Lambert & Meenakshi Parsad
Royal Hampshire County Hospital, Winchester, United Kingdom

Case History
A 61-year-old Caucasian female from Ukraine presented with severe hypercalcaemia following routine blood tests performed by the GP. She reported symptoms of back pain and joint pains. She had renal stones 10 years prior. No history of thiourea or lithium use. No red flags; no change in appetite or weight loss. There was no familial history of Multiple Endocrine Neoplasia (MEN). Examination of her neck, cardiorespiratory, abdomen and breasts were normal.

Investigations
Initial corrected calcium in hospital was 3.81mmol/l (2.2-2.62 mmol/l), with low phosphate 0.63mmol/l (0.8-1.5mmol/l), elevated PTH 173.9pmol/l (1.95-8.49pmol/l), 25-OH vitamin-D 40nmol/l (50-374nmol/l), eGFR 66mls/min, ALP 235U/L (30-130U/L), 24-hour urine calcium was raised 11.3mmol/day (2.5-7.5mmol/day). QT interval was normal on ECG. Urinary tract ultrasound did not demonstrate any calculi. Chest X-ray revealed three opacities projected over right lower lung, arising from the anterior ends of the ribs. Subsequent Chest CT showed multiple expansile lytic rib lesions accounting for the x-ray appearance, with metastasis or myeloma as differential diagnosis. Her myeloma screen was negative. The CT scan also detected a soft tissue lesion 17x24x22mm inferior to the right thyroid lobe, which may represent a parathyroid adenoma in the context of Primary Hyperparathyroidism. This nodule was also identified on neck ultrasound. Whole-body FDG PET-CT confirmed the presence of an enlarged right lower parathyroid gland with multiple brown tumours of the skull, appendicular and axial skeletons. Her DEXA scan demonstrated osteoporosis of the radius, T-score -4.9.

Results and treatment
She was initially treated with aggressive fluid resuscitation and intravenous Pamidronate 90mg, following which calcium level decreased to 3.23nmol/l. She was also started on cinacalcet 30mg daily, in response to this calcium began to fall. Subsequent outpatient reviews had led to multiple admissions for intravenous fluids and Pamidronate over a period of three months, proving that she had refractory hypercalcaemia. She underwent right inferior parathyroidectomy whereby the nodule was fully resected. Histological examination was in keeping with an oncocytic parathyroid adenoma, weighing 7 grams. Calcium was normalised at 2.42mmol/l post-operatively and she is recovering well.

Conclusions and discussion
Primary Hyperparathyroidism with end-organ damage is an indication for surgical intervention. In this case, the timing for parathyroidectomy was relatively urgent due to refractory hypercalcaemia and intolerance to cinacalcet. Ostetis Fibrosa cystica (Brown tumour) is rare occurring in about 2% of patients with Primary Hyperparathyroidism. We expect that the skeletal lesions will regress with normalisation of PTH and calcium levels.

DOI: 10.1530/endoabs.91.P16

P17
47 XY Syndrome; compared to XXY; do both ‘Y’ and Thyroxine differ?
Andrew Solomon, Aiman Haddad & Tabish Saifee
London North West University Healthcare NHS Trust, London, United Kingdom

Endocrine Abstracts (2023) Vol 91
Case history

We presented a 61-year-old male with a background history of 47 XYY syndrome who was referred to the endocrine outpatient service with abnormal thyroid function tests. He has mild learning disabilities, asthma, action tremor, erectile dysfunction, and type 2 diabetes. He was tall in stature with obvious cladoactyly. He had been evaluated for his tremor by our Neurology colleagues.

Investigations

His blood tests results were as follows: TSH 5.38 mIU/L (0.27-4.20), FT4 11.6 pmol/L (12.0-22.0), FT3 4.5 pmol/L (3.1-6.8), Testosterone 16.9 nmol/L (6.3-20.5), LH 15.6 IU/L (1.7-8.6), FSH 7.7 IU/L (1.5-12.4), Prolactin 200 mIU/L (66-324), Cortisol 309 nmol/L, IGF-1 16.3 nmol/L (3.5-5.20). His Anti TPO were negative.

Discussion of results

His testosterone levels were normal with mildly elevated LH and normal FSH. The Thyroid function tests were in keeping with primary hypothyroidism with negative antibodies.

Conclusions and points for discussion

47 XXY Syndrome, also known as Jacobs syndrome (JS), is a rare genetic condition. Hallmark clinical features includes tall stature, cladoactyly, macrocephaly & hypertelorism. Recognized associated complications includes asthma, action tremor, seizure disorders, infertility, and psychological problems (1). An action tremor can be seen in JS and should be a clue to consideration of karyotyping. Also patients should be offered genetic testing to rule out Klleifelter’s syndrome (KS) 47 XXY where some patients sometimes share JS features including tall stature & infertility. In KS, the testes are likely to be small in volume with presence of gynecomastia. There are no previous studies to suggest any correlation between Hypothyroidism and JS, but one multicentre study showed that the prevalence of hypothyroidism in KS was similar to normal male population, showing absence of increased risk of hypothyroidism associated with the XXY karyotype (2).

References


DOI: 10.1530/endoabs.91.P17

P19

Heart failure as the index presentation of Addison’s disease: Case Report

Sibhy Joseph

Dorset County Hospital, Dorchester, United Kingdom

Background

Cardiac failure is an infrequently reported complication of Addison’s disease which is unique in its reversibility. We report a rare case of heart failure as the initial presentation of Addison’s disease.

Case Summary

A 39-year-old gentleman presented with classical features of heart failure and hypotension. His Echocardiogram showed moderately impaired left ventricular function. Addison’s disease was suspected due to hyponatremia, hyperkalaemia and low cortisol levels; A short synacthen test confirmed this and he was started on dual therapy — hydrocortisone and fludrocortisone. His left ventricular function returned to normal in 5 days. He was followed up with hydrocortisone dose curve. Discussion

Heart failure is a rare but acknowledged complication of Addison’s disease. In majority of the cases, the cardiac dysfunction secondary to Addison’s disease is reversible with dual therapy of glucocorticoids and mineralocorticoids. Expeditious recognition and initiation of pharmacotherapy is crucial for the reversibility and resolution of symptoms.

DOI: 10.1530/endoabs.91.P19

P18

Recent recurrent symptomatic pituitary hyperplasia mimicking macroprolactinoma in pregnancy

Michael Onyema1, Quratulain Tunveer1, Samira Khalilova1, Fannie Lajeunesse-Trempe1, Simon Aylwin1 & Georgios K. Dimitriadis1

1King’s College Hospital, London, United Kingdom. 2Croydon University Hospital, London, United Kingdom

(1) 30-year-old woman presenting at 34 weeks of pregnancy with symptoms of persisting headaches, diplopia and nausea. She presented again 4 years later with similar symptoms in a subsequent pregnancy at 35 weeks with additional complaints of blurred peripheral vision. (2) During her first pregnancy biochemistry revealed marked prolactin elevation (14,000 mIU/L). A non-contrast MRI scan of the pituitary revealed significant enlargement of the gland (22 x 14.4 x 12.5mm) beyond expected physiological limits in pregnancy and in close relation to the optic chiasm. Ophthalmology assessment showed normal visual fields, visual acuity and colour vision. She was managed conservatively with spontaneous resolution of symptoms after delivery. A 3 month post-partum contrast MRI showed her pituitary gland had returned to normal. Prolactin levels normalised (156 mIU/L) at 17 months post-partum, after breast feeding had ceased. During her second pregnancy prolactin levels were once again markedly elevated (34,692 mIU/L and 24,855 mIU/L on repeat). A non-contrast MRI scan revealed a 22 x 14.5 x 12mm well defined isointense pituitary lesion reported as a mass effect. The differential diagnosis included testicular cancer, granulomatous diseases, leukemia and adrenal rests. A CT scan showed no metastatic/nodal disease. Blood tests showed normal urea and electrolytes, full blood count, SCC, LDH and alpha-fetoprotein. He was referred to the Royal Marsden Hospital urologists, who reviewed in Testicular Supraneteton MDT meeting, and recommended a bilateral orchidectomy. He had no children but was keen to start a family. Analysis of two semen samples showed azoospermia. He was offered referral to a local fertility centre for micro-surgical testicular sperm extraction or referral to a specialist centre for extraction of sperm at the time of orchidectomy, but was concerned about having cancer and delaying treatment, so he decided to proceed to bilateral orchidectomy. Post-operatively, he was discharged on Testosterone gel 40mg daily. The endocrine team subsequently received a referral as he was fatigued and dizzy post-operatively, with nausea and vomiting and also his histopathology report suggesting the possibility of the adenogenital syndrome with a differential diagnosis of Leydig cell tumours. In endocrine clinic, he reported taking prednisolone throughout his life, but he didn’t know the indication of it, therefore GP was not able to prescribe steroid, so he continued to source it from Romania. He reported was extremely poorly as a neonate and was transferred from the rural hospital to the main hospital in of which were spontaneous) and there was no history of galactorrhea when not breast feeding. No further children were desired, but a recommendation was made for visual field monitoring during any potential future pregnancy. (4) Pituitary hyperplasia is a common entity in pregnancy. Exaggerated symptomatic hyperplasia in pregnancy is a rare occurrence and recurrent episodes in the same individual even more so. Assessment requires review of clinical, hormonal and radiological findings. Surgical intervention is unlikely to be indicated in such cohorts due to its transient nature across the peripartum period. Medical therapy with dopamine agonists should be considered especially when associated with accelerated biochemical hyperprolactinaemia, and visual field monitoring is advisable in future pregnancies.

DOI: 10.1530/endoabs.91.P18
Bucharest. He was of short stature (154 cm), and short compared to his family. His sister was fit and well. Post-operative blood tests showed a low sodium 125 mmol/l, high potassium 5.9 mmol/l, midday cortisol 74 nmol/l. Subsequent biochemical and genetic tests confirmed the diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency (17-OH-P 739 mmol/l). The plasma aldosterone was 170 pmol/l by mass spectrometry, with a renin of 1.2080 mU/L. Re-review of ‘staging’ CT scan confirmed bilateral diffuse nodular adrenal enlargement. Discussion points include whether the diagnosis of testicular adrenal rest tumours should have been made pre-operatively, and if subsequent treatment could have restored fertility. It highlights the importance of discussing testicular swellings prospectively with male patients with CAH to ensure appropriate management.

DOI: 10.1530/endoabs.91.P20

P21

Crystal Healing in endocrine disease
Hester Lacey, Ali Chakera & Anna Crown
Royal Sussex County Hospital, Brighton, United Kingdom

We present two cases of alternative approaches to treating endocrine disease.

Case 1

A 55-year-old man became steroid dependent in 2017, following a skiing accident and C3/4 fracture, for which he received 13-months of high-dose hydrocortisone. Upon cessation, he developed adrenal crisis, confirmed on short synacthen test. Hydrocortisone replacement therapy was begun. His dose was doubled, then tripled to control his symptoms, in addition to frequent rescue injections for crises. His high steroid requirement was felt due to significant neuropathic pain and hyperprolactinaemia. Her pituitary profile was otherwise normal. MRI pituitary demonstrated adenoma with suprasellar extension, diagnosed as a likely non-functioning adenoma. Surgery was discussed, but surveillance agreed. Prolactin levels gradually rose in 2014, associated with slight adenoma enlargement. A diagnosis of non-functioning adenoma was considered, and cabergoline recommended, however the patient was a practitioner of crystal healing and preferred to attempt healing techniques pre-operatively, and if subsequent treatment could have restored fertility. It highlights the importance of discussing testicular swellings prospectively with male patients with CAH to ensure appropriate management.

Investigations:

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Cortisol nmol/L</th>
<th>Case 2</th>
<th>Prolactin (mU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>Baseline 30mins</td>
<td>Date</td>
<td>2011 970</td>
</tr>
<tr>
<td>14/8/2018</td>
<td>48</td>
<td>19/3/2019</td>
<td>10 53</td>
</tr>
<tr>
<td>27/9/2019</td>
<td>312</td>
<td>08/12/2021</td>
<td>451</td>
</tr>
<tr>
<td>29/11/2022</td>
<td>456</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusions

We describe two cases of complementary therapies associated with remarkable improvements in endocrine disease. In case 1, clinical and biochemical resolution of adrenal insufficiency was surprising, given high steroid requirements. However, there is plausibility in his methodology. Methamphetamine is a known HPA-axis stimulant, with marked ACTH-mediated adrenal glucocorticoid secretion following ingestion. Case 2 details a rare but recognised clinical course of non-functioning pituitary adenoma. Resolution also coincided with menopause, which can occur with macroprolactinomas. Crystal healing could have been causative or coincidental in this notable improvement. The patient keeps copies of her sequential imaging to support crystal healing practices. These cases highlight the power of self-belief as an influential healer in medicine.

DOI: 10.1530/endoabs.91.P21

P22

Cystic Prolactinoma unmasking Meningoencephalocele: When medical treatment leads to surgery
Sophie Greenhalgh & Alexander Lewis
Manchester University NHS Foundation Trust, Manchester, United Kingdom

Case history

21-year-old male presented in November 2006 with visual loss, headaches and fatigue. No previous past medical history. Visual field testing confirmed a left temporal hemianopia with right temporal upper quadrant anopia. Investigations

Brain imaging revealed a large macroadenoma with suprasellar and lateral extension. Hormone testing demonstrated abnormalities in TSH 5.13 mU/L, Free T4 7.1 pmol/L, random Cortisol 64nmol/L and Testosterone 2.3nmol/L, with an elevated Prolactin 4661 mU/L (lower than expected for the size of lesion). Cabergoline was initiated from January 2007 in attempt to shrink the tumour prior to surgery, in addition to Hydrocortisone and Levophelyoxirine replacement.

Results and treatment

By May 2007 there was significant reduction in tumour size following up-titration of Cabergoline. This translated to both subjective and objective improvement in vision, with only a small residual left temporal upper quadrant anopia. Prolactin reduced to 494nmU/L. Following MDT discussion, surgery was indefinitely postponed and patient continued on medical therapy. MRI imaging in July 2007 confirmed the lesion was no longer compressing the optic chiasis. Ongoing monitoring demonstrated further radiological shrinkage of the macroadenoma and complete normalisation of visual fields and acuity. In November 2009, the left posterior aspect appeared predominantly cystic and extended into the medial temporal lobe. Cystic degeneration of the lesion continued to increase over the next 7 years, but the patient remained asymptomatic on Cabergoline. In early 2018, he developed increasingly frequent episodes of speech disturbance and lip smacking. Following neurological and neurosurgical assessment, the patient was diagnosed with Temporal lobe epilepsy and initiated on anti-epileptic drugs (AEDs). Further imaging illustrated this was due to formation of a medial temporal meningoencephalocele colliding with the expanding cystic prolactinoma, as a result of dopamine agonist therapy. In November 2018, the patient underwent transphenoidal repair of the meningoencephalocele and resection of the residual treatment-resistant prolactinoma. Histology confirmed anterior pituitary tissue with a lactotroph predominance. Post-surgery, Prolactin suppressed and seizures were eventually controlled on a reduced combination of AEDs. His Cabergoline has been reduced gradually since late 2021 and as of February 2023, Prolactin remains suppressed.

Discussion

Cabergoline remains first line treatment for macroprolactinomas. Its efficacy in reducing tumour size and normalising Prolactin levels, means only a minority of patients go on to require surgical resection. Cystic degeneration can reflect the impact of dopamine agonist therapy on macroprolactinomas, or may represent tumour infarction. Medical treatment can also unmask skull-base defects.

DOI: 10.1530/endoabs.91.P22

P23

A case of persistent hypercalcaemia in the treatment of granulomatous disease
Nadia Osman, Henna Patel & Kirun Gunganah
Barts Health NHS Trust, London, United Kingdom

Section 1: Case history

A 49 year old South Asian gentleman was admitted to the emergency department after monitoring blood tests showed hypercalcaemia (corrected calcium of 3.67mmol/L) and acute kidney injury. He had a recent admission with a new diagnosis of miliary tuberculosis and superadded bacterial infection, complicated by a long and complex ITU admission after initiation of treatment. He was discharged home on colecalciferol 4000 units daily in addition to his anti-tuberculosis agents. On admission, he had an elevated PTH of 515pmol/L and 25 OH vitamin D 95nmol/l, ALP 77units/L, phosphate 1.28mmol/l and serum ACE 73. Blood tests showed a corrected calcium of 3.64mmol/L, PTH 19pmol/L, 25 OH vitamin D 95nmol/L, ALP 77units/L, phosphate 1.28mmol/l and serum ACE 73. Myeloma screen was negative. CT imaging showed some improvement of the original pulmonary changes and no evidence of malignancy. A serum 1,25 dihydroxyvitamin D3 was requested in the context of slow to recover hypercalcaemia and was found to be raised at 149pmol/l.

Section 2: Investigations

Bone densitometry was normal. The patient was discharged home on bisphosphonate infusion, a course of steroids to cover for concomitant anti-tuberculosis therapy and a repeat CT scan confirmed bilateral diffuse nodular adrenal enlargement. Discussion points include whether the diagnosis of testicular adrenal rest tumours should have been made pre-operatively, and if subsequent treatment could have restored fertility. It highlights the importance of discussing testicular swellings prospectively with male patients with CAH to ensure appropriate management.

Section 3: Results and treatment

The patient was managed with a combination of IV fluid rehydration, bisphosphonate infusion, a course of steroids to cover for concomitant
granulomatous disease with eventual normalisation of corrected calcium (2.41 mmol/L) and PTH (2.2 pmol/L).

Section 4: Conclusions and points for discussion
Hypocalcaemia has been described in granulomatous diseases and occurs via endogenous Vitamin D activation through extra-renal production of 1-alpha-hydroxylase. This is mediated through activated macrophages producing 1-alpha-hydroxylase, independently of negative feedback loops; often with a normal 25(OH) Vitamin D. Vitamin D may have a role in the treatment of tuberculosis. In vitro studies have shown that the up-regulation of 1,25(OH)2 Vitamin D can induce an anti-mycobacterial response alongside modifying immune responses. Several randomised controlled trials show varying evidence with Vitamin D supplementation and the rates of sputum smear conversion. However given the potential anti-inflammatory benefits and low cost this remains a part of the treatment regime in many centres. When considering the treatment of hypercalcaemia secondary to granulomatous disease, steroid supplementation will down regulate the immune related activation of 25(OH) vitamin D. Although to avoid the need for these management plans the decision to use Vitamin D in the treatment of TB should be carefully considered given the potential systemic complication of hypercalcaemia in a high risk patient.

DOI: 10.1530/endoabs.91.P23

P24
A case report: Cholestatic hepatitis secondary to carbimazole therapy in the management of Graves’ thyrotoxicosis
Shar Lea Yee & Kamal Abouglila
University Hospital of North Durham, Durham, United Kingdom

Section 1: Case history
A 51-year-old lady was referred to our endocrinology clinic with a 6-month history of palpitations, generalised muscle aches, heat intolerance, increased sweating and significant unintentional weight loss. She is normally fit and well without any significant past medical problem. Her thyroid function tests showed thyrotoxicosis picture with TSH < 0.05 mIU/L, Free T4 7.6 pmol/L, Free T3 > 30.8 pmol/L with positive TSH receptor antibodies (3.49 U/L). Her initial liver function tests were normal. The diagnosis of thyrotoxicosis secondary to Graves’ disease was made and she was started on carbimazole 40 mg once a day with propranolol 80 mg SR twice a day. 4 weeks later, she developed jaundice, itchy skin, diarrhoea and dark urine.

Section 2: Investigations
Her blood results showed cholestatic picture with Bilirubin 83 umol/L, ALT 102 and ALP came down within a couple of days of stopping carbimazole therapy, her hepatitis serology for hepatitis A, B, and C were all negative. While her ALT and hepatitis serology for hepatitis A, B, and C were all negative.

Section 3: Results and treatment
She had a total thyroidectomy done for the definitive management of thyrotoxicosis. She developed symptomatic hypocalcaemia following total thyroidectomy which was treated with one Alpha and calcium replacement therapy. Apart from that, she had a very good recovery from surgery and she was put on levothyroxine therapy for life long. On reviewing her bloods one year after therapy. Apart from that, she had a very good recovery from surgery and she was put on levothyroxine therapy for life long.

Treat the patient not the disease - A case of a Neuroendocrine Tumor presenting as Cushing’s
Bhavna Sharma, Asjdi Qureshi, Aimee Di Marco, Sarah Partridge & Florian Wenig
Hammersmith Hospital, London, United Kingdom

68 years old male was admitted with cough and fever during the second UK covid surge. Recent new diagnosis of hypertension and diabetes with worsening psychotic symptoms on background of schizophrenia. Noted previous hyperem-tremia, hypocalcaemia, hypomagnesemia along with marked refractory hypoka-lemic metabolic alkalosis. Cushing’s syndrome phenotype was not noted.

Failed to suppress cortisol during an overnight dexamethasone suppression test with plasma cortisol remaining 1045 mmol/L. 24-hour urinary free cortisol was 3536 nmol/l and midnight plasma cortisol was 856 nmol/l. Plasma ACTH 275 ng/l with low dose dexamethasone suppression test not revealing fall in cortisol (remaining at 900 nmol/l) Pituitary MRI was normal, CT chest, abdomen and pelvis showed bulky adrenal glands, multiple broncho vascular lung nodules and right lower lobe consolidation and a left supraclavicular soft tissue density of 2 cm which did not show significant DOTATATE uptake. Patient was commenced on metyrapone which was gradually up titrated to 1.5 mg TDS to achieve a mean plasma cortisol of around 300 nmol/l for presumed Cushing’s. Eplerenone was added for hypokalemia. He was gradually switched to high-dose metyrapone and 4mg prednisolone as block and replace regime. He was started on rivaroxaban 10 mg for DVT prophylaxis as well as prophylactic co-trimoxazole. Histology of left supraclavicular lymph node was suggestive of a well differentiated neuroendo-crine tumor with Ki-67 proliferation index of 2%. It stained negative for ACTH and positive for TTF-1, chromogranin and synaptophysin. Plasma calcitonin was raised at 28,000 pg/mL thus confirming a diagnosis of medullary thyroid cancer with probable ectopic ACTH secretion. Planned total thyroidectomy had to be abandoned due to very advanced disease and medical treatment with Cabozantinib was commenced. Despite a good clinical response to cabozatinib due to low tolerance mainly related to abdominal pains patient was switched to a selective RET inhibitor selpercatinib. This patient is a case where patient preferences and choices alongside a provisional diagnosis treatment has been successful in convoluted patient journey to achieve positive outcomes.

DOI: 10.1530/endoabs.91.P25

P26
Non-islet cell tumour hypoglycaemia (NICTH)
Yin Yin, lanitha Srikugan, Cynthia Mohandas, Arthur Ogunko & Iopa Abedo
Dartford and Gravesham NHS Trust, Dartford, United Kingdom

An 87-year-old lady was admitted to hospital with severe unexplained hypoglycaemia and capillary glucose of 1.8 mmol/L and went on develop recurrent episodes of symptomatic hypoglycaemia during this admission. She had a background history of diabetes mellitus, well under controlled with diet and a previous diagnosis of solitary fibrous pleural tumour of left lung, which was resected completely in 2013 but reoccurred in 2022 with left sided pleural effusion. Her liver and renal function tests were within normal reference range. She has a normal cortisol response to synacthen test as follows: 335 nmol/L at zero minutes, 955 nmol/L at 30 minutes and 1066 nmol/L at 60 minutes. CT chest showed a 22 cm solid lesion in the left hemithorax, which had enlarged, considerably in comparison with previous scans and represented a recurrence. Laboratory assessment during one of the hypoglycaemic episodes (venous glucose 1.3 mmol/L (3.6-5.4)) revealed a C-peptide of 25 pmol/l (normal range 370-1470 ) and insulin level of 12 pmol/l (normal level 1-175). Paraneoplastic hypoglycaemia likely due to NICTH was suspected, however IGF-2 level could not be processed due to unavailability of radiolabelled assay. She was deemed an unsuitable candidate for further operation and chemotherapy by the lung multi-disciplinary team. An initial attempt to treat hypoglycaemia with a tapered dose of prednisolone failed, so she was continued on oral prednisolone 15 mg once a day. Unfortunately, hypoglycaemia (capillary blood glucose 1.7mmol/L) re-occurred and she was re-admitted to hospital and Prednisolone dose was increased to 30 mg once daily. This fails Growth hormone injection will be next available treatment option for her although her prognosis is poor in view of the advanced neoplastic disease.

Discussion
• NICTH is a rare cause of paraneoplastic hypoglycaemia and is mostly seen in mesenchymal and epithelial tumours
• It is due to an underlying tumour producing excessive insulin like growth factor (IGF-2) or pro IGF-2.
• It can cause profound and persistent hypoglycaemia and may not respond to medical treatment and the main stay of treatment is surgical excision of underlying tumour

DOI: 10.1530/endoabs.91.P26

Endocrine Abstracts (2023) Vol 91
P27
How we treated a challenging case of Radioliodine (RAI)-refractory Papillary Thyroid Carcinoma in a young woman!

Geethika Thota & Roopa Roy
Saint Peter’s University Hospital, New Brunswick, USA

Case Information
A 39-year-old woman from Guatemala with no significant past medical history initially presented with swelling in neck & obstructive symptoms. She was diagnosed with papillary thyroid carcinoma in March 2017 & underwent a total thyroidectomy & LN Dissection. Pathology showed multifocal, largest tumor size 3.2 cm, with one involved lymph node, significant angiolympathic invasion, and was staged as initially received 121 mCi of radioactive iodine ablation in April 2017. However, she developed recurrence and disease progression over a five-year course are summarized below.

Investigations
• Dec 2017- US Neck mapping - 2 abnormal nodules in lower left thyroid fossa, persistently abnormal speculated lymph node cluster in left mid-neck. FNAB of the Thyroid nodule, LN - Negative for malignancy, TSH <0.1
• Nov 2018 US Neck mapping showed cystic degeneration of lymph nodes 35 mm, and stable thyroid nodules in left fossa, TSH <0.1
• Feb 2019 US Neck showed stable/smaller left lymph node with progressive cystic change.
• Dec 2019 Abnormal left internal jugular chain node. Biopsy positive for MALIGNANCY. Plan was to proceed with LN Dissection, WBS. Surgery was delayed due to COVID Pandemic and family issues.
• June 2020 shows the stability of left internal jugular LN
• Oct 2020 LN Dissection, total of 6 lymph nodes in 1 in Level 4, 3 in Level 2, and 2 in Level 3 positive for PTC with extracapsular extension.
• Feb 2021 stimulated TG 21.6, 125 mci of RAI; pretreatment scan with 0.4%
• Dec 2019 -US Neck mapping - 2 abnormal nodules in lower left thyroid fossa, persistently abnormal speculated lymph node cluster in left mid-neck. FNAB of the Thyroid nodule, LN - Negative for malignancy, TSH <0.1
• Nov 2018 US Neck mapping showed cystic degeneration of lymph nodes 35 mm, and stable thyroid nodules in left fossa, TSH <0.1
• Feb 2019 US Neck showed stable/smaller left lymph node with progressive cystic change.
• Dec 2019 Abnormal left internal jugular chain node. Biopsy positive for MALIGNANCY. Plan was to proceed with LN Dissection, WBS. Surgery was delayed due to COVID Pandemic and family issues.
• June 2020 shows the stability of left internal jugular LN
• Oct 2020 LN Dissection, total of 6 lymph nodes in 1 in Level 4, 3 in Level 2, and 2 in Level 3 positive for PTC with extracapsular extension.
• Feb 2021 stimulated TG 21.6,125 mci of RAI; pretreatment scan with 0.4%
• Feb 2022 FNAB of left thyroid fossa lesion 2/22 positive for malignancy. CT

P28
Mitochondrial DNA Depletion syndrome 1 (MNGIE type) – a rare cause of premature ovarian failure?

Louisa Kent1, Kassim Javid1, Jonathan Marshall1, Deborah Shears2, & Helen E Turner3
1Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals Foundation Trust, Oxford, United Kingdom. 2NHS England Highly Specialised Service for Rare Mitochondrial Disorders, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal sciences, University of Oxford. Windmill Road, Oxford, United Kingdom. 4Gastroenterology, Horton General Hospital, Oxford University Hospitals NHS Trust, Banbury, United Kingdom. 5Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Case History
A 39 year old lady was being investigated and managed for premature ovarian insufficiency (onset aged 29y) associated with an unusual constellation of symptoms. Following normal childhood and pubertal development, she subsequently developed fatigue, multiple gastrointestinal symptoms and was underweight with evidence of weight loss, and a most recent BMI of 17 kg/m². She had previously been reviewed due to marked absence of subcutaneous fat in the lower extremities with acanthosis nigricans. A possible diagnosis of acquired partial lipodystrophy was made, although the cause was unclear (genetic analysis was negative for common causes (LMNA, PPARG and PLIN1)). HBA1c was normal but increased was commenced in view of the marked insulin resistance. She had no other medical problems. She was the oldest child of consanguineous first-cousin parents of Pakistani origin. She had 5 younger siblings. They were all reported to be well apart from one brother who died age 21y, with a history of generalised weakness and failure to thrive throughout childhood.

Investigations
Hormone profile at diagnosis confirmed POI (FSH 81.5 IU/low oestradiol 40 pmol/l). Autonomic body was negative and karyotype was normal (46,XX), with a normal repeat size for FMR1. Ultrasound pelvis demonstrated a thin endometrium and small ovaries. Latest DEXA scan from 2022 showed osteoporosis; T score of -3.4 total hip. Concurrent gastroenterology investigations showed oesophageal dysmotility and severe gastroparesis. Cross-sectional imaging highlighted a 9.9mm angiomyolipoma of the right kidney, prompting MRI head to exclude tuberous sclerosis which incidentally demonstrated symmetrical abnormal diffuse 18F-FDFAIR hyperintensities in the white matter suggestive of a leukodystrophy.

Management
In light of the diagnostic uncertainty, history of consanguinity and features of leukodystrophy on MRI, she underwent whole genome sequencing which identified heterozygosity for the c.559G>T; P.(Gin187*) variant in the thymidine phosphorylase gene (TYMP). This was a novel variant not previously reported in the literature which was considered to be pathogenic and associated with Mitochondrial DNA depletion syndrome 1 (MNGIE type).

Conclusion and points for discussion
Mitochondrial DNA depletion syndrome 1 (MNGIE type) is a rare autosomal recessive progressive degenerative disease. Cardial features are gastrointestinal dysmotility, cachexia, peripheral neuropathy, ocular signs, hearing loss and leukoencephalopathy. Although there are no reports of POF associated with this disorder in the literature, ovarian function is known to be affected in other mitochondrial conditions, and we postulate that this is the cause of her amenorrhea.

DOI: 10.1530/endobs.91.P28

Endocrine Abstracts (2023) Vol 91

P29
Pathological fracture in Osteitis Fibrosa Cystica: a late skeletal complication of uncontrolled primary hyperparathyroidism

Georgia Vellacott, Zaw Htet, Andrew McLaren & Chirabhanu Ballav
Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom

Case History
An 80-year-old woman, with a background of primary hyperparathyroidism (PHPT), presented to the emergency department with a spontaneous pathologial fracture of her left femoral shaft. Blood tests revealed elevated serum calcium levels (corrected calcium 3.26 mmol/l, 2.1 – 2.55) after being lost to follow up for twenty years. She was vitamin D replete after supplementation, had normal renal functions (creatinine 76 umol/L, 50-98), and high parathyroid hormone (PTH 199 pmol/L,1,2), confirming PHPT. A technetium 99-m-sestamibi scan of her parathyroid gland found intense isotope uptake on right and left sides of her neck. Ultrasound correlation was unclear because of the presence of thyroid nodules. She was medically optimised with Cinacalcet, having initially declined parathyroid surgery.

Investigations
Plain radiography demonstrated a displaced fracture of the proximal left femur through a lucent area. Magnetic resonance imaging revealed abnormal tissue within the bone marrow at the point of fracture and two additional abnormal lesions in the right proximal femur. Computerised tomography (CT) of the chest, abdomen and pelvis showed no evidence of underlying malignancy. Whole-body low-dose CT demonstrated multiple, lytic lesions throughout the non-vertebral skeleton; tibiae and femurs, right patella, left radius, right index metacarpals, 2nd and 4th left metacarpals and right 4th middle phalanx. Serum electrolytes and immunoglobulins were within normal ranges, ruling out myeloma as a diagnosis.

Results and treatment
The patient underwent long gamma nail fixation of the left femur and prophylactic intramedullary nail fixation of both the right femur and left tibia, given the extent of fracture. Magnetic resonance imaging revealed abnormal tissue within the bone marrow at the point of fracture and two additional abnormal lesions in the right proximal femur. Computerised tomography (CT) of the chest, abdomen and pelvis showed no evidence of underlying malignancy. Whole-body low-dose CT demonstrated multiple, lytic lesions throughout the non-vertebral skeleton; tibiae and femurs, right patella, left radius, right index metacarpals, 2nd and 4th left metacarpals and right 4th middle phalanx. Serum electrolytes and immunoglobulins were within normal ranges, ruling out myeloma as a diagnosis.

Conclusion and points for discussion
The patient described here had been lost to follow up for almost twenty years and unfortunately presented with uncontrolled PHPT resulting in pathological fracture of the proximal left femur. Blood tests revealed elevated serum calcium levels (corrected calcium 3.26 mmol/l, 2.1 – 2.55) after being lost to follow up for twenty years.

DOI: 10.1530/endobs.91.P29
fracture, and multiple lytic lesions at risk of further fractures requiring significant surgical management. Although extensive bone disease such as this is a rare manifestation of uncontrolled PHPT, it highlights the importance of early parathyroidectomy as the treatment of choice in preventing loss of bone mineral density. Additionally, this case demonstrates that uncontrolled PHPT should be considered in the differential diagnoses of multiple, osteolytic lesions in patients presenting with pathologic fractures.

DOI: 10.1530/endoabs.91.P29

P30
Sleep - associated seizures in a thyrotoxic patient
Ngozi Vivienne Obi & Budh Mendis
Nottingham University Hospitals, Nottingham, United Kingdom

History
A 33-year-old man presented to emergency with weight loss of 3 months duration, intermittent sweating and heat intolerance. He had a brother with thyroid disease treated with levothyroxine and did not smoke. He was tremulous and short of breath, with a regular heart rate of 115/min and blood pressure of 134/71mmHg. Initial assessment showed mildly diffuse non-tender goitre with a bruit, no cervical lymphadenopathy, mild proptosis with mild scleral congestion. TSH 0.01, FT4 48 pmol/l and FT3 30 pmol/l, normal blood glucose and PHI, renal function, electrolytes and complete blood count. Inflammatory screen was normal. He was commenced on carbimazole 40mg daily, propranolol 20mg twice daily, and discharged home. Two days later, he re-presented with generalised tonic-clonic seizures during an afternoon nap. His girlfriend described the event during which he was unresponsive. This lasted for few minutes. There was no tongue biting or incontinence. He denied headaches, nor visual phenomena and had no aura, and had been taking his new medications. Post event, he was drowsy, disorientated and had no recollection of events. During his admission, he had two further seizures as described above, witnessed by staff, with full recovery over some hours. Each time, there was no demonstrable neurological deficits.

Results
Further investigations as below: CT brain normal. Echo: Non-dilated chambers, LV ejection fraction is >55% with no diastolic dysfunction. Immunoglobulins: within normal, no serum paraprotein detected. TPO abs >1300.0 u/ml (0.0 - 60.0) TSH receptor antibodies and TG antibodies present. MRI head: normal EEG: Occasional faster activity over the frontal region. No epileptiform activity and no focal change.

Diagnosis
A diagnosis of autoimmune thyrotoxicosis was made and patient continued carbimazole 40 mg daily, titrated according to biochemical response. He completed twelve-month anti-thyroid therapy, and was successfully weaned off medications, maintaining euthyroidism off carbimazole. He has remained seizure free and did not require treatment with anti-epileptic medications.

Points for Discussion:
1) It is well known that hyperthyroidism is associated with central nervous system dysfunction like hyperexcitation, irritability and disturbance in consciousness but clear-cut seizure disorder is rare prompting us to do a literature search which returned under 15 case reports.
2) Moreover, our patient was started on propranolol to control his symptoms.

Although it was only a small dose, it is unclear what role this played in precipitating the seizures as propranolol has been named as a drug that could lower seizure threshold in overdose.

DOI: 10.1530/endoabs.91.P30

P32
Non-islet cell tumour hypoglycaemia (NICTH) caused by an intrathoracic tumour and responding well to glucocorticoid therapy
Shafana Ahamed Sadiq, Neha Jeyakar, Giuseppe Maltese, Nikhil Johri, Mamtu Joshi & Steve Hyer
Epsom and St Helier University Hospitals NHS FT, Carshalton, United Kingdom

Case History
An 81-year-old gentleman was brought to A&E by ambulance after being found to be hypoglycaemic at home by paramedics. His wife reported that he experienced unsteadiness and slurred speech after waking up in the morning and she called the emergency number. On arrival of paramedics, his capillary blood glucose was found to be 1.2 mmol/l and he was administered intravenous dextrose. He also had a couple of similar episodes which were resolved with food. He is not known to have diabetes or alcohol abuse. He has a past medical history of right lung fibrous mesothelioma for which he underwent radiotherapy in 2016 and had been under surveillance. He had several comorbidities including atrial fibrillation, heart failure and hypertension. His medications included Amlodipine, Bisoprolol, Furosemide, Spironolactone, Ramipril and Edoxaban.

Investigations
As part of an initial work-up, a CT scan of the chest revealed a right hemo-thoracic neoplasm which had marginally increased in size, when compared to imaging organised 6 months earlier. Further laboratory investigations revealed a normal response to short SynActhen test and normal thyroid function. His prolonged supervised fasting test, confirmed spontaneous hypoglycaemia with concomitant undetectable insulin, C-peptide and pro-insulin. Having excluded islet cell tumour as a cause of hypoglycaemia, we requested IGF-2/IGF-1 ratio, which was elevated at 12.7, consistent with the diagnosis of non-islet cell tumour.

Treatment
He was prescribed Prednisolone 10 mg OD at bedtime, and he was asked to carry out pre-meal and mid night capillary glucose testing to establish the dose of steroids. He responded well and his hypoglycaemic episodes were abolished with steroid treatment.

Discussion
Non-islet cell tumour hypoglycaemia (NICTH) is a rare cause of hypoglycaemia which is due to excessive secretion of insulin-like growth factor (IGF)-2 or pro IGF-2. These molecules can activate the insulin receptor and cause hypoglycaemia. NICTH is mostly seen in epithelial and mesenchymal tumours.

Complete tumour resection is curative but is often delayed or unfeasible. For patients with advanced disease, radiation, and/or chemotherapy have been shown to reduce hypoglycaemia, although to a lesser degree. If patients are not suitable for surgery or when hypoglycaemia persists after surgery, radiotherapy, chemotherapy, medical therapy with glucocorticoids or recombinant GH have been utilized. Glucocorticoids act by promoting hepatic gluconeogenesis, lipolysis, and

DOI: 10.1530/endoabs.91.P32

Endocrine Abstracts (2023) Vol 91
reducing peripheral glucose uptake. Glucocorticoids also help to decrease the levels of pro-IGF-2 either by decreased tumour production or by clearance.

DOI: 10.1530/endoabs.91.P32

P33

Aarskog Syndrome - A rare cause of primary hypogonadism

Aparna Chaudhary & Ram Prakash Narayan

Diabetes Centre, St Helens Hospital, St Helens, WA93DA, Liverpool, United Kingdom

Case history

We present a case of a 34-year-old male diagnosed with bilateral gynecomastia referred to the endocrine clinic. Notable background of left cryptorchidism with orchidopexy at the age of 15, andidiopathic pubertal onset of missngmenses, chronic testicular pain and atopic dermatitis. On examination he had short stature, hypertelorism, low set ears, broad short hands, brachydactyly and clinodactyly of 5th fingers. There was no evidence of cleft lip/palate, teeth abnormalities or inguinal/abdominal hernias. Family history of Aarskog syndrome in multiple male family members including nephews who needed orchidopexy in childhood.

Investigations

Biochemistry was suggestive of a primary hypogonadism picture with low-normal testosterone levels 8.7 nmol/l (6.9 – 23.2) high FSH 25.2 IU/L (1.4–18.1) and borderline-high LH 8.3 IU/L (1.5 – 9.3). Normal oestradiol and prolactin levels. US testes confirmed a bilateral small testes. US breast was normal.

Results and treatment

The patient did not himself recollect being formally diagnosed with Aarskog Syndrome, but his childhood records confirmed that this diagnosis had been made. We have referred him to clinical genetics to explain the condition to him in more detail and its associations. A DEXA scan revealed a low Z score for his age, and we commenced him on vitamin D and calcium supplementation. His echocardiogram was unremarkable. Patient was advised for regular dental check.

He has also been referred to the endrology department for sperm assessment and banking in advance of testosterone supplementation.

Conclusions and points for discussion

Aarskog syndrome also known as faciodigitogenital syndrome is a rare and underdiagnosed X linked recessive genetic disorder only discovered in 1970. The prevalence estimates are thought to be 0.4 per million. 20% of cases implicate FG1 gene variants and runs in families with male predominance though there are reports of females with milder phenotypes. Diagnosis is by the characteristic combination of short stature, facial, skeletal, genital and skin anomalies and can be supported genetically. Clinical features can also involve dental and cardiac abnormalities and mild learning/behavioural impairment often confined to childhood. This abstract aims to prompt clinicians to consider Aarskog syndrome in patients who present with the triad of facio-digito-genital symptoms. Timely diagnosis can trigger screening for associated abnormalities, genetic counselling and treatment.

DOI: 10.1530/endoabs.91.P33

P35

Severe hyperprolactinaemia associated with domperidone with normal MRI pituitary

Kerrie Thackray & Felicity Kaplan

East and North Hertfordshire NHS Trust, Stevenage, United Kingdom

Section 1: Case History

A 28 year old female initially presented to Endocrinology in 2020 with hirsutism and irregular menstruation but reassuring biochemistry. In 2022, she was referred to Gastroenterology with weight loss, vomiting and dyspepsia and found to have severe hyperprolactinaemia. Past medical history included anxiety/depression. Current medication was esomeprazole 40mg OD and mebeverine 135mg TDS. Cyclizine 50mg TDS had previously been prescribed, followed by domperidone 10mg TDS started three weeks prior to gastroenterology review. The patient was not taking hormonal contraception and was not pregnant or lactating. She smoked marijuana four times weekly. She had no new signs or symptoms of hyperprolactinaemia or hormone excess.

Section 2: Investigations

Initial biochemistry in 2020 was reassuring with normal thyroid function and gonadotrophins, although prolactin was not checked at this time. Blood tests in November 2022 demonstrated normal thyroid function and gonadotrophins, but prolactin was significantly elevated at 3833 mU/L. Macroprolactin was excluded. Blood tests in December 2022, 20 days after discontinuing domperidone, demonstrated normal pituitary function and normalised prolactin of 211 mU/L. MRI pituitary in December 2022 demonstrated a normal gland with no apparent differential enhancing lesion.

Section 3: Results and treatment

Given the normalised prolactin and no clinical evidence of hyperprolactinaemia, the patient was reassured and discharged from the Endocrinology Clinic.

Section 4: Conclusions and points for discussion

Domperidone in females are generally <500 mU/L, with drug induced hyperprolactinaemia usually associated with only modest hyperprolactinaemia, although severe hyperprolactinaemia is well-recognised as a side effect of metoclopramide, risperidone and phenothiazines. Prolactin >2000 mU/L may indicate a pituitary adenoma. Domperidone is a peripherally selective D2-receptor antagonist acting at the lactotrophs of the anterior pituitary to reduce intracellular cyclic AMP thereby increasing prolactin production. It is thought to cause only mild hyperprolactinaemia. Previous work by Bouwers et al demonstrated that a single dose of domperidone might increase prolactin to 157-2638 mU/L with sustained but lower levels of hyperprolactinaemia following two weeks of treatment. Esomeprazole has been suggested as a cause of hyperprolactinaemia in several case reports, potentially by inhibition of CYP3A4 elevating oestrogen levels. Marijuana has been similarly implicated although literature is mixed with reports of decreased, increased and unchanged prolactin associated with cannabis use. The significant degree of transient hyperprolactinaemia in this patient may have been exacerbated by co-administration of domperidone with long-term esomeprazole and/or by cannabinoid use and resolved with discontinuation of domperidone.

DOI: 10.1530/endoabs.91.P35

P34

Fertility options for a rare cause of primary amenorrhoea

Veronica Chirila-Berbentea & Reas Bhattacharya

Royal United Hospital of Bath, Bath, United Kingdom

Section 1: Case history

A 17 year old lady who was referred to our endocrinology clinic due to primary amenorrhea in 2019. She had well-established secondary sexual characteristics and hyperprolactinaemia. Patient mentioned one episode of PV bleed when she was about 10 years old.

Section 2: Investigations

Bloods (Feb2020) showed: FSH: 6.2 IU/L; LH: 5.1IU/L; prolactin 1.048 mIU/l; testosterone 1.3 nmol/L. MRI pituitary; lipoma of corpus calosum and pituitary gland asymmetry likely microprolactinoma; MRI pelvis; agenesis of the uterus and upper two thirds of her vagina; minimal lower vaginal vault; bilateral intra-pelvic ovaries Genetic testing: 46XX with no mosaicism; Bone densitometry DEXA: normal.

Section 3: Results and treatment

Diagnosis made as MRKH (Mayer-Rokitansky-Küster-Hauser) syndrome type 2. As we know MRKH is a congenital abnormality (1:4,500 live births) affecting the uterus and upper vagina and can be of two sub-types. In type 1 there is isolated congenital aplasia of uterus and two thirds of vagina, while in type 2, there is at least one other organ involvement such as vertebral defect, renal abnormality, hearing defect and cardiac involvement. She was referred for further management to the MRKH national centre in London. Echocardiogram was normal, renogram was normal. MRI spine showed normal spinal cord but a right carotid body tissue lesion suggestive of carotid body paraganglioma. MRI neck pointed towards schwannoma with normal metastaphines and she is under follow up. She was started on Microggonin 30 for 6 months which increased her uterine size significantly from 29 to 49 mm.

Section 4: Conclusions and points for discussion

Endocrinology clinic follow up: brought up a relevant and important question regarding fertility option. She has intact and functioning ovaries but agenetic uterus and vaginal structure. Therefore options and expectation management are vital in such a presentation. Referring to fertility clinic for possibility of donor egg and IVF surrogacy or even egg freezing for future. This is line with the possibility of ovarian failure. Fertility might be achieve via egg collection and IVF surrogacy or even uterus transplantation. We face a few challenges in this situation regarding her oestrogen replacement for bone protection as her ovaries are still producing oestrogens. References

1. Diminished ovarian reserve and ectopic ovaries in patients with MRKH syndrome candidates for Uterus Transplantation: our experience; Author: Basilio Pecorino-
Clinical and Experimental Obstetrics & Gynecology (2021)
2. Uterine transplantation in women with MRKH; Author: Weyers, S; EJOG 273; Netherlands, Amsterdam; 2022

DOI: 10.1530/endoabs.91.P34

Endocrine Abstracts (2023) Vol 91
P36

An unusual presentation of Grave’s disease
Younes R Younes1, Kerushan Thomas1, Kavitha Lakshmipathy1, Vidhu Nayyar2, Sunil Zachariah1, James Clark1, Benjamin C T Field1,2 & Julian Emmanuel1
1East Surrey Hospital, Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey, United Kingdom. 2Section of Clinical Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom

We present a case of a 44-year-old female with fluctuating thyroid function over 12-14 years. The patient originally presented with a high TSH, normal free T3/T4 and a negative anti-TPO antibody. She was initially monitored, then went onto Levothyroxine replacement in an antenatal setting. Subsequently, 12-18 months later, she presented with hyperthyroid symptoms and vastly elevated TSH-receptor-antibody (TSH-RAb) titre of > 10 IU/L, the upper limit of normal being 2.9 IU/L. She was commenced on Carbimazole, with this continuing for 4-years. We have observed a fluctuating thyroid profile and antibody profile, over a 12-14 year period and treatment with Levothyroxine followed by Carbimazole in the same patient. We note that prior to 2018, TSH-RAb assessment was not widely available. This case highlights the fluctuating nature of TSH-RAb titre related symptoms, as interestingly, the same patient displayed both underactive and overactive thyroid physiology over a 12-year period. Her TSH fluctuated between 13.6 to 0.01 mU/L, 10-12 years prior to the initiation of Levothyroxine. Symptoms also fluctuated and so the patient was monitored and not treated, this decision being supported by a negative TPO-antibody titre. There was thought that this could have been sub-acute thyroiditis or sub-clinical presentation. The patient was monitored and as TFT did return to normal range, the patient was discharged. After a period of observation, she presented in florid hyper-thyroid phase finally with very high TSH-RAb titre. According to the American Thyroid Association statement (1), the severity of symptoms is proportional to the amount of antibody titre, as noted in this case. There was no overlap with TPO-antibody titre, as this patient’s TPO-antibody titre was normal. This prompted another endocrinologist to monitor and not treat the fluctuating TFT’s, and this remained the case for some time till final presentation with florid symptoms, high Free T4/ T3 and suppressed TSH.

References

DOI: 10.1530/endobas.91.P36

P37

Cranioopharyngioma: A Comprehensive Overview of a Challenging Pituitary Mass
Patrick Mcgown1, Kavitha Narula2, Ramesh Nair2, Anastasia Gontsarova3, Zane Jaunmuktane2, Mark Ferguson2, Nigel Mendoza1, Niamh Martin2, Karim Meeran2 & Sanjeev Mehta1
1London North West University Healthcare NHS Trust, London, United Kingdom. 2Imperial College Healthcare NHS Trust, London, United Kingdom. 3Faculty of Medicine, University of Surrey, Guildford, Surrey, United Kingdom

Case history
A 44-year-old female presented with 6-week history of gradual deterioration in her left vision associated with eye pain. She saw an ophthalmologist who noted that she had reduced visual acuity (6/24) and colour vision ( Ishihara colour vision score 3/15) in her left eye with left relative afferent pupilary defect (RAPD). It was thought that she may have a left retrobulbar neuritis so she was advised to attend A&E for an urgent neurology assessment. On examination, she was noted to have diplopia on left lateral gaze, with left sided RAPD and a left nasal hemianopia. Investigations
MRI of her orbits and brain demonstrated a 15 x 18 x 20 mm lobulated suprasellar mass compressing the optic chiasma (OC) and left optic radiation. Blood tests on admission showed a normal anterior pituitary profile other than a very mildly elevated prolactin of 581 mU/L (102-496).

Results & treatment
Her case was discussed in the regional pituitary multidisciplinary team (MDT) meeting. Her imaging findings were in keeping with cystic craniopharyngioma. As she had visual impairment with OC and left optic radiation compression, she underwent urgent Extended Endoscopic Transphenoidal removal of suprasellar Craniopharyngioma (EETS). Histopathology showed adamantinomatous craniopharyngioma (ACP) with no unusual features. She initially suffered from post operative complication with CSF leak that was promptly repaired. After a short period of polyuria which was either due to vasopressin deficiency or over-hydration, she developed SIADH. This was managed with strict fluid restriction and resolved promptly. Post-operative imaging demonstrated an excellent resection. As there was a good surgical resection, the plan was to undertake surveillance imaging in the first instance before proceeding to radiotherapy.

Conclusions & points for discussion
Cranioopharyngiomas are tumours of low histological malignancy which originate from remnants of the craniopharyngeal duct epithelium. The commonest histological subtype is ACP, which is diagnosed with a bimodal peak of incidence (5-15 years & 45-60 years). Clinical presentation is usually with symptoms of increased intracranial pressure, visual impairment and endocrine abnormalities. Treatment comprises of neurosurgery and radiotherapy. Although long-term survival is high, quality of life is frequently impaired due to their close proximity to the optic chiasma, hypothalamus and pituitary gland. Hypothalamic involvement and treatment-related hypothalamic damage frequently result in hypothalamic obesity, fatigue and psychosocial problems. Pituitary surgery may be associated with vasopressin deficiency in the first few days, followed by SIADH. Electrolytes should be monitored closely to direct active fluid restriction.

DOI: 10.1530/endoabs.91.P37

P38

Beneficial side effects: A case of difficult hyperthyroidism treated with Lithium
Allan Acosta & Ali Hameed
Causeway Hospital - Northern Health and Social Care Trust, Coleraine, United Kingdom

A case of a 48-year-old lady who is under follow-up in the clinic at Causeway Hospital, Northern Ireland for hyperthyroidism. She has a medical history of SLE with lupus nephritis and bronchial asthma. She presented with palpitations, tremors, sweating, and heat intolerance. On examination, the patient appears anxious. Blood pressure was 130/80, PR 140, RR 20, T 37, RR02 98% A. Her eye examination revealed no lid lag, exophthalmos, and no redness. Examination of the neck revealed diffuse goiter, firm, non-tender, and no retrosternal extension. There are fine tremors on the hands and moist when touched. Laboratory examinations showed FT4 31.5 pmol/l, TSH < 0.02, and FT3 8.3 pmol/l. TSH receptor antibody was positive. ECG showed sinus tachycardia, and normal chest xray. She was initially started with Carbimazole 20 mg once daily, however, she cannot tolerate it and developed a sore throat and skin rash. A full blood count did not reveal any agranulocytosis. Diltiazem was initially started for symptom relief and tachycardia. Patient symptoms worsened prompting admission to the hospital. We have coordinated with her Rheumatologist about whether propylthiouracil can be tried in view of not affecting her current SLE medications. PTU 100 mg BD was started. Cardiology was also consulted to optimize the management of her tachycardia. A cardioselective, Nebivolol 2.5 mg once daily was suggested to replace Diltiazem. Unfortunately, the patient again developed rashes after PTU was started. A decision to try non-conventional medication, Lithium carbonate modified release, for a definitive treatment of radioactive iodine with a plan to stop the Lithium 1 week prior to the RAI treatment. Lithium can be considered as a treatment for hyperthyroidism in case the patient cannot tolerate conventional anti-thyroid drugs like carbimazole and propylthiouracil. Lithium can affect the production in some time till final presentation with florid symptoms, high Free T4/ T3 and suppressed TSH.

Case history
A 48-year-old lady who is under follow-up in the clinic at Causeway Hospital, Northern Ireland for hyperthyroidism. She has a medical history of SLE and other causes of thyrotoxicosis. Thyroid (2016) 26(10):1343–1349. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid (2016) 26(10):1343-421. 10.1089/thy.2016.0029

Allan Acosta & Ali Hameed
Causeway Hospital - Northern Health and Social Care Trust, Coleraine, United Kingdom

P39

An unusual case of neuropathy
Veronica Chirila-Berbentea & Beas Bhattacharya
Royal United Hospital of Bath, Bath, United Kingdom

Endocrine Abstracts (2023) Vol 91
Glucagonoma Syndrome: A Case Report

JISHU WEI,1,* SHIBO LIN,1,* CONG

Glucagonoma syndrome rarely. This case has unique presentation from very start, interesting
diabetes, diarrhoea, sweating, Anaemia and weight loss, but no skin rash.

Most are solitary, but can be associated with Multiple endocrine neoplasia

Glucagonomas are very rare tumours arising from alpha cells of pancreas 1,2.

Refused treatment. Patient still follow up in diabetes clinic. She is unable to gain

chemotherapy after discussion in neuroendocrine and oncology MDT. Patient

ultrasound for tissue confirmation showed Metastatic Well Differentiated neuro
cancer arising from tail of pancreas grade 2, Ki 67 of 7%. Hence diagnosis of

endocrine tumour tail of pancreas grade 2, Ki 67 of 7%. Hence diagnosis of

Diagnosis was made as insulin neuritis or Treatment-induced neuropathy in
diabetes (TIND). TIND is a condition characterized by severe distal distal limb

Twisted to final diagnosis. She has few symptoms of Glucagonoma syndrome

She developed this pain after starting insulin in April 22.

Investigations

May 22: Hb 119, MCV: 85.0; UrE: normal; LFTs: normal; HbA1c:10.7; TSH 1.9,

freeT4 15.4, B12:500, folate 6.7, ferritin 17. Vinditin D 37, TTT 1.1; September

22: HbA1c: 41 Borelria Burgdfordi antibodies: negative; syphilis serology:
negative MRI brain and spinal cord: no areas concerning of demyelination.

Results and treatment

Diagnosis

Case history

A 73 year old lady with metastatic pancreatic cancer referred to diabetes clinic with

was reported on MRI CT chest/abdo/pelvis revealed no extra-pituitary source of

HbA1c, a history of diabetic anorexia or weight loss may be at high risk for TIND

HbA1c, a history of poor glycaemic control. Pathogenesis of TIND is unknown, with

of diabetes;Christopher H. Gibbons and Roy Freeman;BRAIN 2015

References

1. Insulin neuritis and diabetic cachiecal neuropathy: a review; Michael Knopp,


painful autonomic neuropathy. Ann Neurol 2010;

3. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of
diabetes:Christopher H. Gibbons and Roy Freeman;BRAIN 2015

DOI: 10.1530/endoabs.91.P39

Rare Case of Metastatic Glucagonoma, A Diagnostic Twist

Wajihah Arjajad & Joanne Randall

James Paget University Hospital, Gorleston, United Kingdom

Case history

73 year old lady with metastatic pancreatic cancer referred to diabetes clinic with

worsening of her diabetes control. She was primarily under care of

Gastroenterology department, for her symptoms of weight loss, abdominal

pain, diarrhoea, sweating and anaemia. Her scan showed metastatic pancreatic

cancer arising from tail of pancreas with metastasis to liver. The liver biopsy of

secondary liver deposit was not conclusive. She had borderline diabetes at her

presentation worsened over 3 months from 51mmol/mol to 89 mmol/mol. She

secondary liver deposit was not conclusive. She had borderline diabetes at her

Investigations

showed a raised urinary cortisol of 1768nmol/24hr and plasma

ACTH 122ng/L. A 10mm “symmetry” of the pituitary with no obvious adenoma

was reported on MRI CT chest/abdo/pelvis revealed no extra-pituitary source of

ACTH, plus new T7/8 fragility fractures. CRH stimulation test gave a flat

response of 132pg/l to 148ng/L. Inferior petrosal sinus sampling (IPSS) was

undertaken under GA as the patient could not lie flat due to pain. IPSS showed

peripheral ACTH levels between 46 -109 rising to 1265-1560 in the petrosal

sinus, consistent with a pituitary source. Again, a relatively flat ACTH and
cortisol response during IPSS was noted, while prolactin levels indicated good

normalisation of petrosal sinuses.

Results/treatment

A “Block and replace” regimen of Metyrapone / Hydrocortisone was initiated.

Treatment of multiple sequelae of Cushing’s was undertaken, including anti-

hypertensives, glucose monitoring, thromboprophylaxis, bisphosphonates, analgesics and diuretics was commenced while awaiting IPSS. The left side of

the gland was debulked and post-operatively a transient AVP deficiency spontaneously resolved. Day 3 morning cortisol level was 139nmol/l indicating
cure was unlikely. She was discharged on hydrocortisone. Since surgery, abdominal girth, weight and peripheral oedema have reduced but central obesity

remains challenging. Blood pressure is controlled. The patient is undergoing

serial dexamethasone suppression testing and MRI, with further TSS likely in future.

Conclusions/points for discussion

Cushing’s Disease in the time of COVID

Victoria Tyn dall & Stuart Ritchie

NHS Lothian, Edinburgh, United Kingdom

A “Block and replace” regimen of Metyrapone / Hydrocortisone was initiated.

Investigations

showed a raised urinary cortisol of 1768nmol/24hr and plasma

ACTH 122ng/L. A 10mm “symmetry” of the pituitary with no obvious adenoma

was reported on MRI CT chest/abdo/pelvis revealed no extra-pituitary source of

ACTH, plus new T7/8 fragility fractures. CRH stimulation test gave a flat

response of 132pg/l to 148ng/L. Inferior petrosal sinus sampling (IPSS) was

undertaken under GA as the patient could not lie flat due to pain. IPSS showed

peripheral ACTH levels between 46 -109 rising to 1265-1560 in the petrosal

sinus, consistent with a pituitary source. Again, a relatively flat ACTH and
cortisol response during IPSS was noted, while prolactin levels indicated good

normalisation of petrosal sinuses.

Results/treatment

A “Block and replace” regimen of Metyrapone / Hydrocortisone was initiated.

Treatment of multiple sequelae of Cushing’s was undertaken, including anti-

hypertensives, glucose monitoring, thromboprophylaxis, bisphosphonates, analgesics and diuretics was commenced while awaiting IPSS. The left side of

the gland was debulked and post-operatively a transient AVP deficiency spontaneously resolved. Day 3 morning cortisol level was 139nmol/l indicating
cure was unlikely. She was discharged on hydrocortisone. Since surgery, abdominal girth, weight and peripheral oedema have reduced but central obesity

remains challenging. Blood pressure is controlled. The patient is undergoing

serial dexamethasone suppression testing and MRI, with further TSS likely in future.

Conclusions/points for discussion

Cushing’s Disease is diagnostically challenging for non-specialty doctors and Endocrinologists alike, and there is often a significant delay in diagnosis. Medical

management with Metyrapone was challenging due to a paradoxical worsening of

hypokalaemia and hypertension, necessitating additional therapies and monitor-

ing. Regular long term follow up of patients with treated Cushing’s is paramount in

ensuring any recurrence of disease is identified promptly and early second

surgery considered. This case highlights significant long term impact on patient morbidity and cardiovascular risk which can be worsened by clinical and

pandemic-related delays.

DOI: 10.1530/endoabs.91.P41

A treasure hunt! An unusual presentation of benign thyroid tissue as neck masses

Geethika Thota

Saint Peter’s University Hospital, New Brunswick, USA

Case Description

A 66-year-old lady with a past surgical history of partial left lobectomy for unclear reasons 30 years ago was referred by the surgeon for evaluation of thyroid nodules. She reported noticing palpable neck masses but didn’t report associated heat/cold intolerance, palpitations, diarrhoea, tremor, fatigue, skin/hair/sleep

/wight/appetite changes. No associated neck pain, dysphagia, fever, upper respiratory tract infection symptoms, or vaccination. No obstructive symptoms reported. No recent Biotin, herbal or over-the-counter remedies. No similar
complaints in the past and no family history of thyroid disorders. There was no radiation exposure in the past. Medications include Aspirin 81 mg, and Olmesartan-amloplpine-HCTZ. She is postmenopausal. No smoking/ alcohol/ recreational drugs. Vitals normal and BMI 22.7. Physical examination is significant for two right-sided rubbery, non-tender, mobile masses in the right upper neck and palpable right thyroid nodules.

Investigations
The biochemical evaluation revealed normal CBC, CMP.
- TSH 1.33IU/mL, FT4 1.06ng/dl
- Thyroid US: two thyroid nodules 20x19x13mm, 9x8x7mm and several small nodules in right lobe and one Right mid jugular chain lymph node
- US Neck mapping: R level III mid jugular: three lymph nodes measuring 4.5 mm, no fatty hila, other levels and left side are normal
- Lymph node Excisions of two right cervical lymph nodes showed fragments of benign thyroid tissue; no lymphoma, however flow cytometry couldn’t be performed due to lack of significant lymphoid population.
- Thryoseq molecular test from the lymph nodes samples obtained was negative for genetic mutation
- Repeat Thyroid US: Stable thyroid nodules
- Repeat TFT after 2 months. TSH 2.180IU/mL, FT4 1.00ng/dl remained clinically and biochemically euthyroid

Discussion
Ectopic thyroid tissue (ETT) is a rare phenomenon and usually occurs along the normal path of thyroid descent. There have been reports of thyroid tissue found in places such as the abdominal organs, pelvis, axilla, and thoracic cavity. It is, however, rare to find thyroid tissue within lateral neck masses. When thyroid tissue is found in a cervical lymph node, the suspicion of nodal metastasis of differentiated carcinoma of the thyroid should be high. In our case, FNAB of thyroid nodules, excision biopsy of lymph nodes, and a Thryoseq molecular test were negative for malignancy. Our hypothesis is that in our patient with a previous history of thyroid surgery, the seeding of cells from thyroid tissue may be the possible mechanism.

DOI: 10.1530/endoabs.91.P42

P43
Corticosteroids can prolong the duration of COVID-19 shedding, in the absence of symptoms
Kerushan Thomas1, Younes R Younes1, Kavitha Lakshminathy1, Vidhu Nayyar1, Sunil Zachariah1, James Clark1, Benjamin C T Field1,2 & Julian Emmanuel1
1East Surrey Hospital, Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey, United Kingdom. 2Section of Clinical Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom

A recent case series commented on adverse COVID-19 outcomes among patients with Cushing’s syndrome, despite minimal symptoms and low inflammatory markers. Excessive glucocorticoids can impede adaptive immune responses to viruses, leading to increased infection risks (1). Sarker et al discussed glucocorticoids binding to viral spike-proteins, inhibiting receptor interactions and contributing to prolonged positive swabs, in the absence of symptoms (2). We report the case of a 66-year-old Caucasian male who presented with pyrexia (39.2°C), whilst undergoing inpatient rehabilitation. He was recently diagnosed with transverse myelitis and commenced on high dose glucocorticoids (70mg Prednisolone). The patient denied respiratory symptoms, oxygen saturation was stable on air, and chest XR unremarkable. Bloods results showed: lymphocyte 0.9 x 109 L, CRP 51 mg/L. Combined nose and throat swab on March 14th 2020, was SARS-CoV-2 RNA positive via RT-PCR. Repeat testing 24-hours later remained positive (cycle threshold value 21). With no further pyrexia, he was discharged after an observation period. He remained well, until re-presenting two months later with urinary symptoms; suprapubic pain, polyuria and dysuria. He was hypotensive and afebrile. Other levels and left side are normal.

References

DOI: 10.1530/endoabs.91.P43

P44
Challenges in the management of chronic hypoparathyroidism and severe hypocalcaemia in post thyroidecogy- is there a rationale in using recombinant human parathyroid hormone?
Lakshmi Nijh, Sigmond Chan, Lisa Ward, Nicole Bottoms & Ritwik Banerjee
Luton and Dunstable University Hospital, Luton, United Kingdom
39-year-old female, with a past medical history of Graves Hyperthyroidism, underwent total thyroidecotomy 18 years ago, with resultant hypoparathyroidism, hypocalcaemia and hypothyroidism. Her calcium levels are usually in the range of 1.6-1.8 mmol/L, but there are times when it can go to dangerously low levels (range of 1.4-1.5 mmol/L) causing symptoms, sometimes with ECG changes, requiring hospital admissions and IV calcium replacements. There is no parathyroid activity detected when she is hypo calcaemic. Her TSH levels are always high, even on adequate dose of levothyroxine. After careful questioning and assessment, we got to know that the medication compliance seems to be a major concern, but we have never been able to get her to accept that fact. She was very clear that she has been taking all her medications as prescribed, but also mentioned about some episodes of abdominal discomfort, sometimes frequent diarrhoea after taking those, which can sometimes making her to omit doses. Currently she is on AcconitD3 (1500/400) 5 tablets three times a day, alfalcaldic 4.5 mg twice daily and levothyroxine 225 mg daily. Her recent hospital admission was two months ago, when the calcium levels went down to 1.18 mmol/L with symptoms, QT prolongation in ECG, requiring hospital stay, and the calcium levels were 1.82 mmol/L following intravenous calcium infusion. Her levothyroxine absorption test has shown that she was able to absorb levothyroxine when it was given, strongly suggesting that she should be able to absorb her calcium and alfalcaldic. Her recent blood tests showed Serum Calcium (adjusted) of 1.82 mmol/L (post calcium infusion), TSH-12.1 mUI/L. Free T4-13.3 pmol/L. PTH 0.2 pmol/L We are planning for a clinical psychologist review to see if she can benefit from an assessment and to identify extraneous factors contributing to non-compliance. The clinical question is whether there is a role of recombinant parathyroid hormone therapy in this clinical context. There are case reports and studies suggesting the rationale of using these agents to treat post-thyroidectomy hypoparathyroidism, but there are no clear guidelines favouring their use in non-compliance induced severe hypocalcaemia.

DOI: 10.1530/endoabs.91.P44

P45
A case of hypogonadotropic hypogonadism (HH) due to CHARGE syndrome
Maryiam Shazra1, Nour Elkhateeb2, Soo-Mi Park2 & Craig Parkinson1
1Ipswich Hospital, Ipswich, United Kingdom. 2Cambridge University Hospital, Cambridge, United Kingdom

Case history
A 26-year-old man was referred to the Endocrine Clinic due to lack of erections and infrequent shaving for 12 months. An extensive past medical history was noted, the majority of which was attributed to a diagnosis of cerebral palsy. Problems included feeding difficulties from birth with NG, followed by PEG feeding from age 3 to 20, gross motor, speech and language developmental delay, bilateral severe hearing impairment necessitating hearing aids, long sightedness, scoliosis, hypermobility, ataxia and cosmetic colitis. He denied use of exogenous testosterone and was not seeking fertility. He reported normal smell sensation. Examination revealed a pre-pubertal male with small testes (left = 4 mL, right = 6 mL, Tanner stage 3).

DOI: 10.1530/endoabs.91.P44
Investigations
Blood tests confirmed HH. Testosterone = 1.01 nmol/l (8.64-29.0), SHBG 137.2 nmol/l (18.3-54.1), FSH 3.2 IU/l (1.5-12.4), LH 1.5 IU/l (1.7-8.6). Prolactin 373 mIU/l. Short Synacthen test - normal, TSH 2.10 mIU/l, FT4 16.3 pmol/l, IGFI 17.2 nmol/l (11-33) MRI pituitary was normal and he declined a DXA scan. Genetic testing for Kallmann’s syndrome was negative and a normal karyotype was returned. Given the associated phenotypic findings testing of the gene panel (R148.1) for HH was requested. This revealed a pathogenic heterozygous CHD7 mutation known to cause autosomal dominant HH type 5 with or without anosmia. Following review by the Cambridge Clinical Genetics Service a diagnosis of CHARGE syndrome was made.

Treatment
The patient has commenced testosterone treatment and will be assessed for Growth Hormone Deficiency (GHD). Screening for other manifestations of CHARGE syndrome is now underway.

Conclusions and points for discussion
CHARGE syndrome is a rare (approximately 1 in 15000 live births) genetic condition and consists of a cluster of abnormalities - Coloboma, Heart defects, choanal Atresia, Retarded growth and development, Genital abnormalities and Ear anomalies - but a wide range of other manifestations have also been described including cleft lip, oesophageal atresia, GHD (15% of cases), typical facial appearance and HH (present in 60% of cases). Deafness occurs in 90-95% of patients with CHARGE syndrome – thus, the presence of deafness in someone with HH should prompt genetic assessment for this condition allowing the provision of holistic care. This presentation will describe CHARGE syndrome in more detail.

DOI: 10.1530/endoabs.91.P45

P47
Pre-clinical Autoimmune Adrenalitis, biochemically diagnosed; Treat or Not?
Ahmed M Gharib Ahmed & Elizabeth Cheyne
North Bristol Trust, Bristol, United Kingdom

The Case
We are presenting a 51-year-old Caucasian lady with known type 1 diabetes who was diagnosed with Autoimmune Addison’s Disease (AAD) during investigation of persistent hypotremia. She was admitted with DKA back in November 2022 that was believed to be due to gastroenteritis. Usually, her diabetes control has been reasonable over the years with no severe chronic complications or diabetes-related hospital admissions. In the hospital, she suffered from ongoing hypotremia which was thought be due hypovolemia and excessive Dextrose 5% used with IV insulin. On discharge, Sodium and potassium were 126 and 4.9 mmol/l respectively. GP got back to us two weeks after discharge since sodium failed to improve and hence hypotremia work up was initiated. This revealed low morning cortisol that remained stationary after Synacthen stimulation. The ACTH came back strikingly high and adrenal antibodies came back positive. Clinically, the patient was completely asymptomatic with no manifestations of hypothalamic. BP was 120/70 with no orthostasis. She neither had GI symptoms or hyperpigmentation.

Investigations

<table>
<thead>
<tr>
<th>Sodium</th>
<th>121-132 pmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium</td>
<td>4.5-5.9 pmol/l</td>
</tr>
<tr>
<td>ACTH</td>
<td>571.9 ng/l</td>
</tr>
</tbody>
</table>

The rest of routine biochemistry was normal

*Cut off level to diagnose adrenal insufficiency is 450 nmol/l*

Treatment
Despite being asymptomatic, we decided to treat with hydrocortisone and fludrocortisone and monitor clinical and biochemical follow up

Conclusion and points for discussion

- AAD has a long latency before presentation in most patients.
- Adrenal steroidogenic function is on a steep downward trajectory at the time of diagnosis and that declines irrespective of the steroid replacement treatment and changes to ACTH levels.
- This looks like the opposite of honeymoon period in T1DM where there’s slight improvement of B-cell function following insulin therapy.
- A minor subset of patients with AAD like this lady, have residual low-level adrenal steroidogenesis. Whether these patients represent a distinct cohort either in terms of their etiopathogenesis, requirement for steroid replacement or resilience to adrenal crisis and other complications remains unknown.
- This somehow resembles mild C-peptide positivity in some patients with milder forms of T1DM.
- This observation is important, because it likely indicates preservation of adrenal capsular stem cells despite the autoimmune attack. This may open new therapeutic window in the future to ameliorate this chronic condition.

DOI: 10.1530/endoabs.91.P47

P46
An unusual presentation of Pituitary macroadenoma in an acute medical take
Yin Yin, Jessica Tan, Janitha Srikugan, Itopa Abedo, Arthur Ogunko & Cynthia Mohandas
Dartford and Gravesham NHS Trust, Dartford, United Kingdom

Case History
A 64-year-old gentleman presented to the emergency department with acute onset dizziness, nausea, vomiting and difficulty in standing. Although his symptoms lasted only for a few hours, his neurological examination was unremarkable. His past medical history included atrial fibrillation, factor V Leiden deficiency and previous left lower limb DVT. He was not on any medications that can cause hyperprolactinaemia. The stroke team who reviewed him initially diagnosed it as an acute episode of vertigo of a non-vascular aetiology and requested initial CT head that did not show any acute intracranial pathology but it showed a bulky pituitary gland. He was reviewed by the endocrine consultant in the medical take and on further questioning, he denied any history of galactorrhoea, headaches, visual disturbances or symptoms of hypogonadism.

Investigations
Formal Goldmann visual field testing showed no significant abnormality; Pituitary profile showed a raised Prolactin 24886 mIU/L (56-278), random cortisol 284nmol/l, FSH 4.4 IU/l (1.5-18), LH 2.5 IU/l (1.5-9.3), testosterone 3.4 nmol/l (8.4-27.4), TSH 2.8 mIU/l (0.3-4.8), IGFI 17.5nmol/l. MRI Pituitary confirmed a pituitary macroadenoma measuring 12mm x 12mm x 21mm partially obscuring suprasellar cistern and showing a protrusion into the left carotid siphon with no optic chiasm compression or no cavernous sinus invasion.

Results and treatment
He was commenced on cabergoline 500 mg once weekly and then discharged. Pituitary Multidisciplinary team meeting advised treatment with cabergoline. Pituitary Multidisciplinary team meeting advised continuation of dopamine agonist therapy and repeating MRI Pituitary in 6 months.

Conclusions and points for discussion
The novelty in this case is the unusual presentation of an incidental finding of a pituitary macroadenoma in an acute medical take with significant hyperprolactinaemia in a patient who did not display any symptomatology associated with this degree of disease reported in the literature. It was just by chance that his CT scan was reviewed by an endocrinologist earlier on during the admission process and detailed baseline pituitary function was requested. Hence the diagnosis was picked up which could have been easily missed in a busy medical take. The rate of resolution of hyperprolactinaemia on Cabergoline within the first few weeks of treatment is interesting in our case, although there have been similar case reports but with CSF rhinorrhea following treatment of giant invasive macroadenomas, unlike our case who remained well and carefully monitored.

DOI: 10.1530/endoabs.91.P46

P48
Poly Cystic Ovarian Syndrome: Common condition, with unusual presentation
Wajiah Amjad
James Paget University Hospital, Gorleston, United Kingdom

18 year old female was referred to endocrinology from Paediatric and adolescent gynaecology with secondary amenorrhea. She had her menarche at age of 15 years with profuse bleeding for three days only, no spontaneous periods afterwards. She had no symptoms of weight gain, increased hair growth, galactorrhoea, headache or any skin changes. She had significant history of hair loss. She had normal milestones. She achieved her adrenarche and thelarche at age of 12-13 years. Family history unremarkable. She has normal weight BMI= 23, no signs of hirsutism except her Scalp hair line is thin. No Skin changes pertinent to Cushing’s syndrome, insulin resistance. Her hormonal profile revealed normal FSH, LH estradiol and progesterone. Although she has raised Testosterone 4.4-2.5ng/m on consecutive occasions. DHEAS, Androstenedione, 17 OH progesterone normal. Her further workup showed normal ovarian morphology. MRI adrenal unremarkable. She is labelled as case of polycystic syndrome on basis of her oligomenorrhea and increase testosterone level. She received metformin along with mini pill and then medroxyprogesterone without any effect on her cycle. She later received combined oral contraceptive pill
Author Index for Clinical Update

Abbas, Ali WF3
Abbas, Arfoz CB41
Abouglla, Kamal CB36
Abraham, Prakash CB52, WC15, WD11
Abumuaileq, Miral WA12
Aghajafar, Rochan WD4
Ahamed Sadiq, Shafana
WA12
Ahmed, Farouq CB67
AhmedMohamed, Isra CB22
Akbar, Shahzad CB29, WA8
Al Radhi, Balqees CB53
Al-Ansari, Mustafa WG4
Al-Riayhi, Mohammad
WA1
Al-Sahaf, May WD4
Al-Shareef, Ahmed CB53
Albor, Christo WE7
Aldafter, Assad WB2
Ali, Mudasir CB36, CB57
Almond, Max WD6
Aliyamani, Arwa WA11
Anandhakrishnan, Ananthi
CB24, WF4
Anizor, Chinedu CB4
Anthoney, Alan CB41
Anthonypillai, Charles
WA16, WC4
Armeni, Eleni WD15
Arumugairathan, Ganesh
WF10
Asam, Muhammad CB34
Asia, Miriam WD6
Aslam, Aisha CB23
Aung, Pyei WA10
Awadelkareem, Abuzar
CB34, WD8
Awala, Orijomisan WH6
Aziz, Umaima CB50, WC2
Baig, Irfanullah WF6
Bakhit, Mohamed WD5
Banerjee, Amit CB68, WH4
Bano, Gul CB46, CB59, WB3
Basheer, Kefah WG4
Basu, Ansu CB25
Behary, Preeshila CB58, WF3
Behary, Presheela CB63
Bell, Richard CB35, WA6
Berry, Simon WB1
Bhagi, Ridhi CB56
Bhayat, Hasina WF6
Biddanda, Aiyappa WC12
Boelaert, Kristen WC11
Bonanos, Stathis CB28
Bramble, Delanos CB11, CB31
Brooke, Antonio WG6
Buch, Harit WH6
Burri, Sushma WC7
Busti, Stefano CB65
Busu, Zvidzayi WF8
Carroll, Paul CB32, WF7, WG5
Carty, David WA3
Casey, Caomhie WC8
Chagger, Herpreet CB15
Chin-Harty, Lisa CB66
Chopra, Tanya WF5
Cilia, Kyle CB6, WC1
Cominios, Alexander N CB58, WF3, CB63
Coppini, David WA7, WC10, WD3
Cox, Jeremy CB58, CB63, WD4, WF3
Craus, Sarah WA7, WC10, WD3
Cussen, Leanne WG3
Dawood, Huzafa WA5
De Silva, Nipun Lakshitha
WE4
De Silvia, Purnami WH2
Debono, Miguel CB55, WB1
Deshmukh, Harshal WA9
Dewdney, Charlotte
WF7
Dhar, Mill CB40
Dhathiriya, Ketan WG6
Di Marco, Almeec WD9
Dimitriadi, Georgios CB13
Dimitropoulos, Ioannis
CB31, WF9
Dover, Anna WF7
Down, Andrew WC16
Drake, William WB5, WD7
Dugal, Neal WD2
Dugal, Neil WD14
D Costa, Ryan Vernon
WH1
Elayed Mohamed Ali, Nihad CB42
Eyadeh, Ahmad CB64
Faheem, Muhammad
CB50, WC2
Farooqui, Azhar WF8
Flynn, Rachel WC13
Fotinopoulou, Evgenia
WA15
Fraser, Sheila CB41
Gajawweera, Gayan WC4
Galloway, Natasha WA1
Gamage, Kavinga CB5
Gatt, Arifone CB10, CB62
Georgios, Giovos CB54
Ghieth, Sherif CB11
Gilbert, Jacqueline CB12
Gill, Gurmit WE5
Gilroy, Michael CB49
Gopalakrishnan, Prethivin Pillai CB38
Graf, Anneke WH2
Grixti, Lydia WE1
Grossman, Ashley WD15
Gunathilake, Sonali WA16
Gunganah, Kirun CB24, CB69, WF4
Gupta, Piya Sen WG5
Haboosh, Sara CB63, WG5
Hadjiminas, Dimitri J WF3
Hamdan, Sawsan CB11, CB31
Hanson, Petra CB60
Harrolld, Christopher CB60
Hegde, Pallavi WD10
Hill, Arnold WD2
 Hirwa, Kagabo WF9, WH7
Hnin, Thanda CB34
Hope, David CB2
Htet, Soe Nyi Nyi
WH7
Hun, Kyaw Zin WE6
Hte, Nang Poe Poe Han
CB41
Hughes, David WD5
Hunter, Steven J CB28
Hyer, Steve WG2
Irfan, Aisha CB61, CB8
Islam, Quazi WD15
Issuree, Kiran
WC11
Jayasena, Channa WE4
Jegavanthan, Dhulashihla
WA16, WC4
Jeyaka, Neha WG2
Johri, Nikhil WG2
Jones, Ben WD4
Joseph, Angel Mary
WH1
Joshi, Mamta WG2
Julia, Calvo Latorre WC5
Juszczak, Agata WD6
Kabir, Afrin WA9
Kaplan, Felicity WC9
Kapoor, Ashutosh WD4
Karra, Efthimia WD15
Karunasena, Nayananjani
WC4
Khalilova, Samira CB13
Khan, Asra CB9
Khan, Hamza CB18
Khan, Huma Humayun
CB19
Khan, Irfan CB34
Khan, Irfan Iqbal WD8
Khan, Shailla CB63
Khine, May Thin CB20, WB6
Khoo, Bernard WD15
Khoor, Seren Sert Khim
CB38
Khor, Xiao Ying CB21
Khor, Xiao Ying WD16
Kilcoyne, Ciara WC6
Kong, Ngai WA6
Koutroukas, Vaios WG6
Krishnan, Amutha WH5
Krishnasamy Ganapathy, Kavitha Dhevi
CB25
Kumar, Jesse CB4
Kumarathunga, Dineshka
CB54, WA16, WC4
Kumarathunga, P A D M
WE8
Kurera, Irsudy WD1
Kuw, Moe CB68, WH4
Leanne, Cussen WD14
Lewis, Alexander CB23, WA10, WF11
Lin, Nyan WH2
Ling, Yong WG4
Macinerney, Ruth CB44
Madden Doyle, Lauren
WG3
Majeed, Waseem WD16
Malhotra, Gaurav CB50, WC2
Malkik, Amna WE5
Maltese, Giuseppe WG2
Mamojee, Yaasir CB47, CB53, CB57, WD8
Masinghe, Sanjana CB34

Endocrine Abstracts (2022) Vol 91
## Author Index for National Clinical Cases

<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Malek, Mariana</td>
<td>OC6</td>
</tr>
<tr>
<td>Abedo, Itopa</td>
<td>P26, P46</td>
</tr>
<tr>
<td>Abougilla, Kamal</td>
<td>P24</td>
</tr>
<tr>
<td>Acosta, Allan</td>
<td>P38</td>
</tr>
<tr>
<td>Agarwal, Mayuri</td>
<td>OC10</td>
</tr>
<tr>
<td>Ahamed Sadiq, Shafana</td>
<td>P32</td>
</tr>
<tr>
<td>Ahmed, Ahmed M Gharib</td>
<td>P47</td>
</tr>
<tr>
<td>Alameri, Majid</td>
<td>OC6</td>
</tr>
<tr>
<td>Amjad, Wajjha</td>
<td>P40, P48</td>
</tr>
<tr>
<td>Anandhakrishnan,</td>
<td></td>
</tr>
<tr>
<td>Ananthi</td>
<td>OC7</td>
</tr>
<tr>
<td>Anderson, John</td>
<td>P14</td>
</tr>
<tr>
<td>Arlt, Wiebeke OC1</td>
<td></td>
</tr>
<tr>
<td>Aye, Mo</td>
<td>P3</td>
</tr>
<tr>
<td>Aylwin, Simon OC9</td>
<td>P18</td>
</tr>
<tr>
<td>Azman, Nur</td>
<td>P16, P8</td>
</tr>
<tr>
<td>Bahowairath, Fatima</td>
<td>P1</td>
</tr>
<tr>
<td>Ballav, Chirabhanu</td>
<td>P29</td>
</tr>
<tr>
<td>Banerjee, Ritwik</td>
<td>P44</td>
</tr>
<tr>
<td>Behary, Preeshilla</td>
<td>OC6</td>
</tr>
<tr>
<td>Bhata, Kunwar OC6</td>
<td></td>
</tr>
<tr>
<td>Bhatt, Yogesh P9</td>
<td></td>
</tr>
<tr>
<td>Bhattacharya, Beas</td>
<td>P34, P39</td>
</tr>
<tr>
<td>Bottoms, Nicole</td>
<td>P44</td>
</tr>
<tr>
<td>Brady, Stefen</td>
<td>P28</td>
</tr>
<tr>
<td>Bravis, Natalia</td>
<td>P10</td>
</tr>
<tr>
<td>Brooke, Antonia</td>
<td>M OC5</td>
</tr>
<tr>
<td>Brown, Morris</td>
<td>OC1</td>
</tr>
<tr>
<td>Cavlan, Dominic</td>
<td>P5</td>
</tr>
<tr>
<td>Chakera, Ali</td>
<td>P21</td>
</tr>
<tr>
<td>Chan, Sigmond</td>
<td>P44</td>
</tr>
<tr>
<td>Chaudhary, Aparna</td>
<td>P33</td>
</tr>
<tr>
<td>Cheow, Heok OC1</td>
<td></td>
</tr>
<tr>
<td>Cheyne, Elizabeth</td>
<td>P47</td>
</tr>
<tr>
<td>Chirila-Berbentea,</td>
<td></td>
</tr>
<tr>
<td>Veronica</td>
<td>P34, P39</td>
</tr>
<tr>
<td>Chong, Jimmy Li Voon</td>
<td>P16</td>
</tr>
<tr>
<td>Clark, James</td>
<td>P36, P43</td>
</tr>
<tr>
<td>Cohen, Mark</td>
<td>P9</td>
</tr>
<tr>
<td>Commins, Alexander</td>
<td>OC6</td>
</tr>
<tr>
<td>Conti, Alessandro</td>
<td>P14</td>
</tr>
<tr>
<td>Cox, Jeremy OC6</td>
<td></td>
</tr>
<tr>
<td>Crown, Anna</td>
<td>P20, P21</td>
</tr>
<tr>
<td>de Benito-Lopis, Laura</td>
<td>P2</td>
</tr>
<tr>
<td>Deshmukh, Harshal</td>
<td>P3</td>
</tr>
<tr>
<td>Di Marco, Aimee</td>
<td>P25</td>
</tr>
<tr>
<td>Dimitriades, Georgios K.</td>
<td>P18</td>
</tr>
<tr>
<td>Dodzo, Kumbirai</td>
<td>OC7</td>
</tr>
<tr>
<td>Dorward, Neil</td>
<td>OC5</td>
</tr>
<tr>
<td>Drake, William OC1</td>
<td>OC5</td>
</tr>
<tr>
<td>Eapen, Dilip OC10</td>
<td></td>
</tr>
<tr>
<td>Elkhateeb, Nour P45</td>
<td></td>
</tr>
<tr>
<td>Emmanuel, Julian P36, P43</td>
<td></td>
</tr>
<tr>
<td>Eyeson, Josiah OC6</td>
<td></td>
</tr>
<tr>
<td>Ferguson, Mark P37</td>
<td></td>
</tr>
<tr>
<td>Fernandez, Cornelius OC10</td>
<td></td>
</tr>
<tr>
<td>Field, Benjamin C T P36, P43</td>
<td></td>
</tr>
<tr>
<td>Flynn, Rachel OC7</td>
<td></td>
</tr>
<tr>
<td>Forrest, Ian P6</td>
<td></td>
</tr>
<tr>
<td>Gaoatswe, Gadiintshware</td>
<td>OC7</td>
</tr>
<tr>
<td>Gontsurova, Anastasia</td>
<td>P37</td>
</tr>
<tr>
<td>Goodchild, Emily OC1, P14</td>
<td></td>
</tr>
<tr>
<td>Greenhalgh, Sophie</td>
<td>P22</td>
</tr>
<tr>
<td>Guma, Muna OC2, P6</td>
<td></td>
</tr>
<tr>
<td>Gunganah, Kirun OC7, P23</td>
<td></td>
</tr>
<tr>
<td>Haddad, Aiman OC17</td>
<td></td>
</tr>
<tr>
<td>Hameed, Ali P38</td>
<td></td>
</tr>
<tr>
<td>Hamilton, Paul P4</td>
<td></td>
</tr>
<tr>
<td>Haq, Rizwan P4</td>
<td></td>
</tr>
<tr>
<td>Havill, Lynsey P7</td>
<td></td>
</tr>
<tr>
<td>Hla, Mon P15</td>
<td></td>
</tr>
<tr>
<td>Htet, Zaw P29</td>
<td></td>
</tr>
<tr>
<td>Hughes, David P7</td>
<td></td>
</tr>
<tr>
<td>Hyer, Steve P32</td>
<td></td>
</tr>
<tr>
<td>Idowu, Adetokunbo P15</td>
<td></td>
</tr>
<tr>
<td>Ifikhar, Sahar Oc9</td>
<td></td>
</tr>
<tr>
<td>James, Andy OC2</td>
<td></td>
</tr>
<tr>
<td>Jaunnukatane, Zane P37</td>
<td></td>
</tr>
<tr>
<td>Javaid, Kassim P28</td>
<td></td>
</tr>
<tr>
<td>Jeyakar, Neha P32</td>
<td></td>
</tr>
<tr>
<td>Johri, Nikhil P32</td>
<td></td>
</tr>
<tr>
<td>Joseph, Siphy P19</td>
<td></td>
</tr>
<tr>
<td>Joshi, Manta P32</td>
<td></td>
</tr>
<tr>
<td>Kaplan, Felicity P35</td>
<td></td>
</tr>
<tr>
<td>Karpe, Fredrik P28</td>
<td></td>
</tr>
<tr>
<td>Kejem, Helmine P13</td>
<td></td>
</tr>
<tr>
<td>Kent, Louisa P28</td>
<td></td>
</tr>
<tr>
<td>Kethiredhi, Keerthi</td>
<td></td>
</tr>
<tr>
<td>Madhurya P20</td>
<td></td>
</tr>
<tr>
<td>Khalilova, Samira P18</td>
<td></td>
</tr>
<tr>
<td>Khan, Jansher OC7</td>
<td></td>
</tr>
<tr>
<td>Khan, Sairah OC6</td>
<td></td>
</tr>
<tr>
<td>Khan, Shaila P1</td>
<td></td>
</tr>
<tr>
<td>Kinton, Rebecca P7</td>
<td></td>
</tr>
<tr>
<td>Kumar, Mohit OC4</td>
<td></td>
</tr>
<tr>
<td>Lacey, Hester P21</td>
<td></td>
</tr>
<tr>
<td>Lajeunesse-Tremepe, Fannie P18</td>
<td></td>
</tr>
<tr>
<td>Lakshimipathy, Kavitha P36, P43</td>
<td></td>
</tr>
<tr>
<td>Lamb, Chris OC2</td>
<td></td>
</tr>
<tr>
<td>Lambert, Kimberley P16, P8</td>
<td></td>
</tr>
<tr>
<td>Laycock, Kate OC1</td>
<td></td>
</tr>
<tr>
<td>Le Carpentier, Dana P16</td>
<td></td>
</tr>
<tr>
<td>Lee, Jessica P2</td>
<td></td>
</tr>
<tr>
<td>Lewis, Alex P12</td>
<td></td>
</tr>
<tr>
<td>Lewis, Alexander P22</td>
<td></td>
</tr>
<tr>
<td>Lewis, Dylan OC9</td>
<td></td>
</tr>
<tr>
<td>Luo, Hongxu P31</td>
<td></td>
</tr>
<tr>
<td>Maltese, Giuseppe P32</td>
<td></td>
</tr>
<tr>
<td>Mamoojee, Yaasir OC2, P6</td>
<td></td>
</tr>
<tr>
<td>Mankumure, Mohitrame P13</td>
<td></td>
</tr>
<tr>
<td>Marshall, Jonathan P28</td>
<td></td>
</tr>
<tr>
<td>Martin, Niambh P37</td>
<td></td>
</tr>
<tr>
<td>Matheou, Michael P28</td>
<td></td>
</tr>
<tr>
<td>Matson, Matthew OC1</td>
<td></td>
</tr>
<tr>
<td>McConnachie, Alexander OC1</td>
<td></td>
</tr>
<tr>
<td>McDonnell, Fiona OC6</td>
<td></td>
</tr>
<tr>
<td>McGown, Patrick P37</td>
<td></td>
</tr>
<tr>
<td>McIntosh, Alasdair OC1</td>
<td></td>
</tr>
<tr>
<td>McLaren, Andrew P29</td>
<td></td>
</tr>
<tr>
<td>Meenan, Karim P37</td>
<td></td>
</tr>
<tr>
<td>Mehta, Sanjeev P37</td>
<td></td>
</tr>
<tr>
<td>Mendis, Budd P30</td>
<td></td>
</tr>
<tr>
<td>Mendoza, Nigel P37</td>
<td></td>
</tr>
<tr>
<td>Mohandas, Cynthia P26, P46</td>
<td></td>
</tr>
<tr>
<td>Mongolu, Shiva P3</td>
<td></td>
</tr>
<tr>
<td>Monson, John P OC7</td>
<td></td>
</tr>
<tr>
<td>Mukhopadhyay, Suchana OC6</td>
<td></td>
</tr>
<tr>
<td>Mulholland, Sarah P12</td>
<td></td>
</tr>
<tr>
<td>Mullan, Karen P4</td>
<td></td>
</tr>
<tr>
<td>Mumby, Clare P13</td>
<td></td>
</tr>
<tr>
<td>Munisamy, Narmadha P16, P8</td>
<td></td>
</tr>
<tr>
<td>Murray, Emma P4</td>
<td></td>
</tr>
<tr>
<td>Myers, Jenny P13</td>
<td></td>
</tr>
<tr>
<td>Nagarajah, Kalyani OC8</td>
<td></td>
</tr>
<tr>
<td>Nair, Ramesh P37</td>
<td></td>
</tr>
<tr>
<td>Namiq, Parez P20</td>
<td></td>
</tr>
<tr>
<td>Napier, Catherine P6</td>
<td></td>
</tr>
<tr>
<td>Narayanan, Ram Prakash P33</td>
<td></td>
</tr>
<tr>
<td>Narula, Kavita P37</td>
<td></td>
</tr>
<tr>
<td>Nayyar, Vidhu P36, P43</td>
<td></td>
</tr>
<tr>
<td>Nicholson, Clare OC2</td>
<td></td>
</tr>
<tr>
<td>Nijith, Lakshmi P44</td>
<td></td>
</tr>
<tr>
<td>Noel, Lauran P5</td>
<td></td>
</tr>
<tr>
<td>North, Matthew P9</td>
<td></td>
</tr>
<tr>
<td>O'Shea, Donal OC3</td>
<td></td>
</tr>
<tr>
<td>Obi, Ngozi Vivienne P30</td>
<td></td>
</tr>
<tr>
<td>Ogunko, Arthur P26, P46</td>
<td></td>
</tr>
<tr>
<td>Onyema, Michael P18</td>
<td></td>
</tr>
<tr>
<td>Osman, Nadia P23</td>
<td></td>
</tr>
<tr>
<td>Palazzo, Fausto P1</td>
<td></td>
</tr>
<tr>
<td>Panagiotou, Grigoris OC8</td>
<td></td>
</tr>
<tr>
<td>Park, Soo-Mi P45</td>
<td></td>
</tr>
<tr>
<td>Parkinson, Craig P45</td>
<td></td>
</tr>
<tr>
<td>Parsad, Meenakshi P16</td>
<td></td>
</tr>
<tr>
<td>Partridge, Sarah P25</td>
<td></td>
</tr>
<tr>
<td>Patel, Henna P23</td>
<td></td>
</tr>
<tr>
<td>Platts, Julia OC8</td>
<td></td>
</tr>
<tr>
<td>Prête, Alessandro OC1</td>
<td></td>
</tr>
<tr>
<td>Quinton, Richard P6</td>
<td></td>
</tr>
<tr>
<td>Qureshi, Asjid P25</td>
<td></td>
</tr>
<tr>
<td>Qureshi, Sheharyar P15</td>
<td></td>
</tr>
<tr>
<td>Randall, David P5</td>
<td></td>
</tr>
<tr>
<td>Randall, Joanne P40</td>
<td></td>
</tr>
<tr>
<td>Ritchie, Stuart P41</td>
<td></td>
</tr>
<tr>
<td>Roy, Roopa P27</td>
<td></td>
</tr>
<tr>
<td>Safiee, Tabish P17</td>
<td></td>
</tr>
<tr>
<td>Sankar, Adhithya OC4</td>
<td></td>
</tr>
<tr>
<td>Sathyapalan, Thozhukat P3</td>
<td></td>
</tr>
<tr>
<td>Schulte, Klaus-Martin OC9</td>
<td></td>
</tr>
<tr>
<td>Sharma, Aditi P2</td>
<td></td>
</tr>
<tr>
<td>Sharma, Bhavna P25</td>
<td></td>
</tr>
<tr>
<td>Shazra, Mariyam P45</td>
<td></td>
</tr>
<tr>
<td>Shears, Deborah P28</td>
<td></td>
</tr>
<tr>
<td>Solomon, Andrew P17</td>
<td></td>
</tr>
<tr>
<td>Spraggs, Paul P16</td>
<td></td>
</tr>
<tr>
<td>Srikugan, lanitha P26, P46</td>
<td></td>
</tr>
<tr>
<td>Sankaran, Emmanuel P3</td>
<td></td>
</tr>
<tr>
<td>Subramaniam, Yuvanna OC5, P2</td>
<td></td>
</tr>
<tr>
<td>Syed, Maria P16</td>
<td></td>
</tr>
<tr>
<td>Tan, Garry D P28</td>
<td></td>
</tr>
<tr>
<td>Tan, Jessica P46</td>
<td></td>
</tr>
<tr>
<td>Tansey, David OC3</td>
<td></td>
</tr>
</tbody>
</table>

*Endocrine Abstracts (2023) Vol 91*